WorldWideScience

Sample records for biotech uni-gold recombigen

  1. Voices of biotech

    DEFF Research Database (Denmark)

    Amit, Ido; Baker, David; Barker, Roger;

    2016-01-01

    What will be the most important areas of research in biotech over the coming years? Which technologies will be most important to advance knowledge and applications in these areas? Nature Biotechnology reached out to a set of investigators working in research areas representative of the journal...

  2. Biotech as 'Biothreat'?

    DEFF Research Database (Denmark)

    Holmgreen, Lise-Lotte

    2008-01-01

    groups. In this, the paper tries to make up for the limited focus upon the role played by metaphor and discourse in shaping public attitudes of biotechnology. The paper has two parts; a theoretical part discussing the combination of conceptual metaphor studies and critical discourse analysis to provide...... a more comprehensive frame for explaining the function of metaphor in use, and an empirical part analysing biotech-metaphors in the Danish print press. Although not conclusive, the analysis points to metaphorical constructions in the press being both grounded in basic image schematic structures......In Denmark, as in many other European countries, biotechnology continues to be a much debated and controversial issue. The paper takes its starting point in this debate, investigating how metaphorical constructions in media discourse reproduce and promote the viewpoints of particular societal...

  3. Profiles of four projects in Biotech Business

    DEFF Research Database (Denmark)

    Valentin, Finn

    2004-01-01

    In April 2004, Copenhagen Business School opens a centre for research on biotech business. Biotech Business includes a number of senior and junior researchers from CBS. Initially the centre takes its point of departure in four projects included in the research program on Competence, Organisation...... and Management in Biotech Industries (COMBI). Starting in March 2004, COMBI is funded jointly by The Danish Social Research Council, firms and organisations in the Danish biotech industry and CBS. This presentation refers exclusively to four COMBI projects....

  4. NMSBA: Sandia Biotech 2016 Report

    Energy Technology Data Exchange (ETDEWEB)

    Ruffing, Anne [Sandia National Lab. (SNL-NM), Albuquerque, NM (United States)

    2016-06-01

    The objective of this project is to modify the FluorAbody plasmid previously developed by Sandia Biotech to include a binding site for biotin by introducing the biotin carboxyl carrier protein (BCCP)and a gold binding protein (GBP) into a loop of the red fluorescent protein (mRFP).

  5. A global need for women's biotech leadership

    DEFF Research Database (Denmark)

    Smith-Doerr, L.; Kemekliene, G.; Teutonico, R.;

    2011-01-01

    Increasing women's participation in leadership of biotech policy making, funding, research and implementation will strengthen the race to solve global problems......Increasing women's participation in leadership of biotech policy making, funding, research and implementation will strengthen the race to solve global problems...

  6. Chemometrics applications in biotech processes: a review.

    Science.gov (United States)

    Rathore, Anurag S; Bhushan, Nitish; Hadpe, Sandip

    2011-01-01

    Biotech unit operations are often characterized by a large number of inputs (operational parameters) and outputs (performance parameters) along with complex correlations amongst them. A typical biotech process starts with the vial of the cell bank, ends with the final product, and has anywhere from 15 to 30 such unit operations in series. The aforementioned parameters can impact process performance and product quality and also interact amongst each other. Chemometrics presents one effective approach to gather process understanding from such complex data sets. The increasing use of chemometrics is fuelled by the gradual acceptance of quality by design and process analytical technology amongst the regulators and the biotech industry, which require enhanced process and product understanding. In this article, we review the topic of chemometrics applications in biotech processes with a special focus on recent major developments. Case studies have been used to highlight some of the significant applications.

  7. Business Ethics 101 for the biotech industry.

    Science.gov (United States)

    MacDonald, Chris

    2004-01-01

    Biotechnology companies face ethical challenges of two distinct types: bioethical challenges faced on account of the nature of work in the life sciences, and corporate ethical challenges on account of their nature as commercial entities. The latter set of challenges has received almost no attention at all in the academic literature or media. This paper begins to remedy that lacuna, examining ethical issues that arise specifically on account of the status of biotech companies as commercial entities. The focus here is on three representative issues: product safety, corporate social responsibility, and corporate governance. It is argued that each of these issues poses particular ethical challenges for companies in the biotech sector. In the area of product safety, it is noted that biotech companies face particular challenges in determining what counts as a "safe" product, given the contentious nature of what might count as a "harm" in the biotech field. In the area of corporate social responsibility, the adoption of a "stakeholder approach" and an attempt to manage the social consequences of products pose special challenges for biotech companies. This is due to the enormous range of groups and individuals claiming to have a stake in the doings of such companies, and the trenchant controversies over just what the social consequences of various biotechnologies might be. In the area of corporate governance, biotech companies need to seek out and follow best practices regarding the ways in which information, authority, and influence flow between a company's shareholders, managers, and Board of Directors, if they are to avoid duplicating the ethical and financial scandal that brought down ImClone. An important meta-issue, here--one that renders each of these corporate ethical challenges more vexing--is the difficulty of finding the appropriate benchmarks for ethical corporate behavior in a field as controversial, and as rapidly evolving, as biotechnology. Three

  8. Business Ethics 101 for the biotech industry.

    Science.gov (United States)

    MacDonald, Chris

    2004-01-01

    Biotechnology companies face ethical challenges of two distinct types: bioethical challenges faced on account of the nature of work in the life sciences, and corporate ethical challenges on account of their nature as commercial entities. The latter set of challenges has received almost no attention at all in the academic literature or media. This paper begins to remedy that lacuna, examining ethical issues that arise specifically on account of the status of biotech companies as commercial entities. The focus here is on three representative issues: product safety, corporate social responsibility, and corporate governance. It is argued that each of these issues poses particular ethical challenges for companies in the biotech sector. In the area of product safety, it is noted that biotech companies face particular challenges in determining what counts as a "safe" product, given the contentious nature of what might count as a "harm" in the biotech field. In the area of corporate social responsibility, the adoption of a "stakeholder approach" and an attempt to manage the social consequences of products pose special challenges for biotech companies. This is due to the enormous range of groups and individuals claiming to have a stake in the doings of such companies, and the trenchant controversies over just what the social consequences of various biotechnologies might be. In the area of corporate governance, biotech companies need to seek out and follow best practices regarding the ways in which information, authority, and influence flow between a company's shareholders, managers, and Board of Directors, if they are to avoid duplicating the ethical and financial scandal that brought down ImClone. An important meta-issue, here--one that renders each of these corporate ethical challenges more vexing--is the difficulty of finding the appropriate benchmarks for ethical corporate behavior in a field as controversial, and as rapidly evolving, as biotechnology. Three

  9. 77 FR 35353 - Biotech Life Sciences Trade Mission to Australia

    Science.gov (United States)

    2012-06-13

    ... International Trade Administration Biotech Life Sciences Trade Mission to Australia AGENCY: International Trade... Biotech Life Sciences trade mission to Australia, October 29-November 2, 2012. The mission to Australia is... prominent biotech organizations, government meetings, and briefings and receptions during the...

  10. Neuro-oncology biotech industry progress report.

    Science.gov (United States)

    Chakraborty, Shamik; Bodhinayake, Imithri; Chiluwal, Amrit; Langer, David J; Ruggieri, Rosamaria; Symons, Marc; Boockvar, John A

    2016-05-01

    The Brain Tumor Biotech Center at the Feinstein Institute for Medical Research, in collaboration with Voices Against Brain Cancer hosted The Brain Tumor Biotech Summit at in New York City in June 2015. The focus was once again on fostering collaboration between neuro-oncologist, neurosurgeons, scientists, leaders from biotechnology and pharmaceutical industries, and members of the financial community. The summit highlighted the recent advances in the treatment of brain tumor, and specifically focused on targeting of stem cells and EGFR, use of prophage and immunostimulatory vaccines, retroviral vectors for drug delivery, biologic prodrug, Cesium brachytherapy, and use of electric field to disrupt tumor cell proliferation. This article summarizes the current progress in brain tumor research as presented at 2015 The Brain Tumor Biotech Summit.

  11. Perspective: Biotech funding trends: Insights from entrepreneurs and investors.

    Science.gov (United States)

    Gruber, Alexandra C

    2009-08-01

    Based on a qualitative study analyzing a series of interviews with dedicated biotech entrepreneurs and high-level investors, "Biotech Funding Trends" provides a comprehensive overview of current trends in biotech funding by taking a close look behind the scenes of the biotech industry. In particular, it illustrates the tensions between both key players based on their different backgrounds and expectations. Here we outline the various funding opportunities for the biotech industry in Europe and identify ways for both sides, entrepreneurs and investors to overcome their prejudices to successfully thrive in a competitive environment. The results are also discussed in the light of the current financial and economic crisis.

  12. Communicating financials in the biotech industry

    DEFF Research Database (Denmark)

    Holmgreen, Lise-Lotte

    2008-01-01

    In Denmark, biotechnology and its physical product, the genetically modified organism, continues to be controversial, leading to widespread public scepticism. This paper explores the effect of such scepticism on part of the financial communication of one of Denmark's largest biotech companies......, Novozymes. Research indicates that besides accommodating a legal demand for the disclosure of company financial details, the annual report, in particular the letter to the shareholders or the CEO's letter, serves the purpose of marketing the company to its constituents (Bowman 1984; Bülow-Møller 2003......; Hyland 1998). This point is arguably of more importance to a biotech company which in its communication to the public may have to consider promoting an overly favourable and trustworthy image not only of its financial results, but also of the industry in which it is engaged, to ensure continuous...

  13. Much Ado about Something: Cuban Biotech.

    Science.gov (United States)

    2016-07-01

    Cuban advances in biotech have made headlines, particularly since the US-Cuba rapprochement and signing of the historic memorandum of understanding between the US Department of Health and Human Services and Cuba's Ministry of Public Health in June. Some 34 Cuban institutions with 22,000 employees are the backbone of a biotech industry that dates to the early 1980s, obtaining novel products that have sparked interest among potential global partners. While a number of these Cuban products are registered in various countries, their testing in the USA remains ensnared in the red tape of embargo laws that tend to make investors skittish and thus delay, if not curtail, joint research and clinical trial applications to the FDA.

  14. Investor Outlook: After the Biotech Bubble Popped.

    Science.gov (United States)

    Schimmer, Joshua; Breazzano, Steven; Yang, Jerry

    2016-03-01

    After a few torrid years of value appreciation, the biotech "bubble" has precipitously popped over the past few months. In this report, we take a look at some of the factors that drove the run-up in valuations, the triggers that led to their substantial pullback, and where the industry may be headed from here. Gene therapy/editing companies have been particularly affected by these dynamics, raising a new set of questions and challenges for the group.

  15. Fourth Medical Biotech Forum of the Chinese Medical Biotech Association. 8-10 August 2009, Dalian, China.

    Science.gov (United States)

    Felzmann, Thomas

    2009-10-01

    The Chinese Medical Biotech Association's Fourth Medical Biotech Forum held in Dalian, China included topics covering the biotechnology industry in China and new therapeutic developments in the field of immunological approaches to cancer treatment. This conference report highlights selected presentations on China's biotechnology development policy, tumor-specific antigens, clinical applications of antitumor immune therapy, and novel photodynamic tumor therapy. Investigational therapeutics discussed include astuprotimut-r (GlaxoSmithKline plc) and the dendritic cell vaccine Trivax (Trimed Biotech).

  16. Indian Biotech Bazaar: a swot analysis.

    Science.gov (United States)

    Kumar, Abhishek

    2007-05-01

    Biotechnology is a life science-based technique especially used in agriculture, medicine and food sciences. It is generally defined as the manipulation in organisms to generate products for the welfare of the world. Biotechnology combines disciplines such as genetics, biochemistry, microbiology, and cell biology along with information technology, chemical engineering, robotics etc. It includes basic industries such as food processing, tissue culture, plant development and other sophisticated ones such as recombinant therapeutics and diagnostics. Biotechnology, globally recognized as a rapidly emerging and far-reaching technology, is aptly described as the "technology of hope" for its promise of food, health and environmental sustainability. In India, biotechnology employs more than 10 000 people and generates roughly US$ 500 million in revenue annually. The biotechnology market has increased its sales from Rs. 50 billion in 1997 to Rs.70 billion in 2000, and is expected to cross Rs. 240 billion by the year 2010. In India, the human health biotech products account for 60% of the total market; agribiotech and veterinary 25%, medical devices, contract research and development (R&D), reagents and supplies constitute the remaining 15% Moreover, to facilitate foreign investment, capital and government policies are being revised. Other important industries include industrial enzyme manufacture, bioinformatics, and medical devices. Biotechnology has had limited appeal so far on our capital markets, and we have less then a dozen biotech companies listed on the public markets. PMID:17479978

  17. Financial risk of the biotech industry versus the pharmaceutical industry.

    Science.gov (United States)

    Golec, Joseph; Vernon, John A

    2009-01-01

    The biotech industry now accounts for a substantial and growing proportion of total R&D spending on new medicines. However, compared with the pharmaceutical industry, the biotech industry is financially fragile. This article illustrates the financial fragility of the biotech and pharmaceutical industries in the US and the implications of this fragility for the effects that government regulation could have on biotech firms. Graphical analysis and statistical tests were used to show how the biotech industry differs from the pharmaceutical industry. The two industries' characteristics were measured and compared, along with various measures of firms' financial risk and sensitivity to government regulation. Data from firms' financial statements provided accounting-based measures and firms' stock returns applied to a multifactor asset pricing model provided financial market measures. The biotech industry was by far the most research-intensive industry in the US, averaging 38% R&D intensity (ratio of R&D spending to total firm assets) over the past 25 years, compared with an average of 25% for the pharmaceutical industry and 3% for all other industries. Biotech firms exhibited lower and more volatile profits and higher market-related and size-related risk, and they suffered more negative stock returns in response to threatened government price regulation. Biotech firms' financial risks increase their costs of capital and make them more sensitive to government regulations that affect their financial prospects. As biotech products grow to represent a larger share of new medicines, general stock market conditions and government regulations could have a greater impact on the level of innovation of new medicines.

  18. Health care biotech industry (Review Paper

    Directory of Open Access Journals (Sweden)

    G Padmanaban

    2001-10-01

    Full Text Available Modern biotechnology became possible because of the ability to clone genes and produce gene products barriers of species and sex. Potential entrepreneurs are getting interested in venturing into health care biotech industry, stimulated by the success story in information technology. Products of protein therapeutics, such as insulin, growth hormones, interferons, blood proteins, streptokinase and vaccines have received special attention. Pharmaceutical companies got into the field of diagnostics, a major thrust area being products of antigen/antibody and nucleic acid-based diagnostic kits. The ability to clone and sequence genes from a variety of organisms has culminated in the subject of genomics. High throughput screening of thousands of organic molecules against a battery of drug targets using robotic machinery is the current approach to come up with lead molecules. New drug delivery systems for slow, sustained and direct delivery to target tissues are under way. There is hope that hereditary and metabolic disorders may have a cure through replacements of defective genes by normal cloned genes and by blocking the expression of unwanted genes, respectively. This mega approach would call for the availability of DNA chips, a product of collaboration between molecular biologists and electronic engineers. The tendency now-a-days is for a marriage between biotech and pharmaceutical industries. Animal cloning, spearheaded by the birth of Dolly, has revolutionised cell biology and is of promise to generate animal bio-vectors to produce desired protein pharmaceuticals in milk. Stem cell research has assumed a lot of importance. In our country, reasonable competence has been built-up in the field of biotechnology. Around two dozen institutes carry out front-line research in medical biotechnology. Successful commercialisation of a few diagnostic kits and recombinant vaccines has provided an impetus and enthusiasm to exploit biotechnology in a big way

  19. Scientific knowledge dynamics and relatedness in biotech cities

    OpenAIRE

    Boschma, Ron; Heimeriks, Gaston; Balland, Pierre-Alexandre

    2014-01-01

    This paper investigates the impact of scientific relatedness on knowledge dynamics in biotech at the city level during the period 1989-2008. We assess the extent to which the emergence of new research topics and the disappearance of existing topics in cities are dependent on their degree of scientific relatedness with existing topics in those cities. We make use of the rise and fall of title words in scientific publications in biotech to identify major cognitive developments within the field....

  20. Scientific Knowledge Dynamics and Relatedness in Bio-Tech Cities

    OpenAIRE

    Ron Boschma; Gaston Heimeriks; Pierre-Alexandre Balland

    2013-01-01

    This paper investigates the impact of scientific relatedness on knowledge dynamics in biotech at the city level during the period 1989-2008. We assess the extent to which the emergence of new research topics and the disappearance of existing topics in cities are dependent on their degree of scientific relatedness with existing topics in those cities. We make use of the rise and fall of title words in scientific publications in biotech to identify major cognitive developments within the field....

  1. 77 FR 14852 - Advanced Growing Systems, Inc., Advantage Capital Development Corp., Amazon Biotech, Inc...

    Science.gov (United States)

    2012-03-13

    ... From the Federal Register Online via the Government Publishing Office SECURITIES AND EXCHANGE COMMISSION Advanced Growing Systems, Inc., Advantage Capital Development Corp., Amazon Biotech, Inc., Andover... of current and accurate information concerning the securities of Amazon ] Biotech, Inc. because...

  2. Biotech 2011 conference Zurich University of applied sciences.

    Science.gov (United States)

    Demuth, Caspar

    2011-01-01

    More than 160 experts from industry and academia came together this September for the Biotech 2011 at the Zurich University of Applied Sciences (ZHAW) in Wädenswil. As one of the main topics, the conference addressed innovations in sensor technology, where new measurement principles and methods have helped to enhance robustness and user friendliness. Another main emphasis of Biotech 2011 was the application of sensors and related analytical techniques in bioprocesses. In this area, the sensor industry needs to meet the challenges introduced by the increasing use of single-use bioreactors. With its strong focus on sensor applications, Biotech 2011 successfully promoted interaction between professionals in academic and industrial research as well as with experts who apply sensors in biopharmaceutical production.

  3. [Mexico recovers leadership on regulation of biosimilar biotech drugs].

    Science.gov (United States)

    López Silva, Christian

    2012-01-01

    Amid the epidemiological transition that Mexico is currently experiencing, an adequate access to biotech medicines is becoming very important. However, these medicines also involve new challenges for the sanitary authorities, given their higher complexity in structure and function than conventional chemical drugs. Consequently, it has been necessary to update the Mexican legal framework, which has placed Mexico at the forefront in this sector. This article describes briefly what biotech drugs are, why it has been necessary to regulate them differently, the evolution of the regulatory framework in Mexico, and the general features of the new system. PMID:22367313

  4. [Mexico recovers leadership on regulation of biosimilar biotech drugs].

    Science.gov (United States)

    López Silva, Christian

    2012-01-01

    Amid the epidemiological transition that Mexico is currently experiencing, an adequate access to biotech medicines is becoming very important. However, these medicines also involve new challenges for the sanitary authorities, given their higher complexity in structure and function than conventional chemical drugs. Consequently, it has been necessary to update the Mexican legal framework, which has placed Mexico at the forefront in this sector. This article describes briefly what biotech drugs are, why it has been necessary to regulate them differently, the evolution of the regulatory framework in Mexico, and the general features of the new system.

  5. Scientific knowledge dynamics and relatedness in biotech cities

    NARCIS (Netherlands)

    Boschma, Ron; Heimeriks, Gaston; Balland, Pierre-Alexandre

    2014-01-01

    This paper investigates the impact of scientific relatedness on knowledge dynamics in biotech at the city level during the period 1989-2008. We assess the extent to which the emergence of new research topics and the disappearance of existing topics in cities are dependent on their degree of scientif

  6. 76 FR 17621 - Biotech Life Science Trade Mission to China

    Science.gov (United States)

    2011-03-30

    ... issues and biotechnology to discuss industry developments, opportunities, and sales strategies... consumer base and impressive economic growth further reinforce the importance of the market for U.S. firms... trials in Asia. The Biotech Life Science Sector Despite the global financial crisis, China's GDP...

  7. MARKETING OF BIOTECH FUNCTIONAL FOODS IN THE US

    OpenAIRE

    Chema, Kambua; Marks, Leonie A.; Parcell, Joseph L.; Bredahl, Maury E.

    2004-01-01

    To date, most research in Europe and the United States has focused on eliciting consumer WTP for biotech foods without directly addressing strategies for marketing them. We use means-end theory to link consumers' knowledge about functional attributes, to their knowledge about consequences and core values, in order to gain insights into valued attributes for developing potential marketing strategies.

  8. Biotech 101: an educational outreach program in genetics and biotechnology.

    Science.gov (United States)

    East, Kelly M; Hott, Adam M; Callanan, Nancy P; Lamb, Neil E

    2012-10-01

    Recent advances in research and biotechnology are making genetics and genomics increasingly relevant to the lives and health of the general public. For the public to make informed healthcare and public policy decisions relating to genetic information, there is a need for increased genetic literacy. Biotech 101 is a free, short-course for the local community introducing participants to topics in genetics, genomics, and biotechnology, created at the HudsonAlpha Institute for Biotechnology. This study evaluated the effectiveness of Biotech 101 in increasing the genetic literacy of program participants through pre-and-post surveys. Genetic literacy was measured through increases in self-perceived knowledge for each content area covered through the course and the self-reported impact the course had on various aspects of participants' lives. Three hundred ninety-two individuals attended Biotech 101 during the first three course offerings. Participants reported a significant increase in self-perceived knowledge for each content area (p Biotech 101 is an effective mechanism for impacting participants' lives and genetic literacy and serves as a model for other similar programs, adding to the currently limited evidence base regarding public educational strategies in genetics and biotechnology.

  9. Project BIOTECH: Use of Modules in Technician Training

    Science.gov (United States)

    Glazer, Richard B.

    1974-01-01

    Describes Project Biotech, a program that utilizes the audio-tutorial principle to develop skill-oriented modules. The modules are self-pacing, independent units of instruction which concentrate on a few well-defined objectives and allow the student to learn at his own rate with minimal supervision. (PB)

  10. Combining Instructionist and Constructionist Learning in a Virtual Biotech Lab.

    Science.gov (United States)

    Dawabi, Peter; Wessner, Martin

    The background of this paper is an internal research project at the German National Research Center for Information Technology, Integrated Publication and Information Systems Institute, (GMD-IPSI) dealing with software engineering, computer-supported cooperative learning (CSCL) and practical biotech knowledge. The project goal is to develop a…

  11. Impact of America Invents Act on Biotech Intellectual Property.

    Science.gov (United States)

    Murphy, Amanda; Stramiello, Michael; Stroud, Jonathan; Lewis, Stacy; Irving, Tom

    2015-04-27

    This review introduces the America Invents Act (AIA), a comprehensive reform of U.S. law on patentability and patent enforceability that Congress enacted in 2011. The AIA's most publicized change transforms the United States from a "first-to-invent" system to a "first-inventor-to-file" regime, bringing U.S. patent law more in line with the patent systems of nearly every other industrialized country in the world. This new system requires small companies and independent inventors to toe the line against larger competitors in what many have called a "race to the patent office." But a closer look at the AIA reveals several opportunities for smaller entities that may even the playing field, particularly for innovators in the biotech sector. This article addresses changes that the AIA brings to U.S. patent law, keeping an eye toward issues relevant to biotech companies.

  12. Industry progress report on neuro-oncology: Biotech update 2013.

    Science.gov (United States)

    Ottenhausen, Malte; Bodhinayake, Imithri; Banu, Matei; Kesavabhotla, Kartik; Ray, Ashley; Boockvar, John A

    2013-11-01

    For the second time, The Brain Tumor Center of the Weill Cornell Brain and Spine Center, in collaboration with Voices Against Brain Cancer, hosted The Brain Tumor Biotech Summit in New York City in June 2013. After a very successful first summit in 2012, this innovative event has established a platform for intensive networking between neuro-oncologists, neurosurgeons, neuroscientists, members of the biotechnology and pharmaceutical communities, members of the financial community and leaders of non-profit organizations. This year's summit highlighted dendritic cell vaccines, novel antibody, heat shock protein and targeted therapies as well as exosome technologies, MRI-guided therapies and other novel drug delivery tools. This report presents a short overview of the current progress in brain tumor research and therapy as presented at the 2013 Brain Tumor Biotech Summit.

  13. Ethical reasons for narrowing the scope of biotech patents.

    Science.gov (United States)

    Andreassen, Tom

    2015-11-01

    Patents on biotech products have a scope that goes well beyond what is covered by the most widely applied ethical justifications of intellectual property. Neither natural rights theory from Locke, nor public interest theory of IP rights justifies the wide scope of legal protection. The article takes human genes as an example, focusing on the component that is not invented but persists as unaltered gene information even in the synthetically produced complementary DNA, the cDNA. It is argued that patent on cDNA holds this information captive, or illegitimately appropriates it in limiting other researchers and inventors' opportunity to explore new functions and uses based on this non-invented information. A tighter connection between legal IP protection and the use description stated in the patent claim is suggested. By binding protection to the product's foreseeable functions and use, instead of the product itself and all future uses of it, legitimacy of biotech product patents is restored.

  14. Development of polymeric drug delivery systems for biotech products

    OpenAIRE

    Pasqualin, Matteo

    2013-01-01

    Since the early 80’s the forward steps in genetics and proteomics, have led a particular interest to biotech products, such as DNA and proteins. Although difficult, their large-scale production enabled the therapeutic use of this compounds. Proteins and DNA sequences can be very interesting therapeutic molecules owing to their high selectivity/affinity for the receptor or the specific site of action. Unfortunately, some issues still limit their pharmaceutical use, such as the susceptibilit...

  15. Production and Price Impact of Biotech Crops, The

    OpenAIRE

    Graham Brookes; Tun-Hsiang (Edward) Yu; Simla Tokgoz; Amani Elobeid

    2010-01-01

    Biotech crops have now been grown commercially on a substantial global scale since 1996. This paper examines the production effects of the technology and impacts on cereal and oilseed markets through the use of agricultural commodity models. It analyses the impacts on global production, consumption, trade and prices in the soybean, canola and corn sectors. The analysis suggests that world prices of corn, soybeans and canola would probably be, respectively, 5.8%, 9.6% and 3.8% higher, on avera...

  16. The path- and place-dependent nature of scientific knowledge production in biotech 1986-2008

    OpenAIRE

    Gaston Heimeriks; Ron Boschma

    2012-01-01

    This study explores the worldwide spatial evolution of scientific knowledge production in biotechnology in the period 1986-2008. We employ new methodology that identifies new key topics in biotech on the basis of frequent use of title worlds in major biotech journals as an indication of new cognitive developments within this scientific field. Our analyses show that biotech is subject to a path- and place-dependent process of knowledge production. We observed a high degree of re-occurrences of...

  17. Biotech in medicine--the topic of the Olten Meeting 2010.

    Science.gov (United States)

    Heinzelmann, Elsbeth

    2011-01-01

    Since 1998, the biotechnet--the national network of competence in biotech research--has been helping partners from industry to access excellence in R&D, giving them optimal support at low cost. Its annual 'Olten Meeting' is a dynamic hub for companies and research institutes as it highlights the latest trends in biotech. On November 24, 2010, the topical subject was biotech in medicine.

  18. Pharmacokinetics of biotech drugs: peptides, proteins and monoclonal antibodies.

    Science.gov (United States)

    Lin, Jiunn H

    2009-09-01

    With the advances in recombinant DNA biotechnology, molecular biology and immunology, the number of biotech drugs, including peptides, proteins and monoclonal antibodies, available for clinical use has dramatically increased in recent years. Although pharmacokinetic principles are equally applicable to the large molecule drugs and conventional small molecule drugs, the underlying mechanisms for the processes of absorption, distribution, metabolism and excretion (ADME) of large molecule drugs are often very different from that of small molecule drugs. Therefore, a good understanding of the ADME processes of large molecule drugs is essential in support of the development of therapeutic biologics. The purpose of this article is to review the current knowledge of the ADME processes that govern the pharmacokinetics of biotech drugs. The challenges encountered by orally administered peptide and protein drugs, and the nature of lymphatic absorption after subcutaneous administration will be discussed. In addition, molecular mechanisms of biodistribution, metabolism and renal excretion of biotech drugs will also be discussed. Finally, approaches used for prediction of human pharmacokinetics of protein drugs will be briefly discussed.

  19. Industry progress report on neuro-oncology: a biotech update.

    Science.gov (United States)

    Haber, Jessica S; Banu, Matei A; Ray, Ashley; Kesavabhotla, Kartik; Boockvar, John A

    2013-04-01

    With steadily rising revenue and large numbers of clinical trials utilizing novel treatment strategies, the field of neuro-oncology is at the core of the growing cancer therapy industry. In June 2012, the Weill Cornell Brain and Tumor Center hosted the first Brain Tumor Biotech Summit as a forum for fostering and encouraging collaboration between researches and investors to accelerate novel treatments for brain cancer. This event brought together neuro-oncologists, neurosurgeons, academicians, entrepreneurs, non-profits, CEOs and investors in an attempt to bring innovative treatments and concepts to the fore. Specific subjects presented at the meeting included new surgical devices and delivery techniques, targeted therapeutics, immunotherapy, and stem cell biology. The mission of the summit was to provide opportunities for researchers in neuro-oncology to directly interact with leaders from the investment community with insight into the commercial aspects of our work. Our shared goal is to shorten the time for basic science ideas to be translated into the clinical setting. The following serves as a progress report on the biotech industry in neuro-oncology, as presented at the Brain Tumor Biotech Summit.

  20. Social Network Analysis of the Irish Biotech Industry: Implications for Digital Ecosystems

    Science.gov (United States)

    van Egeraat, Chris; Curran, Declan

    This paper presents an analysis of the socio-spatial structures of innovation, collaboration and knowledge flow among SMEs in the Irish biotech sector. The study applies social network analysis to determine the structure of networks of company directors and inventors in the biotech sector. In addition, the article discusses the implications of the findings for the role and contours of a biotech digital ecosystem. To distil these lessons, the research team organised a seminar which was attended by representatives of biotech actors and experts.

  1. Deutsche Biotech-Unternehmen und ihre Innovationsfähigkeit im internationalen Vergleich : eine institutionentheoretische Analyse

    NARCIS (Netherlands)

    Lange, K.S.G.

    2006-01-01

    German Biotech-Companies and their Innovativeness in International Comparison – an Institutionalist Analysis 1 Introduction In the mid-1990s, legal changes and policy initiatives in Germany led to the rapid emergence of a biotechnology industry. Initially, German biotech companies focused on the mar

  2. The path- and place-dependent nature of scientific knowledge production in biotech 1986-2008

    NARCIS (Netherlands)

    Heimeriks, G.J.; Boschma, R.

    2013-01-01

    This study explores the worldwide spatial evolution of scientific knowledge production in biotechnology in the period 1986–2008. We employ new methodology that identifies new key topics in biotech on the basis of frequent use of title worlds in major biotech journals as an indication of new cognitiv

  3. The path- and place-dependent nature of scientific knowledge production in biotech 1986-2008

    NARCIS (Netherlands)

    Heimeriks, Gaston; Boschma, Ron

    2014-01-01

    This study explores the worldwide spatial evolution of scientific knowledge production in biotechnology in the period 1986-2008. We employ new methodology that identifies new key topics in biotech on the basis of frequent use of title worlds in major biotech journals as an indication of new cognitiv

  4. 77 FR 10598 - BIOTECH Holdings Ltd., California Oil & Gas Corp., Central Minera Corp., Chemokine Therapeutics...

    Science.gov (United States)

    2012-02-22

    ... From the Federal Register Online via the Government Publishing Office SECURITIES AND EXCHANGE COMMISSION BIOTECH Holdings Ltd., California Oil & Gas Corp., Central Minera Corp., Chemokine Therapeutics... concerning the securities of BIOTECH Holdings Ltd. because it has not filed any annual reports since...

  5. State Incentives for Innovation, Star Scientists, and Jobs: Evidence from Biotech. Upjohn Institute Working Paper No. 14-203

    Science.gov (United States)

    Moretti, Enrico; Wilson, Daniel J.

    2013-01-01

    We evaluate the effects of state-provided financial incentives for biotech companies, which are part of a growing trend of placed-based policies designed to spur innovation clusters. We estimate that the adoption of subsidies for biotech employers by a state raises the number of star biotech scientists in that state by about 15 percent over a…

  6. A global overview of biotech (GM) crops: adoption, impact and future prospects.

    Science.gov (United States)

    James, Clive

    2010-01-01

    In the early 1990s, some were skeptical that genetically modified (GM) crops, now referred to as biotech crops, could deliver improved products and make an impact at the farm level. There was even more skepticism that developing countries would adopt biotech crops. The adoption of and commercialization of biotech crops in 2008 is reviewed. The impact of biotech crops are summarized including their contribution to: global food, feed and fiber security; a safer environment; a more sustainable agriculture; and the alleviation of poverty, and hunger in the developing countries of the world. Future prospects are discussed. Notably, Egypt planted Bt maize for the first time in 2008 thereby becoming the first country in the Arab world to commercialize biotech crops.

  7. Chemometrics applications in biotech processes: assessing process comparability.

    Science.gov (United States)

    Bhushan, Nitish; Hadpe, Sandip; Rathore, Anurag S

    2012-01-01

    A typical biotech process starts with the vial of the cell bank, ends with the final product and has anywhere from 15 to 30 unit operations in series. The total number of process variables (input and output parameters) and other variables (raw materials) can add up to several hundred variables. As the manufacturing process is widely accepted to have significant impact on the quality of the product, the regulatory agencies require an assessment of process comparability across different phases of manufacturing (Phase I vs. Phase II vs. Phase III vs. Commercial) as well as other key activities during product commercialization (process scale-up, technology transfer, and process improvement). However, assessing comparability for a process with such a large number of variables is nontrivial and often companies resort to qualitative comparisons. In this article, we present a quantitative approach for assessing process comparability via use of chemometrics. To our knowledge this is the first time that such an approach has been published for biotech processing. The approach has been applied to an industrial case study involving evaluation of two processes that are being used for commercial manufacturing of a major biosimilar product. It has been demonstrated that the proposed approach is able to successfully identify the unit operations in the two processes that are operating differently. We expect this approach, which can also be applied toward assessing product comparability, to be of great use to both the regulators and the industry which otherwise struggle to assess comparability.

  8. Can science be a business? Lessons from biotech.

    Science.gov (United States)

    Pisano, Gary P

    2006-10-01

    In 1976, Genentech, the first biotechnology company, was founded by a young venture capitalist and a university professor to exploit recombinant DNA technology. Thirty years and more than 300 billion dollars in investments later, only a handful of biotech firms have matched Genentech's success or even shown a profit. No avalanche of new drugs has hit the market, and the long-awaited breakthrough in R&D productivity has yet to materialize. This disappointing performance raises a question: Can organizations motivated by the need to make profits and please shareholders successfully conduct basic scientific research as a core activity? The question has largely been ignored, despite intense debate over whether business's invasion of basic science-long the domain of universities and nonprofit research institutions- is limiting access to discoveries, thereby slowing advances in science. Biotech has not lived up to its promise, says the author, because its anatomy, which has worked well in other high-tech sectors, can't handle the fundamental challenges facing drug R&D: profound, persistent uncertainty and high risks rooted in the limited knowledge of human biology; the need for the diverse disciplines involved in drug discovery to work together in an integrated fashion; and barriers to learning, including tacit knowledge and murky intellectual property rights, which can slow the pace of scientific advance. A more suitable anatomy would include increased vertical integration; a smaller number of closer, longer collaborations; an emphasis by universities on sharing rather than patenting scientific discoveries; more cross-disciplinary academic research; and more federal and private funding for translational research, which bridges basic and applied science. With such modifications, science can be a business. PMID:17040044

  9. Can science be a business? Lessons from biotech.

    Science.gov (United States)

    Pisano, Gary P

    2006-10-01

    In 1976, Genentech, the first biotechnology company, was founded by a young venture capitalist and a university professor to exploit recombinant DNA technology. Thirty years and more than 300 billion dollars in investments later, only a handful of biotech firms have matched Genentech's success or even shown a profit. No avalanche of new drugs has hit the market, and the long-awaited breakthrough in R&D productivity has yet to materialize. This disappointing performance raises a question: Can organizations motivated by the need to make profits and please shareholders successfully conduct basic scientific research as a core activity? The question has largely been ignored, despite intense debate over whether business's invasion of basic science-long the domain of universities and nonprofit research institutions- is limiting access to discoveries, thereby slowing advances in science. Biotech has not lived up to its promise, says the author, because its anatomy, which has worked well in other high-tech sectors, can't handle the fundamental challenges facing drug R&D: profound, persistent uncertainty and high risks rooted in the limited knowledge of human biology; the need for the diverse disciplines involved in drug discovery to work together in an integrated fashion; and barriers to learning, including tacit knowledge and murky intellectual property rights, which can slow the pace of scientific advance. A more suitable anatomy would include increased vertical integration; a smaller number of closer, longer collaborations; an emphasis by universities on sharing rather than patenting scientific discoveries; more cross-disciplinary academic research; and more federal and private funding for translational research, which bridges basic and applied science. With such modifications, science can be a business.

  10. Exploiting the business opportunities in biotech connections : The power of social networks

    OpenAIRE

    Salehi-Sangari, Esmail

    2007-01-01

    Networks have a well-established importance in business. Here network analysis, grounded in socialnetwork theory, is used to analyse two international biotech business-to-business environments. Ofadditional value, the methodology employed is described for the benefi t of academics and practitionersalike. Swedish and Australian biotech fi rms are analysed through the examination of internet networks.Once gathered and analysed following the described methodology, several features of the networks ...

  11. The Swiss biotech referendum: A case study of science communication

    International Nuclear Information System (INIS)

    On June 7 , 1998, the Swiss citizens voted on a constitutional amendment, which could have jeopardised the future of biotechnological research in Switzerland. Scientists and opinion leaders around the world expected the referendum with great anxiety. 'Nature', in an editorial, had firmly stated that the Swiss way showed 'how not to run a country', the 'Economist', a week prior to the referendum, had written that the Swiss might be the only people in the world who decided on their own to forego a world class position in scientific research. In fact, the Swiss did none of that. They rejected the constitutional amendment with an overwhelming majority of 67 per cent of the votes, and what started out as a dramatic threat to scientific research in Switzerland became a platform in favour of modern biotechnology. The presentation addresses some of the key features of the Swiss biotech campaign, analyses the success factors of the campaign, provides an insight in the most in-depth collection of data on public perception of biotechnology in the world, and draws conclusions as to what extent the Swiss experience can be of use in the way to communicate on modem science. The result of the Swiss referendum has convincingly shown that successful communication of modem science is possible if - scientists, authorities, and the industry accept the challenge to cope with the demands of communicating with the public at large, - there is a clear understanding that the public's needs may often be based on psychological rather than on logic scientific reasons, - all participants in the dialogue are willing to forego scientific jargon for clear understandable language, i.e. understand that it is hardly the public's fault if messages do not get across, - everybody accepts that dialogue, information, and education on modem science is a long-haul task. The Swiss biotech referendum was seen as a major threat to Switzerland as a leading country of scientific research. However, something which

  12. Poor States Urged to Research Biotech, Fight Hunger

    Institute of Scientific and Technical Information of China (English)

    David; Brough; 柯善雪

    2002-01-01

    夜读此文,既兴奋,又悲凉。兴奋,是因为千百年来,人们靠天吃饭,地里的活,种瓜得瓜,种豆得豆。得多少,并非“大跃进”可以吹出来的,而是有一个常规,种地能手,能超出常规亩产20%,已有登天之难。而如今,植物的遗传工程(genetic engineering of plants)令世人一惊:It can improve crop yields and develop resis-tance to drought(干旱),salinity(盐份)and pests(害虫)。Biotechnology is also used todevelop drugs to treat diseases such as diabetes and hepatitis(肝炎);悲凉的是,这些专利正紧锁于富国的保险柜中待价而沽:The big biotech companies are locking uppatents at an incredible(难以置信的)rate!其另一个借口是:The full impact of thesenew life sciences on health and the environment is not known。 本文末尾的一句话又让我们另有想法: Biotechnology is by no means the only answer to the problem of hunger as the words already producing more food than it needs。】

  13. 3D-BioPrinting: The future of Red Biotech

    International Nuclear Information System (INIS)

    Every day Science moves little steps forward, contributing to the progress of our society. Sometimes, however, a single invention revolutionizes the world. Indeed, the invention of woodblock printing and development of industrial-scale printing-press in the 15. century have changed our society. 3D-printing is now boosting another revolution. The production of custom-made objects from a virtual model will trigger a rapid development of a more versatile, less expensive manufacturing sector for the on-demand market. The real revolution, however, is represented by 3D-printing in biomedicine. 3D-bioprinting represents the future of the Red-Biotech. This technology, indeed, will be able to build ex-novo organs using biocompatible materials and human cells; replace the allograft transplants, eliminating waiting lists that often make the difference between life and death; and provide more predictive, less expensive experimental models, replacing animal tests. The high innovation content of this technology, can make the difference between being obsolete and new

  14. Where is the biotech industry in China headed to?%中国生物技术产生的发展方向

    Institute of Scientific and Technical Information of China (English)

    苏慰国

    2009-01-01

    @@ 2008 was a year marked with changes and turns for biotech industry in China. 2008 began with tremendous promises riding on the waves of a history-making, exceptionally strong year in 2007. However, the biotech industry in China was not immune to the macroeconomic changes during 2008. This report will attempt to examine changes and new trends in biotech industry in China.

  15. Trends in global approvals of biotech crops (1992-2014).

    Science.gov (United States)

    Aldemita, Rhodora R; Reaño, Ian Mari E; Solis, Renando O; Hautea, Randy A

    2015-01-01

    With the increasing number of genetically modified (GM) events, traits, and crops that are developed to benefit the global population, approval of these technologies for food, feed, cultivation and import in each country may vary depending on needs, demand and trade interest. ISAAA established a GMO Approval Database to document global approvals of biotech crops. GM event name, crops, traits, developer, year of approval for cultivation, food/feed, import, and relevant dossiers were sourced from credible government regulatory websites and biosafety clearinghouses. This paper investigates the trends in GM approvals for food, feed and cultivation based on the number of approving countries, GM crops, events, and traits in the last 23 y (1992-2014), rationale for approval, factors influencing approvals, and their implications in GM crop adoption. Results show that in 2014, there was an accumulative increase in the number of countries granting approvals at 29 (79% developing countries) for commercial cultivation and 31 (70% developing countries) for food and 19 (80% developing developing) for feed; 2012 had the highest number of approving countries and cultivation approvals; 2011 had the highest number of country approvals for feed, and 2014 for food approvals. Herbicide tolerance trait had the highest events approved, followed by insect tolerance traits. Approvals for food product quality increased in the second decade. Maize had the highest number of events approved (single and stacked traits), and stacked traits product gradually increased which is already 30% of the total trait approvals. These results may indicate understanding and acceptance of countries to enhance regulatory capability to be able to benefit from GM crop commercialization. Hence, the paper provided information on the trends on the growth of the GM crop industry in the last 23 y which may be vital in predicting future GM crops and traits. PMID:26039675

  16. Trends in global approvals of biotech crops (1992-2014).

    Science.gov (United States)

    Aldemita, Rhodora R; Reaño, Ian Mari E; Solis, Renando O; Hautea, Randy A

    2015-01-01

    With the increasing number of genetically modified (GM) events, traits, and crops that are developed to benefit the global population, approval of these technologies for food, feed, cultivation and import in each country may vary depending on needs, demand and trade interest. ISAAA established a GMO Approval Database to document global approvals of biotech crops. GM event name, crops, traits, developer, year of approval for cultivation, food/feed, import, and relevant dossiers were sourced from credible government regulatory websites and biosafety clearinghouses. This paper investigates the trends in GM approvals for food, feed and cultivation based on the number of approving countries, GM crops, events, and traits in the last 23 y (1992-2014), rationale for approval, factors influencing approvals, and their implications in GM crop adoption. Results show that in 2014, there was an accumulative increase in the number of countries granting approvals at 29 (79% developing countries) for commercial cultivation and 31 (70% developing countries) for food and 19 (80% developing developing) for feed; 2012 had the highest number of approving countries and cultivation approvals; 2011 had the highest number of country approvals for feed, and 2014 for food approvals. Herbicide tolerance trait had the highest events approved, followed by insect tolerance traits. Approvals for food product quality increased in the second decade. Maize had the highest number of events approved (single and stacked traits), and stacked traits product gradually increased which is already 30% of the total trait approvals. These results may indicate understanding and acceptance of countries to enhance regulatory capability to be able to benefit from GM crop commercialization. Hence, the paper provided information on the trends on the growth of the GM crop industry in the last 23 y which may be vital in predicting future GM crops and traits.

  17. Detection methods for biotech cotton MON 15985 and MON 88913 by PCR.

    Science.gov (United States)

    Lee, Seong-Hun; Kim, Jin-Kug; Yi, Bu-Young

    2007-05-01

    Plants derived through agricultural biotechnology, or genetically modified organisms (GMOs), may affect human health and ecological environment. A living GMO is also called a living modified organism (LMO). Biotech cotton is a GMO in food or feed and also an LMO in the environment. Recently, two varieties of biotech cotton, MON 15985 and MON 88913, were developed by Monsanto Co. The detection method is an essential element for the GMO labeling system or LMO management of biotech plants. In this paper, two primer pairs and probes were designed for specific amplification of 116 and 120 bp PCR products from MON 15985 and MON 88913, respectively, with no amplification from any other biotech cotton. Limits of detection of the qualitative method were all 0.05% for MON 15985 and MON 88913. The quantitative method was developed using a TaqMan real-time PCR. A synthetic plasmid, as a reference molecule, was constructed from a taxon-specific DNA sequence of cotton and two construct-specific DNA sequences of MON 15985 and MON 88913. The quantitative method was validated using six samples that contained levels of biotech cotton mixed with conventional cotton ranging from 0.1 to 10.0%. As a result, the biases from the true value and the relative deviations were all within the range of +/-20%. Limits of quantitation of the quantitative method were all 0.1%. Consequently, it is reported that the proposed detection methods were applicable for qualitative and quantitative analyses for biotech cotton MON 15985 and MON 88913.

  18. Parameters of Regional Cooperative Behavior in the German Biotech Industry – A Quantitative Social Network Analysis

    DEFF Research Database (Denmark)

    Mitze, Timo; Strotebeck, Falk

    We analyse the determinants of network formation in Germany’s biotechnology industry using social network analysis combined with a regression approach for count data. Outcome variable of interest is the degree centrality of German regions, which is specified as a function of the region’s innovative...... and economic performance as well as biotech-related policy variables. The inclusion of the latter allows us to shed new light on the question to what extent R&D-based cluster policies are able to impact on the formation of the German biotech network. Our results show that policy indicators such as the volume...

  19. Biotech/GM crops in horticulture: plum cv. HoneySweet resistant to plum pox virus

    Science.gov (United States)

    Commercialization of Biotech crops started in 1995. By 2011, genetically modified (GM) crops were grown world-wide on 160 million ha. Only 114.507 ha of GM crops were grown in Europe, of that, 114.490 ha were Bt maize and 17 ha were potato for industrial starch production. Currently, developing c...

  20. How Is Corporate Social Responsibility Addressed by Biotech Firms? a Case Study Analysis

    Science.gov (United States)

    Pérez-Bustamante, Guillermo

    2013-01-01

    This paper explores corporate social responsibility (CSR) in the biotech high-tech sector as a way to achieve competitive advantages. After presenting the importance of science for high-tech firms, the paper focuses on the social and economic role of CSR. Next, the primary reasons for firms' engagement in CSR activities are presented,…

  1. 76 FR 42682 - China Biotech Life Sciences Trade Mission-Clarification and Amendment

    Science.gov (United States)

    2011-07-19

    ... publishing this supplement to the Notice of the Biotech Life Science Trade Mission to China, 76 FR 17,621..., 76 FR 17621, Mar. 30, 2011, are revised to read October 14-18, 2011. In addition, revise the Proposed... Trade Mission to China, 76 FR 17,621, Mar. 30, 2011, is amended to read as follows: Timeframe...

  2. Does Cluster Policy Trigger R&D Activity? – Evidence from German Biotech Contests

    DEFF Research Database (Denmark)

    Engel, Dirk; Mitze, Timo; Patuelli, Roberto;

    in research clusters. We apply a Difference-in-Differences estimation technique in a generalized linear model framework, which allows us to control for different initial regional conditions in R&D activity of the biotech sector. Our econometric findings support the view that winners generally outperform non...

  3. The written description rejection as a barrier to biotech patent prosecution.

    Science.gov (United States)

    Wang, Shyh-Jen

    2011-05-01

    Biotech firms always pursue broad claims to secure new discoveries, new technologies and even as yet undiscovered results of future research. However, expansive claims without sufficient description violate the principal of granting the patentee the right to exclude others from using the technical development for a certain amount of time in return for disclosing the innovation. Based on this investigation, a written description can be a barrier to biotech patents with broad claims. To avoid a written description rejection during patent prosecution or invalidation in litigation, the patent applicant or assignee should demonstrate possession of the claimed invention by describing the claimed invention with all of its limitations using descriptive means such as words, structures, figures, diagrams, and formulas that fully set forth the claimed invention. Although the court cases analyzed in this study were not directly related to vaccines, the guideline indeed is applicable to patents of vaccine. Furthermore, a vaccine patent application is also demonstrated. PMID:21552000

  4. Knowledge management in the QbD paradigm: manufacturing of biotech therapeutics.

    Science.gov (United States)

    Herwig, Christoph; Garcia-Aponte, Oscar F; Golabgir, Aydin; Rathore, Anurag S

    2015-07-01

    In the quality by design (QbD) paradigm, global regulatory agencies have introduced the concepts of quality risk management and knowledge management (KM) as enablers for an enhanced pharmaceutical quality system. Although the concept of quality risk management has been well elucidated in the literature, the topic of KM has received relatively scant attention. In this paper we present an opinion on KM in the QbD paradigm as it relates to the manufacturing of biotech therapeutic products. Both academic and industrial viewpoints have been considered and key gaps have been elucidated. The authors conclude that there is an urgent need for the biotech industry to create efficient KM approaches if they wish to be successful in QbD implementation. PMID:25980924

  5. Knowledge management in the QbD paradigm: manufacturing of biotech therapeutics.

    Science.gov (United States)

    Herwig, Christoph; Garcia-Aponte, Oscar F; Golabgir, Aydin; Rathore, Anurag S

    2015-07-01

    In the quality by design (QbD) paradigm, global regulatory agencies have introduced the concepts of quality risk management and knowledge management (KM) as enablers for an enhanced pharmaceutical quality system. Although the concept of quality risk management has been well elucidated in the literature, the topic of KM has received relatively scant attention. In this paper we present an opinion on KM in the QbD paradigm as it relates to the manufacturing of biotech therapeutic products. Both academic and industrial viewpoints have been considered and key gaps have been elucidated. The authors conclude that there is an urgent need for the biotech industry to create efficient KM approaches if they wish to be successful in QbD implementation.

  6. The written description rejection as a barrier to biotech patent prosecution.

    Science.gov (United States)

    Wang, Shyh-Jen

    2011-05-01

    Biotech firms always pursue broad claims to secure new discoveries, new technologies and even as yet undiscovered results of future research. However, expansive claims without sufficient description violate the principal of granting the patentee the right to exclude others from using the technical development for a certain amount of time in return for disclosing the innovation. Based on this investigation, a written description can be a barrier to biotech patents with broad claims. To avoid a written description rejection during patent prosecution or invalidation in litigation, the patent applicant or assignee should demonstrate possession of the claimed invention by describing the claimed invention with all of its limitations using descriptive means such as words, structures, figures, diagrams, and formulas that fully set forth the claimed invention. Although the court cases analyzed in this study were not directly related to vaccines, the guideline indeed is applicable to patents of vaccine. Furthermore, a vaccine patent application is also demonstrated.

  7. Which Model of Technology Transfer for Nanotechnology? A Comparison with Biotech and Microelectronics

    OpenAIRE

    Genet, Corine; Errabi, Khalid; Gauthier, Caroline

    2012-01-01

    International audience Nanotechnologies are often presented as breakthrough innovations, where technology transfer and knowledge-bridging will play a pivotal role in the industrial dynamics. This article investigates the model of knowledge transfer in the nanotechnologies in depth, by comparing it with the models of two recently emerged technologies: biotech and microelectronics. Our results show that the nanotechnology transfer model is very different from that involved in biotechnology e...

  8. The Effects of Information on Consumer Demand for Biotech Foods: Evidence from Experimental Auctions

    OpenAIRE

    Tegene, Abebayehu; Huffman, Wallace E; Rousu, Matthew C.; Shogren, Jason F.

    2003-01-01

    Consumers' willingness to pay for food products decreases when the food label indicates that a food product is produced with the aid of modern biotechnology. This bulletin presents empirical evidence on consumers' willingness to pay for biotech foods based on the presence or absence of labels advising that the food was prepared with the aid of biotechnology. The authors designed and conducted an experimental auction to elicit consumers' willingness to pay for "genetically modified" (GM)-label...

  9. Role of R&D alliances in Pharma-Biotech Industry Case study of Indian Industry

    OpenAIRE

    Hanzra, Inderpreet Kaur

    2007-01-01

    In today's intensely competitive business milieu, pharmaceutical companies are increasing their product pipelines by both developing drugs on their own and also by R&D alliances. This study attempts to understand the importance and need of R&D alliances in pharmaceutical and biotech industry. Declining product pipelines and astringent patent law across the world are bothering the companies and they are relying on strategic alliances to speed up the process of innovation. Strategic alliances a...

  10. NTN Swiss Biotech - A Look at Support Measures for Dynamic Start-ups.

    Science.gov (United States)

    Heinzelmann, Elsbeth

    2016-01-01

    The Swiss biotech landscape seems to be on a healthy footing: There are many imaginative start-ups, we have first-class hospitals, highly advanced clinical research and the availability of a great deal of capital. But we have no reason to rest on our laurels as countries like the USA lead the field. We must lay down the tracks today to remain an attractive country and maintain our ranking among the 10 best locations.

  11. Simplex and duplex event-specific analytical methods for functional biotech maize.

    Science.gov (United States)

    Lee, Seong-Hun; Kim, Su-Jeong; Yi, Bu-Young

    2009-08-26

    Analytical methods are very important in the control of genetically modified organism (GMO) labeling systems or living modified organism (LMO) management for biotech crops. Event-specific primers and probes were developed for qualitative and quantitative analysis for biotech maize event 3272 and LY 038 on the basis of the 3' flanking regions, respectively. The qualitative primers confirmed the specificity by a single PCR product and sensitivity to 0.05% as a limit of detection (LOD). Simplex and duplex quantitative methods were also developed using TaqMan real-time PCR. One synthetic plasmid was constructed from two taxon-specific DNA sequences of maize and two event-specific 3' flanking DNA sequences of event 3272 and LY 038 as reference molecules. In-house validation of the quantitative methods was performed using six levels of mixing samples, from 0.1 to 10.0%. As a result, the biases from the true value and the relative deviations were all within the range of +/-30%. Limits of quantitation (LOQs) of the quantitative methods were all 0.1% for simplex real-time PCRs of event 3272 and LY 038 and 0.5% for duplex real-time PCR of LY 038. This study reports that event-specific analytical methods were applicable for qualitative and quantitative analysis for biotech maize event 3272 and LY 038.

  12. Biotech crops: imperative for achieving the millenium development goals and sustainability of agriculture in the climate change era.

    Science.gov (United States)

    Husaini, Amjad M; Tuteja, Narendra

    2013-01-01

    Biotechnological intervention in the development of crops has opened new vistas in agriculture. Central to the accomplishment of the Millennium Development Goals (MDGs), biotech-agriculture is essential in meeting these targets. Biotech crops have already made modest contributions toward ensuring food and nutrition security by reducing losses and increasing productivity, with less pesticide input. These crops could help address some of the major challenges in agriculture-based economies created by climate change. Projections of global climate change expect the concentration of greenhouse gases to increase, aridization of the environment to increase, temperature fluctuations to occur sharply and frequently, and spatial and temporal distribution of rainfall to be disturbed-all of which will increase abiotic stress-related challenges to crops. Countering these challenges and to meet the food requirement of the ever-increasing world population (expected to reach 9 billion by 2030) we need to (1) develop and use biotech crops for mitigating adverse climatic changes; (2) develop biotech crops resilient to adverse environmental conditions; and (3) address the issues/non-issues raised by NGO's and educate the masses about the benefits of biotech crops.

  13. Safety assessment of nonbrowning potatoes: opening the discussion about the relevance of substantial equivalence on next generation biotech crops.

    Science.gov (United States)

    Llorente, Briardo; Alonso, Guillermo D; Bravo-Almonacid, Fernando; Rodríguez, Vanina; López, Mariana G; Carrari, Fernando; Torres, Héctor N; Flawiá, Mirtha M

    2011-02-01

    It is expected that the next generation of biotech crops displaying enhanced quality traits with benefits to both farmers and consumers will have a better acceptance than first generation biotech crops and will improve public perception of genetic engineering. This will only be true if they are proven to be as safe as traditionally bred crops. In contrast with the first generation of biotech crops where only a single trait is modified, the next generation of biotech crops will add a new level of complexity inherent to the mechanisms underlying their output traits. In this study, a comprehensive evaluation of the comparative safety approach on a quality-improved biotech crop with metabolic modifications is presented. Three genetically engineered potato lines with silenced polyphenol oxidase (Ppo) transcripts and reduced tuber browning were characterized at both physiological and molecular levels and showed to be equivalent to wild-type (WT) plants when yield-associated traits and photosynthesis were evaluated. Analysis of the primary metabolism revealed several unintended metabolic modifications in the engineered tubers, providing evidence for potential compositional inequivalence between transgenic lines and WT controls. The silencing construct sequence was in silico analysed for potential allergenic cross-reactivity, and no similarities to known allergenic proteins were identified. Moreover, in vivo intake safety evaluation showed no adverse effects in physiological parameters. Taken together, these results provide the first evidence supporting that the safety of next generation biotech crops can be properly assessed following the current evaluation criterion, even if the transgenic and WT crops are not substantially equivalent.

  14. The income and production effects of biotech crops globally 1996-2010.

    Science.gov (United States)

    Brookes, Graham; Barfoot, Peter

    2012-01-01

    A critical feature in evaluating the global value of crop biotechnology in agriculture must include an assessment of its economic impact at the farm level. This paper follows earlier studies which examined economic impacts on yields, key costs of production, direct farm income, indirect (non-pecuniary) farm level income effects and impacts on the production base of the four main crops of soybeans, corn, cotton and canola. The commercialization of biotech crops is continuing to proceed rapidly, with significant changes in the overall level of adoption and impact taking place in 2010. This updated analysis shows that there have been substantial net economic benefits at the farm level amounting to $14 billion in 2010 and $78.4 billion for the 15-year period (in nominal terms). The non-pecuniary benefits associated with the use of the technology have also had a positive impact on adoption (in the US accounting for the equivalent of 22% of the total US direct farm income benefit). Biotech crops are, moreover, making important contributions to increasing global production levels of the four main crops. They have, for example, now added 97.5 million tons and 159 million tons respectively, to the global production of soybeans and corn since the introduction of the technology in the mid-1990s.

  15. Intuitive Expertise and Empowerment: The Long-Term Impact of Simulation Training on Changing Accountabilities in a Biotech Firm

    Science.gov (United States)

    DiBello, Lia; Missildine, Whit; Struttman, Marie

    2009-01-01

    This paper describes a two-year study in which high levels of performance were achieved and sustained among so-called low-level workers in a biotech company. The purpose of the study--funded by National Science Foundation and lnvitrogen Corporation--were to explore the effectiveness of an accelerated learning Operational Simulation (OpSim)…

  16. Quality Control and Performance of HIV Rapid Tests in a Microbicide Clinical Trial in Rural KwaZulu-Natal

    OpenAIRE

    Nina von Knorring; Mitzy Gafos; Motsei Ramokonupi; Ute Jentsch

    2012-01-01

    Background Quality control (QC) and evaluation of HIV rapid test procedures are an important aspect of HIV prevention trials. We describe QC and performance of two rapid tests, Determine™ and Uni-Gold™ used in a microbicide clinical trial in rural KwaZulu-Natal, South Africa. Methods/Results Internal QC of both HIV rapid tests was conducted at the trial site using a Uni-Gold control kit (Uni-Gold™Recombigen® HIV). Both assays produced the expected results for a total of 4637 QC tes...

  17. The industrial application requirement for biotech inventions in light of recent EPO & UK case law:

    DEFF Research Database (Denmark)

    Minssen, Timo; Nilsson, David

    2012-01-01

    In this study we illuminate and discuss the most recent developments in respect of the interpretation of the “industrial application” requirement with respect to gene and protein related inventions in Europe. The analysis will focus on the relevant provisions of the EPC and decisional practice from...... discussion, we will elaborate on two issues in particular; (i) determine which types of qualities an invention should have in order to meet the industrial application requirement in the first place; and (ii) what type of evidence an applicant is expected to present in respect of (potential) applications......-depth background, and maybe repetition for some readers, as to why the industrial application requirement raises particular concerns and questions in respect of biotech inventions....

  18. BIOTECH CHINA 2007新闻发布会在沪举行

    Institute of Scientific and Technical Information of China (English)

    2007-01-01

    本着“整合资源,培育品牌,多方受益”的原则,世博集团上海现代国际展览有限公司、上海科技会展有限公司和德国汉诺威展览公司将在2007年7月4-6日联手推出“2007中国国际生物技术和仪器设备博览会。(BIOTECH CHINA 2007),三大展览公司携手打造的此次展会预计展出面积6000m2。

  19. Implementing quality by design for biotech products: Are regulators on track?

    Science.gov (United States)

    Luciani, Francesca; Galluzzo, Sara; Gaggioli, Andrea; Kruse, Nanna Aaby; Venneugues, Pascal; Schneider, Christian K; Pini, Carlo; Melchiorri, Daniela

    2015-01-01

    Quality by design (QbD) is an innovative approach to drug development that has started to be implemented into the regulatory framework, but currently mainly for chemical drugs. The recent marketing authorization of the first monoclonal antibody developed using extensive QbD concepts in the European Union paves the way for future further regulatory approvals of complex products employing this cutting-edge technological concept. In this paper, we report and comment on insights and lessons learnt from the non-public discussions in the European Medicines Agency's Biologicals Working Party and Committee for Medicinal Products for Human Use on the key issues during evaluation related to the implementation of an extensive QbD approach for biotechnology-derived medicinal products. Sharing these insights could prove useful for future developments in QbD for biotech products in general and monoclonal antibodies in particular.

  20. Capacity optimization and scheduling of a multiproduct manufacturing facility for biotech products.

    Science.gov (United States)

    Shaik, Munawar A; Dhakre, Ankita; Rathore, Anurag S; Patil, Nitin

    2014-01-01

    A general mathematical framework has been proposed in this work for scheduling of a multiproduct and multipurpose facility involving manufacturing of biotech products. The specific problem involves several batch operations occurring in multiple units involving fixed processing time, unlimited storage policy, transition times, shared units, and deterministic and fixed data in the given time horizon. The different batch operations are modeled using state-task network representation. Two different mathematical formulations are proposed based on discrete- and continuous-time representations leading to a mixed-integer linear programming model which is solved using General Algebraic Modeling System software. A case study based on a real facility is presented to illustrate the potential and applicability of the proposed models. The continuous-time model required less number of events and has a smaller problem size compared to the discrete-time model.

  1. Science communication in policy making:A qualitative research about the motivation of academic biotech scientists to participate in policy making in Europe

    OpenAIRE

    Coumou, Hilde; van der Werf Kulichova, Z.; Wehrmann, C.; Osseweijer, P.

    2014-01-01

    Policy making regarding application of agricultural biotechnology has been controversial. This study investigates what determines the motivation of European biotech scientists to actively participate in policy making. To do this, a conceptual framework was developed based on the Theory of Planned Behavior. The framework was operationalized in semi-structured interviews with 17 European biotech scientists to collect data about their motivation to involve in GMO policy making. The results of th...

  2. Dynamics of center-periphery patterns in knowledge networks - the case of China's biotech science and technology system

    CERN Document Server

    Hennemann, Stefan; Liefner, Ingo

    2011-01-01

    Science and technology systems - and their epistemic communities - are usually hierarchical and composed of a number of strong, large, leading organizations, along with a number of smaller and less influential ones. Moreover, these hierarchical patterns have a spatial structure: the leading organizations are concentrated in a few places, creating a science and technology center, whereas the majority of locations are peripheral. In the example of biotech research in China, we found dynamic changes in center-periphery patterns. These results are based on a network analysis of evolving co-authorship networks from 2001 to 2009 that were built combining national and international databases. Therefore, our results are not only relevant for evaluating the spatial structure and dynamics in the Chinese biotech system and its integration into the global knowledge network, but also revive a discussion on persistence and processes of change in the systems theory for sciencebased industries.

  3. Trait stacking for biotech crops: an essential consideration for agbiotech development projects for building trust

    Directory of Open Access Journals (Sweden)

    Ezezika Obidimma C

    2012-05-01

    Full Text Available Abstract The development of agricultural biotechnology humanitarian projects for food security in the last five years has been rapid in developing countries and is expected to rise sharply over the coming years. An extremely critical issue in these projects involves building trust with the community and farmers they aim to serve. For the first time, our social audit engagement with one of these initiatives, the Water Efficient Maize for Africa project, has revealed that a critical but unrecognized component of building trust with farmers involves publicly addressing the concerns surrounding stacked trait crops. As a result, we argue in this article that it is critical to actively anticipate the concerns that could be raised over trait stacking by incorporating them into global access plans of such initiatives early in order to facilitate adoption, provide the best value to the small-scale farmer and gain trust with the community whom these projects aim to serve. This perspective, based on an actual international social audit, should be of value to scientists, funders and partners involved in biotech development initiatives for food security.

  4. Next biotech plants: new traits, crops, developers and technologies for addressing global challenges.

    Science.gov (United States)

    Ricroch, Agnès E; Hénard-Damave, Marie-Cécile

    2016-08-01

    Most of the genetically modified (GM) plants currently commercialized encompass a handful of crop species (soybean, corn, cotton and canola) with agronomic characters (traits) directed against some biotic stresses (pest resistance, herbicide tolerance or both) and created by multinational companies. The same crops with agronomic traits already on the market today will continue to be commercialized, but there will be also a wider range of species with combined traits. The timeframe anticipated for market release of the next biotech plants will not only depend on science progress in research and development (R&D) in laboratories and fields, but also primarily on how demanding regulatory requirements are in countries where marketing approvals are pending. Regulatory constraints, including environmental and health impact assessments, have increased significantly in the past decades, delaying approvals and increasing their costs. This has sometimes discouraged public research entities and small and medium size plant breeding companies from using biotechnology and given preference to other technologies, not as stringently regulated. Nevertheless, R&D programs are flourishing in developing countries, boosted by the necessity to meet the global challenges that are food security of a booming world population while mitigating climate change impacts. Biotechnology is an instrument at the service of these imperatives and a wide variety of plants are currently tested for their high yield despite biotic and abiotic stresses. Many plants with higher water or nitrogen use efficiency, tolerant to cold, salinity or water submergence are being developed. Food security is not only a question of quantity but also of quality of agricultural and food products, to be available and accessible for the ones who need it the most. Many biotech plants (especially staple food) are therefore being developed with nutritional traits, such as biofortification in vitamins and metals. The main

  5. Next biotech plants: new traits, crops, developers and technologies for addressing global challenges.

    Science.gov (United States)

    Ricroch, Agnès E; Hénard-Damave, Marie-Cécile

    2016-08-01

    Most of the genetically modified (GM) plants currently commercialized encompass a handful of crop species (soybean, corn, cotton and canola) with agronomic characters (traits) directed against some biotic stresses (pest resistance, herbicide tolerance or both) and created by multinational companies. The same crops with agronomic traits already on the market today will continue to be commercialized, but there will be also a wider range of species with combined traits. The timeframe anticipated for market release of the next biotech plants will not only depend on science progress in research and development (R&D) in laboratories and fields, but also primarily on how demanding regulatory requirements are in countries where marketing approvals are pending. Regulatory constraints, including environmental and health impact assessments, have increased significantly in the past decades, delaying approvals and increasing their costs. This has sometimes discouraged public research entities and small and medium size plant breeding companies from using biotechnology and given preference to other technologies, not as stringently regulated. Nevertheless, R&D programs are flourishing in developing countries, boosted by the necessity to meet the global challenges that are food security of a booming world population while mitigating climate change impacts. Biotechnology is an instrument at the service of these imperatives and a wide variety of plants are currently tested for their high yield despite biotic and abiotic stresses. Many plants with higher water or nitrogen use efficiency, tolerant to cold, salinity or water submergence are being developed. Food security is not only a question of quantity but also of quality of agricultural and food products, to be available and accessible for the ones who need it the most. Many biotech plants (especially staple food) are therefore being developed with nutritional traits, such as biofortification in vitamins and metals. The main

  6. 7 Leadership Blind Spots: Adult Development, Emotional Intelligence, and Leadership Effectiveness Among Biotech R&D Leaders

    OpenAIRE

    Shiner, Michael

    2015-01-01

    In this multiple-case study of 6 mid-level leaders working in biotech R&D--an archetype of a complex, uncertain, turbulent, and, multidisciplinary 21st-Century workplace--I explore the importance and interaction of mental complexity (MC), an aspect of adult development, and emotional intelligence (EI) for leadership effectiveness (LE). MC concerns the sophistication of the mindsets we use to construct stories for ourselves about the meaning of things. EI refers to one’s ability to manage one’...

  7. Explaining ICT Infrastructure and E-Commerce Uses and Benefits in Industrial Clusters-Evidence from a Biotech Cluster

    DEFF Research Database (Denmark)

    Scupola, Ada; Steinfield, Charles

    2006-01-01

    industrial cluster might utilize and derive benefit from a public, broadband ICT infrastructure, particularly in support of e-commerce applications. A case study of a successful biotech cluster in Denamrk and Sweden-The Medicon Valley-provides a preliminary test of these expectations. Distinctions in uses...... and benefits based upon firm size are considered. A key finding is that small firms that would not otherwise be expected to gain from global e-commerce can rely on the cluster "brand" to enable trade with unknown and distant partners....

  8. Explaining ICT Infrastructure and E-Commerce Uses and Benefits in Industrial Clusters-Evidence from a Biotech Cluster

    DEFF Research Database (Denmark)

    Scupola, Ada; Steinfield, Charles

    2006-01-01

    in an industrial cluster might utilize and derive benefit from a public, broadband ICT infrastructure, particularly in support of e-commerce applications. A case study of a successful biotech cluster in Denamrk and Sweden-The Medicon Valley-provides a preliminary test of these expectations. Distinctions in uses...... and benefits based upon firm size are considered. A key finding is that small firms that would not otherwise be expected to gain from global e-commerce can rely on the cluster "brand" to enable trade with unknown and distant partners....

  9. 《科学新闻》携手“科学网”亮相BIOTECH CHINA2009

    Institute of Scientific and Technical Information of China (English)

    2009-01-01

    6月1日,“中国国际生物技术和仪器设备博览会”(BIOTECH CHINA2009)暨“上海国际生物技术与医药研讨会”(BIO—FOURM)在上海国际展览中心隆重开幕,《科学新闻》杂志携手“科学网”共同参加了这一生物技术界的集会。

  10. High Added Value - but Many Stumbling Blocks along the Way NTN Biotech Identifies where the Shoe Pinches.

    Science.gov (United States)

    Heinzelmann, Elsbeth

    2016-01-01

    The year 1958, when DNA was first made in a test tube, marked the birth of modern biotechnology. DNA has now developed into an important technology that makes a key contribution in various sectors such as agriculture, environment and cleansing, and it has triggered a veritable boom in medicine. Today, biologics account for more than 60% of newly approved drugs. They are efficient, save time and money and have few or minimal side effects, fuelling the appetite of big pharma to take over biotech companies. Where will the journey lead?

  11. Judicial activism, the Biotech Directive and its institutional implications – Is the Court acting as a legislator or a court when defining the ‘human embryo’?

    DEFF Research Database (Denmark)

    Faeh, Andrea Beata

    2015-01-01

    The Court of Justice of the European Union (Court) delivered a preliminary ruling in 2011 in the case of Oliver Brüstle v Greenpeace on the interpretation of Article 6(2) of the Biotech Directive and thereby established an autonomous concept of the term ‘human embryo’. The Brüstle decision raises...... for it to be regarded as a “human embryo”.’ This contribution discusses the two judgments both in relation to the role of the EU institutions and the potential effects of the judgments on biotech inventions, in particular on medical innovation...

  12. The present status of commercialized and developed biotech (GM) crops, results of evaluation of plum 'HoneySweet" for resistance to plum pox virus in the Czech Republic

    Science.gov (United States)

    Commercialization of biotech (GM) crops started in 1996. A significant increase of 9 million hectars was realized in 1996-2009. In the years 2010-2011, it was already 12 million hectars (8 percent of total crop area). 16.7 million farmers in 29 countries planted 160 million hectars of GM crops in...

  13. Accumulation and Circulation of the Knowledge Needed for Biotech Business Promotion by Engineers of R&D Section in an IT Enterprise: The Case of Hitachi Software Engineering Co., Ltd

    Directory of Open Access Journals (Sweden)

    Hirofumi Ota

    2012-01-01

    Full Text Available Much research has been carried out on the accumulation and effective use of knowledge as a company-specific form of intellectual property. However, insufficient attention has been given to research focusing on the effects of micro-level knowledge absorption and its effective use. In this paper, we try to demonstrate what should be done in order to promote new biotech business from the perspective of each engineer’s knowledge, through a micro-level investigation focusing on the life science business section of one IT enterprise. Based on the results of a questionnaire survey of engineers, interviews of several engineers, and patent data analysis, we discuss the progress of the biotech business in an IT enterprise from the aspect of accumulation and circulation of knowledge in a core technology field, the IT business, and a technology field of new entry, the biotech business. This paper reports that the positive growth cycle of biotech business promotion in an IT enterprise, using Hitachi Software Engineering Co., Ltd. as a case, attained by incorporating the latest biotech knowledge from junior engineers and utilizing IT knowledge from middle engineers leads to the recruiting of qualified students.Keywords: accumulation and circulation of the knowledge, biotech business, open innovation, patent data analysis, questionnaire survey

  14. 强强联手 盛会空前——前瞻BIOTECH CHINA 2008,BIO-FORUM 2008

    Institute of Scientific and Technical Information of China (English)

    顾定槐

    2008-01-01

    @@ 2008"中国国际生物技术和仪器设备博览会"(BIOTECH CHINA)和"上海国际生物技术与医药研讨会"(BIO-FOURM).将于5月28~30日在上海国际展览中心及上海国际会议中心举办.

  15. Solid lipid nanoparticles for hydrophilic biotech drugs: optimization and cell viability studies (Caco-2 & HEPG-2 cell lines).

    Science.gov (United States)

    Severino, Patrícia; Andreani, Tatiana; Jäger, Alessandro; Chaud, Marco V; Santana, Maria Helena A; Silva, Amélia M; Souto, Eliana B

    2014-06-23

    Insulin was used as model protein to developed innovative Solid Lipid Nanoparticles (SLNs) for the delivery of hydrophilic biotech drugs, with potential use in medicinal chemistry. SLNs were prepared by double emulsion with the purpose of promoting stability and enhancing the protein bioavailability. Softisan(®)100 was selected as solid lipid matrix. The surfactants (Tween(®)80, Span(®)80 and Lipoid(®)S75) and insulin were chosen applying a 2(2) factorial design with triplicate of central point, evaluating the influence of dependents variables as polydispersity index (PI), mean particle size (z-AVE), zeta potential (ZP) and encapsulation efficiency (EE) by factorial design using the ANOVA test. Therefore, thermodynamic stability, polymorphism and matrix crystallinity were checked by Differential Scanning Calorimetry (DSC) and Wide Angle X-ray Diffraction (WAXD), whereas the effect of toxicity of SLNs was check in HepG2 and Caco-2 cells. Results showed a mean particle size (z-AVE) width between 294.6 nm and 627.0 nm, a PI in the range of 0.425-0.750, ZP about -3 mV, and the EE between 38.39% and 81.20%. After tempering the bulk lipid (mimicking the end process of production), the lipid showed amorphous characteristics, with a melting point of ca. 30 °C. The toxicity of SLNs was evaluated in two distinct cell lines (HEPG-2 and Caco-2), showing to be dependent on the concentration of particles in HEPG-2 cells, while no toxicity in was reported in Caco-2 cells. SLNs were stable for 24 h in in vitro human serum albumin (HSA) solution. The resulting SLNs fabricated by double emulsion may provide a promising approach for administration of protein therapeutics and antigens.

  16. What affects the innovation performance of small and medium-sized enterprises (SMEs) in the biotechnology industry? An empirical study on Korean biotech SMEs.

    Science.gov (United States)

    Kang, Kyung-Nam; Lee, Yoon-Sik

    2008-10-01

    Research-intensive small and medium-sized enterprises (SMEs) play a crucial role in the advancement of the biotechnology industry. This paper explored the impacts of internal and contextual variables on innovative activity in Korea and compared the results of this analysis with previous studies of other countries. Our analysis of 149 Korean biotech SMEs showed that the ratio of R&D expenditure to sales, the ratio of R&D employees to total employees, CEO characteristics, governmental support and international networking are positively correlated with a firm's innovation performance. The results may help decision makers to better foster SMEs in the Korean biotechnology industry.

  17. What affects the innovation performance of small and medium-sized enterprises (SMEs) in the biotechnology industry? An empirical study on Korean biotech SMEs.

    Science.gov (United States)

    Kang, Kyung-Nam; Lee, Yoon-Sik

    2008-10-01

    Research-intensive small and medium-sized enterprises (SMEs) play a crucial role in the advancement of the biotechnology industry. This paper explored the impacts of internal and contextual variables on innovative activity in Korea and compared the results of this analysis with previous studies of other countries. Our analysis of 149 Korean biotech SMEs showed that the ratio of R&D expenditure to sales, the ratio of R&D employees to total employees, CEO characteristics, governmental support and international networking are positively correlated with a firm's innovation performance. The results may help decision makers to better foster SMEs in the Korean biotechnology industry. PMID:18506395

  18. The present state of research and exploitation of biotech (GM) crops in horticulture: results of research on plum cv. 'HoneySweet' resistant to plum pox virus (Sharka) and the deregulation of this cultivar in the CR & Europe

    Science.gov (United States)

    Gentically modified (GM) crops were grown world-wide on 160 million ha in 2011. Only 114.57 ha of GM crops were grown in Europe, of that, 114.90 ha were Bt maize and 17 ha were potato for industrial starch production. Commercialization of Biotech crops started in 1995. Currently, developing count...

  19. 生物技术药物中残留DNA检测方法的比较%Comparison of testing methods for residual DNA in biotech drugs

    Institute of Scientific and Technical Information of China (English)

    彭燕

    2016-01-01

    Biotech drugs are drugs made by modem biotechnology with bioactive substances and their synthetic analogs,using biomass as raw materials.Biotech drugs,including cytokines,recombinant proteins,antibodies,vaccines,and oligonucleotides,have begun to be widely used clinically,and brought revolutionary change for the pharmaceutical industry.However,residual DNA in biological products may be potentially dangerous,so purification processes need to be validated to confirm its clearance.The new United States pharmacopoeia will recommend real-time quantitative PCR method be the only standard method for testing host residual DNA in biotech drugs.This method has the technical advantage of high specificity,high sensitivity,good reproducibility,and quantitative detection,making results more accurate,thereby provides a reliable means of detection in process research and product quality control for biopharmaceutical enterprises.This review compares 4 types of testing methods and focuses on two real-time quantitative methods.%生物技术药物是所有以生物质为原料的生物活性物质及其人工合成类似物通过现代生物技术制得的药物,包括细胞因子、重组蛋白、抗体、疫苗和寡核苷酸等,临床上已开始广泛应用,为制药工业带来了革命性变化.但是生物技术药物中残留DNA可能存在安全性问题,因此应尽可能将产品中残留DNA的水平降到最低.新版美国药典将推荐实时定量PCR法作为生物技术药物中宿主残留DNA检定的唯一标准方法.该法的技术优势在于序列特异性高、灵敏度高、重现性好,还可以实现定量检测,使得结果更为精确,从而为生物技术药物企业在工艺研究和成品质量控制方面提供了可靠的检测手段.此综述对4类检测方法进行了比较,重点比较两种实时定量方法.

  20. Plant Biotech Lab Manual.

    Science.gov (United States)

    Tant, Carl

    This book provides laboratory experiments to enhance any food science/botany curriculum. Chapter 1, "Introduction," presents a survey of the techniques used in plant biotechnology laboratory procedures. Chapter 2, "Micronutrition," discusses media and nutritional requirements for tissue culture studies. Chapter 3, "Sterile Seeds," focuses on the…

  1. 近年来我国生物技术药物研究进展和趋势%The Research Progress and Trend of Biotech Drugs in Recent Years in China

    Institute of Scientific and Technical Information of China (English)

    王友同; 吴文俊; 李谦; 高美风

    2013-01-01

    Biological technology is the topic height at the development of economy and technology in the 21st century all over the world . The authors based on the world biotech- drugs total development trend, summarized the biotech drugs research achievements in recent five years in China. The content includes: cytokine, protein and peptide drugs, fusion protein, cell-penetrating peptides, enzymes,gene therapy,stem cells,monoclonal antibodies,therapeutic vaccine,polysaccharide drugs,etc. It is found in the survey that the development of biotech drugs has a bright future in treating complicated diseases, protecting the human health, improving the life quality, and developing the biotech drugs industry, thank to the emerging of many creative biotech drug researches within our country. This paper provides the reference for establishing the relevant research plan, deciding the research project, setting development goals for enterprise research,and choosing professional development direction,and to biological pharmaceutical researchers.%生物技术是21世纪世界各国竞相发展的经济、技术的制高点,作者站在世界生物技术药物发展总趋势的高度上,具体而微地调查和总结了我国近5年来生物技术药物研究所取得的成果,内容包括:细胞因子、其它蛋白质和多肽药物、融合蛋白、穿膜肽、酶、基因治疗、干细胞、单克隆抗体、治疗性疫苗及多糖药物等.调查发现,在攻克人类顽疾、保障人民身体健康、提高生活质量和发展我国生物技术药物产业方面,由于国内成批有创见的研究成果持续涌现,发展前景一片光明.该文可为有关部门科研规划、确定研究项目、企业锁定发展目标及生物制药人员选择专业发展方向提供参考.

  2. Identification of the factors that result in obviousness rulings for biotech patents: an updated analysis of the US Federal Circuit decisions after KSR.

    Science.gov (United States)

    Lin, Fangyu; Wang, Shyh-Jen

    2013-11-01

    To demonstrate the influence of the US Supreme Court's KSR case, our analysis has shown that the ratio of obvious ruling increased from 0.42 to 0.62 after this case, whereas the ratio of non-obvious ruling decreased from 0.47 to 0.28. Therefore, without the rigid application of a "teaching, suggestion or motivation" test, the trends of obvious and non-obvious CAFC rulings significantly increased and decreased, respectively.   Based on this analysis, biotech inventors should contemplate the factors that have resulted in ruling of obviousness, which include claims that are too broad, the lack of secondary considerations, the reasonable expectation of success, and the reason or motivation to create a structure based on structural similarity. The presence of these factors most likely would result in the rejection of the claim during patent prosecution or the invalidation of the claim in patent litigation. Two immunotherapy and vaccine cases have applied these factors to overcome the obvious rejections. PMID:23899509

  3. Identification of the factors that result in obviousness rulings for biotech patents: an updated analysis of the US Federal Circuit decisions after KSR.

    Science.gov (United States)

    Lin, Fangyu; Wang, Shyh-Jen

    2013-11-01

    To demonstrate the influence of the US Supreme Court's KSR case, our analysis has shown that the ratio of obvious ruling increased from 0.42 to 0.62 after this case, whereas the ratio of non-obvious ruling decreased from 0.47 to 0.28. Therefore, without the rigid application of a "teaching, suggestion or motivation" test, the trends of obvious and non-obvious CAFC rulings significantly increased and decreased, respectively.   Based on this analysis, biotech inventors should contemplate the factors that have resulted in ruling of obviousness, which include claims that are too broad, the lack of secondary considerations, the reasonable expectation of success, and the reason or motivation to create a structure based on structural similarity. The presence of these factors most likely would result in the rejection of the claim during patent prosecution or the invalidation of the claim in patent litigation. Two immunotherapy and vaccine cases have applied these factors to overcome the obvious rejections.

  4. The impact of Myriad and Mayo: will advancements in the biological sciences be spurred or disincentivized? (Or was biotech patenting not complicated enough?).

    Science.gov (United States)

    Gordon, Jennifer

    2014-12-11

    For years, purified and isolated naturally occurring biological substances of great medical importance--including genes--have been the subject of U.S. patents. Similarly, methods in which the detection of a biological substance (e.g., in a blood sample) dictates subsequent actions, as in disease diagnostics and treatment, have long enjoyed patent protection. However, two recent Supreme Court cases, Association for Molecular Pathology v. Myriad Genetics, Inc. (133 S. Ct. 2107) (2013) and Mayo Collaborative Services v. Prometheus Laboratories, Inc. (132 S. Ct. 1289) (2012), have shaken up the status quo of biotech patenting. The highest court in our land unanimously agreed with patent challengers that much of what we took for granted as patentable subject matter is not, as a matter of law, eligible for patenting after all. This review discusses the Myriad and Mayo cases, their impact on which biology-based innovations we may or may not continue to patent, and whether the altered status quo is benignly corrective or gravely disruptive. Is what happened here a good thing or not?

  5. Space Biotech: Hindsight, Insight, Foresight

    Science.gov (United States)

    Harper, Lynn

    2015-01-01

    Over the past forty years, microgravity has inspired and enabled applications in a wide range of sectors including medicine, materials, computers, communications, and national defense. Trends show that demand for high-tech solutions is increasing in these sectors, solutions that require higher resolution, greater precision, novel materials, innovative processes, and more sophisticated tools. These are areas where microgravity can offer unique capabilities for innovation. The Emerging Space Office (ESO) has engaged in multiple studies over the past year that have found that microgravity RD is one of the most promising technology areas for contributing to economic growth and to NASAs mission. The focus of these studies was on terrestrial markets rather than NASA applications, applied research rather than basic research, and commercial rather than academic investigators. There have been more success stories than are generally appreciated and there are significant areas of promising future potential. Many of the problems that have limited commercial microgravity development in the past are being solved. Microgravity research and development (RD) requires iteration and learning, as rapidly as possible. New technologies enable high throughput and rapid data collection in increasingly small payloads. The International Space Station is in orbit and provides a laboratory that is available 247 at least until 2024. Frequent flights by commercial space providers to and from the ISS now enable the fast learning cycles needed by high-tech industries. Launch costs are decreasing and the ability to return payloads to Earth is increasing. New commercial space laboratories, such as those being developed by SpaceX and Bigelow Aerospace, are in the final stages of development and testing. This ecosystem for microgravity RD has never been available before. These are game-changer conditions for attracting high-tech industries to space for terrestrial, as well as NASA, applications. However, few know that these capabilities are available or how to use them. In aggregate, the potential value for new applications from microgravity RD over the next ten years could add billions of dollars per year in terrestrial applications to the future economy, create new jobs, and generate a wide range of public benefits in medical advances, while broadening the customer base for the emerging space industry.

  6. Scientific Basis for Biotech Crops

    Science.gov (United States)

    Efforts to change the genetic makeup of plants have been ongoing since the beginning of agriculture, thousands of years ago. Early plant improvements relied on simply cross-breeding cultivars with desired traits. Advancements in mutation breeding through chemicals and radiation ...

  7. La intervención del derecho penal en materia de bioseguridad: la criminalización de la actividad empresarial biotecnológica de liberación intencional en el ambiente con fines comerciales y de comercialización de productos biotech

    OpenAIRE

    Tanus Job e Meira, Bruno

    2009-01-01

    [ES] El objetivo general del presente trabajo reside en analizar el sistema de control del riesgo biotecnológico relativo a las principales actividades por las cuales se utilizan las empresas biotech en el ámbito agroalimentario, es decir, las conductas de liberación en el ambiente con fines comerciales, así como la comercialización de “organismos modificados genéticamente” (OMGs) y sus derivados. Tales actividades son consideradas como las más importantes en el ámbito mercantil y, efectivame...

  8. PHP-HT (VitaResc Biotech).

    Science.gov (United States)

    Baldwin, A; Wiley, E

    2001-04-01

    VitaResc (formerly Apex) is developing PHP-HT, pyridoxalated hemoglobin polyoxyethylene conjugate, for the potential treatment of nitric oxide-induced shock (characterized by hypotension), associated with various etiologies, initially in septic shock. A phase I safety study and an initial phase I/II patient trial for NO-induced shock have been completed, and VitaResc has enrolled patients in three of five planned cohorts in a continuation of these trials to include a protocol of continuous infusion and dose escalation [330680,349187,390918]. The results from the dose escalation trials are expected to provide the basis for a randomized, controlled phase II/III pivotal trial of PHP-HT [390918]. VitaResc has licensed PHP-HT exclusively from Ajinomoto for all indications, worldwide, except Japan [275263]. Ajinomoto originally developed the human derived and chemically modified hemoglobin preparation as a blood substitute, but no development has been reported by the company since 1997 [275277,303577]. The other potential indications of PHP-HT include shock associated with burns, pancreatitis, hemodialysis and cytokine therapies [275277]. VitaResc expects the annual market potential of PHP-HT to exceed 1 billion dollars [330680].

  9. Structure, Employment and Performance in Biotech Firms

    DEFF Research Database (Denmark)

    Valentin, Finn; Dahlgren, Johan Henrich; Lund Jensen, Rasmus

    2006-01-01

    .g. universities, firms and venture capital. That makes DDFs a sensitive "seismograph" for the ability of the Danish innovation system to foster new science-based technologies.Key words: Employment, Biotechnology, Firm size distribution, Industry structure,Firm performanceJEL Codes: J21, L11, L22, L25, L65, O57...

  10. Genetic resources, biotech patents and gene ownership.

    Science.gov (United States)

    Lucchi, Nicola

    2014-01-01

    Human genetic resources are increasingly considered as ordinary commercial goods, but their value and utility go beyond the simple and immediate private profit. In contrast to other biological resources, commercial use does not focus upon the material itself but rather upon the genetic information it contains. Information goods are then usually subject to intellectual property rights, but in the biological and life science domains, property rights can have a negative influence upon the proper allocation of several goods, including genetic material or goods that are related to it. This scenario reflects the facts of recent litigations in the United States and Europe. In particular, these lawsuits have revived the debate over private ownership and control over genes. Within this context, the objective of the paper is to discuss how to recast the traditional right to access to and use of biochemical and human genetic material currently considered as part of the market framework. Looking beyond the protection of traditional public goods, the paper emphasizes the debate around the progressive commodification of human genetic resources facilitated by an improper use of intellectual property rights. Different scenarios are analyzed to evaluate alternative instruments and new regulatory approaches to avoid the private appropriation of human genetic resources and other natural assets. PMID:25845208

  11. How to start a biotech company.

    Science.gov (United States)

    Tajonar, Adriana

    2014-11-01

    The spirit of life science entrepreneurship is alive and well, with outstanding innovation hubs arising throughout the country and the world. Of note, many of these hubs flourish in close proximity to research universities. If universities are the engine for discovery, then startups are the vehicle for innovation. The creativity and drive of young researchers has the potential to explore novel or underserved applications and revolutionize industries. PMID:25360051

  12. Biotech Tradeoffs in the Rural Economy.

    Science.gov (United States)

    Buttel, Frederick H.

    1987-01-01

    Synthesizes findings with personal estimates of likely impacts of biotechnology on nonmetropolitan economy, farming, public research institutions. Indicates biotechnology's benefit to rural America may come in expanded demand for raw materials although drawbacks may include declining farm numbers and displacement of rural workers in…

  13. Initial Accuracy of HIV Rapid Test Kits Stored in Suboptimal Conditions and Validity of Delayed Reading of Oral Fluid Tests.

    Directory of Open Access Journals (Sweden)

    Augustine T Choko

    Full Text Available To evaluate the effect of storing commonly used rapid diagnostic tests above manufacturer-recommended temperature (at 37°C, and the accuracy of delayed reading of oral fluid kits with relevance to HIV self-testing programmes.A quality assurance study of OraQuick (OraSure, Determine HIV 1/2™ (Alere and Uni-Gold™ (Recombigen®.Consecutive adults (≥18y attending Ndirande Health Centre in urban Blantyre, Malawi in January to April 2012 underwent HIV testing with two of each of the three rapid diagnostic test kits stored for 28 days at either 18°C (optimally-stored or at 37°C (pre-incubated. Used OraQuick test kits were stored in a laboratory for delayed day 1 and subsequent monthly re-reading was undertaken for one year.Of 378 individuals who underwent parallel testing, 5 (1.3% were dropped from the final analysis due to discordant or missing reference standard results (optimally-stored Determine and Uni-Gold. Compared to the diagnostic reference standard, OraQuick had a sensitivity of 97.2% (95% CI: 93.6-99.6. There were 7 false negative results among all test kits stored at 37°C and three false negatives among optimally stored kits. Excellent agreement between pre-incubated tests and optimally-stored tests with Kappa values of 1.00 for Determine and Uni-Gold; and 0.97 (95% CI: 0.95; 1.00 for OraQuick were observed. There was high visual stability on re-reading of OraQuick, with only 1/375 pre-incubated and 1/371 optimally-stored OraQuick kits changing from the initial result over 12 months.Erroneous results observed during HIV testing in low income settings are likely to be due to factors other than suboptimal storage conditions. Re-reading returned OraQuick kits may offer a convenient and accurate quality assurance approach, including in HIV self-testing programmes.

  14. Initial Accuracy of HIV Rapid Test Kits Stored in Suboptimal Conditions and Validity of Delayed Reading of Oral Fluid Tests

    Science.gov (United States)

    Choko, Augustine T.; Taegtmeyer, Miriam; MacPherson, Peter; Cocker, Derek; Khundi, McEwen; Thindwa, Deus; Sambakunsi, Rodrick S.; Kumwenda, Moses K.; Chiumya, Kondwani; Malema, Owen; Makombe, Simon D.; Webb, Emily L.; Corbett, Elizabeth L.

    2016-01-01

    Objectives To evaluate the effect of storing commonly used rapid diagnostic tests above manufacturer-recommended temperature (at 37°C), and the accuracy of delayed reading of oral fluid kits with relevance to HIV self-testing programmes. Design A quality assurance study of OraQuick (OraSure), Determine HIV 1/2™ (Alere) and Uni-Gold™ (Recombigen®). Methods Consecutive adults (≥18y) attending Ndirande Health Centre in urban Blantyre, Malawi in January to April 2012 underwent HIV testing with two of each of the three rapid diagnostic test kits stored for 28 days at either 18°C (optimally-stored) or at 37°C (pre-incubated). Used OraQuick test kits were stored in a laboratory for delayed day 1 and subsequent monthly re-reading was undertaken for one year. Results Of 378 individuals who underwent parallel testing, 5 (1.3%) were dropped from the final analysis due to discordant or missing reference standard results (optimally-stored Determine and Uni-Gold). Compared to the diagnostic reference standard, OraQuick had a sensitivity of 97.2% (95% CI: 93.6–99.6). There were 7 false negative results among all test kits stored at 37°C and three false negatives among optimally stored kits. Excellent agreement between pre-incubated tests and optimally-stored tests with Kappa values of 1.00 for Determine and Uni-Gold; and 0.97 (95% CI: 0.95; 1.00) for OraQuick were observed. There was high visual stability on re-reading of OraQuick, with only 1/375 pre-incubated and 1/371 optimally-stored OraQuick kits changing from the initial result over 12 months. Conclusion Erroneous results observed during HIV testing in low income settings are likely to be due to factors other than suboptimal storage conditions. Re-reading returned OraQuick kits may offer a convenient and accurate quality assurance approach, including in HIV self-testing programmes. PMID:27336161

  15. Biotech potatoes in the 21st century: 20 years since the first biotech potato

    Science.gov (United States)

    Potato is the world's most important vegetable crop, with nearly 400 million tons produced worldwide every year, lending to stability in food supply and socioeconomics. In general, potato is an intensively managed crop, requiring irrigation, fertilization, and frequent pesticide applications in orde...

  16. Biotechnology regulation: limiting or contributing to biotech development?

    DEFF Research Database (Denmark)

    Hansen, Anne Grethe

    2001-01-01

    Modern biotechnology has been characterized by being surrounded by scientific and public debate and by interest conflicts. An early Danish debate and regulation has been criticized for inhibiting or retarding development and thus growth. Though much regulation and debate have been transferred...... to the European arena, their role and extension are still an issue. In this paper, the often anticipated innovation-inhibiting effects of regulation are questioned by giving an account of regulations and debates in Denmark. An account which includes the shifting positions of industry, the research community...... that regulation and debate changed the rate and direction of new biotechnology development, contributing to technology acceptance, without however ensuring it. The paper thus questions the caricatured assumptions in economics and industrial policy that regulation restrict techno-economic growth. The paper further...

  17. Hunger Fighters See Biotech Hope for Poor Nations

    Institute of Scientific and Technical Information of China (English)

    Julie; Ingwersen; 钱民徵

    2002-01-01

    基因,转基因,基因工程……与“基因”有关的这几个词,几乎成了上世纪末以来的热门词语。这似乎印证了“21世纪属于生物学世纪”这一著名预言。“genetically modified(GM)crops”也成了一个英语热门词汇。本文详细介绍了上世纪六、七十年代所谓绿色革命之父,诺贝尔奖获得者Norman Borlaug对(GM)crops这场新革命的观点。他的观点有两点值得我们关注: 1/为什么当今世界有人反对这场崭新意义的绿色革命?Borlaug的观点非常犀利: If we sit in Europe or North America and decide that because we don’t need that scientific approach for our food supply, therefore they can’t have it either, that is grossly (非常) unethical (不道德的). 2/凡是革命。那就必然会有风险:no agricultural advance is risk-free. Borlaug称,当年的绿色革命也同样遭受了人们的反对:Critics(批评家们)in the past accused the Green Revolution of popularizing (普及) chemical fertilizers, pesticides and irrigation that jeopardized (危害) the environment in developing countries.】

  18. Exploring Business Models for SMEs in the Biotech Industry

    OpenAIRE

    Holm-Bergqvist, Linus; Ödmark, Victor

    2013-01-01

    The interest in business models has lately increased, which could be traced back to the dot-com burst during the 2000s. There exists no general definition of business models. Howev-er, researchers all agree that business models are used to illustrate the design and architec-ture of the value creation process of companies. Today’s research of business models has mainly been focused on e-commerce. This thesis contributes to the research of business models by extending the research to focus on S...

  19. The Industrial Application Requirement for Biotech Inventions in Europe

    DEFF Research Database (Denmark)

    Minssen, Timo; Nilsson, David

    2016-01-01

    New Research CollectionEuropean Intellectual Property Law. Edited by Jan Rosén, Stockholm University and former ATRIP President. This one volume collection thoroughly covers and systematically displays the three main areas of Intellectual Property (IP) Law - Patents, Trademarks and Copyright - wi...

  20. Evaluation and Audience Acceptance in Biotech News Texts

    DEFF Research Database (Denmark)

    Holmgreen, Lise-Lotte; Vestergaard, Torben

    2009-01-01

    It is well known that news texts are not value neutral and that in these texts even genuinely factual statements can function as evaluations. Hence, only an analysis of the types of evaluation used will reveal the true picture of the attitudinal import of reporting texts. The paper explores...... these features by analysing the coverage of the biotechnology debate in one of the largest Danish newspapers, Politiken, during the first 9 months of 2004. The aim of this analysis is to uncover how seemingly objective and ‘neutral' accounts of events and state of affairs can be used by journalists...... to significantly influence the attitudes of the readership. In the analysis, it is shown that the feature Judgement (of people) is virtually absent, whereas Appreciation (of things) is quite frequent, reflecting the fact that the perceived risk factor associated with biotechnology was paramount in the said period...

  1. Licensing biotech intellectual property in university-industry partnerships.

    Science.gov (United States)

    Drozdoff, Vladimir; Fairbairn, Daryl

    2015-03-01

    Appropriate negotiation and drafting of license agreements are critical to successfully establishing and managing the expansive and complex relationships that are becoming more common between industry and universities. More often than not, the resulting licensing agreements become quite lengthy and complex, and the key principles become difficult to discern among all the details. This summary provides a short, nonexhaustive introduction to some of the essential components of these licenses with the intent of providing the non-licensing professional a better appreciation of some of the key commercial and legal terms from both an academic and company perspective, keeping in mind some of the considerations that particularly apply to biotechnology deals. PMID:25605752

  2. RNA triplexes: from structural principles to biological and biotech applications.

    Science.gov (United States)

    Devi, Gitali; Zhou, Yuan; Zhong, Zhensheng; Toh, Desiree-Faye Kaixin; Chen, Gang

    2015-01-01

    The diverse biological functions of RNA are determined by the complex structures of RNA stabilized by both secondary and tertiary interactions. An RNA triplex is an important tertiary structure motif that is found in many pseudoknots and other structured RNAs. A triplex structure usually forms through tertiary interactions in the major or minor groove of a Watson-Crick base-paired stem. A major-groove RNA triplex structure is stable in isolation by forming consecutive major-groove base triples such as U·A-U and C(+) ·G-C. Minor-groove RNA triplexes, e.g., A-minor motif triplexes, are found in almost all large structured RNAs. As double-stranded RNA stem regions are often involved in biologically important tertiary triplex structure formation and protein binding, the ability to sequence specifically target any desired RNA duplexes by triplex formation would have great potential for biomedical applications. Programmable chemically modified triplex-forming oligonucleotides (TFOs) and triplex-forming peptide nucleic acids (PNAs) have been developed to form TFO·RNA2 and PNA·RNA2 triplexes, respectively, with enhanced binding affinity and sequence specificity at physiological conditions. Here, we (1) provide an overview of naturally occurring RNA triplexes, (2) summarize the experimental methods for studying triplexes, and (3) review the development of TFOs and triplex-forming PNAs for targeting an HIV-1 ribosomal frameshift-inducing RNA, a bacterial ribosomal A-site RNA, and a human microRNA hairpin precursor, and for inhibiting the RNA-protein interactions involving human RNA-dependent protein kinase and HIV-1 viral protein Rev. PMID:25146348

  3. Models of Transparency and Accountability in the Biotech Age

    Science.gov (United States)

    Andersson, Kjell; Drottz-Sjoberg, Britt-Marie; Espejo, Raul; Fleming, Patricia Ann; Wene, Clas-Otto

    2006-01-01

    Today, societal decisions in areas of complexity are often dominated by one of three alternative ways: (a) by scientists, nowadays often in combination with commercial interest; (b) by politicians alone; and (c) by simply "laissez-faire," or "the tyranny of small steps." None of these three ways of decision making is fully democratic because they…

  4. West German Biotech Institute Trains Third World Scientists.

    Science.gov (United States)

    O'Sullivan, Dermot A.

    1987-01-01

    Describes a six-week program designed to give scientists from developing countries advanced training in biotechnology methods. Stresses the need to provide the participants with "hands-on" experiences to enhance their ability to contribute to biotechnology programs in their home countries and to train others locally. (TW)

  5. Research in the Biotech Age: Can Informational Privacy Compete?

    Science.gov (United States)

    Peekhaus, Wilhelm

    2008-01-01

    This article examines the privacy of personal medical information in the health research context. Arguing that biomedical research in Canada has been caught up in the government's broader neoliberal policy agenda that has positioned biotechnology as a strategic driver of economic growth, the author discusses the tension between informational…

  6. The Evolution of the French Public Policy to Promote Biotech Innovation : The Case of Genomics

    OpenAIRE

    Branciard, Anne; Mangematin, Vincent

    2001-01-01

    Working Paper European Biotechnology companies and public policy-makers face to a number of crucial problems related to the development of Biotechnology in Europe : European industrial competitiveness, the relative under-exploitation of the European science base in Biotechnology, poor technology transfer mechanisms and difficulties in starting 'spin-off' firms. The aim of this paper on innovation in genomics and biomedical related biotechnologies is to study the relative impact of the diff...

  7. The Sociology of the Gene: Genetics and Education on the Eve of the Biotech Century.

    Science.gov (United States)

    Rifkin, Jeremy

    1998-01-01

    Researchers in molecular biology are discovering an increasing genetic basis for a wide range of mental diseases, moods, behaviors, and personality traits. Findings are creating the context for a new sociobiology favoring a genetic interpretation of human motivations and drives. Genetic engineering will give some people unprecedented power over…

  8. Who benefits from gm crops? Feeding the biotech giants, not the world's poor

    Energy Technology Data Exchange (ETDEWEB)

    Lopez Villar, J.; Freese, B.; Holder, H.; Chandrasekaran, K.; Rodriguez, L.

    2009-02-15

    The biotechnology industry has aggressively touted GM as a solution to hunger and the global food crisis. Their arguments have been accepted by many politicians. This Friends of the Earth International (FoEI) report looks behind the spin and exposes the reasons why GM crops cannot, and are unlikely to ever, contribute to poverty reduction, global food security or sustainable farming (authors' abstract)

  9. Epitope-driven DNA vaccine design employing immunoinformatics against B-cell lymphoma: a biotech's challenge.

    Science.gov (United States)

    Iurescia, Sandra; Fioretti, Daniela; Fazio, Vito Michele; Rinaldi, Monica

    2012-01-01

    DNA vaccination has been widely explored to develop new, alternative and efficient vaccines for cancer immunotherapy. DNA vaccines offer several benefits such as specific targeting, use of multiple genes to enhance immunity and reduced risk compared to conventional vaccines. Rapid developments in molecular biology and immunoinformatics enable rational design approaches. These technologies allow construction of DNA vaccines encoding selected tumor antigens together with molecules to direct and amplify the desired effector pathways, as well as highly targeted vaccines aimed at specific epitopes. Reliable predictions of immunogenic T cell epitope peptides are crucial for rational vaccine design and represent a key problem in immunoinformatics. Computational approaches have been developed to facilitate the process of epitope detection and show potential applications to the immunotherapeutic treatment of cancer. In this review a number of different epitope prediction methods are briefly illustrated and effective use of these resources to support experimental studies is described. Epitope-driven vaccine design employs these bioinformatics algorithms to identify potential targets of vaccines against cancer. In this paper the selection of T cell epitopes to develop epitope-based vaccines, the need for CD4(+) T cell help for improved vaccines and the assessment of vaccine performance against tumor are reviewed. We focused on two applications, namely prediction of novel T cell epitopes and epitope enhancement by sequence modification, and combined rationale design with bioinformatics for creation of new synthetic mini-genes. This review describes the development of epitope-based DNA vaccines and their antitumor effects in preclinical research against B-cell lymphoma, corroborating the usefulness of this platform as a potential tool for cancer therapy. Achievements in the field of DNA vaccines allow to overcome hurdles to clinical translation. In a scenario where the vaccine industry is rapidly changing from a mostly empirical approach to a rational design approach, these new technologies promise to discover and develop high-value vaccines, creating a new opportunity for future markets.

  10. Market entry and exit by biotech and device companies funded by venture capital.

    Science.gov (United States)

    Burns, Lawton R; Housman, Michael G; Robinson, Charles A

    2009-01-01

    Start-up companies in the biotechnology and medical device sectors are important sources of health care innovation. This paper describes the role of venture capital in supporting these companies and charts the growth in venture capital financial support. The paper then uses longitudinal data to describe market entry and exit by these companies. Similar factors are associated with entry and exit in the two sectors. Entries and exits in one sector also appear to influence entry in the other. These findings have important implications for developing innovative technologies and ensuring competitive markets in the life sciences.

  11. Venture Capitalist Induced Relational Fit and New Venture Performance : a Dutch biotech comparative case analysis

    NARCIS (Netherlands)

    Faber, J.; Castaldi, Carolina; Muskens, Roel

    2016-01-01

    Venture capitalists contribute financially as well as non-financially to new venture development. Their non-financial support consists of both direct strategic advice and indirect advice via networking. But the effectiveness of this advice is more dependent on its acceptance by a new venture than on

  12. Biotech Approaches to Overcome the Limitations of Using Transgenic Plants in Organic Farming

    Directory of Open Access Journals (Sweden)

    Luca Lombardo

    2016-05-01

    Full Text Available Organic farming prohibits the use of genetically modified organisms (GMOs inasmuch as their genetic material has been altered in a way that does not occur naturally. In actual fact, there is a conventional identity between GMOs and transgenic organisms, so that genetic modification methods such as somatic hybridization and mutagenesis are equalized to conventional breeding. A loophole in this system is represented by more or less innovative genetic engineering approaches under regulatory discussion, such as cisgenesis, oligonucleotide-directed mutagenesis, and antisense technologies, that are redefining the concept of GMOs and might circumvent the requirements of the GMO legislation and, indirectly, of organic farming.

  13. Research in Undergraduate Instruction: A Biotech Lab Project for Recombinant DNA Protein Expression in Bacteria

    Science.gov (United States)

    Brockman, Mark; Ordman, Alfred B.; Campbell, A. Malcolm

    1996-06-01

    In the sophomore-level Molecular Biology and Biotechnology course at Beloit College, students learn basic methods in molecular biology in the context of pursuing a semester-long original research project. We are exploring how DNA sequence affects expression levels of proteins. A DNA fragment encoding all or part of the guanylate monokinase (gmk) sequence is cloned into pSP73 and expressed in E. coli. A monoclonal antibody is made to gmk. The expression level of gmk is determined by SDS gel elctrophoresis, a Western blot, and an ELISA assay. Over four years, an increase in enrollment in the course from 9 to 34 students, the 85% of majors pursuing advanced degrees, and course evaluations all support the conclusion that involving students in research during undergraduate courses encourages them to pursue careers in science.

  14. Validation of cross-contamination control in biological safety cabinet for biotech/pharmaceutical manufacturing process.

    Science.gov (United States)

    Hu, Shih-Cheng; Shiue, Angus; Tu, Jin-Xin; Liu, Han-Yang; Chiu, Rong-Ben

    2015-12-01

    For class II, type A2 biological safety cabinets (BSC), NSF/ANSI Standard 49 should be conformed in cabinet airflow velocity derivation, particle contamination, and aerodynamic flow properties. However, there exists a potential problem. It has been built that the cabinet air flow stabilize is influenced by the quantity of downflow of air and the height above the cabinet exhaust opening. Three air downflow quantities were compared as an operating apparatus was placed from 20 to 40 cm above the bench of the cabinet. The results show that the BSC air downflow velocity is a function of increased sampling height, displaying that containment is improvingly permitted over product protection as the sampling height decreases. This study investigated the concentration gradient of particles at various heights and downflow air quantity from the bench of the BSC. Experiment results indicate that performance near the bench was better than in the rest of the BSC. In terms of height, the best cleanliness was measured at a height of 10 cm over the bench; it reduced actually with add in height. The empirical curves accommodate, founded on the concentration gradient of particle created was elaborated for evaluating the particle concentration at different heights and downflow air quantity from the source of the bench of the BSC. The particle image velocimetry system applied for BSC airflow research to fix amount of airflow patterns and air distribution measurement and results of measurements show how obstructions can greatly influence the airflow and contaminant transportation in a BSC.

  15. Process-driven information management system at a biotech company: concept and implementation.

    Science.gov (United States)

    Gobbi, Alberto; Funeriu, Sandra; Ioannou, John; Wang, Jinyi; Lee, Man-Ling; Palmer, Chris; Bamford, Bob; Hewitt, Robin

    2004-01-01

    While established pharmaceutical companies have chemical information systems in place to manage their compounds and the associated data, new startup companies need to implement these systems from scratch. Decisions made early in the design phase usually have long lasting effects on the expandability, maintenance effort, and costs associated with the information management system. Careful analysis of work and data flows, both inter- and intradepartmental, and identification of existing dependencies between activities are important. This knowledge is required to implement an information management system, which enables the research community to work efficiently by avoiding redundant registration and processing of data and by timely provision of the data whenever needed. This paper first presents the workflows existing at Anadys, then ARISE, the research information management system developed in-house at Anadys. ARISE was designed to support the preclinical drug discovery process and covers compound registration, analytical quality control, inventory management, high-throughput screening, lower throughput screening, and data reporting.

  16. Blueprints for green biotech: development and application of standards for plant synthetic biology.

    Science.gov (United States)

    Patron, Nicola J

    2016-06-15

    Synthetic biology aims to apply engineering principles to the design and modification of biological systems and to the construction of biological parts and devices. The ability to programme cells by providing new instructions written in DNA is a foundational technology of the field. Large-scale de novo DNA synthesis has accelerated synthetic biology by offering custom-made molecules at ever decreasing costs. However, for large fragments and for experiments in which libraries of DNA sequences are assembled in different combinations, assembly in the laboratory is still desirable. Biological assembly standards allow DNA parts, even those from multiple laboratories and experiments, to be assembled together using the same reagents and protocols. The adoption of such standards for plant synthetic biology has been cohesive for the plant science community, facilitating the application of genome editing technologies to plant systems and streamlining progress in large-scale, multi-laboratory bioengineering projects.

  17. Potential for false positive HIV test results with the serial rapid HIV testing algorithm

    OpenAIRE

    Baveewo Steven; Kamya Moses R; Mayanja-Kizza Harriet; Fatch Robin; Bangsberg David R; Coates Thomas; Hahn Judith A; Wanyenze Rhoda K

    2012-01-01

    Abstract Background Rapid HIV tests provide same-day results and are widely used in HIV testing programs in areas with limited personnel and laboratory infrastructure. The Uganda Ministry of Health currently recommends the serial rapid testing algorithm with Determine, STAT-PAK, and Uni-Gold for diagnosis of HIV infection. Using this algorithm, individuals who test positive on Determine, negative to STAT-PAK and positive to Uni-Gold are reported as HIV positive. We conducted further testing o...

  18. 2012 AAPS National Biotech Conference Open Forum: a perspective on the current state of immunogenicity prediction and risk management.

    Science.gov (United States)

    Rajadhyaksha, Manoj; Subramanyam, Meena; Rup, Bonnie

    2013-10-01

    The immunogenicity profile of a biotherapeutic is determined by multiple product-, process- or manufacturing-, patient- and treatment-related factors and the bioanalytical methodology used to monitor for immunogenicity. This creates a complex situation that limits direct correlation of individual factors to observed immunogenicity rates. Therefore, mechanistic understanding of how these factors individually or in concert could influence the overall incidence and clinical risk of immunogenicity is crucial to provide the best benefit/risk profile for a given biotherapeutic in a given indication and to inform risk mitigation strategies. Advances in the field of immunogenicity have included development of best practices for monitoring anti-drug antibody development, categorization of risk factors contributing to immunogenicity, development of predictive tools, and development of effective strategies for risk management and mitigation. Thus, the opportunity to ask "where we are now and where we would like to go from here?" was the main driver for organizing an Open Forum on Improving Immunogenicity Risk Prediction and Management, conducted at the 2012 American Association of Pharmaceutical Scientists' (AAPS) National Biotechnology Conference in San Diego. The main objectives of the Forum include the following: to understand the nature of immunogenicity risk factors, to identify analytical tools used and animal models and management strategies needed to improve their predictive value, and finally to identify collaboration opportunities to improve the reliability of risk prediction, mitigation, and management. This meeting report provides the Forum participant's and author's perspectives on the barriers to advancing this field and recommendations for overcoming these barriers through collaborative efforts.

  19. Analytical criteria for performance characteristics of IgE binding methods for evaluating safety of biotech food products.

    Science.gov (United States)

    Holzhauser, Thomas; Ree, Ronald van; Poulsen, Lars K; Bannon, Gary A

    2008-10-01

    There is detailed guidance on how to perform bioinformatic analyses and enzymatic degradation studies for genetically modified crops under consideration for approval by regulatory agencies; however, there is no consensus in the scientific community on the details of how to perform IgE serum studies. IgE serum studies are an important safety component to acceptance of genetically modified crops when the introduced protein is novel, the introduced protein is similar to known allergens, or the crop is allergenic. In this manuscript, we describe the characteristics of the reagents, validation of assay performance, and data analysis necessary to optimize the information obtained from serum testing of novel proteins and genetically modified (GM) crops and to make results more accurate and comparable between different investigations.

  20. R&D and knowledge dynamics in university-industry relationships in biotech and pharmaceuticals: An agent-based model

    OpenAIRE

    Triulzi, Giorgio; Scholz, Ramon; Pyka, Andreas

    2011-01-01

    In the last two decades, University-Industry Relationships have played an outstanding role in shaping innovation activities in Biotechnology and Pharmaceuticals. Despite the growing importance and the considerable scope of these relationships, there still is an intensive and open debate on their short and long term effects on the research system in life sciences. So far, the extensive literature on this topic has not been able to provide a widely accepted answer. This work introduces a new wa...

  1. Incubating Innovation: A standard model for nurturing new businesses, the incubator gains prominence in the world of biotech.

    Science.gov (United States)

    Grifantini, Kristina

    2015-01-01

    Incubators, accelerators, innovation centers, launch pads. Everyone defines the idea a bit differently, but, generally, these infrastructures refer to a subsidized space where fledgling companies get support?a combination of mentorship, funding, low rent, networking opportunities, and other training?with the goal of propelling early businesses to success.

  2. Teaching and implementing autonomous robotic lab walkthroughs in a biotech laboratory through model-based visual tracking

    Science.gov (United States)

    Wojtczyk, Martin; Panin, Giorgio; Röder, Thorsten; Lenz, Claus; Nair, Suraj; Heidemann, Rüdiger; Goudar, Chetan; Knoll, Alois

    2010-01-01

    After utilizing robots for more than 30 years for classic industrial automation applications, service robots form a constantly increasing market, although the big breakthrough is still awaited. Our approach to service robots was driven by the idea of supporting lab personnel in a biotechnology laboratory. After initial development in Germany, a mobile robot platform extended with an industrial manipulator and the necessary sensors for indoor localization and object manipulation, has been shipped to Bayer HealthCare in Berkeley, CA, USA, a global player in the sector of biopharmaceutical products, located in the San Francisco bay area. The determined goal of the mobile manipulator is to support the off-shift staff to carry out completely autonomous or guided, remote controlled lab walkthroughs, which we implement utilizing a recent development of our computer vision group: OpenTL - an integrated framework for model-based visual tracking.

  3. Analytical criteria for performance characteristics of IgE binding methods for evaluating safety of biotech food products.

    Science.gov (United States)

    Holzhauser, Thomas; Ree, Ronald van; Poulsen, Lars K; Bannon, Gary A

    2008-10-01

    There is detailed guidance on how to perform bioinformatic analyses and enzymatic degradation studies for genetically modified crops under consideration for approval by regulatory agencies; however, there is no consensus in the scientific community on the details of how to perform IgE serum studies. IgE serum studies are an important safety component to acceptance of genetically modified crops when the introduced protein is novel, the introduced protein is similar to known allergens, or the crop is allergenic. In this manuscript, we describe the characteristics of the reagents, validation of assay performance, and data analysis necessary to optimize the information obtained from serum testing of novel proteins and genetically modified (GM) crops and to make results more accurate and comparable between different investigations. PMID:18727951

  4. The value of trust in biotech crop development: a case study of Bt cotton in Burkina Faso

    Directory of Open Access Journals (Sweden)

    Ezezika Obidimma C

    2012-11-01

    Full Text Available Abstract Background Agricultural biotechnology public-private partnerships (PPPs have been recognized as having great potential in improving agricultural productivity and increasing food production in sub-Saharan Africa. However, there is much public skepticism about the use of GM (genetically modified crops and suspicion about private sector involvement in agbiotech projects. This case study sought to understand the role of trust in the Bacillus thuringiensis (Bt cotton in Burkina Faso project by exploring practices and challenges associated with trust-building, and determining what makes these practices effective from the perspective of multiple stakeholders. Methods We conducted semi-structured, face-to-face interviews to obtain stakeholders’ understanding of trust in general as well as in the context of agbiotech PPPs. Relevant documents and articles were analyzed to generate descriptions of how trust was operationalized in this evolving agbiotech PPP. Data was analyzed based on emergent themes to create a comprehensive narrative on how trust is understood and built among the partners and with the community. Results We derived four key lessons from our findings. First, strong collaboration between research, industry and farmers greatly contributes to both the success of, and fostering of trust in, the partnership. Second, this case study also revealed the important, though often unrecognized, role of researchers as players in the communication strategy of the project. Third, effective and comprehensive communication takes into account issues such as illiteracy and diversity. Fourth, follow-up at the field level and the need for a multifaceted communications strategy is important for helping push the project forward. Conclusions Burkina Faso’s well-established and effective cotton selling system laid the foundation for the implementation of the Bt cotton project – particularly, the strong dialogue and the receptivity to collaboration. Interviewees reported that establishing and maintaining trust among partners, researchers and the community in Burkina Faso greatly contributed to the success of the PPP. By addressing challenges to building trust and engaging in trust-building practices early on, improvements in the effectiveness of agbiotech PPPs are likely.

  5. Electrochemical sensor for multiplex screening of genetically modified DNA: identification of biotech crops by logic-based biomolecular analysis.

    Science.gov (United States)

    Liao, Wei-Ching; Chuang, Min-Chieh; Ho, Ja-An Annie

    2013-12-15

    Genetically modified (GM) technique, one of the modern biomolecular engineering technologies, has been deemed as profitable strategy to fight against global starvation. Yet rapid and reliable analytical method is deficient to evaluate the quality and potential risk of such resulting GM products. We herein present a biomolecular analytical system constructed with distinct biochemical activities to expedite the computational detection of genetically modified organisms (GMOs). The computational mechanism provides an alternative to the complex procedures commonly involved in the screening of GMOs. Given that the bioanalytical system is capable of processing promoter, coding and species genes, affirmative interpretations succeed to identify specified GM event in terms of both electrochemical and optical fashions. The biomolecular computational assay exhibits detection capability of genetically modified DNA below sub-nanomolar level and is found interference-free by abundant coexistence of non-GM DNA. This bioanalytical system, furthermore, sophisticates in array fashion operating multiplex screening against variable GM events. Such a biomolecular computational assay and biosensor holds great promise for rapid, cost-effective, and high-fidelity screening of GMO.

  6. Two-Year Community: The Impact of the Clinical Social Worker in a Community College Biotech Program: A Cohort Study

    Science.gov (United States)

    Tanski, Anne E.; Bobick, Sandra; Mosley-Turner, Katherine; Garofalo, Giovanni

    2016-01-01

    Given biotechnology's emergence as a major competitor in the Pittsburgh region, critically linking education to industry through the Community College of Allegheny County's Biotechnology Workforce Collaborative (BWC) provided a well-trained workforce. The collaborative also sought to increase the number of women in the sciences, specifically…

  7. Sectoral Innovatiohn Performance in the Biotechnology Sector. Final Report. Task 1

    NARCIS (Netherlands)

    Enzing, C.M.; Valk, T. van der

    2010-01-01

    In general the biotechnology sector can be qualified as a science driven and high tech sector. This applies for both the group of biotech start-ups that are present in each of the three sub-sectors (red biotech: health/pharma, green biotech: agrifood and white biotech: chemicals) as for the red biot

  8. Association of a hi-tech with a bio-tech technique in the treatment of early osteoarthritis of the knee: a case report

    OpenAIRE

    UBOLDI, FRANCESCO MATTIA; FERRUA, PAOLO; PARENTE, ANDREA; Pasqualotto, Stefano; Berruto, Massimo

    2016-01-01

    Meniscal replacement to treat early osteoarthritis of the knee after meniscectomy may be accompanied by other surgical procedures to treat factors predisposing to a negative intervention outcome. Overload of the medial compartment in slight varus can be reduced by applying the new KineSpring system, which can promote the best possible outcome of a biodegradable meniscal scaffold implantation, without producing biomechanical and anatomical alterations of the joint. This is the first case repor...

  9. Collaborative pre-competitive preclinical drug discovery with academics and pharma/biotech partners at Sanford|Burnham: infrastructure, capabilities & operational models.

    Science.gov (United States)

    Chung, Thomas D Y

    2014-03-01

    There has been increased concern that the current "blockbuster" model of drug discovery and development practiced by "Big Pharma" are unsustainable in terms of cost (> $1 billion/approved drug) and time to market (10 - 15 years). The recent mergers and acquisitions (M&A), shuttering of internal research programs, closure of "redundant" sites of operations, senior management turnover and continued workforce reductions among the top 10 major pharmaceutical companies reflect draconian responses to reduce costs. However, the resultant exodus of intellectual capital, loss in motivation and momentum, and exit from early stage discovery programs by pharmaceutical companies has contributed to an "innovation deficit". Disease advocacy groups, investment communities and the government are calling for new innovative business models to address this deficit. In particular they are looking towards academia and clinical trials centers to catalyze new innovations in translational research. Indeed over the last decade many academic institutions have launched drug discovery centers largely comprising high-throughput screening (HTS) to accelerate "translational" research. A major impetus for this "open innovation" effort has been the National Institutes of Health (NIH) "Roadmap" and Molecular Libraries Initiative/Program (MLI/MLP), which is in its last year, and will be transitioned into the National Center for the Advancement of Translational Sciences (NCATS). With the end of Roadmap funding, general reduction in Federal government funding and its recent sequestration, academic drug discovery centers are being challenged to become selfsustaining, adding financial value, while remaining aligned with the missions of their respective academic non-profit institutions. We describe herein, a brief history of our bi-coastal Conrad Prebys Center for Chemical Genomics (Prebys Center) at the Sanford|Burnham Medical Research Institute (SBMRI), the key components of its infrastructure, core competencies of its fully integrated drug discovery expertise, best practices adopted in our day-to-day operations, and finally some of our current funding and collaboration and/or strategic alliance models for pre-competitive drug discovery with other academic/clinical partners, other governmental agencies, and with pharmaceutical and biotechnology companies. PMID:24409951

  10. Sharpening a biotech patent through methods claims under the litigation strategy of induced infringement: a message from the US Federal Circuit full court decision.

    Science.gov (United States)

    Wang, Shyh-Jen

    2014-01-01

    A CAFC en banc case from 2012 holds that all of the steps of a claimed method must be performed, but it is not necessary that all steps be performed by a single entity, which are the requirements of the traditional "all-elements rule," for induced infringement to occur. An induced infringement is that an alleged infringer knowingly induces infringement and possesses intention to encourage another's infringement. In this way, even when the entity omits a part or property from the claims of an existing patent, which has been a common and successfully used practice to avoid direct patent infringement, may still be liable for induced infringement. A case study discussed in this article demonstrates this possibility. To design-around a patent, one should pay attention to the methods claims to avoid both direct and induced infringement. On the contrary, a patentee should increase the scope of the methods claims for better protection. The patent owner may thus increase the patent's power with the methods claims because not all steps of a claimed method would have to be committed by a single entity to find the induced infringement.

  11. Current barriers, challenges and opportunities for the development of effective STI vaccines: point of view of vaccine producers, biotech companies and funding agencies.

    Science.gov (United States)

    Dodet, Betty

    2014-03-20

    Several barriers limit the development of vaccines against sexually transmitted diseases (STIs). Critical scientific information is missing that makes the feasibility and the likelihood of success of vaccines against genital herpes, chlamydia, gonorrhea and trichomonas uncertain: the immunity induced by natural infection is absent or imperfect which seriously limits the capacity to define the types of immune responses that an effective vaccine must induce. Reliable animal models are lacking and a number of crucial clinical questions are still unanswered about the goal of these vaccines and definition of endpoints for clinical trials. In the absence of a clear recognition of the need for vaccines against these diseases, there is no motivation for public or private research and industry to invest in the development of vaccines against STIs. The STI burden should be evaluated not only in terms of mortality and morbidity, but also in terms of economic and psycho-social impact. A global public-private consortium could mobilize the joint efforts of all stakeholders involved in the research, development and implementation of STI vaccines of the public and private sectors; ensure that sufficient resources are applied to R&D of vaccines against these STIs; and provide the pull-push forces that are necessary to overcome the barriers to develop safe and effective vaccines against these diseases. PMID:23994377

  12. Collaborative pre-competitive preclinical drug discovery with academics and pharma/biotech partners at Sanford|Burnham: infrastructure, capabilities & operational models.

    Science.gov (United States)

    Chung, Thomas D Y

    2014-03-01

    There has been increased concern that the current "blockbuster" model of drug discovery and development practiced by "Big Pharma" are unsustainable in terms of cost (> $1 billion/approved drug) and time to market (10 - 15 years). The recent mergers and acquisitions (M&A), shuttering of internal research programs, closure of "redundant" sites of operations, senior management turnover and continued workforce reductions among the top 10 major pharmaceutical companies reflect draconian responses to reduce costs. However, the resultant exodus of intellectual capital, loss in motivation and momentum, and exit from early stage discovery programs by pharmaceutical companies has contributed to an "innovation deficit". Disease advocacy groups, investment communities and the government are calling for new innovative business models to address this deficit. In particular they are looking towards academia and clinical trials centers to catalyze new innovations in translational research. Indeed over the last decade many academic institutions have launched drug discovery centers largely comprising high-throughput screening (HTS) to accelerate "translational" research. A major impetus for this "open innovation" effort has been the National Institutes of Health (NIH) "Roadmap" and Molecular Libraries Initiative/Program (MLI/MLP), which is in its last year, and will be transitioned into the National Center for the Advancement of Translational Sciences (NCATS). With the end of Roadmap funding, general reduction in Federal government funding and its recent sequestration, academic drug discovery centers are being challenged to become selfsustaining, adding financial value, while remaining aligned with the missions of their respective academic non-profit institutions. We describe herein, a brief history of our bi-coastal Conrad Prebys Center for Chemical Genomics (Prebys Center) at the Sanford|Burnham Medical Research Institute (SBMRI), the key components of its infrastructure, core competencies of its fully integrated drug discovery expertise, best practices adopted in our day-to-day operations, and finally some of our current funding and collaboration and/or strategic alliance models for pre-competitive drug discovery with other academic/clinical partners, other governmental agencies, and with pharmaceutical and biotechnology companies.

  13. 78 FR 26784 - David Freeman: Debarment Order

    Science.gov (United States)

    2013-05-08

    ... each package. The pills were in blister packs on which was written ``Omega Biotech LTD.'' Mr. Freeman... relevant times, neither Muhi Trading Corporation nor Omega Biotech LTD. were registered to...

  14. 78 FR 25456 - Ashley Brandon Foyle: Debarment Order

    Science.gov (United States)

    2013-05-01

    ... blister packs on which was written ``Omega Biotech LTD.'' Mr. Foyle and his co-defendant, David Freeman... nor Omega Biotech LTD. were registered to manufacture, prepare, propagate, compound, or process...

  15. 77 FR 29399 - Order of Suspension of Trading; In the Matter of 1-800-ATTORNEY, Inc., et al.

    Science.gov (United States)

    2012-05-17

    ... securities of Enhance Biotech, Inc. because questions have arisen as to its operating status, if any. Enhance Biotech, Inc. is quoted on OTC Link operated by OTC Markets Group, Inc. under the ticker symbol...

  16. Potential for false positive HIV test results with the serial rapid HIV testing algorithm

    Directory of Open Access Journals (Sweden)

    Baveewo Steven

    2012-03-01

    Full Text Available Abstract Background Rapid HIV tests provide same-day results and are widely used in HIV testing programs in areas with limited personnel and laboratory infrastructure. The Uganda Ministry of Health currently recommends the serial rapid testing algorithm with Determine, STAT-PAK, and Uni-Gold for diagnosis of HIV infection. Using this algorithm, individuals who test positive on Determine, negative to STAT-PAK and positive to Uni-Gold are reported as HIV positive. We conducted further testing on this subgroup of samples using qualitative DNA PCR to assess the potential for false positive tests in this situation. Results Of the 3388 individuals who were tested, 984 were HIV positive on two consecutive tests, and 29 were considered positive by a tiebreaker (positive on Determine, negative on STAT-PAK, and positive on Uni-Gold. However, when the 29 samples were further tested using qualitative DNA PCR, 14 (48.2% were HIV negative. Conclusion Although this study was not primarily designed to assess the validity of rapid HIV tests and thus only a subset of the samples were retested, the findings show a potential for false positive HIV results in the subset of individuals who test positive when a tiebreaker test is used in serial testing. These findings highlight a need for confirmatory testing for this category of individuals.

  17. Potential for false positive HIV test results with the serial rapid HIV testing algorithm

    Science.gov (United States)

    2012-01-01

    Background Rapid HIV tests provide same-day results and are widely used in HIV testing programs in areas with limited personnel and laboratory infrastructure. The Uganda Ministry of Health currently recommends the serial rapid testing algorithm with Determine, STAT-PAK, and Uni-Gold for diagnosis of HIV infection. Using this algorithm, individuals who test positive on Determine, negative to STAT-PAK and positive to Uni-Gold are reported as HIV positive. We conducted further testing on this subgroup of samples using qualitative DNA PCR to assess the potential for false positive tests in this situation. Results Of the 3388 individuals who were tested, 984 were HIV positive on two consecutive tests, and 29 were considered positive by a tiebreaker (positive on Determine, negative on STAT-PAK, and positive on Uni-Gold). However, when the 29 samples were further tested using qualitative DNA PCR, 14 (48.2%) were HIV negative. Conclusion Although this study was not primarily designed to assess the validity of rapid HIV tests and thus only a subset of the samples were retested, the findings show a potential for false positive HIV results in the subset of individuals who test positive when a tiebreaker test is used in serial testing. These findings highlight a need for confirmatory testing for this category of individuals. PMID:22429706

  18. Vývoj a optimalizace metodiky pro detekci GMO brambor

    OpenAIRE

    ČERMÁKOVÁ, Jitka

    2008-01-01

    Genetically modified (GM) or transgenic crops, now more often called "Biotech crops" they are commercially cultivated since 1996. And also since 1996, the first year of commercialization of biotech crops, GM potatoes were cultivated in USA, Mexico, Canada and later in South Africa, China and India. The global area of approved biotech crops in 2006 was 102 million hectares and 22 countries grew biotech crops, 11 developing countries and 11 industrial countries. The Czech Republic is on of the ...

  19. 76 FR 2807 - New Animal Drugs; Change of Sponsor

    Science.gov (United States)

    2011-01-18

    ... from Biopure Corp. to OPK Biotech, LLC. DATES: This rule is effective January 18, 2011. FOR FURTHER... Biotech, LLC, 11 and 39 Hurley St., Cambridge, MA 02141. There is no change in drug labeler code... addition, OPK Biotech, LLC, is not currently listed in the animal drug regulations as a sponsor of...

  20. GMO Biosafety Management, Suggestions and Biotech Public Acceptance in China%我国转基因作物安全管理体系介绍、发展建议及生物技术舆论导向

    Institute of Scientific and Technical Information of China (English)

    康乐; 陈明

    2013-01-01

    17年间,转基因作物在全球的种植面积逐渐扩大了100倍,截止2012年已经达到1.7亿公顷,产生了巨大的经济效益、社会效益和生态效益.我国转基因作物发展迅速,目前已有7种转基因植物获得生产应用安全证书,转基因棉花占全国棉花种植面积的80%.为保障转基因生物安全,我国已建立了完整的转基因生物安全管理体系,包括安全管理机构、政策、法规,转基因生物及其产品如环境安全评价、食品安全性评价及成份测定的技术标准.另一方面,我国转基因作物安全管理及安全评价体系仍然需要完善,本文针对现阶段存在的问题提出了改进及完善的建议.同时,本文分析了我国转基因作物舆情,列举了近来国内外所谓的转基因作物安全事件并揭示了事件的真实情况,提倡理性看待转基因作物的发展,为我国转基因研发与产业化营造积极的舆论氛围.%GM crops have been commercialized for 17 years all over the world,and brought great economic,social and ecological benefits to growers and the world.China has approved 7 GM crops for planting,among which Bt cotton accounts for 80% of cotton planting area.In this article,we reviewed development and application of GM crop internationally and domestically.The policy on GM crops in China including regulations,guidelines,food and environmental safety assessment are also briefly introduced.Some existing problems and suggestions on China's biosafety management and regulator process are also described in this review.Finally,the authors advocate rational understanding of GM crops to create a positive atmosphere for public acceptance,which will benefit research,development and commercialization of GM crops in China.

  1. Create a translational medicine knowledge repository--research downsizing, mergers and increased outsourcing have reduced the depth of in-house translational medicine expertise and institutional memory at many pharmaceutical and biotech companies: how will they avoid relearning old lessons?

    Science.gov (United States)

    Littman, Bruce H; Marincola, Francesco M

    2011-05-10

    Pharmaceutical industry consolidation and overall research downsizing threatens the ability of companies to benefit from their previous investments in translational research as key leaders with the most knowledge of the successful use of biomarkers and translational pharmacology models are laid off or accept their severance packages. Two recently published books may help to preserve this type of knowledge but much of this type of information is not in the public domain. Here we propose the creation of a translational medicine knowledge repository where companies can submit their translational research data and access similar data from other companies in a precompetitive environment. This searchable repository would become an invaluable resource for translational scientists and drug developers that could speed and reduce the cost of new drug development.

  2. Create a translational medicine knowledge repository - Research downsizing, mergers and increased outsourcing have reduced the depth of in-house translational medicine expertise and institutional memory at many pharmaceutical and biotech companies: how will they avoid relearning old lessons?

    Directory of Open Access Journals (Sweden)

    Marincola Francesco M

    2011-05-01

    Full Text Available Abstract Pharmaceutical industry consolidation and overall research downsizing threatens the ability of companies to benefit from their previous investments in translational research as key leaders with the most knowledge of the successful use of biomarkers and translational pharmacology models are laid off or accept their severance packages. Two recently published books may help to preserve this type of knowledge but much of this type of information is not in the public domain. Here we propose the creation of a translational medicine knowledge repository where companies can submit their translational research data and access similar data from other companies in a precompetitive environment. This searchable repository would become an invaluable resource for translational scientists and drug developers that could speed and reduce the cost of new drug development.

  3. Sipuleucel-T (Provenge(®))-Autopsy of an Innovative Paradigm Change in Cancer Treatment: Why a Single-Product Biotech Company Failed to Capitalize on its Breakthrough Invention.

    Science.gov (United States)

    Jarosławski, Szymon; Toumi, Mondher

    2015-10-01

    Approved by the US Food and Drug Administration (FDA) in 2010, sipuleucel-T (Provenge(®)) was the first 'personalized' cancer vaccine for the treatment of prostate cancer in a metastatic, non-symptomatic population of 30,000 men in the USA. Sipuleucel-T is prepared individually for each patient and infused in three sessions over a period of 1 month. However, in 2015, Dendreon, the owner of sipuleucel-T, filed for bankruptcy. This opinion paper reviews the probable reasons this innovative product failed to achieve commercial success. PubMed and internet searches were performed focused on pricing, reimbursement, and market access. We found that sipuleucel-T's FDA approval was delayed by 3 years, reportedly because of the vaccine's new mechanism of action. Sipuleucel-T was cleared by the European Medicines Agency 2 years later, but other national agencies were not approached. It was priced at $US93,000 for a course of treatment, and this high price combined with the company's late securement of reimbursement for the vaccine by the US Centers for Medicare and Medicaid Services (CMS) resulted in another year's delay in accessing the market. Despite a positive recommendation by the National Comprehensive Cancer Network, sipuleucel-T's complex administration, high price, and uncertainty about the reimbursement status deterred doctors from prescribing the product. Furthermore, the vaccine's supply was limited during the first year of launch due to limited manufacturing capacity. In addition, two oral metastatic prostate cancer drugs with similar survival benefits reached the US market 1 and 2 years after sipuleucel-T. Also, even though Dendreon's market capitalization topped $US7.5 billion following the FDA's approval of sipuleucel-T, this value degraded gradually until the firm's bankruptcy 5 years later. We conclude that the bankruptcy of Dendreon was largely due to the delay in securing FDA approval and CMS coverage, as well as the high cost that had to be incurred by providers up-front. Licensing sipuleucel-T to a pharmaceutical company more experienced in the market access pathway may have saved the company and the product.

  4. IMPLICATIONS OF RICE BIOTECHNOLOGY ON OPTIMAL RICE CROP ROTATION IN THE MISSISSIPPI RIVER DELTA REGION

    OpenAIRE

    Annou, Mamane Malam; Thomsen, Michael R.; Hansen, James M.; Wailes, Eric J.; Cramer, Gail L.

    2001-01-01

    Availability of new herbicide-resistant biotech rice varieties may affect traditional rice rotation practices to control red rice and enhance yields. This research evaluates the adoption of biotech rice and its effects on the current practice of crop rotation in the Mississippi River Delta region. The optimal utilization of biotech rice rotation is analyzed using a nonlinear mathematical programming model with mixed integers. Optimal rotation was found to be sensitive to the technology fee, r...

  5. Learning Outcomes Associated with Classroom Implementation of a Biotechnology-Themed Video Game

    Science.gov (United States)

    Barko, Tim; Sadler, Troy D.

    2013-01-01

    The educational video game Mission Biotech provides a virtual experience for students in learning biotechnology materials and tools. This study explores the use of Mission Biotech and the associated curriculum by three high school teachers and their students. All three classes demonstrated gains on a curriculum-aligned test of science content.…

  6. Innovative Tools for Scientific and Technological Education in Italian Secondary Schools

    Science.gov (United States)

    Santucci, Annalisa; Mini, Roberta; Ferro, Elisa; Martelli, Paola; Trabalzini, Lorenza

    2004-01-01

    This paper describes the project "Biotech a Scuola" ("Biotech at School"), financed by the Italian Ministry of Education within the SeT program (Special Project for Scientific-Technological Education). The project involved the University of Siena, five senior and junior secondary schools in the Siena area, and a private company. Twenty-three…

  7. Doing business with the NIH

    Science.gov (United States)

    Ben-Menachem, Gil; Ferguson, Steven M; Balakrishnan, Krishna

    2009-01-01

    Young biotech startups can benefit hugely from the US National Institutes of Health (NIH), not least because of the agency's non-dilutive funding, guidance, and opportunities for collaboration. Increasingly, however, there is a fair bit of misunderstanding about what the NIH can and cannot do for a biotech entrepreneur. PMID:16475248

  8. Increased chromosomal breakage in Tourette syndrome predicts the possibility of variable multiple gene involvement in spectrum phenotypes: Preliminary findings and hypothesis

    Energy Technology Data Exchange (ETDEWEB)

    Gericke, G.S.; Simonic, I.; Cloete, E.; Buckle, C. [Univ. of Pretoria (South Africa)] [and others

    1995-10-09

    Increased chromosomal breakage was found in 12 patients with DSM-IV Tourette syndrome (TS) as compared with 10 non-TS control individuals with respect to untreated, modified RPM1-, and BrdU treated lymphocyte cultures (P < 0.001 in each category). A hypothesis is proposed that a major TS gene is probably connected to genetic instability, and associated chromosomal marker sites may be indicative of the localization of secondary genes whose altered expression could be responsible for associated comorbid conditions. This concept implies that genes influencing higher brain functions may be situated at or near highly recombigenic areas allowing enhanced amplification, duplication and recombination following chromosomal strand breakage. Further studies on a larger sample size are required to confirm the findings relating to chromosomal breakage and to analyze the possible implications for a paradigmatic shift in linkage strategy for complex disorders by focusing on areas at or near unstable chromosomal marker sites. 32 refs., 1 tab.

  9. The Role of Transgenic Crops in the Future of Global Food and Feed

    OpenAIRE

    O. Škubna; H. Řezbová

    2012-01-01

    The paper is aimed on the problematic of biotech crops planting (GM, transgenic crops). The main aim of this paper is to analyze the trends in the main biotech crops planting groups in the sense of their use for food and feed in the future. The selected groups of biotech crops analyzed in this article are soybeans, maize (corn), cotton and rapeseed (canola). The used methods are chain and basic indexes and regression analysis of times series/ trend data - for predicting on next four years (20...

  10. Gene cuisine or Frankenfood? The theory of reasoned action as an audience segmentation strategy for messages about genetically modified foods.

    Science.gov (United States)

    Silk, Kami J; Weiner, Judith; Parrott, Roxanne L

    2005-12-01

    Genetically modified (GM) foods are currently a controversial topic about which the lay public in the United States knows little. Formative research has demonstrated that the lay public is uncertain and concerned about GM foods. This study (N = 858) extends focus group research by using the Theory of Reasoned Action (TRA) to examine attitudes and subjective norms related to GM foods as a theoretical strategy for audience segmentation. A hierarchical cluster analysis revealed four unique audiences based on their attitude and subjective norm toward GM foods (ambivalent-biotech, antibiotech, biotech-normer, and biotech individual). Results are discussed in terms of the theoretical and practical significance for audience segmentation.

  11. Scientific Opinion on the safety and efficacy of vitamin D3 (cholecalciferol as a feed additive for pigs, piglets, bovines, ovines, calves, equines, chickens for fattening, turkeys, other poultry, fish and other animal species or categories, based on a dossier submitted by Fermenta Biotech Ltd

    Directory of Open Access Journals (Sweden)

    EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP

    2013-07-01

    Full Text Available The principal physiological role of vitamin D in all vertebrates is in calcium and phosphorus homeostasis. The classic clinical deficiency syndrome is rickets. The FEEDAP Panel notes that for turkeys for fattening, equines, bovines, ovines and pigs the maximum content for vitamin D3 in feed does not provide any margin of safety, and that, except for pigs, the maximum content is above the upper safe level, according to National Research Council data when animals were fed a supplemented diet for more than 60 days. No safety concern was identified for the use of vitamin D3 in chickens for fattening and fish. The FEEDAP Panel is not in a position to draw final conclusions on the safety of vitamin D for target animals but considers the current maximum contents temporarily acceptable pending a review of the recent scientific literature. Current nutritional surveys in 14 European countries showed that vitamin D intake is sufficiently below the upper safe limit. The FEEDAP Panel assumes that foodstuffs of animal origin were produced following current production practices, including vitamin D3 supplementation of feed and concludes that the use of vitamin D in animal nutrition at the currently authorised maximum dietary content has not and will not cause the tolerable upper intake level to be exceeded. Vitamin D3 should be considered as irritant to skin and eyes, and as a skin sensitiser. Inhaled vitamin D3 is highly toxic; exposure to dust is harmful. No risk to the environment resulting from the use of vitamin D3 in animal nutrition is expected. The vitamin D3 under application is regarded as an effective dietary source of the vitamin in animal nutrition.

  12. Global Status of Commercialized Biotech/GM Crops:2008%2008年全球生物技术/转基因作物商业化发展态势——第一个十三年(1996-2008)

    Institute of Scientific and Technical Information of China (English)

    Clive James

    2009-01-01

    @@ 本文介绍了2008年转基因作物的主要情况.由于采用转基因作物取得了巨大经济、环境和社会效益,2008年(转基因作物商业化的第十三个年头),全世界上百万小型和资源匮乏型农户继续种植转基因作物,种植面积有了较大增长(图1).

  13. Estonian science breeds world-class researches / ToivoTänavsuu, Hille Tänavsuu

    Index Scriptorium Estoniae

    Tänavsuu, Toivo

    2010-01-01

    Eesti teadusfirmadest: biotehnoloogia ettevõtted Celecure AS, Protobios OÜ, Icosagen AS, Asper Biotech AS ja Solis BioDyne OÜ, geenitehnoloogia firma Genorama OÜ, keemiatehnoloogia ettevõte AS Cambrex Tallinn

  14. Experiment list: SRX029315 [Chip-atlas[Archive

    Lifescience Database Archive (English)

    Full Text Available | cell type=CD34+CD133+ hematopoietic progenitor cells (HPCs) || antibody=anti-GABP-alpha || antibody manufacturer=Santa Cruz Biotech...nology http://dbarchive.biosciencedbc.jp/kyushu-u/hg19/e

  15. Between Precautionary Principle and "Sound Science": Distributing the Burdens of Proof

    NARCIS (Netherlands)

    Belt, v.d. H.; Gremmen, B.

    2002-01-01

    Opponents of biotechnology ofteninvoke the Precautionary Principle to advancetheir cause, whereas biotech enthusiasts preferto appeal to ``sound science.'' Publicauthorities are still groping for a usefuldefinition. A crucial issue in this debate isthe distribution of the burden of proof amongthe pa

  16. Experiment list: SRX150700 [Chip-atlas[Archive

    Lifescience Database Archive (English)

    Full Text Available z Biotech || antibody vendorid=sc-66882 || control=std || control description=Standard input signal for most experiments.... || control=std || control description=Standard input signal for most experiments. || controlid

  17. Experiment list: SRX150627 [Chip-atlas[Archive

    Lifescience Database Archive (English)

    Full Text Available Cruz Biotech || antibody vendorid=sc-764 || control=std || control description=Standard input signal for most experiments.... || control=std || control description=Standard input signal for most experiments. || control

  18. Experiment list: SRX150691 [Chip-atlas[Archive

    Lifescience Database Archive (English)

    Full Text Available a Cruz Biotech || antibody vendorid=sc-345 || control=std || control description=Standard input signal for most experiments.... || control=std || control description=Standard input signal for most experiments. || contro

  19. Experiment list: SRX150435 [Chip-atlas[Archive

    Lifescience Database Archive (English)

    Full Text Available Biotech || antibody vendorid=sc-7202 || control=std || control description=Standard input signal for most experiments.... || control=std || control description=Standard input signal for most experiments. || controlid=wg

  20. Experiment list: SRX150551 [Chip-atlas[Archive

    Lifescience Database Archive (English)

    Full Text Available name=Santa Cruz Biotech || antibody vendorid=sc-345 || control=std || control description=Standard input signal for most experiments.... || control=std || control description=Standard input signal for most experiments.

  1. Experiment list: SRX150561 [Chip-atlas[Archive

    Lifescience Database Archive (English)

    Full Text Available ta Cruz Biotech || antibody vendorid=sc-1703 || control=std || control description=Standard input signal for most experiments.... || control=std || control description=Standard input signal for most experiments. || cont

  2. Experiment list: SRX150546 [Chip-atlas[Archive

    Lifescience Database Archive (English)

    Full Text Available e=Santa Cruz Biotech || antibody vendorid=sc-1694 || control=std || control description=Standard input signal for most experiments.... || control=std || control description=Standard input signal for most experiments. ||

  3. Experiment list: SRX150445 [Chip-atlas[Archive

    Lifescience Database Archive (English)

    Full Text Available Biotech || antibody vendorid=sc-866 || control=std || control description=Standard input signal for most experiments.... || control=std || control description=Standard input signal for most experiments

  4. Experiment list: SRX150681 [Chip-atlas[Archive

    Lifescience Database Archive (English)

    Full Text Available rname=Santa Cruz Biotech || antibody vendorid=sc-1694 || control=std || control description=Standard input signal for most experiment...s. || control=std || control description=Standard input signal for most experiments

  5. Small company mergers--good for whom?

    Science.gov (United States)

    Maybeck, Vanessa; Bains, William

    2006-11-01

    An analysis of 105 mergers among small UK biotech companies over a 10-year period shows that the improvement of shareholder positions, rather than product pipelines or business opportunities, is the main motivation for such transactions. PMID:17093475

  6. Experiment list: SRX190285 [Chip-atlas[Archive

    Lifescience Database Archive (English)

    Full Text Available tem cell development, cell senescence and death, and tumorigenesis || antibody vendorname=Santa Cruz Biotech...erous genes and are involved in stem cell development, cell senescence and death, and tumorigenes

  7. Development of carotenoid-enriched vegetables with increased nutritional quality and visual appearance

    Science.gov (United States)

    Carotenoids are a class of red, orange and yellow pigments widely distributed in nature. Biotech approach has been proved to be effective in successfully engineering of carotenoid content in food crops with better health and visual appearance....

  8. Keeping enzymes kosher

    DEFF Research Database (Denmark)

    Fischer, Johan

    2015-01-01

    Biotech companies increasingly seek certification for compliance with religious and dietary requirements in order to address new consumer markets. Technology plays a crucial role in such inspections alongside centuries old traditions and practices...

  9. A GOLDEN HANDSHAKE FOR CH NA'S B OFUEL

    Institute of Scientific and Technical Information of China (English)

    2011-01-01

    Friendly policies for overseas investors to invest in China's biofuel sector have influenced partnerships between domestic and foreign companies to develop the alternative to fossil fuel. For example, Green Biologics (GBL), a British biotech company, has

  10. Beyond The Needle: Biotech’s Delivery Challenge

    OpenAIRE

    FELCONE, LINDA HULL

    2004-01-01

    Some biotech companies are devoting sizeable resources to finding more mainstream forms of drug delivery, including oral, transdermal, inhaled, and ocular administration. P&T committees, watch closely: Easier dosing could bring broader acceptance.

  11. 生物产业与生物经济

    Institute of Scientific and Technical Information of China (English)

    王宏广

    2004-01-01

    At the turn of 21 th century, breakthroughs have been made continuously in the biology technology. That gives a great help to the quick emergence of biotech industry. Some tendencies can be seen in the industry: 1) Biotech has become the research focus in many countries. 2)Biotech industry has been the emphasis of international high-tech and economic competition.3) Biology economy is becoming a new economic growth point after Internet.4)Biology security has become the key of the state security. The emergence of biotech industry will accelerate the formation of the 4th economy upsurge and will have great effect on the world economy and the development of human society.

  12. MA Common Tern Census

    Data.gov (United States)

    US Fish and Wildlife Service, Department of the Interior — The official State census period for common terns was June 1-10. The survey was conducted on June 4 by Biologist Healey, Biotech Springfield, and Maintenance...

  13. Eesti teadlaste HIV-vaktsiini süstitakse katseks aafriklastele / Villu Päärt

    Index Scriptorium Estoniae

    Päärt, Villu, 1972-

    2006-01-01

    Vt. ka Postimees : na russkom jazõke 5. apr., lk. 2. Tartu teadlaste leiutatud ning Soome biotehnoloogiafirma FIT Biotech arendatavat vaktsiini katsetatakse Lõuna-Aafrika Vabariigis 60 surmaviirusega nakatunud inimese peal. Lisa: Eestlaste HIV-vaktsiini senine lugu

  14. Eestis levinud HIVi erilisus jätab nakatunud vaktsiinilootuseta / Villu Päärt

    Index Scriptorium Estoniae

    Päärt, Villu, 1972-

    2002-01-01

    Soome biotehnoloogiafirma FIT Biotech on loobumas kavast katsetada Eesti teadlaste leiutatud vaktsiini ka siinsete HIV-positiivsete katserühmal, sest Eestis on levinud maailmas üliharuldane HI-viiruse G-alatüüp

  15. Tissue Microarray A New Tool for Cancer Research

    Institute of Scientific and Technical Information of China (English)

    2005-01-01

    Shanghai Outdo Biotech Co.Ltd. (Outdo Biotech) is a leading company in human/animal Tissue Microarrays (TMA) and "Clinical-Type" Gene Chip (CTGC) in China. Our shareholders are Shanghai Biochip Co., Ltd. & National Engineering Center for Biochip at Shanghai, Shanghai Cancer institute and Eastern Liver and Bladder Hospital of Second Military Medical University. TMA is a mean of combining tens to hundreds of specimens of tissue, paraffin embedded or frozen, onto a single slide for analysis at once. Our constr...

  16. New challenges and opportunities for industrial biotechnology

    OpenAIRE

    Chen Guo-Qiang

    2012-01-01

    Abstract Industrial biotechnology has not developed as fast as expected due to some challenges including the emergences of alternative energy sources, especially shale gas, natural gas hydrate (or gas hydrate) and sand oil et al. The weaknesses of microbial or enzymatic processes compared with the chemical processing also make industrial biotech products less competitive with the chemical ones. However, many opportunities are still there if industrial biotech processes can be as similar as th...

  17. Keeping enzymes kosher

    DEFF Research Database (Denmark)

    Fischer, Johan

    2015-01-01

    Biotech companies increasingly seek certification for compliance with religious and dietary requirements in order to address new consumer markets. Technology plays a crucial role in such inspections alongside centuries old traditions and practices......Biotech companies increasingly seek certification for compliance with religious and dietary requirements in order to address new consumer markets. Technology plays a crucial role in such inspections alongside centuries old traditions and practices...

  18. The Role of Transgenic Crops in the Future of Global Food and Feed

    Directory of Open Access Journals (Sweden)

    O. Škubna

    2012-06-01

    Full Text Available The paper is aimed on the problematic of biotech crops planting (GM, transgenic crops. The main aim of this paper is to analyze the trends in the main biotech crops planting groups in the sense of their use for food and feed in the future. The selected groups of biotech crops analyzed in this article are soybeans, maize (corn, cotton and rapeseed (canola. The used methods are chain and basic indexes and regression analysis of times series/ trend data - for predicting on next four years (2012-2015. The trends are able to determine the necessity of implementation the biotech crops planting into the agricultural systems everywhere (also in EU and it is without the questions if the impact are mainly positive or negative. The dependence of world agricultural commodity market on the biotech crops is undeniable and the prediction acknowledges that the importance is increasing. Pieces of knowledge introduced in this paper resulted from solution of an institutional research intention MSM 6046070906 „Economics of resources of Czech agriculture and their efficient use in frame of multifunctional agri-food systems“.

  19. Bioprocessing of wheat straw into nutritionally rich and digested cattle feed

    OpenAIRE

    Shrivastava, Bhuvnesh; Jain, Kavish Kumar; Kalra, Anup; Kuhad, Ramesh Chander

    2014-01-01

    Wheat straw was fermented by Crinipellis sp. RCK-1, a lignin degrading fungus, under solid state fermentation conditions. The fungus degraded 18.38% lignin at the expense of 10.37% cellulose within 9 days. However, when wheat straw fermented for different duration was evaluated in vitro, the 5 day fungal fermented wheat straw called here “Biotech Feed” was found to possess 36.74% organic matter digestibility (OMD) and 5.38 (MJ/Kg Dry matter) metabolizable energy (ME). The Biotech Feed was als...

  20. Experiment list: SRX102975 [Chip-atlas[Archive

    Lifescience Database Archive (English)

    Full Text Available eric_male || labversion=baseAlignCounts.pl v 1,p-value cutoff: 0.01,fseq v 1.84, iff_generic...ta Cruz Biotech || antibody vendorid=sc-764 || controlid=generic_male || labversion=align_on_cluster_bwa.pl ...astic disease || antibody vendorname=Santa Cruz Biotechnology || antibody vendorid=sc-764 || controlid=gen

  1. Innnovation and new business models for the regional development: travel and transportation

    OpenAIRE

    Tafur Segura, José Javier

    2011-01-01

    Regional development could present different strategies: •Relocation of industry clusters •Foreign Direct Investment attraction •Innovation based on new business models The Regional Government of Madrid (3rd largest GDP in the EU) selected strategic industries to compete & innovate: •Travel & Transportation •Aerospace •Nanotech. & •Biotech. •ICTs. •Energy

  2. Akadeemikust ettevõtja võitleb viirustega / Kaire Talviste

    Index Scriptorium Estoniae

    Talviste, Kaire, 1979-

    2012-01-01

    Molekulaarbioloog Mart Ustavi tööst bioloogiliste ravimite väljatöötamisel. HIV1/AIDS vaktsiini väljatöötamisest FIT Biotech Oy Eesti filiaalis a-tel 2000-2011. M. Ustavi biotehnoloogia firma Icosagen Grupp tehnoloogilistest arendustest

  3. Two tobacco AP1-like gene promoters with highly specific, tightly regulated and uniquely expressed activity during floral transition, initiation and development

    Science.gov (United States)

    Biotech engineering of agronomic traits requires an array of highly specific and tightly regulated promoters in flower or other tissues. In this study, we isolated and characterized two tobacco AP1-like promoters (termed NtAP1La and NtAP1Lb1) in transgenic plants using GUS reporter and tissue-speci...

  4. New insights on the relationships between geographic and institutional distance in research collaborations: a long period analysis

    OpenAIRE

    D'Amore, Rosamaria; Iorio, Roberto

    2014-01-01

    This paper analyses the relationship between institutional and geographic distance in scientific collaborations, evaluating the possible changes when a long period (sixteen years) is taken into consideration and discussing the use of some alternative measures of institutional distance. The main result, obtained by analysing the publications of the Italian biotech firms, is that international publications present an higher institutional distance than national papers, particularl...

  5. Detecting authorized and unauthorized genetically modified organisms containing vip3A by real-time PCR and next-generation sequencing

    NARCIS (Netherlands)

    Liang, C.; Dijk, van J.P.; Scholtens, I.M.J.; Staats, M.; Prins, T.W.; Voorhuijzen, M.M.; Silva, A.M.; Maisonnave Arisi, A.C.; Dunnen, den J.T.; Kok, E.J.

    2014-01-01

    The growing number of biotech crops with novel genetic elements increasingly complicates the detection of genetically modified organisms (GMOs) in food and feed samples using conventional screening methods. Unauthorized GMOs (UGMOs) in food and feed are currently identified through combining GMO ele

  6. TECHcitement: Advances in Technological Education, 2004

    Science.gov (United States)

    American Association of Community Colleges (NJ1), 2004

    2004-01-01

    This edition of "TECHcitement" contains the following articles: (1) ATE Program Leads to Student Success; (2) Doing Whatever It Takes for Aquaculture; (3) The Bridge to Biotech; (4) Girls See What They Can Do With Technology at Camp; (5) Students Advancing Solutions to Business Problems; (6) CREATE Recreates Technical Education in California; (7)…

  7. Experiment list: SRX262787 [Chip-atlas[Archive

    Lifescience Database Archive (English)

    Full Text Available IH3T3_MRTFA_LAT || cell line=NIH3T3 fibroblasts || genotype=normal || chip antibody=MRTF-A || chip antibody vendor=Santa Cruz Biotech...nology http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/ea

  8. INNOVATIVE AND INDUSTRIAL-PERFORMANCE IN PHARMACEUTICAL RESEARCH-AND-DEVELOPMENT, A MANAGEMENT CONTROL PERSPECTIVE

    NARCIS (Netherlands)

    OMTA, SWF; BOUTER, LM; VANENGELEN, JML

    1994-01-01

    In this paper management control is related to innovative and industrial performance in 14 non-biotech pharmaceutical companies. The study consisted of questionnaires, sent to the heads of the different research departments of European research laboratories of leading pharmaceutical companies, combi

  9. Against Free Markets, against Science? Regulating the Socio-Economic Effects of Biotechnology

    Science.gov (United States)

    Kinchy, Abby J.; Kleinman, Daniel Lee; Autry, Robyn

    2008-01-01

    This study challenges the assumption that abstract "globalization" forces are driving transformations in the relationships between states and markets. Employing three cases of policy debate regarding the regulation of agricultural biotechnology (ag-biotech), we examine the role of discourse in the formation of neoliberal regulatory schemes. We…

  10. Plant Research Department annual report 2003

    DEFF Research Database (Denmark)

    Kossmann, J.; Jakobsen, Iver; Nielsen, K.K.;

    2004-01-01

    In 2003 the Plant Research Department (PRD) at Risø National Laboratory was involved in establishing the consortium Plant Biotech Denmark, which is unifying most of the Danish Plant Biotechnology activities. Within the consortium, PRD has the uniqueopportunity to be the only life science department...

  11. Technology and international strategies in born global firms: evidence from The Netherlands

    NARCIS (Netherlands)

    Kundu, Sumit; Roelfsema, Hein; Delft, Anne van

    2010-01-01

    This paper analyzes the internationalization strategies of biotech firms in the Netherlands. We find that many of these firms are born internationals in the sense that from their inception they are actively engaged in international cooperation. However, we find that the nature of potential intellect

  12. Pharmaceutical Economics

    OpenAIRE

    2008-01-01

    Pharmaceutical Economics begins with an investigation of the structure of the industry and its three main components: the research firms which produce innovative products; the generic drug industry and its expanding role; and the biotech industry, which is regarded as the future for pharmaceuticals. Further sections discuss topics including demand and incentives, pricing and regulation.

  13. Informational Environments: Organizational Contexts of Online Information Use.

    Science.gov (United States)

    Lamb, Roberta; King, John Leslie; Kling, Rob

    2003-01-01

    Examines sustained use and non-use of online services within organizations using an open-systems view that overcomes limitations of traditional approaches that led to over-estimates of use. Focuses on the informational environments of firms in three industries: law, real estate, and biotech/pharmaceuticals; and discusses insights from an intranets…

  14. Uninformed and disinformed society and the GMO market.

    Science.gov (United States)

    Twardowski, Tomasz; Małyska, Aleksandra

    2015-01-01

    The EU has a complicated regulatory framework, and this is slowing down the approval process of new genetically modified (GM) crops. Currently, labeling of GM organisms (GMOs) is mandatory in all Member States. However, the USA, in which GMO labeling is not mandatory, continues to lead the production of biotech crops, biopharmaceuticals, biomaterials, and bioenergy.

  15. Biotechnology Education in India: An Overview

    Science.gov (United States)

    Joshi, Kirti; Mehra, Kavita; Govil, Suman; Singh, Nitu

    2013-01-01

    Among the developing countries, India is one of those that recognises the importance of biotechnology. The trajectory of different policies being formulated over time is proof that the government is progressing towards achieving self-sufficiency. However, to cater to the ever-growing biotech industry, skilled manpower is required. This article…

  16. The integrated web service and genome database for agricultural plants with biotechnology information

    OpenAIRE

    Kim, ChangKug; Park, DongSuk; Seol, YoungJoo; Hahn, JangHo

    2011-01-01

    The National Agricultural Biotechnology Information Center (NABIC) constructed an agricultural biology-based infrastructure and developed a Web based relational database for agricultural plants with biotechnology information. The NABIC has concentrated on functional genomics of major agricultural plants, building an integrated biotechnology database for agro-biotech information that focuses on genomics of major agricultural resources. This genome database provides annotated genome information...

  17. Teachers' Implementation of a Game-Based Biotechnology Curriculum

    Science.gov (United States)

    Eastwood, Jennifer L.; Sadler, Troy D.

    2013-01-01

    Research in education suggests that computer games can serve as powerful learning environments, however, teachers perceive many obstacles to using games as teaching tools. In this study, we examine three science teachers' implementation and perceptions of a curriculum unit incorporating the game, Mission Biotech (MBt) and a set of supporting…

  18. Reporter-based screening and selection of enzymes

    NARCIS (Netherlands)

    Rossum, van T.; Kengen, S.W.M.; Oost, van der J.

    2013-01-01

    The biotech industry is continuously seeking for new or improved biocatalysts. The success of these efforts is often hampered by the lack of an efficient screening assay. Thus, to be able to extend the number of enzymes available for industrial applications, high-throughput screening and selection m

  19. Molecular characteristics and efficacy of 16D10 siRNAs in inhibiting root-knot nematode infection in transgenic grape hairy roots

    Science.gov (United States)

    Root-knot nematodes (RKNs) infect many annual and perennial crops and are the most devastating soil-born pests in vineyards. To develop a biotech-based solution for controlling RKNs in grapes, we evaluated the efficacy of plant-derived RNA interference (RNAi) silencing of a conserved RKN effector ge...

  20. Public perceptions of farm animal cloning in Europe

    OpenAIRE

    Lassen, Jesper

    2005-01-01

    This report presents a picture of European opinion on farm animal cloning. In the report, both agricultural and biomedical applications of farm animal cloning are considered. With the arrival of Dolly, animal cloning became an integral part of the biotech debate, but this debate did not isolate animal cloning as a single issue.

  1. Experiment list: SRX262791 [Chip-atlas[Archive

    Lifescience Database Archive (English)

    Full Text Available nology http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/ea...IH3T3_MRTFB_LAT || cell line=NIH3T3 fibroblasts || genotype=normal || chip antibody=MRTF-B || chip antibody vendor=Santa Cruz Biotech

  2. Preliminary format design guidelines

    DEFF Research Database (Denmark)

    Tosello, Guido; Calaon, Matteo; Nørregaard, J.;

    2013-01-01

    The strategic research centre PolyNano aims at becoming the Danish competence centre for production-ready fabrication of polymer, nano-scale lab-on-a-chip (LoC) devices. In order to provide a competitive edge for Danish biotech companies launching LoC products by removal of the technology barrier...

  3. 76 FR 52670 - 2011 Technology Transfer Summit North America Conference

    Science.gov (United States)

    2011-08-23

    ... the TTS Initiative Business Social Network, an online business- networking platform powered by JuJaMa... From the Federal Register Online via the Government Publishing Office DEPARTMENT OF HEALTH AND... institutes together with biotech & pharma licensing & business development executives, VCs,...

  4. How to get exogenous DNA to cross the cell membrane of plants. Comment on “Physical methods for genetic transformation in plants” by Rivera et al.

    Science.gov (United States)

    Cruz Hernández, Andrés; Campos Guillén, Juan

    2012-09-01

    Physical methods for genetic transformation in plants. The most commonly applied methods in plant transformation include Agrobacterium infection and protoplast or microprojectile bombardment. A plant transformation system is a prerequisite for the development of a plant improvement program. The global area utilized for biotech crops increases every year.

  5. Networked Success and Failure at Hybritech

    Science.gov (United States)

    Jones, Mark Peter

    2011-01-01

    The author presents an historical account of scientific work conducted at a commercial biotech firm in San Diego called Hybritech. It tells of disruptions in research programs following the acquisition of the company by the pharmaceutical giant Eli Lilly in 1986. The story centers on responses to an organizational challenge that research managers…

  6. Bioprocessing of wheat straw into nutritionally rich and digested cattle feed.

    Science.gov (United States)

    Shrivastava, Bhuvnesh; Jain, Kavish Kumar; Kalra, Anup; Kuhad, Ramesh Chander

    2014-01-01

    Wheat straw was fermented by Crinipellis sp. RCK-1, a lignin degrading fungus, under solid state fermentation conditions. The fungus degraded 18.38% lignin at the expense of 10.37% cellulose within 9 days. However, when wheat straw fermented for different duration was evaluated in vitro, the 5 day fungal fermented wheat straw called here "Biotech Feed" was found to possess 36.74% organic matter digestibility (OMD) and 5.38 (MJ/Kg Dry matter) metabolizable energy (ME). The Biotech Feed was also observed to be significantly enriched with essential amino acids and fungal protein by fungal fermentation, eventually increasing its nutritional value. The Biotech Feed upon in vitro analysis showed potential to replace 50% grain from concentrate mixture. Further, the calves fed on Biotech Feed based diets exhibited significantly higher (p<0.05) dry matter intake (DMI: 3.74 Kg/d), dry matter digestibility (DMD: 57.82%), total digestible nutrients (TDN: 54.76%) and comparatively gained 50 g more daily body weight. PMID:25269679

  7. Cryoperservation of Balanus amphitrite nauplii

    Digital Repository Service at National Institute of Oceanography (India)

    Anil, A.C.; Tulaskar, A.S.; Khandeparker, D.C.; Wagh, A.B.

    , 030, 040, orexplored as an innovative adjunct in biotech- nology. In this area, cryopreservation was first 0507C), and transfer from these temperatures into liquid nitrogen.used to store the spermatozoa of invertebrates and fish (7, 11–13). Toledo...

  8. DTREEv2, a computer-based support system for the risk assessment of genetically modified plants

    NARCIS (Netherlands)

    Pertry, I.; Nothegger, C.; Sweet, J.; Kuiper, H.A.; Davies, H.; Iserentant, D.; Hull, R.; Mezzetti, B.; Messens, K.; Loose, De M.; Oliveira, de D.; Burssens, S.; Gheysen, G.; Tzotzos, G.

    2014-01-01

    Risk assessment of genetically modified organisms (GMOs) remains a contentious area and a major factor influencing the adoption of agricultural biotech. Methodologically, in many countries, risk assessment is conducted by expert committees with little or no recourse to databases and expert systems t

  9. Ben's Plastic Brain

    Science.gov (United States)

    Kaplan, Susan L.

    2010-01-01

    This article shares a story of Ben who as a result of his premature birth, suffered a brain hemorrhage resulting in cerebral palsy, which affected his left side (left hemiparesis) and caused learning disabilities. Despite these challenges, he graduated from college and currently works doing information management for a local biotech start-up…

  10. 7 CFR 774.17 - Loan application.

    Science.gov (United States)

    2010-01-01

    ... claim in the AgriBiotech bankruptcy proceedings; (c) If the applicant is a business entity, any legal documents evidencing the organization and any State recognition of the entity; (d) Documentation of compliance with the Agency's environmental regulations contained in 7 CFR part 1940, subpart G; (e) A...

  11. Global scenario on crop biotechnology: Communication setting

    Science.gov (United States)

    Various indications that research and development efforts are escalating in developing countries indicate the slight shift of such countries from just being end markets to being developers. The aggregate adoption of biotech crops in developing countries is clearly approaching that in developed count...

  12. Experiment list: SRX821798 [Chip-atlas[Archive

    Lifescience Database Archive (English)

    Full Text Available nologies http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/...riment type=PPARG ChIP-seq || strain=N/A || tissue=NA || chip antibody=anti-PPAR? antibody || chip antibody vendor=Santa Cruz Biotech

  13. Patent Assessment Quality

    DEFF Research Database (Denmark)

    Burke, Paul F.; Reitzig, Markus

    2006-01-01

    of the European Patent Office's (EPO's) granting and opoposition decisions for individual patents. We use the historical example of biotech patens filed between 1978 until 1986, the early stage of the industry. Our results indicate that the EPO shows systematically different assessments of technological quality...

  14. Do-it-yourself biology

    NARCIS (Netherlands)

    Golinelli, Stefano; Ruivenkamp, Guido

    2016-01-01

    Do-it-yourself biology, or garage biology, is a set of practices through which lay people can practice biotechnology and thus also challenge the exclusive control exercised on biotech R&D by Big Bio. This article describes how garage biologists aim to radically transform biotechnological soci

  15. Public perceptions of farm animal cloning in Europe

    DEFF Research Database (Denmark)

    Lassen, Jesper

    This report presents a picture of European opinion on farm animal cloning. In the report, both agricultural and biomedical applications of farm animal cloning are considered. With the arrival of Dolly, animal cloning became an integral part of the biotech debate, but this debate did not isolate...... animal cloning as a single issue....

  16. Social Capital, ICT Use and Company Performance

    DEFF Research Database (Denmark)

    Scupola, Ada; Steinfield, Charles; Lopez-Nicolas, Carolina

    2010-01-01

    This study explores how some uses of ICTs, as well as having social capital and other means of access to knowledge resources, are related to company performance in a knowledge-intensive business cluster. Data were collected through a survey of companies in the Medicon Valley biotech region locate...

  17. Experiment list: SRX142525 [Chip-atlas[Archive

    Lifescience Database Archive (English)

    Full Text Available Cruz Biotech || antibody vendorid=sc-197 || control=Control_50bp || control description=This data represents a control being compare...on=Immortal cells || control=Control_50bp || control description=This data represents a control being compared

  18. The Rhetorical Helix of the Biotechnology and Pharmaceutical Industries: Strategies of Transformation through Definition, Description and Ingratiation

    Science.gov (United States)

    Gretton, Linda Burak

    2009-01-01

    The current pharmaceutical industry, whose origins date from the early 20th century, and the biotechnology industry, which emerged in the 1980s both have foundations built on the modern scientific method and share a mission to develop new drugs for humans and animals. At the same time, they are also made distinct by size (small biotechs versus…

  19. Tartu teadlased aitavad välja mõelda Ebola-vastast vaktsiini / Aime Jõgi

    Index Scriptorium Estoniae

    Jõgi, Aime, 1958-

    2014-01-01

    Eesti biotehnoloogiafirma Icosagen hakkab koos Soome ettevõtte FIT Biotech Oy'ga välja töötama Ebola viiruse vastast vaktsiini, arendustöös osaleb ka Tartu Ülikooli Tehnoloogiainstituudi rakendusviroloogia labor

  20. Ryntäys Viroon jatkuu / Eeva-Riitta Seies

    Index Scriptorium Estoniae

    Seies, Eeva-Riitta

    2002-01-01

    Soome kontsern Vapo ostis ASi Tootsi Turvas enamusaktsiad. Soome ettevõte Fit Biotech ostis Tartu biotehnoloogiaettevõtte Quattromed ja Soome toiduainetetööstuse ettevõte Saarioinen Oy Eesti tütarfirma omandas üle 66-protsendilise osaluse valmistoidufirmas Meleco AS

  1. On the Strategy of the Bioeconomy Development%试论生物经济成长(GREW)战略

    Institute of Scientific and Technical Information of China (English)

    邓心安; 封颖; 曾海燕

    2010-01-01

    生命科学与生物技术的发展推动了"生物经济"概念的形成与生物经济时代的来临,进而导致农业、健康医疗、环保、工业制造等产业的生产与消费方式正在发生深刻变革.分别从生物经济对未来农业、健康医疗、环保及制造业的影响进行分析,提出了生物经济成长(GREW)战略.作为一个战略体系,GREW战略包括相互交叉、相互依存与影响的四个子战略:新型农业(Green biotech based)战略、健康医疗(Red biotech based)战略、绿色环保(Grey or Environmental biotech based)战略,以及绿色制造业(White biotech based)战略.GREW战略的及时提出与逐步形成,对于生物产业发展规划及政策制定具有高度前瞻性意义和指导作用.

  2. Eesti firma hakkab koostöös soomlastega välja töötama Ebola viiruse ravimit / Joosep Värk

    Index Scriptorium Estoniae

    Värk, Joosep

    2014-01-01

    Eesti biotehnoloogiafirma Icosagen hakkab koos Soome ettevõtte FIT Biotech Oy'ga välja töötama Ebola viiruse vastast vaktsiini, arendustöös osaleb professor Andres Meritsa juhtimisel ka Tartu Ülikooli Tehnoloogiainstituudi rakendusviroloogia labor. Vestlusest Tartu Ülikooli biomeditsiinitehnoloogia professori Mart Ustaviga

  3. The Provincial Capital's Future

    Institute of Scientific and Technical Information of China (English)

    DING WENLEI

    2010-01-01

    @@ A new city is in the making on the eastern outskirts of Guangzhou.In lieu of the average citizen,the city will be home to thousands of biotech engineers or new energy researchers.It will be a green city.It will be a hi-tech city.It will be a city of the future.

  4. Pikkani osalusega ettevõte jahib rahamahukat geenianalüüsi / Väinu Rozental

    Index Scriptorium Estoniae

    Rozental, Väinu, 1957-

    2002-01-01

    Geenivaramu lepingusüsteem mängib geenianalüüsi tegemisel suured trumbid kätte geenivaramu eestvedajate Jaanus Pikani ja Andres Metspalu osalusega Tartus geenianalüüsiga tegelevale AS-ile Asper Biotech

  5. 正在崛起的生物技术产业

    Institute of Scientific and Technical Information of China (English)

    孙爱仙

    2004-01-01

    Biotech,electron,nano technology and coginitive science are seen as four mainstreams as well as the leading trend of the development in future science and technology and the relaged industries.Biotech industry is in the red globally but the most popular field,enjoying the largest amount of investment among the four above industries,which possibly indicates high technology's advantage.China biotech industry starts up is 1980s and cover a number of fields like agriculture.medication and food.Though lage in start and far lagged behind US in its industry scale,it is growing considerable.From 1985 to 2000,its sales has increased by 75.9 times with annual growth of 33.58%.In 2000,China biotech industry has reached over RMB 20 billion yuan porduct.Gene engineering pharmacy industry is ,in particular,growing remarkably.In 1996,the sales of gene engineering medicine and bacterin was RMB 220 million yuan and in 2000.it has to RMB 2.28 billion.With a year-on-year growth of 79.42%.And its annual growth rate has since then always maintained above 20%.

  6. Eesti HIVi alatüüp jõuab registrisse / Villu Päärt

    Index Scriptorium Estoniae

    Päärt, Villu, 1972-

    2005-01-01

    Ülemaailmses HIV- andmebaasis on registreerimisel HI-viiruse alatüüp, mida on seni avastatud ainult Eestis. Mosaiik-HIV on segu peamiselt Aafrikas esinevast viiruse vormist ning Ukrainas levinud tüübist, selgub biotehnoloogiafirma FIT Biotech uuringust. Kommenteerib Tartu Ülikooli tehnoloogiainstituudi direktor Mart Ustav

  7. Final Report: Northern Virginia Community College Training for Biotechnology Workers

    Energy Technology Data Exchange (ETDEWEB)

    Weiss, Johanna V

    2010-05-31

    The intent of this project was to expand Northern Virginia Community College's capability to offer training to support the Biotechnology Industry in the northern Virginia region. The general goal of this project was to create a College Biotechnology Program; specific goals of the project were to a) design curricula/courses to prepare students to become entry-level lab technicians, b) redesign and equip lab space to better suit the needs of the program, c) develop partnerships with the local industry through outreach and the formation on an advisory board, d) recruit students into the program, and e) provide instructional support for local high school teachers. At the end of the grant period, NOVA has successfully created two new curricula in biotechnology: an Associate of Applied Science (A.A.S.) in Biotechnology (initiated in Fall 2008) and a Career Studies Certificate for Biotechnology Lab Technicians (to be initiated in Fall 2010). These curricula were designed with advice from an external advisory committee which is comprised of representatives from industry, transfer institutions and high school administrators. To date, almost all courses have been designed and piloted; the equipment needed for the courses and the initial supplies were paid for by the grant as was the re-modeling of some lab space to be used for the biotech courses. In order to market the program, the NOVA Biotech Program has also established relationships with the local high schools. Presentations were given at several local high schools and on-site workshops were held for high school students and teachers. As a result, close to 1000 students have attended program open houses, presentations within the high schools, or workshops held in the summer. Over 100 teachers have received information and/or training in biotechnology. These outreach efforts as well as high quality curricula have started to attract a number of students to the program – for example, there are currently 70 students

  8. Parallel rapid HIV testing in pregnant women at Tijuana General Hospital, Baja California, Mexico.

    Science.gov (United States)

    Viani, Rolando M; Araneta, Maria Rosario G; Spector, Stephen A

    2013-03-01

    The objectives of this study were to evaluate the performance of parallel rapid HIV testing and the presence of HIV-associated risk factors in pregnant women with unknown HIV status in Baja California, Mexico. Pregnant women attending the delivery unit or the prenatal clinic at Tijuana General Hospital had blood drawn for parallel rapid HIV testing with Determine™ HIV-1/2 and Uni-Gold™ Recombigen(®) HIV. The parallel rapid HIV test performance was compared to the enzyme immunoassay (EIA) and western blot. From September 2007 to July 2008, 1,383 (94%) of 1,464 women in labor and 1,992 (96%) of 2,075 women in prenatal care were enrolled. The HIV seroprevalence among women screened during labor (19/1,383, 1.37%, 95% CI: 0.85-2.18%) was significantly higher compared to those seeking prenatal care (5/1,992, 0.25%, 95% CI: 0.09-0.62%; pwomen testing positive by parallel rapid HIV testing 24 had a positive confirmatory western blot and one (0.03%) was confirmed as false positive. Additionally, two (0.06%) women had parallel rapid HIV discordant testing results; both tested negative by western blot. All women who tested negative by rapid testing had negative results on pooled EIA antibody testing. The overall sensitivity, specificity, and positive and negative predictive values of parallel rapid HIV testing were 100%, 99.9%, 96%, and 100%, respectively. These findings document a very high acceptance rate and an excellent performance of the parallel rapid HIV testing strategy during pregnancy.

  9. Satraplatin: BMS 182751, BMY 45594, JM 216.

    Science.gov (United States)

    2007-01-01

    Satraplatin [BMS 182751, BMY 45594, JM 216] belongs to a series of orally-active platinum compounds with anticancer activity. It was jointly originated by Bristol-Myers Squibb, Johnson Matthey and the Institute of Cancer Research in the UK; however, Johnson Matthey has since ceased involvement with drug development. Subsequently, the agent has been licensed to and is under development with GPC Biotech, Pharmion and Spectrum Pharmaceuticals. Clinical trials are underway to evaluate satraplatin among patients with different tumour types, including prostate, breast, cervical and lung cancers. The compound is under regulatory review with the US FDA for the treatment of hormone-refractory prostate cancer. NeoTherapeutics (now Spectrum Pharmaceuticals) granted GPC Biotech an exclusive worldwide licence to develop and market satraplatin in October 2002. Under the terms of the agreement, GPC Biotech is fully funding development costs and commercialisation requirements for the drug. The deal also involves GPC Biotech paying a signing fee, milestone and royalty payments. Spectrum is a member of a joint development committee headed by GPC Biotech to govern development of satraplatin. Previously in October 2001, NeoOncoRx (Spectrum Pharmaceuticals) gained the rights to develop and market the compound worldwide. In December 2005, GPC Biotech and Pharmion Corporation entered into a co-development and license agreement for satraplatin. Under the agreement terms, Pharmion has exclusive commercialisation rights for Europe, Turkey, the Middle East, Australia and New Zealand, while GPC Biotech retains rights to North America and all other territories. Pharmion made an upfront payment of $US37.1 million to GPC Biotech, which included reimbursement for past clinical development costs plus funding for ongoing and certain clinical development activities to be jointly conducted by the companies. In addition, both parties will pursue a joint development plan for satraplatin in a variety of

  10. Evaluation of nine HIV rapid test kits to develop a national HIV testing algorithm in Nigeria

    Directory of Open Access Journals (Sweden)

    Orji Bassey

    2015-05-01

    Full Text Available Background: Non-cold chain-dependent HIV rapid testing has been adopted in many resource-constrained nations as a strategy for reaching out to populations. HIV rapid test kits (RTKs have the advantage of ease of use, low operational cost and short turnaround times. Before 2005, different RTKs had been used in Nigeria without formal evaluation. Between 2005 and 2007, a study was conducted to formally evaluate a number of RTKs and construct HIV testing algorithms. Objectives: The objectives of this study were to assess and select HIV RTKs and develop national testing algorithms. Method: Nine RTKs were evaluated using 528 well-characterised plasma samples. These comprised 198 HIV-positive specimens (37.5% and 330 HIV-negative specimens (62.5%, collected nationally. Sensitivity and specificity were calculated with 95% confidence intervals for all nine RTKs singly and for serial and parallel combinations of six RTKs; and relative costs were estimated. Results: Six of the nine RTKs met the selection criteria, including minimum sensitivity and specificity (both ≥ 99.0% requirements. There were no significant differences in sensitivities or specificities of RTKs in the serial and parallel algorithms, but the cost of RTKs in parallel algorithms was twice that in serial algorithms. Consequently, three serial algorithms, comprising four test kits (BundiTM, DetermineTM, Stat-Pak® and Uni-GoldTM with 100.0% sensitivity and 99.1% – 100.0% specificity, were recommended and adopted as national interim testing algorithms in 2007. Conclusion: This evaluation provides the first evidence for reliable combinations of RTKs for HIV testing in Nigeria. However, these RTKs need further evaluation in the field (Phase II to re-validate their performance.

  11. Science communication in policy making

    DEFF Research Database (Denmark)

    Coumou, Hilde; van der Werf Kulichova, Z.; Wehrmann, C.;

    2014-01-01

    Policy making regarding application of agricultural biotechnology has been controversial. This study investigates what determines the motivation of European biotech scientists to actively participate in policy making. To do this, a conceptual framework was developed based on the Theory of Planned...... Behavior. The framework was operationalized in semi-structured interviews with 17 European biotech scientists to collect data about their motivation to involve in GMO policy making. The results of this qualitative study suggest that the attitude of the scientists towards active participation in policy...... making is dependent on their view of the way science and decision making relate to each other. The respondents who are currently active in policy making seem to be driven by commitment to the public good. However, many respondents feel social pressure from environmental NGOs to withdraw from engagement...

  12. Strategic alliances and market risk.

    Science.gov (United States)

    Havenaar, Matthias; Hiscocks, Peter

    2012-08-01

    Strategic alliances in product development and marketing are crucial to the biotechnology industry. Many alliances, however, are terminated before the drug reaches the market. In this article we make the case that strategic alliances can fail because of how they are negotiated. Alliance contracts are often inflexible and do not allow for changes in market conditions. We propose a model for contract valuation that can assist biotech and/or pharma deal makers in negotiating alliances that have a higher chance of survival in uncertain market conditions. The model makes use of variable royalties and milestone payments. Because licensing is key to the biotech and/or pharma business model this article will be of interest not only to professionals in licensing, but to all professionals active in the industry. PMID:22484547

  13. Considerations on patent valuation based on patent classification and citation in biotechnological field

    Science.gov (United States)

    Mihara, Kenji

    Regarding innovation measurement utilizing patent information, a number of researchers are making great efforts to measure a "patent value (patent quality)." For patent valuation, patent classification and citation are often utilized as patent information. Also, biotechnological field is attracting attention from the viewpoint of application to environmental or medical study, and considerable researches on patent valuation are ongoing in this technical field. However, it is not enough recognized that researchers cannot be too careful when they deal with classification information in the biotech field because patent classification structure in this field is not well-established. And also, it is not known enough that citation patterns of both academic papers and patent documents are so complicated that the patterns cannot be easily generalized. In this article, the issues above were verified from a position based on working experiences of biotech patent examiner at Japan Patent Office, and considerations and implications were given on what patent valuation should be.

  14. Media Release for Immediate Release

    Directory of Open Access Journals (Sweden)

    Lee Ling Ling

    2015-12-01

    Full Text Available New regional BioPharma Services hub offers larger operational space and advanced equipment to meet increasing clinical supply needs for Pharma and biotech customers. SINGAPORE, 18 November 2015 –To address the growing global demand for clinical services, Thermo Fisher Scientific, the world leader in serving science, today announced the official opening of its new state-of-the-art GMP1 facility. Having established its first clinical services facility in Singapore in 2001, the move to this newly built facility will meet the growing demand for clinical supply services in the region. The new site will provide both regional and global pharmaceutical and biotech companies with a one-stop service for clinical supplies − from GMP storage, local labeling, secondary packaging, comparator sourcing, handling and distribution of ambient and cold chain supplies to returns management.

  15. New challenges and opportunities for industrial biotechnology

    Directory of Open Access Journals (Sweden)

    Chen Guo-Qiang

    2012-08-01

    Full Text Available Abstract Industrial biotechnology has not developed as fast as expected due to some challenges including the emergences of alternative energy sources, especially shale gas, natural gas hydrate (or gas hydrate and sand oil et al. The weaknesses of microbial or enzymatic processes compared with the chemical processing also make industrial biotech products less competitive with the chemical ones. However, many opportunities are still there if industrial biotech processes can be as similar as the chemical ones. Taking advantages of the molecular biology and synthetic biology methods as well as changing process patterns, we can develop bioprocesses as competitive as chemical ones, these including the minimized cells, open and continuous fermentation processes et al.

  16. The gap between science and perception: the case of plant biotechnology in Europe.

    Science.gov (United States)

    Einsele, Arthur

    2007-01-01

    Although the global area of biotech crops continues to climb for the tenth consecutive year at a sustainable double-digit growth rate, the acceptance of biotech products from agriculture in Europe is still low. There is a gap between science and perception. It is a strong belief that the public turning against science and against GM food has been encouraged by the negative activities of NGO groups. Scientists have to overcome the purely risk-based discussion, and the benefits of plant biotechnology have to be made literally visible. GM food should be available, the benefits should be tangible and the consumer should have fun with such novel food. The gap could be reduced if genetically modified plants and the products thereof were regulated in the same way as classical products. PMID:17522817

  17. Intellectual Property Rights and Agro-Biotechnology: Limitations and Alternatives

    Directory of Open Access Journals (Sweden)

    Mary Luz Yaya-Lancheros

    2008-11-01

    Full Text Available Intellectual property rights have led to stimulating innovation in different fields such as biotechnology. Patents, plant variety protection, industrial secrets and material transfer agreements are legal terms individually and/or collectively protecting materials or processes deemed necessary for agricultural-biotech product development. Such terms may often accumulate to such an extent that this hinders a product’s development and commercial release. Some current initiatives are aimed at facilitating access to basic technology for agricultural-biotech product development, including public organisation cooperation networks, requests for special licences for humanitarian programmes and open access projects. These may be good short-and medium-term alternatives for carrying out biotechnological research in countries like Colombia.

  18. Economic governance of property rights: comparative analysis on the collection of royalties in genetically modified soybean seeds

    Directory of Open Access Journals (Sweden)

    Guilherme Fowler de Avila Monteiro

    2013-03-01

    Full Text Available This paper examines the governance of property rights on genetically modified (GM soybean seeds. Specifically, the article undertakes a comparative analysis on the collection of royalties in GM soybean seeds in the U.S. and Brazil. For each country, the authors describe the regulatory framework governing the protection of biotechnology innovations in agriculture and investigate the mechanisms of royalty collection in GM soybean seeds. The paper also offers econometric evidence linking the capture of value on biotech innovations and the protection mechanisms deployed by biotech firms. The results suggest that, subject to the institutional environment, firms may choose to transact a GM attribute separated from the seed, building specialized governance structures framed around the genetic attribute and not around the seed as a whole.

  19. 生物农药产业及市场分析

    Institute of Scientific and Technical Information of China (English)

    萧文湧

    2004-01-01

    From the point of macroscopical ecosystem,matching with the application of biotech the biology agrochemicals-especially focusing on the biology antisetics.pesticides and microorganism fertilizers which are used in farm crops and their seeding are developed.At the same time.combining with the construction of the large scale seeding cultivating center and the planning of the ecosystem farm,a natural organic pest-free agricultural environment is constructed.From the aspects of technology ,fund,knowledge and management,the competition capability of agriculture products is developed to the best.Besides the visible products such as biology agrochemicals ,microorganism fertilizers,seeding,farm corps,etc.,the "microorganism organism agriculture method" is configured to provide peasants with the usage system of biotech products,the blue print of "green agriculture"is gradually constructed ,the competiton capability is enhanced and finally,high rewards are out.

  20. Aproveitamento sustentável de biomassa e de recursos naturais na inovação química Sustainable use fo biomass and natural resources for chemical innovation

    OpenAIRE

    Fernando Galembeck; César Augusto Sales Barbosa; Rafael Arromba Sousa

    2009-01-01

    Increased production of biomass is currently the only immediately accessible alternative for large-scale carbon sequestration and it can produce large amounts of food, fuel and raw materials for the chemical industry that can in turn growingly replace oil as a source of organic building blocks and also of hydrogen and sulfur. Development of processes for biomass and abundant minerals transformation into chemical raw materials should now benefit from large inputs from nanotechnologies, biotech...

  1. Structural change in agriculture induced by innovative biobased technologies, an agent-based approach

    OpenAIRE

    Maes, Dries

    2015-01-01

    Industry and policy makers pursue the development of a biobased economy. The biobased economy emerged first as a promising segment of new biotech applications. But during the last years, the term evolved to cover a much larger concept. It currently has grown to a vision for a new industrial structure where all products, from energy carriers, plastics and food to high value additives and pharmaceuticals, are entirely based on organic matter, thereby annihilating any need for fossil fuels. ...

  2. Treponema-specific tests for serodiagnosis of syphilis: comparative evaluation of seven assays.

    Science.gov (United States)

    Binnicker, M J; Jespersen, D J; Rollins, L O

    2011-04-01

    The diagnosis of syphilis is challenging and often relies on serologic tests to detect treponemal or nontreponemal antibodies. Recently, the Centers for Disease Control and Prevention and the Association of Public Health Laboratories proposed an update to the syphilis serology testing algorithm, in which serum samples are first tested using a treponema-specific test and positive samples are analyzed with a nontreponemal assay. The goal of this study was to compare the performance of seven treponemal assays (BioPlex 2200 syphilis IgG [Bio-Rad, Hercules, CA], fluorescent treponemal antibody [FTA] assay [Zeus Scientific, Raritan, NJ], Treponema pallidum particle agglutination [TP-PA; Fujirebio Diagnostics, Malvern, PA], Trep-Sure enzyme immunoassay [EIA; Phoenix Biotech, Oakville, Ontario, Canada], Trep-Chek EIA [Phoenix Biotech], Trep-ID EIA [Phoenix Biotech], and Treponema ViraBlot IgG [Viramed Biotech AG, Planegg, Germany]) using serum samples (n = 303) submitted to our reference laboratory. In addition to testing with these 7 assays, all samples were tested by a rapid plasma reagin (RPR) assay and a treponemal IgM Western blot assay (Viramed ViraBlot). Compared to the FTA assay as the gold standard, the evaluated treponemal tests demonstrated comparable levels of performance, with percent agreement ranging from 95.4% (95% confidence interval, 92.3 to 97.3) for the Trep-Sure EIA to 98.4% (96.1 to 99.4) for the Trep-ID EIA. Compared to a "consensus of the test panel" (defined as at least 4 of 7 treponemal tests being in agreement), the percent agreement ranged from 95.7% (92.7 to 97.5) for Trep-Sure to 99.3% (97.5 to 99.9) for Trep-ID. These data may assist clinical laboratories that are considering implementing a treponemal test for screening or confirmatory purposes.

  3. NEW INSIGHTS ON THE RELATIONSHIPS BETWEEN GEOGRAPHIC AND INSTITUTIONAL DISTANCE IN RESEARCH COLLABORATIONS:A LONG PERIOD ANALYSIS

    OpenAIRE

    Rosamaria D’Amore; Roberto Iorio

    2014-01-01

    This paper analyses the relationship between institutional and geographic distance in scientific collaborations, evaluating the possible changes when a long period (sixteen years) is taken into consideration and discussing the use of some alternative measures of institutional distance. The main result, obtained by analysing the publications of the Italian biotech firms, is that international publications present an higher institutional distance than national papers, particularly in the early ...

  4. Young people's perspectives on genetics, identity and society using film and discussion

    OpenAIRE

    Murphy, Padraig

    2005-01-01

    Since Darwin, knowledge about biology has, for many, had a diminishing effect on ideas of identity and humanity's place in the world. In recent years biotechnology has raised further public concerns about 'playing God' and 'interfering with life.' School biology curricula however rarely open up the socio-scientific debate to allow students to explore such philosophical issues. This study aimed to identify connections biology students make between current accepted genetic knowledge, biotech...

  5. Wheat straw lignin degradation induction to aromatics by por Aspergillus spp. and Penicillium chrysogenum

    OpenAIRE

    Baltierra-Trejo Eduardo; Silva-Espino Eliseo; Márquez-Benavides Liliana; Sánchez-Yáñez Juan Manuel

    2016-01-01

    Wheat straw is a recalcitrant agricultural waste; incineration of this material represents an important environmental impact. Different reports have been made regarding the use of the structural components of wheat straw, i.e. cellulose, hemicellulose and lignin; however, lignin has been less exploited because it is largely considered the recalcitrant part. Residual wheat straw lignin (REWSLI) has a potential biotech-nological value if depolymerization is attained to produce aromatics. Lignin...

  6. Consumer Acceptance of Genetically Modified Foods: Traits, Labels and Diverse Information

    OpenAIRE

    Huffman, Wallace E

    2010-01-01

    New experimental economic methods are described and used to assess consumers' willingness to pay for food products that might be made from new transgenic and intragenic genetically modified (GM) traits. Participants in auctions are randomly chosen adult consumers in major US metropolitan areas and not college students. Food labels are kept simple and focus on key attributes of experimental goods. Diverse private information from the agricultural biotech industry (largely Monsanto and Syngenta...

  7. Frame dynamics and stakeholders in risk governance

    OpenAIRE

    Bengtsson, Beatrice

    2011-01-01

    The EU governance of food safety and GM food and feed has gone through significant changes since the BSE crisis and food scares during the 1990s. This work focuses on one particular new feature; the role of stakeholders representing the food chain: biotech associations, farmer organizations, food and feed processors, consumer organizations and environmental NGOs. These stakeholders are not merely lobbyists exerting influence on EU institutions; they are knowledge producers with a certain expe...

  8. A systematic review of the use of genetically modified food in China

    OpenAIRE

    Gao, Rong; 高溶

    2013-01-01

    Introduction: The Genetically Modified (GM) food, which is one of the fruit of the modern biotechnology, is closely related to people's lives. GM food, specifically, GM crops, also known as biotech food, are produced from genetically modified organisms (GMO), which use genetic engineering techniques to introduce, recombine and modify DNA. The safety of GM food still do not have final conclusion at present. Although GM food has been introduced into China for over 15 years, many of the surveys ...

  9. THE EVOLUTION OF RESEARCH AND DEVELOPMENT ON CONVENTIONAL VARIETIES IN BRAZIL 2003-2009 CULTIVARS INSTITUTIONAL FRAMEWORK AND AGROBIODIVERSITY MENACES IN BRAZIL

    OpenAIRE

    Rocha Dos Santos, Roseli; Lucht, Evelin

    2010-01-01

    N° ISBN - 978-2-7380-1284-5 International audience The aim of this paper is to discuss the role of cultivar protection regulations in the availability of conventional seeds in Brazilian agriculture. The expansion of intellectual property rights has stimulated innovative research on breeding in Brazil, mainly on the biotech applications, but this may constitute a challenge to the adoption of policies aiming to preserve agrobiodiversity. The institutional apparatus tends to reward standar...

  10. バイオ産業の課題と展望(<特集>生命科学の事業化)

    OpenAIRE

    藤原, 孝男

    2009-01-01

    An introductory and short explanation is summarized here for following five papers from the U.S.A., Germany, India, China, and Japan. Main topics include the reason of attention to biopharmaceutical industry, the global trend of commercialization of life science, the characteristics of advanced countries as the U.S.A. and Europe and of emerging countries as India and China, and Japan's trend of number of biotech start-ups, business areas, and venture capital.

  11. CONSUMER ACCEPTANCE OF GENETICALLY MODIFIED FOODS: ROLE OF PRODUCT BENEFITS AND PERCEIVED RISKS

    OpenAIRE

    Onyango, Benjamin M.

    2003-01-01

    This study examines consumer willingness to consume genetically modified food products with clearly stated benefits and risks. Results suggest that male; white, Southerners, and those with some college education are more likely to consume genetically modified fruits and vegetables. Trust in government, biotech industry, and medical professional on matters relating GM foods also have a positive impact on the willingness to consume GM foods; such trust allays fears associated with risks posed b...

  12. Characterization nanoparticles-based vaccines and vaccine candidates: a Transmission Electron Microscopy study

    Directory of Open Access Journals (Sweden)

    I. Menéndez I

    2016-05-01

    Full Text Available Transmission Electron Microscopy (TEM is a valuable tool for the biotech industry. This paper summarizes some of the contributions of MET in the characterization of the recombinant antigens are part of vaccines or vaccine candidates obtained in the CIGB. It mentions the use of complementary techniques MET (Negative staining, and immunoelectron that enhance visualization and ultrastructural characterization of the recombinant proteins obtained by Genetic Engineering.

  13. Resistance to agricultural biotechnology: the importance of distinguishing between weak and strong public attitudes.

    Science.gov (United States)

    Aerni, Philipp

    2013-10-01

    Empirical research shows that European governments and retailers are unlikely to be directly punished by taxpayers and consumers if they move away from their anti-GMO positions and policies. However, it is ultimately not the weak attitudes of taxpayers and consumers that matter to governments and retailers but the strong attitudes of the noisy anti-biotech movement. (Image: Highway signs: ©maxmitzu - Fotolia.com; woman and balance: ©lassedesignen - Fotolia.com).

  14. Development of food crops by modern biotechnology techniques in Central America Desarrollo de cultivos y alimentos por técnicas de biotecnología moderna en Centroamérica

    OpenAIRE

    Giovanni Garro Monge

    2012-01-01

    In the last decade, the adoption of Genetically Modified Crops (GMC) has increased in stages worldwide. The worldwide total area planted with biotech crops reached 148 million hectares by 2010, also increasing the number of farmers around the world who decided to produce crops with this technology. At the regional level there are different responses of government agencies by generating rules and regu- lations according to the reality of these countries. In Central America, countries with grea...

  15. TECHNOLOGY DEVELOPMENT FOR THE FOOD INDUSTRY: A CONCEPTUAL MODEL

    OpenAIRE

    Khramtsov, Andrey; Evdokimov, Ivan; Lodygin, Aleksey; Budkevich, Roman

    2014-01-01

    The information available on high technology in food industry is systematized. Different approaches to the development and integration of scientific knowledge are discussed. According to the European Institute for Food Processing (EU-IFP), there are three possible areas where a breakthrough in food science can occur: biotechnology (BIOTECH), nanotechnology (NANO), and information and communication technology (ICT). A transition is expected of high technology in food industry to convergent tec...

  16. A venture capital view of challenges, opportunities, and innovation in biomedical research.

    Science.gov (United States)

    Ratcliffe, L T

    2011-02-01

    Small biotech companies have been an important source of innovation, pipelines, and new products for the pharmaceutical industry, and are primarily financed by venture capital (VC). The significant changes happening within the VC industry have broad implications for these small companies. This includes a shift to financing later-stage programs with increasing interest in orphan or specialty indications. Nontraditional sources of capital and innovative risk-sharing structures can enable early-stage companies.

  17. Technological Diversity and Future Product Diversity in the Drug Industry

    OpenAIRE

    Cantner, Uwe; Plotnikova, Tatiana

    2009-01-01

    This paper deals with the topic of related R&D and innovation strategies of large firms. We ask what determines the diversity of a firm's product portfolio. More specifically, we try to explain large firms' expansion into new product markets driven by the characteristics of their technological knowledge. Empirically, we study firms in the pharmaceutical and biotech industries, using relevant data on product development and technological knowledge. We find a positive relationship between the d...

  18. Despite benefits, commercialization of transgenic horticultural crops lags

    OpenAIRE

    Clark, David; Klee, Harry; Dandekar, Abhaya

    2004-01-01

    The acreage of agronomic crops (soybean, cotton, corn and canola) developed using recombinant DNA technology has expanded dramatically since their introduction in 1996, while the commercialization of biotech horticultural crops (vegetables, fruits, nuts and ornamentals) has languished. This is not due to a lack of both current and potential traits that could be utilized in horticultural crops, as ongoing research is identifying a diverse array of applications. However, commercialization is st...

  19. NANOTECHNOLOGY: A PROMISING CARRIER FOR INTRACELLULAR DRUG DELIVERY SYSTEM

    OpenAIRE

    Malakar Jadupati; Ghosh Amitava; Basu Aalok; Nayak Amit Kumar

    2012-01-01

    Nanotechnology is on its way to make a big impact in Biotech, Pharmaceutical and Medical diagnostics sciences. Nanotechnology holds a tremendous potential when it applied in the fields of drug delivery. In this review it has been discussed how nanotechnology can implemented to design formulations which can effectively carry drug molecule to the targeted cell organelles. Introduction of certain functional groups or addition of surface active agents may alter the characteristics of the carrier ...

  20. Development and tuning of an original search engine for patent libraries in medicinal chemistry

    OpenAIRE

    Pasche, Emilie; Gobeill, Julien; Kreim, Olivier; Oezdemir-Zaech, Fatma; Vachon, Therese; Lovis, Christian; Ruch, Patrick

    2014-01-01

    BACKGROUND: The large increase in the size of patent collections has led to the need of efficient search strategies. But the development of advanced text-mining applications dedicated to patents of the biomedical field remains rare, in particular to address the needs of the pharmaceutical & biotech industry, which intensively uses patent libraries for competitive intelligence and drug development. METHODS: We describe here the development of an advanced retrieval engine to search information ...

  1. Empowered Antibody Therapies - IBC conference.

    Science.gov (United States)

    Herold, Jens

    2010-10-01

    The Empowered Antibody Therapies conference, held in Burlingame, CA, USA, included topics covering new therapeutic developments in the field of multispecific antibodies. This conference report highlights selected presentations on DVD-Igs from Abbott Laboratories, ImmTACs from Immunocore, 'Dock-and-Lock' technology from Immunomedics, the bispecific BiTE antibody blinatumomab from Micromet, and Triomabs from TRION Pharma and Fresenius Biotech. PMID:20878591

  2. Comparison of four enzyme immunoassays for detection of human T-cell lymphotropic virus type 2 antibodies.

    OpenAIRE

    Gallo, D; Yeh, E T; Moore, E S; Hanson, C V

    1996-01-01

    Four licensed enzyme immunoassay (EIA) kits for the measurement of antibody to human T-cell lymphotropic virus (HTLV) type 1, one from Organon Teknika Corp. (OTC), one from Cambridge Biotech Corp. (CBC), and two from Abbott Laboratories (the 1993 modification [Abb 93] and the 2.0 version licensed in 1995 [Abb 95]), were evaluated for sensitivity and specificity in the detection of HTLV type 2 antibody, and the results were compared with those previously obtained with earlier kit versions. The...

  3. Validation, Performance under Field Conditions, and Cost-Effectiveness of Capillus HIV-1/HIV-2 and Determine HIV-1/2 Rapid Human Immunodeficiency Virus Antibody Assays Using Sequential and Parallel Testing Algorithms in Tanzania▿

    OpenAIRE

    Mayhood, Meghan K.; Afwamba, Isaac A.; Odhiambo, Christopher O.; Ndanu, Epimack; Thielman, Nathan M.; Morrissey, Anne B.; Shao, John F; Wells Pence, Brian; Crump, John A.

    2008-01-01

    Rapid human immunodeficiency virus (HIV) antibody tests support the effort to expand access to HIV testing and counseling services in remote, rural, and poor parts of the world. We validated the Capillus HIV-1/HIV-2 (Trinity Biotech PLC, Bray, County Wicklow, Ireland) and Determine HIV-1/2 (Abbott Laboratories, Abbott Park, IL) rapid tests in a reference laboratory using patient samples from Tanzania and evaluated the performance of the tests under field conditions in northern Tanzania. We us...

  4. Utah Science Vol. 53 No. 4, Winter 1992

    OpenAIRE

    1992-01-01

    The Center for Meat Processing Technologies: 106 Trimming the Meeknees from Red Meat Marketing The Center for Value Added Seed Technology: 113 Taming Apomixis to Create New Wheat Hybrids 119 Research in Brief 124 Better Resistance Against Dwarf Smut 125 Taming Range Grasses to Create Better Turf Grass 126 Removing a Biotech Bottleneck The Center for Dairy Foods Technology: 128 Helping the Dairy Industry Gear Up for the next Century 1992 Index 133 New Publicati...

  5. Low-cost Negative-pressure Wound Therapy Using Wall Vacuum: A 15 Dollars by Day Alternative

    OpenAIRE

    Chaput, Benoit; Garrido, Ignacio; Eburdery, Harold; Grolleau, Jean Louis; Chavoin, Jean Pierre

    2015-01-01

    Background: Negative-pressure wound therapy (NPWT) has been marketed for about 20 years and remains popular. The only real obstacle to NPWT is the cost; therefore, we designed an inexpensive NPWT connected to a wall vacuum. Here, we report the feasibility and safety of this product, which we call PROVACUUM (Z-Biotech, Saint-Avertin, France). Methods: As a first step, the constraints imposed on the manufacturer were equipment quality similar to that of commercial NPWT systems, with an average ...

  6. How to Deal with the Upcoming Challenges in GMO Detection in Food and Feed

    OpenAIRE

    Sylvia R. M. Broeders; De Keersmaecker, Sigrid C.J.; Nancy H C Roosens

    2012-01-01

    Biotech crops are the fastest adopted crop technology in the history of modern agriculture. The commercialisation of GMO is in many countries strictly regulated laying down the need for traceability and labelling. To comply with these legislations, detection methods are needed. To date, GM events have been developed by the introduction of a transgenic insert (i.e., promoter, coding sequence, terminator) into the plant genome and real-time PCR is the detection method of choice. However, new ty...

  7. The integrated web service and genome database for agricultural plants with biotechnology information

    Science.gov (United States)

    Kim, ChangKug; Park, DongSuk; Seol, YoungJoo; Hahn, JangHo

    2011-01-01

    The National Agricultural Biotechnology Information Center (NABIC) constructed an agricultural biology-based infrastructure and developed a Web based relational database for agricultural plants with biotechnology information. The NABIC has concentrated on functional genomics of major agricultural plants, building an integrated biotechnology database for agro-biotech information that focuses on genomics of major agricultural resources. This genome database provides annotated genome information from 1,039,823 records mapped to rice, Arabidopsis, and Chinese cabbage. PMID:21887015

  8. Golden Rice and the Looming GMO Trade Debate: Implications for the Poor

    OpenAIRE

    Anderson, Kym; Pohl Nielsen, Chantal

    2004-01-01

    The first generation of genetically modified crop varieties, currently most widespread in the maize and soybean sectors, sought to increase farmer profitability by improving agronomic traits. The next generation of biotech research is focusing also on breeding for attributes desired by consumers. Although not yet commercially available, a new variety of rice, known as ‘Golden Rice’, has been genetically engineered to contain a higher level of vitamin A. Thus in contrast with the current comme...

  9. Golden Rice and the Looming GMO Trade Debate: Implication for the Poor

    OpenAIRE

    Chantal Pohl Nielsen; Kym Anderson

    2003-01-01

    The first generation of genetically modified crop varieties, currently most widespread in the maize and soybean sectors, sought to increase farmer profitability by improving agronomic traits. The next generation of biotech research is focusing also on breeding for attributes desired by consumers. Although not yet commercially available, a new variety of rice, known as ‘Golden Rice’, has been genetically engineered to contain a higher level of vitamin A. Thus in contrast with the current com...

  10. CONSUMER BIOTECHNOLOGY FOOD AND NUTRITION INFORMATION SOURCES: THE TRUST FACTOR

    OpenAIRE

    Ekanem, Enefiok P.; Muhammad, Safdar; Tegegne, Fisseha; Singh, Surendra P.

    2004-01-01

    Although much has been written on consumer attitudes toward genetically modified foods, not much is known about how or where consumers get the information for the decisions they make about genetically modified foods. This paper reports on the media used by consumers in acquiring information about biotech food and nutrition issues, and examines how much trust consumers put in selected information sources. The paper also discusses how socio-economic variables affect level of trust in selected s...

  11. Relevance of Crop Biology for Environmental Risk Assessment of Genetically Modified Crops in Africa

    OpenAIRE

    Akinbo, Olalekan; Hancock, James F.; Makinde, Diran

    2015-01-01

    Knowledge about the crop biology of economic crops in Africa is needed for regulators to accurately review dossiers and conduct comprehensive environmental risk assessments (ERAs). This information allows regulators to decide whether biotech crops present a risk to biodiversity, since crossing between domesticated crops and their wild relatives could affect the adaptations of the wild species. The criteria that should be used in the evaluation of African crops for ERA include growth habit, ce...

  12. A capital market's view on Industrial Biotechnology:proper valuation is the key for picking the right investment opportunities in stormy times

    OpenAIRE

    Schneider, B.W. (Bernd)

    2009-01-01

    Industrial biotechnology, also known as white biotechnology, is considered to be a revolutionary biotechnology field beside red and green biotechnology. After red (medicine) and green (agriculture), white biotechnology is now gaining momentum. With numerous applications e.g. in biocatalysis and fermentation technology, white biotech companies are able to produce – often from biomass out of agricultural products - biobased chemicals (like vitamins, amino acids or enzymes for textile finishing ...

  13. Innovation in biotechnology: current and future states.

    Science.gov (United States)

    Woollett, G R

    2012-01-01

    Innovation is assumed to be a good thing in health care, just as it is elsewhere, and to be crucial to the availability of greater choices for consumers. But what is it? Very little definition is provided when the term is used. This report discusses the following aspects of biotech innovation: innovation in medicinal products, innovation in manufacturing processes, and innovation in regulatory science (both oversight and licensure).

  14. TECHNOLOGICAL FIELDS AND CONCENTRATION OF INNOVATION AMONG FOOD AND BEVERAGE MULTINATIONALS

    OpenAIRE

    Alfranca, Oscar; Rama, Ruth; von Tunzelmann, Nicholas

    2003-01-01

    With a sample of nearly 18,611 utility patents, this paper studies the technology mix of 90 of the world's leading food and beverage multinationals (FBMs) over 1969-1994. It explores the statistical association between patenting in food technology and in non-food technological fields. Food patenting is always associated with patenting in Biotech, Chemistry, Machinery and Other patenting, whatever the home country of the company. The strength of the association, however, could vary. Herfindahl...

  15. Genetic basis and detection of unintended effects in genetically modified crop plants

    OpenAIRE

    Ladics, Gregory S.; Bartholomaeus, Andrew; Bregitzer, Phil; Doerrer, Nancy G.; Gray, Alan; Holzhauser, Thomas; Jordan, Mark; Keese, Paul; Kok, Esther; Macdonald, Phil; Parrott, Wayne; Privalle, Laura; Raybould, Alan; Rhee, Seung Yon; Rice, Elena

    2015-01-01

    In January 2014, an international meeting sponsored by the International Life Sciences Institute/Health and Environmental Sciences Institute and the Canadian Food Inspection Agency titled “Genetic Basis of Unintended Effects in Modified Plants” was held in Ottawa, Canada, bringing together over 75 scientists from academia, government, and the agro-biotech industry. The objectives of the meeting were to explore current knowledge and identify areas requiring further study on unintended effects ...

  16. Effects and Value of Verifiable Information in a Controversial Market: Evidence from Lab Auctions of Genetically Modified Food

    OpenAIRE

    Rousu, Matthew; Huffman, Wallace; Shogren, Jason F.; Tegene, Abebayehu

    2007-01-01

    Food products containing genetically modified (GM) ingredients have entered the market over the past decade. The biotech industry and environmental groups have disseminating conflicting private information about GM foods. This paper develops a unique methodology for valuing independent third-party information in such a setting and applies this method to consumersï¾’ willingness to pay for food products that might be GM. Data are collected from real consumers in an auction market setting with ...

  17. Interactions between trade policies and GM food regulations

    OpenAIRE

    Kym Anderson

    2005-01-01

    Agricultural biotechnologies, and especially transgenic crops, have the potential to offer higher incomes to biotech firms and farmers, and lower-priced and better quality food for consumers. However, the welfare effects of adoption of genetically modified (GM) food and feed crop varieties are being affected not only by some countriesÂ’ strict regulations governing GM food production and consumption, but also by their choice of food trade policy instruments. Specifically, notwithstanding the ...

  18. Estudio de la intención emprendedora en el ámbito científico público. El caso de las ciencias de la vida en España.

    OpenAIRE

    RODRÍGUEZ BATALLA, FIDEL

    2015-01-01

    [EN] Predicting entrepreneurial behaviour within the environment of public sector research is considered to be of great interest, because this is what will determine the creation of new technology-based start-ups - often known as spin-offs - in universities, hospitals and other public research bodies. In the framework of the knowledge economy, and specifically in the life sciences sector, or "bioeconomy" (European Commission, 2012), the creation and development of a biotech company is conside...

  19. Long-term Socioeconomic Challenges for Russia and Demand for New Technology

    OpenAIRE

    Alexander Apokin; Dmitry Belousov; Vladimir Salnikov(Laboratoire de Mathématiques Nicolas Oresme, Université de Caen Basse-Normandie, CS 14032, Bd. Maréchal Juin, BP 5186, 14032 Caen Cedex, France); Igor Frolov

    2015-01-01

    The primary long-term socio-economic challenges facing Russia – both global and country-specific in nature — drive demand for a range of technologies. We explore several groups of challenges, namely urbanization, demographic, socio-economic, the consequences of ageing, geopolitical, restricted access to key technological competences, climate change and its ecological consequences, as well as technological challenges largely associated with risks in ICT and biotech deve...

  20. Progress in the toxicological researches for quantum dots

    Institute of Scientific and Technical Information of China (English)

    LI HongCheng; ZHOU QunFang; LIU Wei; YAN Bing; ZHAO Yibing; JIANG GuiBin

    2008-01-01

    Quantum dots (QDs) have Received more and more attention as a novel example of nanomaterials. Due to their unique fluorescent characteristics, quantum dots have been successfully applied in biotech-nology and medicine applications. Recently, the toxicity and the potential environmental effects of QDs have become a research hotspot. In this paper, toxicological effects of QDs are reviewed, and the prospects and research directions are given based on the analysis of this research field.

  1. Sea plant and blue cosmetics%海洋植物与蓝色化妆品

    Institute of Scientific and Technical Information of China (English)

    查布立昂

    2006-01-01

    讲述了海藻和人体皮肤之间的相似处以及它为什么能让蓝色化妆品起到有效的皮肤护理作用,并着重讲述了碧欧特海洋精华Biotech Marine公司的10个功效很全面的重点产品.

  2. Eesti teadlaste kiip võitleb vähiga

    Index Scriptorium Estoniae

    2007-01-01

    Vt. ka Linnaleht : Tallinn : na russkom jazõke 28. sept., lk. 4. Biotehnoloogiaettevõte Asper Biotech alustas Valgamaal kogutud DNA-proovide analüüsimist kahe kõige enam levinud päriliku vähi - rinnavähi ja jämesoolevähi - suhtes spetsiaalselt selle uuringu jaoks Eesti biokeskuses väljatöötatud ja maailmas unikaalse geenikiibi abil

  3. Progress in the toxicological researches for quantum dots

    Institute of Scientific and Technical Information of China (English)

    2008-01-01

    Quantum dots (QDs) have received more and more attention as a novel example of nanomaterials. Due to their unique fluorescent characteristics,quantum dots have been successfully applied in biotech-nology and medicine applications. Recently,the toxicity and the potential environmental effects of QDs have become a research hotspot. In this paper,toxicological effects of QDs are reviewed,and the prospects and research directions are given based on the analysis of this research field.

  4. Nutritional and safety assessments of foods and feeds nutritionally improved through biotechnology: lysine maize as a case study.

    Science.gov (United States)

    Glenn, Kevin C

    2007-01-01

    During the last decade, the area of biotech crops modified for agronomic input traits (e.g., herbicide tolerance and insect protection) has increased to 90 million halyear, grown by over 8 million farmers in a total of 17 countries. As adoption of these improved agronomic trait biotech crops has grown, so has interest in biotech crops that have improved nutritional characteristics for use as feed and food. A previous publication by the International Life Sciences Institute (ILSI) reported on the principles and concepts proposed for the nutritional and safety assessments of foods and feeds nutritionally improved through biotechnology. In this paper, the guidelines and principles recommended in the earlier publication are discussed relative to a specific case study, Lysine maize. Lysine maize is a feed ingredient with enhanced nutritional characteristics for poultry and swine and provides an alternative to the need for addition of supplemental lysine to some diets for these animals. The 2004 Task Force of the ILSI has also applied the concepts from that report to 4 other case studies: sweet potato enriched in provitamin A (2 examples, one using biotechnology and one using conventional breeding); Golden Rice 2; double-embryo maize; and ASP-1 enhanced protein sweet potato. PMID:17955996

  5. SUDBIOTECH: A Training Initiative in Plant Biotechnology Dedicated to Scientific Communities in Developing and Emerging Countries

    Directory of Open Access Journals (Sweden)

    Alain RIVAL

    2010-09-01

    Full Text Available The SudBiotech project is targeting PhD and Masters Programmes in Universities and Excellence Research Centres located in developing countries. It proposes an integrative and multidisciplinary approach under the form of a one-week discovery and training itinerary. SudBiotech is aimed at addressing various different fields of Plant Biotechnology, under the specific socioeconomic context of scientific communities from these countries. Our main goal is to train students, research staff, deciders, professionals and journalists to the basic knowledge underlying applications of plant biotechnologies, in order to both update the amount of knowledge which is requested at Master’s level and to acquire a solid body of information which is indispensable for any decision making, in a field of research which is often the target of political, social and media-related pressure. The team of Professors involved in the project shares a strong experience in teaching and training in overseas French Speaking Universities (AUPELF-UREF projects in Marocco, Tunisia, Togo, Côte d’Ivoire, TEMPUS Programme in Lebanon, AUF-Actions de Recherche en Réseau in Benin. The team is composed of senior scientists acting in various complementary fields, namely: Biochemistry/Physiology (A. Nato, Plant Breeding/Molecular Biology (Y. Henry, Tropical Agriculture/Epigenetics (A. Rival. Thanks to these complementarities, SudBiotech is able to propose a training itinerary which is diversified and integrated, covering areas from the plant cell and its original potentialities to the most recent industrial applications of plant biotechnologies (GMOs, their public acceptance in developing and emerging nations and their applicability to tropical plant commodities. The training offer is amplified and enriched through the active role of local research and training staff, who are encouraged to actively participate in the SudBiotech project under various forms including lectures, field visits

  6. The evaluation of a rapid in situ HIV confirmation test in a programme with a high failure rate of the WHO HIV two-test diagnostic algorithm.

    Directory of Open Access Journals (Sweden)

    Derryck B Klarkowski

    Full Text Available BACKGROUND: Concerns about false-positive HIV results led to a review of testing procedures used in a Médecins Sans Frontières (MSF HIV programme in Bukavu, eastern Democratic Republic of Congo. In addition to the WHO HIV rapid diagnostic test algorithm (RDT (two positive RDTs alone for HIV diagnosis used in voluntary counselling and testing (VCT sites we evaluated in situ a practical field-based confirmation test against western blot WB. In addition, we aimed to determine the false-positive rate of the WHO two-test algorithm compared with our adapted protocol including confirmation testing, and whether weakly reactive compared with strongly reactive rapid test results were more likely to be false positives. METHODOLOGY/PRINCIPAL FINDINGS: 2864 clients presenting to MSF VCT centres in Bukavu during January to May 2006 were tested using Determine HIV-1/2 and UniGold HIV rapid tests in parallel by nurse counsellors. Plasma samples on 229 clients confirmed as double RDT positive by laboratory retesting were further tested using both WB and the Orgenics Immunocomb Combfirm HIV confirmation test (OIC-HIV. Of these, 24 samples were negative or indeterminate by WB representing a false-positive rate of the WHO two-test algorithm of 10.5% (95%CI 6.6-15.2. 17 of the 229 samples were weakly positive on rapid testing and all were negative or indeterminate by WB. The false-positive rate fell to 3.3% (95%CI 1.3-6.7 when only strong-positive rapid test results were considered. Agreement between OIC-HIV and WB was 99.1% (95%CI 96.9-99.9% with no false OIC-HIV positives if stringent criteria for positive OIC-HIV diagnoses were used. CONCLUSIONS: The WHO HIV two-test diagnostic algorithm produced an unacceptably high level of false-positive diagnoses in our setting, especially if results were weakly positive. The most probable causes of the false-positive results were serological cross-reactivity or non-specific immune reactivity. Our findings show that the OIC

  7. Evaluation of Performance of Two Rapid Tests for Detection of HIV-1 and -2 in High- and Low-Prevalence Populations in Nigeria.

    Science.gov (United States)

    Manak, Mark M; Njoku, Ogbonnaya S; Shutt, Ashley; Malia, Jennifer; Jagodzinski, Linda L; Milazzo, Mark; Suleiman, Aminu; Ogundeji, Amos A; Nelson, Robert; Ayemoba, Ojor R; O'Connell, Robert J; Singer, Darrell E; Michael, Nelson L; Peel, Sheila A

    2015-11-01

    The availability of reliable human immunodeficiency virus types 1 and 2 (HIV-1/2) rapid tests in resource-limited settings represents an important advancement in the accurate diagnosis of HIV infection and presents opportunities for implementation of effective prevention and treatment interventions among vulnerable populations. A study of the potential target populations for future HIV vaccine studies examined the prevalence of HIV infections at six selected sites in Nigeria and evaluated the use of two rapid diagnostic tests (RDTs) for HIV. The populations included market workers at sites adjacent to military installations and workers at highway settlements (truck stops) who may have a heightened risk of HIV exposure. Samples from 3,187 individuals who provided informed consent were tested in parallel using the Determine (DT) and Stat-Pak (SP) RDTs; discordant results were subjected to the Uni-Gold (UG) RDT as a tiebreaker. The results were compared to those of a third-generation enzyme immunoassay screen with confirmation of repeat reactive samples by HIV-1 Western blotting. One participant was HIV-2 infected, yielding positive results on both RDTs. Using the laboratory algorithm as a gold standard, we calculated sensitivities of 98.5% (confidence interval [CI], 97.1 to 99.8%) for DT and 98.1% (CI, 96.7 to 99.6%) for SP and specificities of 98.7% (CI, 98.3 -99.1%) for DT and 99.8% (CI, 99.6 to 100%) for SP. Similar results were obtained when the sites were stratified into those of higher HIV prevalence (9.4% to 22.8%) versus those of lower prevalence (3.2% to 7.3%). A parallel two-test algorithm requiring both DT and SP to be positive resulted in the highest sensitivity (98.1%; CI, 96.7 to 99.6%) and specificity (99.97%; CI, 99.9 to 100%) relative to those for the reference laboratory algorithm. PMID:26311857

  8. GETTING TESTY

    Institute of Scientific and Technical Information of China (English)

    MATT; YOUNG

    2006-01-01

    Chinese labs begin R&D for Big Pharma and other biotech companies It came down to three countries for Bridge Pharmaceuticals' new animal testing lab: India, Singapore and China. In the process India fell out of the equation. "India doesn't have primates or dogs," said Glenn Rice, the Menlo Park, California-based company's president and CEO. India is a great place for small molecule manufacturing but not for toxicology testing on animals because the right breeders are not available there, Rice

  9. Industrial processes influenced by gravity

    Science.gov (United States)

    Ostrach, Simon

    1988-01-01

    In considering new directions for low gravity research with particular regard to broadening the number and types of industrial involvements, it is noted that transport phenomena play a vital role in diverse processes in the chemical, pharmaceutical, food, and biotech industries. Relatively little attention has been given to the role of gravity in such processes. Accordingly, numerous industrial processes and phenomena are identified which involve gravity and/or surface tension forces. Phase separations and mixing are examples that will be significantly different in low gravity conditions. A basis is presented for expanding the scope of the low gravity research program and the potential benefits of such research is indicated.

  10. [Generic and biosimilar drug substitution: a panacea?].

    Science.gov (United States)

    Daly, M J; Guignard, B; Nendaz, M

    2015-10-14

    Drugs are the third largest source of expenditure under Switzerland's compulsory basic health insurance. Generics, the price of which should be at least 30 per cent less than the cost of the original drugs, can potentially allow substantial savings. Their approval requires bioequivalence studies and their use is safe, although some factors may influence patients' and physicians' acceptance. The increased substitution of biosimilar drugs for more expensive biotech drugs should allow further cost savings. In an attempt to extend the monopoly granted by the original drug patent, some pharmaceutical companies implement "evergreening" strategies including small modifications of the original substance for which the clinical benefit is not always demonstrated.

  11. Review on Micro- and Nanolithography Techniques and Their Applications

    Directory of Open Access Journals (Sweden)

    Werayut Srituravanich

    2012-01-01

    Full Text Available This article reviews major micro- and nanolithography techniques and their applications from commercial micro devices to emerging applications in nanoscale science and engineering. Micro- and nanolithography has been the key technology in manufacturing of integrated circuits and microchips in the semiconductor industry. Such a technology is also sparking a magnificent transformation of nanotechnology. The lithography techniques including photolithography, electron beam lithography, focused ion beam lithography, soft lithography, nanoimprint lithography and scanning probe lithography are discussed. Furthermore, their applications are reviewed and summarized into four major areas: electronics and microsystems, medical and biotech, optics and photonics, and environment and energy harvesting.

  12. Le marché des variétés de coton-Bt : analyse de la situation en Chine dans une perspective internationale

    OpenAIRE

    Fok, Michel; Xu, Naiyin

    2010-01-01

    texte publié disponible à : http://www.john-libbey-eurotext.fr/fr/revues/agro_biotech/agr/e-docs/00/04/52/90/resume.phtml International audience About ten countries have adopted Bt-cotton since its commercial release in the USA in 1996. This release immediately has led to raise the concern of Monsanto's monopoly and loss of varietal diversity in adopting countries. There are very few studies addressing the actual state of the cotton variety markets in the adopting countries. This articl...

  13. Managing Networks

    DEFF Research Database (Denmark)

    Jørgensen, Heidi; Vintergaard, Christian

    isprovided, that the relation between a company's strategy, structure and processesin fact have a considerable influence on its pattern of network behaviour. Threecase studies from the Danish biotech industry exemplify and illustrate how acompany's strategy is directly correlated with how it manages its...... of networkbehaviour, knowing how to manage this relation becomes essential, especiallyduring the development of new strategies.......Logically it seems that companies pursuing different business strategies wouldalso manage their relationships with other firms accordingly. Nevertheless, due tothe lack of research in the field of network strategies, this link still remainsinadequately examined. Based on the well-known framework...

  14. Experiment list: SRX150477 [Chip-atlas[Archive

    Lifescience Database Archive (English)

    Full Text Available osis=Fibrocystic Disease 70636654,97.7,24.3,106225 GSM935397: Harvard ChipSeq MCF10A-Er-Src 4OHTAM 1uM 4hr c-Fos Harvard... Control source_name=MCF10A-Er-Src || biomaterial_provider=Struhl laboratory || lab=Harvard || l... a leucine-zipper. || antibody vendorname=Santa Cruz Biotech || antibody vendorid=sc-7202 || control=Harvard..._Control || control description=input library was prepared at Harvard. || control=Harvard..._Control || control description=input library was prepared at Harvard. || controlid=wgEncodeEH002871

  15. Experiment list: SRX150570 [Chip-atlas[Archive

    Lifescience Database Archive (English)

    Full Text Available osis=Fibrocystic Disease 64692659,93.8,19.3,37417 GSM935491: Harvard ChipSeq MCF10A-Er-Src 4OHTAM 1uM 4hr c-Myc Harvard... Control source_name=MCF10A-Er-Src || biomaterial_provider=Struhl laboratory || lab=Harvard || la...ntibody vendorname=Santa Cruz Biotech || antibody vendorid=sc-764 || control=Harvard_Control || control desc...ription=input library was prepared at Harvard. || control=Harvard_Control || cont...rol description=input library was prepared at Harvard. || controlid=wgEncodeEH002871 || replicate=1 http://d

  16. Experiment list: SRX150479 [Chip-atlas[Archive

    Lifescience Database Archive (English)

    Full Text Available gnosis=Fibrocystic Disease 36921541,91.0,24.5,48136 GSM935399: Harvard ChipSeq MCF10A-Er-Src 4OHTAM 1uM 12hr STAT3 Harvard... Control source_name=MCF10A-Er-Src || biomaterial_provider=Struhl laboratory || lab=Harvard ||... lab description=Struhl - Harvard University || datatype=ChipSeq || datatype desc...esses such as cell growth and apoptosis. || antibody vendorname=Santa Cruz Biotech || antibody vendorid=sc-482 || control=Harvard..._Control || control description=input library was prepared at Harvard. || control=Harvard

  17. Experiment list: SRX150476 [Chip-atlas[Archive

    Lifescience Database Archive (English)

    Full Text Available osis=Fibrocystic Disease 60050220,94.5,18.5,85444 GSM935396: Harvard ChipSeq MCF10A-Er-Src 4OHTAM 1uM 36hr c-Fos Harvard... Control source_name=MCF10A-Er-Src || biomaterial_provider=Struhl laboratory || lab=Harvard || l...is a leucine-zipper. || antibody vendorname=Santa Cruz Biotech || antibody vendorid=sc-7202 || control=Harvard..._Control || control description=input library was prepared at Harvard. || control=Harvard..._Control || control description=input library was prepared at Harvard. || controlid=wgEncodeEH0028

  18. Experiment list: SRX150517 [Chip-atlas[Archive

    Lifescience Database Archive (English)

    Full Text Available osis=Fibrocystic Disease 50667127,93.3,23.9,80828 GSM935438: Harvard ChipSeq MCF10A-Er-Src EtOH 0.01pct c-Fos Harvard... Control source_name=MCF10A-Er-Src || biomaterial_provider=Struhl laboratory || lab=Harvard || lab description=Struhl - Harv...me=Santa Cruz Biotech || antibody vendorid=sc-7202 || control=Harvard_Control || control description=input l...ibrary was prepared at Harvard. || control=Harvard_Control || control description...=input library was prepared at Harvard. || controlid=wgEncodeEH002871 || replicate=1 http://dbarchive.biosci

  19. Experiment list: SRX150480 [Chip-atlas[Archive

    Lifescience Database Archive (English)

    Full Text Available nosis=Fibrocystic Disease 61955386,94.5,36.1,18987 GSM935400: Harvard ChipSeq MCF10A-Er-Src 4OHTAM 1uM 36hr E2F4 Harvard... Control source_name=MCF10A-Er-Src || biomaterial_provider=Struhl laboratory || lab=Harvard || l...antibody vendorname=Santa Cruz Biotech || antibody vendorid=sc-866 || control=Harvard_Control || control des...cription=input library was prepared at Harvard. || control=Harvard_Control || control description=input library was prepared at Harva...ab description=Struhl - Harvard University || datatype=ChipSeq || datatype descri

  20. Experiment list: SRX150478 [Chip-atlas[Archive

    Lifescience Database Archive (English)

    Full Text Available osis=Fibrocystic Disease 66690540,98.1,24.9,110111 GSM935398: Harvard ChipSeq MCF10A-Er-Src 4OHTAM 1uM 12hr c-Fos Harvard... Control source_name=MCF10A-Er-Src || biomaterial_provider=Struhl laboratory || lab=Harvard || ...lab description=Struhl - Harvard University || datatype=ChipSeq || datatype descr... is a leucine-zipper. || antibody vendorname=Santa Cruz Biotech || antibody vendorid=sc-7202 || control=Harvard..._Control || control description=input library was prepared at Harvard. || control=Harvard

  1. Standing on shaky ground- US patent-eligibility of isolated DNA and genetic diagnostics after AMP v. USPTO - Part II (practical implications & chances for Supreme Court Review)

    DEFF Research Database (Denmark)

    Minssen, Timo; Nilsson, David

    2012-01-01

    and so-called "Beauregard"- claims, but also for biotech-claims directed to personalized medicine, biological correlations and compounds containing biological information. As far as possible, this part will also incorporate new developments that can be expected in the coming months, such as the pending...... of subsequent case law addressing the patent-eligibility of biological correlations and software-related "inventions" (6). These subsequent decisions indicate a serious split at the Federal Circuit with potentially broad implications not only for the patent eligibility of software-related patent applications...... European developments (7). This will provide the basis for summarizing conclusions (8)....

  2. Deficiencia de glucosa 6 fosfato deshidrogenasa: análisis enzimático y molecular en una población de Bogotá

    OpenAIRE

    Magda Carolina Sánchez; Victoria Eugenia Villegas; Dora Fonseca

    2008-01-01

    bjetivo: Determinar qué tan frecuente es la deficiencia de glucosa 6 fosfato deshidrogenasa (G6PD) y realizar análisis molecular para identificar las variantes A+, A- y mediterránea en una población de residentes en Bogotá.Métodos: Se analizaron 348 personas que residen en Bogotá, pertenecientes a la Policía Nacional y a la Universidad del Rosario. La actividad enzimática se determinó en muestras de sangre mediante espectrofotometría con el kit Trinity Biotech (Cat 345-B). Los valores de hemo...

  3. Valuable biomolecules from nine North Atlantic red macroalgae

    DEFF Research Database (Denmark)

    Razi Parjikolaei, Behnaz; Bruhn, Annette; Eybye, Karin Loft;

    2016-01-01

    In modern society, novel marine resources are scrutinized pursuing compounds of use in the medical, pharmaceutical, biotech, food or feed industry. Few of the numerous marine macroalgae are currently exploited. In this study, the contents of nutritional compounds from nine common North Atlantic red...... macroalgae were compared: the lipid content was low and constant among the species, whereas the fatty acid profiles indicated that these species constitute interesting sources of polyunsaturated fatty acids (PUFA). The dominating essential and non-essential amino acids were lysine and leucine, aspartic acid...

  4. Development and characterization of a cell culture manufacturing process using quality by design (QbD) principles.

    Science.gov (United States)

    Marasco, Daniel M; Gao, Jinxin; Griffiths, Kristi; Froggatt, Christopher; Wang, Tongtong; Wei, Gan

    2014-01-01

    The principles of quality by design (QbD) have been applied in cell culture manufacturing process development and characterization in the biotech industry. Here we share our approach and practice in developing and characterizing a cell culture manufacturing process using QbD principles for establishing a process control strategy. Process development and characterization start with critical quality attribute identification, followed by process parameter and incoming raw material risk assessment, design of experiment, and process parameter classification, and conclude with a design space construction. Finally, a rational process control strategy is established and documented. PMID:23828505

  5. WRIB Poster Award winners.

    Science.gov (United States)

    2016-09-01

    The 10th Workshop on Recent Issues in Bioanalysis (WRIB) held in Orlando, USA, in April 2016. It drew close to 500 professionals representing large pharmas, biotechs, CROs and multiple regulatory agencies from around the world, working on both small- and large-molecule bioanalysis. This year, bioanalysis and bioanalysis zone were proud to support the WRIB Poster Awards and we feature profiles of the authors of the winning posters. Go to www.bioanalysis-zone.com to see the winning posters in full. Winning posters. PMID:27523325

  6. Biopharma business models in Canada.

    Science.gov (United States)

    March-Chordà, I; Yagüe-Perales, R M

    2011-08-01

    This article provides new insights into the different strategy paths or business models currently being implemented by Canadian biopharma companies. Through a case-study methodology, seven biopharma companies pertaining to three business models were analyzed, leading to a broad set of results emerging from the following areas: activity, business model and strategy; management and human resources; and R&D, technology and innovation strategy. The three business models represented were: model 1 (conventional biotech oriented to new drug development, radical innovation and search for discoveries); model 2 (development of a technology platform, usually in proteomics and bioinformatics); and model 3 (incremental innovation, with shorter and less risky development timelines). PMID:21708279

  7. Bioceres: AG Biotechnology from Argentina

    Directory of Open Access Journals (Sweden)

    Roberto Feeney

    2016-04-01

    Full Text Available In this case we present a business decision-making situation in which the CEO of an Argentine Ag Biotech company, Bioceres, has to decide the best way to commercialize a new drought-tolerant transgenic technology. The company was founded by twenty three farmers, who shared a common dream that Argentina could become a benchmark in the development of Ag biotechnology. The case has strategic and financial implications, as well as decision-making situation involving a joint venture with an American biotechnology company. It also introduces to discussion the business models of Ag biotechnology companies in developing countries.

  8. Platform for a Technological Leap in Antibiotics.

    Science.gov (United States)

    Heinzelmann, Elsbeth

    2015-01-01

    NTN Swiss Biotech™ brings together the Swiss Biotech Association SBA, which is involved in regulatory, financial and legal issues, and biotechnet Switzerland, which is active in translational R&D, to provide a technology base for joint projects. Biotechnet aims to push promising domains by creating topic-oriented platforms that enable academia and industry to work together to produce R&D results of major importance to society and the economy. The first activity initiated by biotechnet is the Antibiotics Platform that has now been launched. PMID:26842338

  9. Towards ontology based search and knowledgesharing using domain ontologies

    DEFF Research Database (Denmark)

    Zambach, Sine

    This paper reports on work in progress. We present work on domain specific verbs and their role as relations in domain ontologies. The domain ontology which is in focus for our research is modeled in cooperation with the Danish biotech company Novo Nordic. Two of the main purposes of domain...... verbs for relations in the ontology modeling. For this work we use frequency lists from a biomedical text corpus of different genres as well as a study of the relations used in other biomedical text mining tools. In addition, we discuss how these relations can be used in broarder perspective....

  10. The current status of immunotoxins: an overview of experimental and clinical studies as presented at the Third International Symposium on Immunotoxins.

    Science.gov (United States)

    Uckun, F M; Frankel, A

    1993-02-01

    The Third International Symposium on Immunotoxins was held on June 19-21, 1992 in Orlando, Florida. This symposium was sponsored by NATO, NIH, Pierce Chemical Company, Walt Disney Cancer Institute at Florida Hospital, Duke Comprehensive Cancer Center, Xoma, Immunogen, Seragen, Bristol-Myers Squibb, Chiron, Ortho Biotech, Upjohn, Merck Sharp & Dohme Research Laboratories, Abbot Laboratories, Lilly Research Laboratories, and Evans & Sutherland. The Pierce Immunotoxin Award which recognizes outstanding contributions to immunotoxin research and development, was presented to Drs David FitzGerald, Fatih Uckun, David Eisenberg, and Ira Wool, for their contributions to the immunotoxin field.

  11. Assessing the impacts of industrial water use in Life Cycle Assessment

    DEFF Research Database (Denmark)

    Lévová, Tereza; Hauschild, Michael Zwicky

    2011-01-01

    use also depends on the local sensitivity to freshwater extraction, and the change in the quality from water intake to discharge of the usedwater. A methodology is presented catering to these characteristics of the water use issue and demonstrated on an industrial case study from the biotech industry.......Use of freshwater gives rise to important environmental impacts to consider in the sustainability analysis of an industry or a product. Water use impacts are highly dependent on the local or regional conditions, and apart from the quantity that is extracted and used, the impact of the freshwater...

  12. Thematic Platform in vitro Diagnostics Technological Progress with a Powerful Network.

    Science.gov (United States)

    Heinzelmann, Elsbeth

    2016-01-01

    In vitro diagnostics (IVD) has huge potential. Primary drivers in the global market are the patient's awareness of infectious diseases, the introduction of advanced molecular and tissue diagnostic tests for patient-stratified and targeted anti-cancer therapy and, last but not least, the growing geriatric population. Rapid progress in device miniaturization and information technology (IT) offers new possibilities in decentralized testing. Grand View Research Inc. expects the global market for IVD to reach US $ 74.3 billion by 2020. Hence the launch in 2015 by the NTN Swiss Biotech - together with the driving forces of Biotechnet Switzerland - of the 'Thematic Platform in vitro Diagnostics'.

  13. Life cycle inventory and risk assessment of genetic modified perennial ryegrass in a technology foresight perspective

    DEFF Research Database (Denmark)

    Borch, K.; Rasmussen, B.; Schleisner, L.

    2000-01-01

    Due to the complexity and advanced nature of modern biotechnology and to its content of risk and ethic matters it is necessary to face the challenge of making the prospect comprehensible and transparent to society. Using life cycle inven-tory (LCI),expert panels and weighted expert questionnaires......, a methodological approach is suggested to analyse the uncertainties that the biotech industry and the authorities face when implementing genetically modified (GM) crops. These uncertainties embracescientific rationality regarding technological development and risk assessments, as well as ethic political and social...

  14. Dépendance à la trajectoire et création d’une trajectoire dans les controverses sur la sphère bioénergétique au Danemark

    DEFF Research Database (Denmark)

    Andersen, Bente Hessellund; Jørgensen, Michael Søgaard

    2015-01-01

    and a measure to reduce climate impact and nuisances from slurry, while NGOs fear slurry-based biogas is used as argument for increased animal husbandry. A biotech company develops enzymes for processing of biomass for second generation biofuels, which has obtained some support, while others see this as merely...... and the environmental impacts of using bioenergy: Energy companies convert coal fired power plants into imported biomass to sustain the role of these power plants in the transition towards renewable energy, while some NGOs claim that this practice will not reduce emissions. Farmers see slurry as a source for biogas...

  15. Innovation and wound healing.

    Science.gov (United States)

    Harding, Keith

    2015-04-01

    Innovation in medicine requires unique partnerships between academic research, biotech or pharmaceutical companies, and health-care providers. While innovation in medicine has greatly increased over the past 100 years, innovation in wound care has been slow, despite the fact that chronic wounds are a global health challenge where there is a need for technical, process and social innovation. While novel partnerships between research and the health-care system have been created, we still have much to learn about wound care and the wound-healing processes.

  16. IMPORTANCE OF NANOROBOTS IN HEALTH CARE

    Directory of Open Access Journals (Sweden)

    Prajapati P M.

    2012-03-01

    Full Text Available A nanorobot is a tiny machine designed to perform a specific tasks repeatedly and with precision at nanoscale dimensions. Nanorobotics will have a diameter of about 0.5 to 3 microns and will be constructed out of parts with dimensions in the range of 1 to 100 nanometres. Nanorobotics has strong potential to revolutionize healthcare, to treat disease in future. It opens up new ways for vast, abundant research work. Nanotechnology will change health care and human life more profoundly than other developments. Consequently they will change the shape of the industry, broadening the product development and marketing interactions between Pharma, Biotech, Diagnostic and Healthcare industries.

  17. Microfluidic very large-scale integration for biochips: Technology, testing and fault-tolerant design

    DEFF Research Database (Denmark)

    Araci, Ismail Emre; Pop, Paul; Chakrabarty, Krishnendu

    2015-01-01

    paper is on continuous-flow biochips, where the basic building block is a microvalve. By combining these microvalves, more complex units such as mixers, switches, multiplexers can be built, hence the name of the technology, “microfluidic Very Large-Scale Integration” (mVLSI). A roadblock in the......Microfluidic biochips are replacing the conventional biochemical analyzers by integrating all the necessary functions for biochemical analysis using microfluidics. Biochips are used in many application areas, such as, in vitro diagnostics, drug discovery, biotech and ecology. The focus of this...

  18. Leadership decisions that shaped the destiny of Genzyme: Lessons from 30 years of entrepreneurial leadership: critical decisions for growth

    OpenAIRE

    Steen, van der, M.

    2011-01-01

    This article is based on an interview of Marianne van der Steen with Henri Termeer‐the long time CEO of Genzyme. Within Europe, Genzyme’s state-of-the-art cell culture production facility for therapeutic proteins is located in Geel, Belgium, and is among the largest bio‐manufacturing sites in Europe. This month, the company announced that it will build an additional manufacturing plant in Geel. The topic of the interview was growth decisions from biotech start-up to a fully integrated biophar...

  19. Fostering a new dialogue to improve access to finance for European biopharma SMEs.

    Science.gov (United States)

    Chantelot, Emmanuel; Suojanen, Christian

    2010-12-31

    This article reviews the current economic crisis as it impacts upon European biopharma SMEs and their ability to secure investment and funding. In particular it presents an analysis of a broader, pre-crisis structural problem in Europe related to the lack of institutional investors for Europe's life sciences venture capital funds and the impact this has both on the funds available for investment by VCs into Europe's biotech companies, and the effect on the type and stage of biopharma companies able to raise money. This article also presents an overview of an on-going stakeholder dialogue to address these issues and the proposals raised so far for possible solutions. PMID:20678597

  20. Identification and characterization of novel activities from plant stem cell extracts regulating epidermal cell proliferation and homeostasis

    OpenAIRE

    di Martino, Orsola

    2015-01-01

    My PhD program included two phases, the first was carried out in the laboratory of Molecular Genetics, under the supervision of Professor Viola Calabrò, and the latter in the laboratory of Arterra Biosciene Srl. Arterra Bioscience is an Italian research-based biotech company with a strong know-how in biological science and an extensive experience in screening for the discovery of active molecules. The opportunity to join these two different scientific groups allows me to gain a more co...

  1. Clinical Comparison of the Treponema pallidum CAPTIA Syphilis-G Enzyme Immunoassay with the Fluorescent Treponemal Antibody Absorption Immunoglobulin G Assay for Syphilis Testing

    OpenAIRE

    Halling, V. W.; Jones, M. F.; Bestrom, J. E.; Wold, A D; Rosenblatt, J E; Smith, T. F.; Cockerill, F R

    1999-01-01

    Recently, a treponema-specific immunoglobulin G (IgG) enzyme immunoassay (EIA), the CAPTIA Syphilis-G (Trinity Biotech, Jamestown, N.Y.), has become available as a diagnostic test for syphilis. A total of 89 stored sera previously tested by the fluorescent treponemal antibody absorption (FTA-ABS) IgG assay were evaluated by the CAPTIA EIA. The FTA-ABS IgG procedure was performed by technologists unblinded to results of rapid plasmid reagin (RPR) testing of the same specimens. Borderline CAPTI...

  2. IR light source based on LED for endoscopy applications

    OpenAIRE

    Ruiz López, Mabel

    2009-01-01

    Tesina final de master feta en col.laboració amb Transmural Biotech S.L A specific endoscopy technology uses an InfraRed (IR) light to achieve specific imaging of the vascular system. This IR light is obtained by an IR laser source. The aim of this study is to find a new IR illumination built with LEDs to substitute the existing IR source. LEDs may contribute in the endoscopy application with their advantage: LEDs cost is lower than lasers, LEDs have a longer lifetime, LEDs are...

  3. Brachymetatarsia of the fourth metatarsal, lengthening scarf osteotomy with bone graft

    Directory of Open Access Journals (Sweden)

    Ankit Desai

    2013-09-01

    Full Text Available A 16-year-old girl presented with left fourth metatarsal shortening causing significant psychological distress. She underwent lengthening scarf osteotomy held with an Omnitech® screw (Biotech International, France with the addition of two 1 cm cancellous cubes (RTI Biologics, United States. A lengthening z-plasty of the extensor tendons and skin were also performed. At 6 weeks the patient was fully weight bearing and at one-year follow up, the patient was satisfied and discharged. A modified technique of lengthening scarf osteotomy is described for congenital brachymatatarsia. This technique allows one stage lengthening through a single incision with graft incorporation by 6 weeks.

  4. 08076 Bharat Biotech应用VLP技术研发流感疫苗

    Institute of Scientific and Technical Information of China (English)

    罗娟(摘)

    2006-01-01

    印度的Bharat Biotech International公司将被获准使用Novavax公司的病毒样质粒(VLP)疫苗技术为印度和其他南亚市场研发流行性感冒疫苗。Bharat将为所有临床前和临床研究提供资金,帮助开发生产程序并负责所有的商业活动。

  5. Biorefineries to integrate fuel, energy and chemical production processes

    Directory of Open Access Journals (Sweden)

    Enrica Bargiacchi

    2007-12-01

    Full Text Available The world of renewable energies is in fast evolution and arouses political and public interests, especially as an opportunity to boost environmental sustainability by mitigation of greenhouse gas emissions. This work aims at examining the possibilities related to the development of biorefineries, where biomass conversion processes to produce biofuels, electricity and biochemicals are integrated. Particular interest is given to the production processes of biodiesel, bioethanol and biogas, for which present world situation, problems, and perspectives are drawn. Potential areas for agronomic and biotech researches are also discussed. Producing biomass for biorefinery processing will eventually lead to maximize yields, in the non food agriculture.

  6. The influence of human factor on financial sustainability of agricultural production

    Directory of Open Access Journals (Sweden)

    Peter Ivanovich Ogorodnikov

    2012-06-01

    Full Text Available The analysis of functioning ofcomplex production systems in agroindustrial sphere — largecrop farms and livestock farms — shows that the basis for dynamic development of their productive activities is based on a reliable and stable operation of the complex biotech (human-machine systems. Urgent problems, whose solution promotes a dynamic and efficient operation of complex biotechnological systems, are to create mathematical models of the total biotech system, allowing sufficiently informatively guide the work of major agricultural organizations. This paper discusses an alternative methodological approach to assessing and forecasting financial sustainability of an enterprise. An important place among the factors that shape the financial stability of the economic entity, takes the human factor (decision maker. Financial sustainability of the enterprise is seen from the perspective of bio-approach that includes elements of the system MME (man, machine, and environment. This approach improves the results when evaluating the adequacy of the financial stability of companies in various states of the economy. Newly developed approaches and mathematical models to managesystems of biotechnology makeit possibleto significantly increase the productivity of animals, crop production and the level of socio-economic status of people in the country.

  7. Maize transformation technology development for commercial event generation

    Directory of Open Access Journals (Sweden)

    Qiudeng eQue

    2014-08-01

    Full Text Available Maize is an important food and feed crop in many countries. It is also one of the most important target crops for the application of biotechnology. Currently, there are more biotech traits available on the market in maize than in any other crop. Generation of transgenic events is a crucial step in the development of biotech traits. For commercial applications, a high throughput transformation system producing a large number of high quality events in an elite genetic background is highly desirable. There has been tremendous progress in Agrobacterium-mediated maize transformation since the publication of the Ishida et al. (1996 paper and the technology has been widely adopted for transgenic event production by many labs around the world. We will review general efforts in establishing efficient maize transformation technologies useful for transgenic event production in trait research and development. The review will also discuss transformation systems used for generating commercial maize trait events currently on the market. As the number of traits is increasing steadily and two or more modes of action are used to control key pests, new tools are needed to efficiently transform vectors containing multiple trait genes. We will review general guidelines for assembling binary vectors for commercial transformation. Approaches to increase transformation efficiency and gene expression of large gene stack vectors will be discussed. Finally, recent studies of targeted genome modification and transgene insertion using different site-directed nuclease technologies will be reviewed.

  8. Multivariate Statistical Process Optimization in the Industrial Production of Enzymes

    DEFF Research Database (Denmark)

    Klimkiewicz, Anna

    In modern biotech production, a massive number of diverse measurements, with a broad diversity in information content and quality, is stored in data historians. The potential of this enormous amount of data is currently under-employed in process optimization efforts. This is a result of the deman......In modern biotech production, a massive number of diverse measurements, with a broad diversity in information content and quality, is stored in data historians. The potential of this enormous amount of data is currently under-employed in process optimization efforts. This is a result...... and difficulties related to ‘recycling’ of historical data from a full-scale manufacturing of industrial enzymes. First, the crucial and tedious step of retrieving the data from the systems is presented. The prerequisites that need to be comprehended are discussed, such as sensors accuracy and reliability, aspects...... of the system under investigation. If thisleads to new knowledge, it could be used for optimization of future production runs.Data reduced to mean value per run, combined with some other relevant features,has been used together with PLS2 regression in the primary investigation. It allowedus to identify...

  9. Status of Genetically Modiifed Crops Planting in the World%全球转基因作物种植现状及启示

    Institute of Scientific and Technical Information of China (English)

    杜艳艳; 刘阳

    2015-01-01

    Based on the data released by the International Service for the Acquisition of Agri-biotech Applications(ISAAA), the paper ifrst gives a statistical analysis on the global genetically modiifed (GM) crops planted in 1996-2014 in terms of planted acres, countries, varieties, characteristics and economic beneifts , then summarizes the development status of global genetically modiifed crops, and ifnally gives some suggestions on the development of corresponding GM crops in China.%本文以国际农业生物技术应用服务组织(International Service for the Acquisition of Agri-biotech Applications,ISAAA)公布的相关数据为基础,对1996-2014年全球转基因农作物种植的面积、国家、品种、特性以及经济效益等进行统计分析,总结全球转基因作物种植的发展态势,并提出中国发展转基因作物的建议。

  10. Exploring the characteristics of innovation alliances of Dutch Biotechnology SMEs and their policy implications

    Directory of Open Access Journals (Sweden)

    Philipp J.P. Garbade

    2013-05-01

    Full Text Available Policy makers are becoming increasingly aware of the fact that R&D intensive SMEs play a pivotal role in providing sustainable economic growth by maintaining a high rate of innovation. To compensate for their financial vulnerability, these SMEs increasingly conduct innovation in alliances. This paper aims to explore the impact of different alliance characteristics on the performance of Dutch biotechnology SMEs. The conceptual model was tested using a sample of 18 biotech SMEs reporting about 40 alliances. The main findings indicate that alliance performance is positively related to the level of complementarity, the cognitive distance and tacit knowledge transfer by the human resources exchanges. Policy makers are recommended to support innovation alliances by providing the infrastructure in which alliances can flourish, e.g. through stimulating the foundation of cluster organizations that can function as innovation brokers. These cluster organizations can provide network formation, demand articulation, internationalization and innovation process support to their member companies and can act as a go-between among alliance partners. As part of the innovation process support activities, they can organize special workshops for biotech SMEs on how to successfully behave in an innovation alliance.

  11. Essential Drugs Production in Brazil, Russia, India, China and South Africa (BRICS: Opportunities and Challenges

    Directory of Open Access Journals (Sweden)

    Zoheir Ezziane

    2014-12-01

    Full Text Available The objective of this work is to elucidate various essential drugs in the Brazil, Russia, India, China and South Africa (BRICS countries. It discusses the opportunities and challenges of the existing biotech infrastructure and the production of drugs and vaccines in member states of the BRICS. This research is based on a systematic literature review between the years 2000 and 2014 of documents retrieved from the databases Embase, PubMed/Medline, Global Health, and Google Scholar, and the websites of relevant international organizations, research institutions and philanthropic organizations. Findings vary from one member state to another. These include useful comparison between the BRICS countries in terms of pharmaceuticals expenditure versus total health expenditure, local manufacturing of drugs/vaccines using technology and know-how transferred from developed countries, and biotech entrepreneurial collaborations under the umbrella of the BRICS region. This study concludes by providing recommendations to support more of inter collaborations among the BRICS countries as well as between BRICS and many developing countries to shrink drug production costs. In addition, this collaboration would also culminate in reaching out to poor countries that are not able to provide their communities and patients with cost-effective essential medicines.

  12. Energy from waste

    International Nuclear Information System (INIS)

    In accordance with the fast growing population, the demand for energy and the discharge of waste are also increasing day by day. So, there is two method of waste treatment that practiced by our company, centralised and de centralised. For de centralised treatment, there are some advantages like no collection, no transportation, small investment and for disadvantages, more treatment plants are needed. Waste of food materials and other bio degradable wastes generated in Factory canteens, Convents, Hospitals, Hostels, Hotels and other industrial organizations can be treated in an eco-friendly way for the production of cooking gas in very large scale. BIOTECH has completed the installation of 52 Nos. power generation projects using market /slaughter house waste. The power generated from these projects is being utilized for energy requirements of the concerned markets and to meet the in-house requirements of the projects. In recognition of our selfless services to the society through our system of waste management and the generation of Energy from waste. BIOTECH was honored by conferring on it the prestigious International Ashden Award GREEN OSCAR 2007. (Author)

  13. An Asian perspective on GMO and biotechnology issues.

    Science.gov (United States)

    Teng, Paul P S

    2008-01-01

    Of the 102 million hectares that made up the global area of biotech crops in 2006, less than 8% (7.6 million ha) were in Asia. Three biotech crops are currently planted in significant areas in four Asian countries with government regulatory approval; namely, cotton, corn (maize), and canola. However, the amount of GM crop material imported into the Asian region for processing into food and animal feed is very substantial, and almost every country imports GM food. The issues which concern Asian scientists, regulators, and the lay public resemble those of other regions - biosafety, food safety, ethics and social justice, competitiveness, and the "EU" trade question. Most Asian countries now have regulatory systems for approving the commercialization of GM crops, and for approving food safety of GM crops. In Asia, because of the varied cultures, issues concerning the use of genes derived from animals arouse much emotion for religious and diet choice reasons. Because many Asian producers and farmers are small-scale, there is also concern about technology dependency and to whom the benefits accrue. All consumers surveyed have expressed concern about potential allergenic and long-term toxic effects, neither of which is grounded on scientific facts. Because of Asia's growing demand for high volumes of quality food, it is likely that GM crops will become an increasing feature of our diet. PMID:18296345

  14. Essential drugs production in Brazil, Russia, India, China and South Africa (BRICS): opportunities and challenges.

    Science.gov (United States)

    Ezziane, Zoheir

    2014-12-01

    The objective of this work is to elucidate various essential drugs in the Brazil, Russia, India, China and South Africa (BRICS) countries. It discusses the opportunities and challenges of the existing biotech infrastructure and the production of drugs and vaccines in member states of the BRICS. This research is based on a systematic literature review between the years 2000 and 2014 of documents retrieved from the databases Embase, PubMed/Medline, Global Health, and Google Scholar, and the websites of relevant international organizations, research institutions and philanthropic organizations. Findings vary from one member state to another. These include useful comparison between the BRICS countries in terms of pharmaceuticals expenditure versus total health expenditure, local manufacturing of drugs/vaccines using technology and know-how transferred from developed countries, and biotech entrepreneurial collaborations under the umbrella of the BRICS region. This study concludes by providing recommendations to support more of inter collaborations among the BRICS countries as well as between BRICS and many developing countries to shrink drug production costs. In addition, this collaboration would also culminate in reaching out to poor countries that are not able to provide their communities and patients with cost-effective essential medicines. PMID:25489593

  15. Genetically modified crops: the fastest adopted crop technology in the history of modern agriculture

    Directory of Open Access Journals (Sweden)

    Khush Gurdev S

    2012-09-01

    Full Text Available Abstract The major scientific advances of the last century featured the identification of the structure of DNA, the development of molecular biology and the technology to exploit these advances. These breakthroughs gave us new tools for crop improvement, including molecular marker-aided selection (MAS and genetic modification (GM. MAS improves the efficiency of breeding programs, and GM allows us to accomplish breeding objectives not possible through conventional breeding approaches. MAS is not controversial and is now routinely used in crop improvement programs. However, the international debate about the application of genetic manipulation to crop improvement has slowed the adoption of GM crops in developing as well as in European countries. Since GM crops were first introduced to global agriculture in 1996, Clive James has published annual reports on the global status of commercialized GM crops as well as special reports on individual GM crops for The International Service for the Acquisition of Agri-biotech Applications (ISAAA. His 34th report, Global Status of Commercialized Biotech/ GM crops: 2011 [1] is essential reading for those who are concerned about world food security.

  16. The Court of Justice of the European Union changes its case law on patentability of human embryonic stem cells.

    Science.gov (United States)

    Bonadio, Enrico; Rovati, Angelo Maria

    2015-01-01

    On 18 December 2014, in International Stem Cell Corporation v. Comptroller General of Patents, Designs and Trade Marks (C-364/13), the Court of Justice of the European Union (CJEU) delivered an important decision regarding the scope of the exclusion from patentability on morality-related grounds under Article 6(2) of the EU Biotech Directive. The Court made an important distinction between embryonic stem cell technologies based on fertilised human ovum and those based on unfertilised human ovum stimulated by parthenogenesis. The CJEU held, in particular, that a human ovum: (i) who is unfertilized and (ii) whose division and further development has been stimulated by parthenogenesis, is not a human embryo under Article 6(2)(c) of the Biotech Directive, if it in itself has not the inherent capacity of developing into a human being, this matter to be ascertained by the national court in the light of current scientific knowledge. By doing so, the Court clarified its previous ruling in Brüstle (October 2011). PMID:26665350

  17. Essential drugs production in Brazil, Russia, India, China and South Africa (BRICS): opportunities and challenges.

    Science.gov (United States)

    Ezziane, Zoheir

    2014-12-01

    The objective of this work is to elucidate various essential drugs in the Brazil, Russia, India, China and South Africa (BRICS) countries. It discusses the opportunities and challenges of the existing biotech infrastructure and the production of drugs and vaccines in member states of the BRICS. This research is based on a systematic literature review between the years 2000 and 2014 of documents retrieved from the databases Embase, PubMed/Medline, Global Health, and Google Scholar, and the websites of relevant international organizations, research institutions and philanthropic organizations. Findings vary from one member state to another. These include useful comparison between the BRICS countries in terms of pharmaceuticals expenditure versus total health expenditure, local manufacturing of drugs/vaccines using technology and know-how transferred from developed countries, and biotech entrepreneurial collaborations under the umbrella of the BRICS region. This study concludes by providing recommendations to support more of inter collaborations among the BRICS countries as well as between BRICS and many developing countries to shrink drug production costs. In addition, this collaboration would also culminate in reaching out to poor countries that are not able to provide their communities and patients with cost-effective essential medicines.

  18. The JIM interview. Art Levinson, PhD.

    Science.gov (United States)

    Levinson, A

    1997-06-01

    In the early 1980s several prominent scientists left the hallowed halls of respected universities seeking to exploit the revolution occurring in biology in an environment devoid of the bureaucratic and political confines of academia. The emergence of the biotechnology industry has been marked by both spectacular failures and success stories. Genentech was founded in 1976 by biochemist Herbert Boyer and venture capitalist Robert Swanson and went public in 1980. In 1995 Genentech merged with Roche Holdings Ltd., of Basel Switzerland. Distinguished from other biotech companies by the varied array of products it has brought to market, Genentech has also developed a unique corporate culture embodying many traditional academic values. Just as Genentech went public in 1980, Arthur D. Levinson, PhD, finished a post-doctoral appointment in Michael Bishop's lab at the University of California, San Francisco. Despite the disapproval of colleagues, he joined the fledgling company as a senior scientist. Working his way though the ranks, Levinson became Vice President of Research Technology in 1989 and was named President and CEO in 1995. Interviewed at the sprawling corporate headquarters in South San Francisco, Levinson reflected on the process of high risk science, the benefits of the private sector, and the changing relationship between biotech companies and the academic world.

  19. Breeding and Application of New Tropical Hybrid Rice Combination SIRAJ with High Yield and Fine Quality%热带优质高产杂交水稻新组合SIRAJ的选育与应用

    Institute of Scientific and Technical Information of China (English)

    胡继银; 陈俊兴; 李柄华; 唐奕; 刘家龙

    2012-01-01

    SIRAJ, derived from SIRAJ-A(CMS line) and SIRAJ-R(restorer line) , both of which are developed by the RB Biotech Sdn. Bhd. , Malaysia, is a new hybrid rice variety for tropical areas. It is characteristic of fine grain quality, high yield, strong disease resistance and suitable maturity for the tropics. In March, 2010, it was certified and released to commercial production in Malaysia and became the first hybrid rice variety registered local-ly in Malaysia. In the paper, the breeding procedure, main characteristics and techniques for high-yielding cultiva-tion and hybrid seed production of SIRAJ were related in detail.%SIRAJ是马来西亚RB Biotech Sdn.Bhd.用自育的三系不育系SIRAJ -A与恢复系SIRAJ -R配组育成的热带杂交水稻新组合,具有米质优、产量高、抗性较强、熟期适宜、适合热带栽培等特点,2010年3月通过马来西亚国家审定,为马来西亚第1个通过审定的杂交水稻组合.介绍了其选育过程、主要特征特性及栽培、制种技术要点.

  20. Commercialisation of science in Australia

    International Nuclear Information System (INIS)

    Major changes are occurring across the science and technology (S and T) landscape in this country. Messages from Federal and State Governments in recent times could not have been clearer - in return for 'taxpayer $ into ideas' (in other words, funding for front end basic research) there is an expectation that 'ideas will be translated into $' (in other words, commercialisation will be pursued aggressively). As we in Australian S and T are constantly reminded, with part justification only, Australian researchers (especially in the life sciences) are good at generating a wealth of ideas but not much wealth from ideas. It is claimed that despite scientific excellence, many in the sector are risk averse, immobile, prone to academic snobbery, better employees than employers, not entrepreneurial etc, etc. Regardless of the veracity of any of this, the 1990s has seen a change with many more scientists interested in pursuing the progression of ideas to research to invention to intellectual property to competitive advantage to commercialisation to wealth, jobs and social development to profits and tax dollars to increased support for innovation, R and D, basic research etc. In regard to biomedical research, it has been said that '... medical biotechnology was the first business with enough glamour to persuade eminent scientists that the entrepreneurial spirit and academic respectability are not mutually exclusive. Maybe it's OK to be a science-literate businessman and to make money from science. Successful biotech companies emerge when good science meets excellent management and that combination, in an enabling environment, attracts informed investors and partners. Biotech companies may focus on a single product, a portfolio, or a technology platform and the majority are destined not to become, and have no intention of becoming, an integrated biopharmaceutical or agrochemical company. Their capacity to raise funds is influenced by 'signals' that the technology, the people

  1. Biotechnology for Sustainable Crop Production and Protection: Challenges and Opportunities

    Directory of Open Access Journals (Sweden)

    T. M. Manjunath

    2010-07-01

    Full Text Available In 2009, transgenic crops were grown on 134 million hectares in 25 countries, including India, in six continents by about 14million farmers, marking an 80-fold increase in the area since their first commercialization on 1.7 m ha in the USA and fiveother countries in 1996. The dominant transgenic traits were herbicide tolerance and insect resistance, deployed either alone orboth stacked in the same plant. A recent survey of the global impact of biotech crops estimated that in 2008 alone, the totalcrop production gain globally for the 4 principal biotech crops - maize, soybean, cotton and canola - was 29.6 million metrictons while the net economic benefit to the biotech farmers was US$ 9.2 billion. The cumulative benefits for the period 1996-2008 were yield gains of 167 million tons and economic returns of US$ 51.9 billion. In India, the area planted with Bt-cottonincreased significantly from year to year since its introduction in 2002 and reached 8.4 million hectares in 2009. The overallbenefits from Bt-cotton included an yield increase of up to 63% due to effective control of bollworms, pesticide reduction by50%, net profit to farmers up to Rs.10,000/hectare and turned India from an importer to a major exporter of cotton. Theseindicate that biotechnology has made significant contributions to higher productivity, lower costs of production and increasedeconomic benefits and that it has enormous potential for the future with new traits, events and crops. Over 60 countries,including India, are engaged in research on about 55 crop species to incorporate transgenes to bestow various traits such asresistance to pests, diseases or herbicides; tolerance to environmental stresses like drought, cold or salinity; enhanced cropyields, nutrition or shelf-life, etc. However, unreasonable opposition to biotechnology and undue delays in regulatoryapprovals are some of the major challenges that need to be addressed so as to make full use of this technology which

  2. Nucleopolyhedrovirus Introduction in Australia

    Institute of Scientific and Technical Information of China (English)

    Patrick Buerger; Caroline Hauxwell; David Murray

    2007-01-01

    Nucleopolyhedrovirus (NPV) has become an integral part of integrated pest management (IPM) in many Australian agricultural and horticultural crops. This is the culmination of years of work conducted by researchers at the Queensland Department of Primary Industries and Fisheries (QDPI&F) and Ag Biotech Australia Pty Ltd. In the early 1970's researchers at QDPI&F identified and isolated a virus in Helicoverpa armigera populations in the field. This NPV was extensively studied and shown to be highly specific to Helicoverpa and Heliothis species. Further work showed that when used appropriately the virus could be used effectively to manage these insects in crops such as sorghum, cotton, chickpea and sweet corn. A similar virus was first commercially produced in the USA in the 1970's. This product, Elcar(R), was introduced into Australia in the late 1970's by Shell Chemicals with limited success. A major factor contributing to the poor adoption of Elcar was the concurrent enormous success of the synthetic pyrethroids. The importance of integrated pest management was probably also not widely accepted at that time. Gradual development of insect resistance to synthetic pyrethroids and other synthetic insecticides in Australia and the increased awareness of the importance of IPM meant that researchers once again turned their attentions to environmentally friendly pest management tools such NPV and beneficial insects. In the 1990's a company called Rhone-Poulenc registered an NPV for use in Australian sorghum, chickpea and cotton. This product, Gemstar(R), was imported from the USA. In 2000 Ag Biotech Australia established an in-vivo production facility in Australia to produce commercial volumes of a product similar to the imported product. This product was branded, ViVUS(R), and was first registered and sold commercially in Australia in 2003. The initial production of ViVUS used a virus identical to the American product but replicating it in an Australian Helicoverpa

  3. Pharmaceutical and biomedical applications of lipid-based nanocarriers.

    Science.gov (United States)

    Carbone, Claudia; Leonardi, Antonio; Cupri, Sarha; Puglisi, Giovanni; Pignatello, Rosario

    2014-03-01

    Increasing attention is being given to lipid nanocarriers (LNs) as drug delivery systems, due to the advantages offered of a higher biocompatibility and lower toxicity compared with polymeric nanoparticles. Many administration routes are being investigated for LNs, including topical, oral and parenteral ones. LNs are also proposed for specific applications such as cancer treatment, gene therapy, diagnosis and medical devices production. However, the high number of published research articles does not match an equal amount of patents. A recent Review of ours, published in Pharmaceutical Patent Analyst, reported the patents proposing novel methods for the production of LNs. This review work discusses recent patents, filed in 2007-2013 and dealing with the industrial applications of lipid-based nanocarriers for the vectorization of therapeutically relevant molecules, as well as biotech products such as proteins, gene material and vaccines, in the pharmaceutical, diagnostic and biomedical areas. PMID:24588596

  4. The "real world" barriers and solutions to Candida vaccine patent prosecutions: an analysis of U.S. Patent and Trademark Office actions on related applications.

    Science.gov (United States)

    Wang, Shyh-Jen

    2012-10-01

    The US Patent and Trademark Office (USPTO) adopts recent patent courts' opinions (such as KSR In re Fisher and Ariad v. Lilly) in patent examinations, which would certainly create barriers to biotech patent prosecution. To identify the barriers to Candida vaccine patent prosecution, we analyzed 99 US-granted patents from January 2001 to May 2012 related to Candida vaccines. The rejections were based on factors that included obviousness, novelty, indefiniteness, double patenting, enablement, written description and utility. Based on this investigation, we find that some of these rejections were actually avoidable, and then further provide workable solutions to avoid some of the barriers, especially those related to patentability. These principles recited in this study should also be applicable to other fields of vaccines and immunotherapeutics. PMID:22894949

  5. Nanofibrous Synthetic Dural Patch for Skull Base Defects: Preliminary Experience for Reconstruction after Extended Endonasal Approaches.

    Science.gov (United States)

    Zenga, Francesco; Tardivo, Valentina; Pacca, Paolo; Garzaro, Massimiliano; Garbossa, Diego; Ducati, Alessandro

    2016-03-01

    Setting One of the consequences of the widespread use of endoscopic endonasal approaches (EEA) to skull base pathologies is the management of complex skull base defects. Nowadays, the gold standard is a multilayer closure that reproduces the physiological tissue barriers. Several techniques have been described in the literature; however, skull base reconstruction after EEA still represents a matter of debate, especially after extended EEA. A watertight closure is paramount to prevent cerebrospinal fluid leak and meningitis. Design Regarding this issue, we present our experience with a new synthetic dural patch, ReDura (Medprin Biotech, La Mirada, California, United States), as a subdural inlay in three patients who underwent endoscopic endonasal removal of sellar and suprasellar lesions. Conclusions ReDura patch showed the same versatility of autologous iliotibial tract. A dural patch that easily adapts to all defects, revealed to be a useful tool for performing watertight closure, possibly in a short operative time, after endoscopic approaches.

  6. MICROALGAE AS TOCOPHEROL PRODUCERS

    Directory of Open Access Journals (Sweden)

    V. M. Mokrosnop

    2014-04-01

    Full Text Available Microalgae are able to accumulate considerable amounts of tocopherols (up to 4 mg/g dry weight. The content of α-tocopherol to plant oils is low, whereas microalgae contain up to 97% of the tocochromanols that provides high bioactivity. The data about the content of tocopherols in eukaryotic microalgae Dunaliella tertiolecta, Nannochloropsis oculata, Isochrysis galbana, Euglena gracilis, Tetraselmis suecica, Diacronema vlkianum, as well as in the cyanobacterium Spirulina platensis are given in the paper. The largest amounts of tocopherols are synthesized by Euglena gracilis cells at mixotrophic cultivation. The level of tocopherols in microalgae depends on cultivation conditions. Two-stage biotech cultivation techniques, limiting nutrition in some biogenic elements, the introduction of exogenous carbon sources are used to increase the yield of tocopherol from microalgae. The approaches to the genetic transformation of plants leading to higher content of active vitamin E are rewieved as well.

  7. Applications of recombinant Pichia pastoris in the healthcare industry.

    Science.gov (United States)

    Weinacker, Daniel; Rabert, Claudia; Zepeda, Andrea B; Figueroa, Carolina A; Pessoa, Adalberto; Farías, Jorge G

    2013-12-01

    Since the 1970s, the establishment and development of the biotech industry has improved exponentially, allowing the commercial production of biopharmaceutical proteins. Nowadays, new recombinant protein production is considered a multibillion-dollar market, in which about 25% of commercial pharmaceuticals are biopharmaceuticals. But to achieve a competitive production process is not an easy task. Any production process has to be highly productive, efficient and economic. Despite that the perfect host is still not discovered, several research groups have chosen Pichia pastoris as expression system for the production of their protein because of its many features. The attempt of this review is to embrace several research lines that have adopted Pichia pastoris as their expression system to produce a protein on an industrial scale in the health care industry. PMID:24688491

  8. Identifying Local Determinants Of Research Commercialization Strategies In Iranian Biotechnology Sector

    Directory of Open Access Journals (Sweden)

    Jahangir Yadollahi Fars

    2012-06-01

    Full Text Available Biotechnology industry has a special place among novel industries. The majority of biotech companies are start-ups or small companies that have been working for several years yet are not profitable. Evidences showed that firms and researchers have problems in turning academic findings to commercial revenue and there is problem in commercialization process and choosing method of the exploitation academic opportunities or choosing proper commercialization strategy in this industry. In this study, firstly, the local determinants of commercialization strategy in 41 Iranian young biotechnology companies were identified through interview and then a questionnaire was prepared integrating these determinants and the rest of them exist in literature and was distributed among a larger sample in order to obtain the integrity. Finally, after analyzing the questionnaires, the local determinants of commercialization strategies for Iranian researcher in biotechnology sector were identified.

  9. Structure-Based Virtual Screening of Commercially Available Compound Libraries.

    Science.gov (United States)

    Kireev, Dmitri

    2016-01-01

    Virtual screening (VS) is an efficient hit-finding tool. Its distinctive strength is that it allows one to screen compound libraries that are not available in the lab. Moreover, structure-based (SB) VS also enables an understanding of how the hit compounds bind the protein target, thus laying ground work for the rational hit-to-lead progression. SBVS requires a very limited experimental effort and is particularly well suited for academic labs and small biotech companies that, unlike pharmaceutical companies, do not have physical access to quality small-molecule libraries. Here, we describe SBVS of commercial compound libraries for Mer kinase inhibitors. The screening protocol relies on the docking algorithm Glide complemented by a post-docking filter based on structural protein-ligand interaction fingerprints (SPLIF). PMID:27316988

  10. Genome mining reveals unlocked bioactive potential of marine Gram-negative bacteria

    DEFF Research Database (Denmark)

    Machado, Henrique; Sonnenschein, Eva; Melchiorsen, Jette;

    2015-01-01

    Background: Antibiotic resistance in bacteria spreads quickly, overtaking the pace at which new compounds are discovered and this emphasizes the immediate need to discover new compounds for control of infectious diseases. Terrestrial bacteria have for decades been investigated as a source......- and Gammaproteobacteria collected during the Galathea 3 expedition were sequenced and mined for natural product encoding gene clusters. Results: Independently of genome size, bacteria of all tested genera carried a large number of clusters encoding different potential bioactivities, especially within the Vibrionaceae...... of bioactive compounds leading to successful applications in pharmaceutical and biotech industries. Marine bacteria have so far not been exploited to the same extent; however, they are believed to harbor a multitude of novel bioactive chemistry. To explore this potential, genomes of 21 marine Alpha...

  11. Standing on shaky ground- US patent-eligibility of isolated DNA and genetic diagnostics after AMP v. USPTO - Part III (unsolved questions & subsequent case law)

    DEFF Research Database (Denmark)

    Minssen, Timo; Nilsson, David

    2012-01-01

    -claims directed to personalized medicine, biological correlations and compounds containing biological information. As far as possible, this part also incorporates new developments that can be expected in the coming months, such as the pending certiorari decision in AMP v. USPTO and the pending Supreme Court......-eligibility of biological correlations and software-related "inventions" (6). These subsequent decisions indicate a serious split at the Federal Circuit with potentially broad implications not only for the patent eligibility of software-related patent applications and so-called "Beauregard"- claims, but also for biotech...... decision in Prometheus v. Mayo. Part IV, which is to be published in issue 4, will finally offer a broader discussion of the recent US patent-eligibility developments from an innovation policy perspective including brief references to recent European developments (7). This will provide the basis...

  12. Standing on shaky ground- US patent-eligibility of isolated DNA and genetic diagnostics after AMP v. USPTO - Part IV

    DEFF Research Database (Denmark)

    Minssen, Timo; Schwartz, Robert M.

    2013-01-01

    -claims directed to personalized medicine, biological correlations and compounds containing biological information. Part IV, which is to be published in issue 4, finally offers a broader discussion of the recent US patent-eligibility developments from an innovation policy perspective including brief references......-eligibility of biological correlations and software-related "inventions" (6). These subsequent decisions indicate a serious split at the Federal Circuit with potentially broad implications not only for the patent eligibility of software-related patent applications and so-called "Beauregard"- claims, but also for biotech...... to recent European developments (7). This provides the basis for summarizing conclusions (8). This final part, which was completed, reviewed and accepted for publication in February 2012, also incorporates new developments that can be expected in the coming months, such as the pending certiorari decision...

  13. STRENGTHENING BIOTECHNOLOGY RESEARCH IN INDONESIA

    Directory of Open Access Journals (Sweden)

    S. Sastrapradja

    2012-09-01

    Full Text Available The wave of biotechnology promises has struck not only the developed countries but the developing countries as well. The scientific community in Indonesia is aware of the opportunities and is eager to take an active part in this particular endeavour. Meanwhile resources are required to welcoming the biotech­nology era. The need of trained manpower, appropriate infrastructure and equipment, operational and maintenance costs requires serious consideration if a unit or a laboratory is expected to be functional in biotechnology. There is a good opportunity of applying biotechnology in the field of agriculture and industry considering the availability of biological resources in Indonesia. This paper outlines what have been done so far, the difficulties encountered and the efforts made to strengthening biotechnology research in Indonesia.

  14. Meeting report VLPNPV: Session 3: Immune responses.

    Science.gov (United States)

    Morrison, Trudy G

    2014-01-01

    Virus-like particles (VLPs) and nano-particles (NP) are increasingly considered for both prophylactic and therapeutic vaccines for a wide variety of human and animal diseases. Indeed, 2 VLPs have already been licensed for use in humans, the human papilloma virus vaccine and the hepatitis B virus vaccine. (1) Reflecting this increased interest, a second international conference with a specific focus on VLPs and NP was held at the Salk Institute for Biological Studies in La Jolla, California, in June 2014. Approximately 100 attendees, hailing from many nations, came from academic institutions, research institutes, and biotech companies. A wide variety of topics were discussed, ranging from development and characterization of specific VLP and NP vaccine candidates to methods of production of these particles. Session three was focused on the general question of immune responses to VLPs. PMID:25529229

  15. Nanofibrous Synthetic Dural Patch for Skull Base Defects: Preliminary Experience for Reconstruction after Extended Endonasal Approaches.

    Science.gov (United States)

    Zenga, Francesco; Tardivo, Valentina; Pacca, Paolo; Garzaro, Massimiliano; Garbossa, Diego; Ducati, Alessandro

    2016-03-01

    Setting One of the consequences of the widespread use of endoscopic endonasal approaches (EEA) to skull base pathologies is the management of complex skull base defects. Nowadays, the gold standard is a multilayer closure that reproduces the physiological tissue barriers. Several techniques have been described in the literature; however, skull base reconstruction after EEA still represents a matter of debate, especially after extended EEA. A watertight closure is paramount to prevent cerebrospinal fluid leak and meningitis. Design Regarding this issue, we present our experience with a new synthetic dural patch, ReDura (Medprin Biotech, La Mirada, California, United States), as a subdural inlay in three patients who underwent endoscopic endonasal removal of sellar and suprasellar lesions. Conclusions ReDura patch showed the same versatility of autologous iliotibial tract. A dural patch that easily adapts to all defects, revealed to be a useful tool for performing watertight closure, possibly in a short operative time, after endoscopic approaches. PMID:26937335

  16. Development of an agricultural biotechnology crop product: testing from discovery to commercialization.

    Science.gov (United States)

    Privalle, Laura S; Chen, Jingwen; Clapper, Gina; Hunst, Penny; Spiegelhalter, Frank; Zhong, Cathy X

    2012-10-17

    "Genetically modified" (GM) or "biotech" crops have been the most rapidly adopted agricultural technology in recent years. The development of a GM crop encompasses trait identification, gene isolation, plant cell transformation, plant regeneration, efficacy evaluation, commercial event identification, safety evaluation, and finally commercial authorization. This is a lengthy, complex, and resource-intensive process. Crops produced through biotechnology are the most highly studied food or food component consumed. Before commercialization, these products are shown to be as safe as conventional crops with respect to feed, food, and the environment. This paper describes this global process and the various analytical tests that must accompany the product during the course of development, throughout its market life, and beyond.

  17. The rise (and decline?) of biotechnology.

    Science.gov (United States)

    Kinch, Michael S

    2014-11-01

    Since the 1970s, biotechnology has been a key innovator in drug development. An analysis of FDA-approved therapeutics demonstrates pharmaceutical companies outpace biotechs in terms of new approvals but biotechnology companies are now responsible for earlier-stage activities (patents, INDs or clinical development). The number of biotechnology organizations that contributed to an FDA approval began declining in the 2000s and is at a level not seen since the 1980s. Whereas early biotechnology companies had a decade from first approval until acquisition, the average acquisition of a biotechnology company now occurs months before their first FDA approval. The number of hybrid organizations that arise when pharmaceutical companies acquire biotechnology is likewise declining, raising questions about the sustainability of biotechnology.

  18. Next generation vaccines.

    Science.gov (United States)

    Riedmann, Eva M

    2011-07-01

    In February this year, about 100 delegates gathered for three days in Vienna (Austria) for the Next Generation Vaccines conference. The meeting held in the Vienna Hilton Hotel from 23rd-25th February 2011 had a strong focus on biotech and industry. The conference organizer Jacob Fleming managed to put together a versatile program ranging from the future generation of vaccines to manufacturing, vaccine distribution and delivery, to regulatory and public health issues. Carefully selected top industry experts presented first-hand experience and shared solutions for overcoming the latest challenges in the field of vaccinology. The program also included several case study presentations on novel vaccine candidates in different stages of development. An interactive pre-conference workshop as well as interactive panel discussions during the meeting allowed all delegates to gain new knowledge and become involved in lively discussions on timely, interesting and sometimes controversial topics related to vaccines. PMID:22002157

  19. Offshoring of Innovation

    DEFF Research Database (Denmark)

    Haakonsson, Stine

    2013-01-01

    This chapter is an investigation into the internationalization of innovation in the Danish food-related biotech industry. The process of the internationalization of innovation in food and ingredients into new markets has followed a similar path: first, the companies enter new markets......’ by collaborating with local research facilities and suppliers. The companies engage in various constructs of global innovation networks more or less simultaneously according to the type of technology. The type of engagement and entry mode relates to the host location. Similar companies develop different network...... constructs. Furthermore, companies face many difficulties in organizing innovation internationally. These challenges are dealt with through either virtual or physical centres of excellence. Communication and communication tools provide a key for companies to manage these centres, and new forms...

  20. Social Capital in the Internationalization of Knowledge-Intensive new Ventures

    DEFF Research Database (Denmark)

    Madsen, Henning; Neergaard, Helle

    2005-01-01

    It has long been recognised that social capital in the shape of network relationships plays a significant role in the internationalisation process of a business. This research seeks to further the discussion of how social capital influences the early internationalization of new technology...... no international activities. Based on statistical analysis it elucidates the relationship among a number of factors related to social capital which may influence the internationalization process. These factors include the number and types of contacts as well as how these contacts are utilized. The results indicate......-based ventures. It is based on survey data provided by 98 entrepreneurs and in-depth interviews with the founders of 24 ventures in the Danish IT/communication and biotech/medico industries. The paper focuses on contrasting new ventures already operating on the international scene with those that have...

  1. Research Strategies in Science-based Start-ups

    DEFF Research Database (Denmark)

    Valentin, Finn; Dahlgren, Johan Henrich; Lund Jensen, Rasmus

    instead the attention to the quality of their science, or the roles of boards, management, and collaborative networks etc. Using a unique comprehensive dataset on Danish and Swedish biotech start-ups in drug discovery this paper analyzes their research strategies. Adopting a Simonean point of departure we...... develop a contingency view on complex problem solving which structures the argument into three steps:1) Characterising the problem architectures addressed by different types of DBFs;2) Testing and confirming that DBFs form requisite research strategies, by which we refer to problem solving approaches...... developed as congruent responses to problem architectures; 3) Testing and confirming that financial valuation of firms is driven by achievements conforming to requisite research strategies. These strategies, in turn, require careful combination of multiple dimensions of research.Findings demonstrate...

  2. In vitro engineering of microbial enzymes with multifarious applications: prospects and perspectives.

    Science.gov (United States)

    Joshi, Swati; Satyanarayana, Tulasi

    2015-01-01

    The discovery of a novel enzyme from a microbial source takes anywhere between months to years, and therefore, there has been an immense interest in modifying the existing microbial enzymes to suit the present day needs of the industry. The redesigning of industrially useful enzymes for improving their performance has become a challenge because bioinformatics databases have been revealing new facts on a day-to-day basis. Modification of the existing enzymes has become a trend for fine tuning of biocatalysts in the biotech industry. Hydrolases are employed in pharmaceutical, biofuel, detergent, food and feed industries that significantly contribute to the global annual revenue, and therefore, the emphasis has been on engineering them. Although a large data is accumulating on making alterations in microbial enzymes, there is a lack of definite information on redesigning industrial enzymes. This review focuses on the recent developments in improving the characteristics of various biotechnologically important enzymes.

  3. What Finance Can Learn from Biopharma Industry: A Transfer of Innovation Models

    Directory of Open Access Journals (Sweden)

    Francesco COREA

    2015-12-01

    Full Text Available The financial sector is living a profound crisis in order to keep pace with the continuous technological breakthroughs that come out daily, while other sectors seem to be historically more growth-by-innovation-based (e.g., the pharma/biotech sector. This work focuses on an interdisciplinary approach to innovation, and on insights that the banking sector can draw from the pharmaceutical one. Hence, a unique dataset has been built, and it collects information on the most relevant players for both the fields. Different indicators have been created as well in order to empirically test whether the financial industry is actually less innovative with respect to the pharmaceutical one, and to understand the best growing strategy for the banking industry. The results confirm that there is an innovation gap between the two industries, as well as identify the corporate venture capital as the best mean to drive business growth through innovation.

  4. The Battle for Patent Rights in Plant Biotechnology

    DEFF Research Database (Denmark)

    Schneider, Cédric

    2011-01-01

    This paper describes and analyzes the occurrence and extent of oppositions initiated against plant biotechnology patents granted by the European Patent Office (EPO). The opposition mechanism is a legal procedure that allows any third party to challenge the validity of patents awarded by the EPO....... Results indicate that the opposition rate is far greater in plant biotechnology than in other emerging industries. Consistent with theoretical predictions, the empirical findings suggest that opposed patents are disproportionately those that score high on features that proxy for their “value” or “quality......”. In contrast to previous findings, however, the results show that large-volume applicants are more likely to be opposed. Because the boundaries of plant biotech patents are ill-defined, large patent portfolios do not promote cooperative behavior such as licensing or settlements. The analysis rejects...

  5. NANOTECHNOLOGY: A PROMISING CARRIER FOR INTRACELLULAR DRUG DELIVERY SYSTEM

    Directory of Open Access Journals (Sweden)

    Malakar Jadupati

    2012-02-01

    Full Text Available Nanotechnology is on its way to make a big impact in Biotech, Pharmaceutical and Medical diagnostics sciences. Nanotechnology holds a tremendous potential when it applied in the fields of drug delivery. In this review it has been discussed how nanotechnology can implemented to design formulations which can effectively carry drug molecule to the targeted cell organelles. Introduction of certain functional groups or addition of surface active agents may alter the characteristics of the carrier molecule, thus increasing the sensitivity to site selection of the carrier. It has been predicted that in the near future, nanoparticles with the ability of carrying multiple drug molecules, will be designed. They can maintain the delivery of drugs at specific time interval.

  6. Social Capital, ICT Use and Company Performance

    DEFF Research Database (Denmark)

    Steinfield, Charles; Scupola, Ada; López-Nicolás, Carolina

    2009-01-01

    This study explores how some kinds of ICT uses, as well as social capital and other means of access to knowledge resources, are related to company performance in a knowledge-intensive business cluster. Data were collected through a survey of companies in the Medicon Valley biotech region located in...... Denmark and Southern Sweden. Responding companies included established producers of biotechnology-related products as well as small biotechnology start-up firms emphasizing research and development.  The results suggest that when ICT use was aimed at accessing and enhancing human and intellectual capital......, such as use of online databases for recruitment, intranets to enhance employee access to information and education, and collaborative tools to connect with off-premise researchers, companies reported better performance outcomes. Social capital in the form of connections to people who can provide access...

  7. Traditional Knowledge and Patent Protection: Conflicting Views On International Patent Standards

    Directory of Open Access Journals (Sweden)

    A Andrzejewski

    2010-12-01

    Full Text Available As diseases continue to spread around the globe, pharmaceutical and biotech companies continue to search for new and better drugs to treat them. Most of these companies have realised that useful compounds for these purposes may be found in the natural resources that indigenous and local communities use. And yet, even though the importance of these biological resources to global health and economic livelihood is well recognised, the legal ownership and control of this traditional knowledge is still very controversial. This article undertakes a comparative analysis of American and European, as well as international legal regulations on patent law and traditional knowledge. Key questions include: What is traditional knowledge? How have the national patent laws of these countries treated the protection of plant variety and plant genetic resources? What are the existing international standards for patents, and what implications do they have for protecting traditional knowledge? And finally, what protection systems are emerging for the future?

  8. Stakeholder Thinking in Sustainability Management

    DEFF Research Database (Denmark)

    Gjerdrum Pedersen, Esben Rahbek; Hove Henriksen, Morten; Frier, Claus;

    2013-01-01

    Purpose – The objective of the paper is to describe and discuss how the biotech company Novozymes integrates stakeholder thinking into everyday sustainability practices. Design/methodology/approach – The paper is based on first-hand experiences as well as secondary information from Novozymes......' stakeholder-oriented sustainability activities. Findings – The paper illustrates how a company is striving to transform the general stakeholder principles into concrete, manageable actions. Moreover, the paper describes some of the needs, challenges, and paradoxes experienced by an organisation that is trying...... to make sense of stakeholder thinking. Originality/value – The contribution of this paper is to provide a detailed analysis of how various stakeholder relations management methods can be used in practice to integrate sustainability in an organisation....

  9. The establishment of genetically engineered canola populations in the U.S.

    Directory of Open Access Journals (Sweden)

    Meredith G Schafer

    Full Text Available Concerns regarding the commercial release of genetically engineered (GE crops include naturalization, introgression to sexually compatible relatives and the transfer of beneficial traits to native and weedy species through hybridization. To date there have been few documented reports of escape leading some researchers to question the environmental risks of biotech products. In this study we conducted a systematic roadside survey of canola (Brassica napus populations growing outside of cultivation in North Dakota, USA, the dominant canola growing region in the U.S. We document the presence of two escaped, transgenic genotypes, as well as non-GE canola, and provide evidence of novel combinations of transgenic forms in the wild. Our results demonstrate that feral populations are large and widespread. Moreover, flowering times of escaped populations, as well as the fertile condition of the majority of collections suggest that these populations are established and persistent outside of cultivation.

  10. How Search in Science Impacts on the Value of Inventions at Early and Late Stages in the R&D cycle

    DEFF Research Database (Denmark)

    Beukel, Karin; Valentin, Finn; Lund Jensen, Rasmus

    contradictory results. The contributions to R&D from science are particularly elusive. To achieve some transparency on these issues we study R&D in biotech drug discovery, where the role of science is pervasive and structured into a recurrent sequence of inventions required to build a drug candidate....... The patents filed on these inventions offer, through their citations to prior art, a fine-grained view of the role of science along the R&D cycle. Applying a unique text-mining algorithm we categorize a set of 1,058 patens from Scandinavian drug discovery firms into six types of drug-related inventions. Tests...... confirm a significantly decreasing presence of science vis a vis technology over the R&D cycle. Effects of the composition of search on the value of single inventions show notable differences. In early R&D increasing predominance of search in science detracts from invention value. In late R&D, inventions...

  11. Clinical and Immunological Effects in Patients with Advanced Non-Small Cell Lung-Cancer after Vaccination with Dendritic Cells Exposed to an Allogeneic Tumor Cell Lysate*

    DEFF Research Database (Denmark)

    Engell-Noerregaard, Lotte; Kvistborg, Pia; Zocca, Mai-Britt;

    2013-01-01

    and celecoxib were used as adjuvants to the vaccines. The objective of the study was to evaluate specific T cell response in vitro by IFN EliSpot. Secondary objec- tives were overall survival, response and quality of life (QoL). Results: Twenty-two patients initiated the vaccination program consisting of ten...... patients showed an un- expectedly prolonged survival. The treatment was well tolerated and only minor adverse events were reported. Quality of life did not change during the study period. In four of the seven patients with SD, vaccine-specific T cells were de- tected by IFNγ EliSpot assays, whereas only......Background: We evaluated the clinical and immunological effects of dendritic cell (DC) vaccination of patients with NSCLC. Autologous DCs were pulsed with a MAGE containing allogeneic melanoma cell lysate (MelCancerVac®, Dandrit Biotech, Copenhagen, Denmark). Imiquimod cream, proleukin...

  12. Purines: from premise to promise.

    Science.gov (United States)

    Williams, M

    2000-07-01

    Geoff Burnstock's remarkable insight and tenacity has established the area of purinergic research as a bona fide target for drug discovery. While efforts in P1 receptor-based medicinal chemistry and biology efforts over the past 25 years have not reached the level of success that the pharmaceutical industry investment may have anticipated, the P2 area, with knowledge of the selective localization of members of the P2X and P2Y family members and data from transgenic knockouts, has identified several potential therapeutic areas of major promise including cystic fibrosis, chronic bronchitis, male contraception and neurodegeneration. In addition, interest in the potential of purinergic therapeutics has extended outside the major pharmaceutical companies to the 'biotech industry' resulting in an environment where the inherent risks of 'first in field' in a therapeutic area may be more appropriately nurtured.

  13. CVD 908, CVD 908-htrA, and CVD 909 live oral typhoid vaccines: a logical progression.

    Science.gov (United States)

    Tacket, Carol O; Levine, Myron M

    2007-07-15

    Typhoid fever remains an important public health problem in many parts of the world. Despite the availability of oral Ty21a (Vivotif; Berna Biotech) and parenteral Vi polysaccharide vaccine (Typhim Vi; Aventis Pasteur), improved typhoid fever vaccines have been sought. These include a series of vaccine candidates developed at the Center for Vaccine Development, University of Maryland, based on attenuation of Salmonella enterica serovar Typhi by deletions in the aroC, aroD, and htrA genes. These vaccine candidates, designated "CVD 908," "CVD 908-htrA," and "CVD 909," have been developed and tested in volunteers with variable success. This review summarizes the clinical data that directed the logical progression of this vaccine development strategy.

  14. National differences in FEI support and innovation management

    DEFF Research Database (Denmark)

    Aagaard, Annabeth

    2012-01-01

    This paper explores how Front End Innovation (FEI) is supported among companies of different nationality within the context of Pharmaceutical R&D. The present study is carried out in order to contribute to the development of a clearer understanding of active facilitation of innovation management...... and front end innovation in theory and practice. I aim to show how different aspects of company size, type and nationality affect the way innovation management and FEI is supported within organizations. This is examined through an in-depth case study of the Danish pharmaceutical company, H. Lundbeck A....../S, and a comparative study including seven European and American Biotech and Pharmaceutical companies. The findings from the study reveal a number of similarities and differences in innovation management and FEI support among the different companies and present propositions of important aspects to consider...

  15. Marine Bacterial Genomics

    DEFF Research Database (Denmark)

    Machado, Henrique

    For decades, terrestrial microorganisms have been used as sources of countless enzymes and chemical compounds that have been produced by pharmaceutical and biotech companies and used by mankind. There is a need for new chemical compounds, including antibiotics,new enzymatic activities and new...... microorganisms to be used as cell factories for production. Therefore exploitation of new microbial niches and use of different strategies is an opportunity to boost discoveries. Even though scientists have started to explore several habitats other than the terrestrial ones, the marine environment stands out...... as a hitherto under-explored niche. This thesis work uses high-throughput sequencing technologies on a collection of marine bacteria established during the Galathea 3 expedition, with the purpose of unraveling new biodiversity and new bioactivities. Several tools were used for genomic analysis in order...

  16. The Controversies over Bioenergy in Denmark

    DEFF Research Database (Denmark)

    Jørgensen, Michael Søgaard; Andersen, Bente Hessellund

    2012-01-01

    a prominent role in several Danish climate and energy plans, alongside with wind and solar energy, and energy savings. There are major controversies about targets for bioenergy with respect to acceptable types, sources and amounts of biomass. Strong path dependency is identified. Energy companies in Denmark...... convert coal fired power plants to biomass in order to sustain the role of these power plants. Their increasing use of imported wood pellets is criticized for increasing greenhouse gas emissions because of fast logging of years of forest growth. A Danish biotech company is developing enzymes...... digested manure. Such biogas is questioned by some NGOs who fear manure-based biogas is used as argument for increased animal husbandry. The bioenergy controversies concern also methodologies for environmental assessments, including for indirect land use changes (ILUC), and reliability of certification...

  17. LIGNOCELLULOSE AS AN ALTERNATIVE SOURCE FOR OBTAINING OF BIOBUTANOL

    Directory of Open Access Journals (Sweden)

    S. M. Shulga

    2013-04-01

    Full Text Available Energy and environmental crisis facing the world force us to reconsider the effectiveness or find an alternative use of renewable natural resources, especially organic «waste» by using environmentally friendly technologies. Microbial conversion of renewable resources of biosphere to produce useful products, including biofuels, currently is an actual biotech problem. Anaerobic bacteria of Clostridiaceae family are known as butanol producers, but unfortunately, the microbiological synthesis is currently not economical one. In order to make cost-effective aceton-butanol-ethanol fermentation, solventproducing strains using available cheap raw materials, such as agricultural waste or plant biomass, are required. Opportunities and ways to obtaine economic and ecological processing of lignocellulosic wastes for biobutanol creation are described in the review .

  18. What is human in humans? Responses from biology, anthropology, and philosophy.

    Science.gov (United States)

    Bibeau, Gilles

    2011-08-01

    Genomics has brought biology, medicine, agriculture, psychology, anthropology, and even philosophy to a new threshold. In this new context, the question about "what is human in humans" may end up being answered by geneticists, specialists of technoscience, and owners of biotech companies. The author defends, in this article, the idea that humanity is at risk in our age of genetic engineering, biotechnologies, and market-geared genetic research; he also argues that the values at the very core of our postgenomic era bring to its peak the science-based ideology that has developed since the time of Galileo, Newton, Descartes, and Harvey; finally, it shows that the bioindustry has invented a new genomythology that goes against the scientific evidence produced by the research in human sciences in which life is interpreted as a language.

  19. Patentability of Parthenogenic Stem Cells: International Stem Cell Corporation v. Comptroller General of Patents.

    Science.gov (United States)

    Mansnérus, Juli

    2015-06-01

    The European Court of Justice (ECJ) has recently issued a ruling in Case C-364/13 International Stem Cell Corporation v. Comptroller General of Patents Designs and Tademarks (Case) that aims at harmonising the patenting practices regarding interpretation of Article 6.2.c of Directive 98/44/EC (Biotech Patent Directive) in respect of patentability of human parthenogenic stem cells (hpSCs). The Case alters the patenting regime for human embryonic stem cell (hESC) applications, by stating that moral restrictions against hESC-patents are only applicable to such cells derived from embryos that had the potential to develop into a human being. Consequently, hpSC-based inventions may be patentable in Europe. This Case represents a leap forward to striking a balance between protecting human dignity and integrity whilst granting patent incentives for biomedical research. PMID:26399046

  20. Managing Demands for Social Engagement

    DEFF Research Database (Denmark)

    Glerup, Cecilie

    In recent years numerous calls have been made to enhance the social responsibility of biotechnology from both social scientists (e.g. Nowotny et. al. 2001) and political institutions (e.g. Royal Society 2004; U.S. Congress 2003; EEA 2002). The demands vary in form and content: From state incentives...... pressure on the biotech research organizations that find themselves in a jumble of demands to engage themselves with society. Mccarthy and Kelty, for instance, quote a nano-technologist for saying that he is afraid of “too much responsibility” (2010: 407). Based on a laboratory ethnography, this paper...... explores how two research organizations in the field of synthetic biology strategically manoeuvre among the many discourses on scientific responsibility. One of the labs defines itself through user-inspired science and focuses on the development of ‘products’ that benefit abstract stakeholders such as ‘the...

  1. Biotechnology SMEs, start-ups, spin-offs or microenterprises are they molecules coming from the research results? If so, what place do they hold in the global industrial tissue?

    Science.gov (United States)

    Doddoli, Roberto

    2007-02-01

    In recent years, the number of biotech enterprises in Europe has grown spectacularly, largely fueled by the increasing number of entrepreneurial initiatives from Europe's leading research institutes. The place held on the economic market by these enterprises, is a question that market analysts have been asking themselves since their rapid growth and, more particularly, their over valuation which, at times, has led to the crash of their shares on the stock markets. To be sure, this article does not claim to go into an in-depth financial analysis to explain the details of certain "shipwrecks". Rather, it just would like to provide some useful indications for all those having embarked, or desirous of doing so, in the creation of biomedical enterprises. PMID:16887388

  2. Biotechnology and Biopharmaceutical Industry in the 21st Century-Development on Biopharmaceuticals%21世纪生物技术和生物制药

    Institute of Scientific and Technical Information of China (English)

    吴梧桐; 王友同; 吴文俊

    2001-01-01

    根据最新信息资料,评价了生物技术产业在国民经济发展中的重要地位,重点介绍了生物技术产业市场发展状况,对于了解国内外生物技术发展动态与客观决策具有参考价值。%Based on a thorough review,authors analized and categorized thetrend for the development on biotech-drugs and biopharmaceuticals market,also evaluated the importance of biotechnology in the national economic of China and illustrated their opinion on the direction of development on biopharmaceutical market and biophar maceutical industry in China.

  3. Applications of recombinant Pichia pastoris in the healthcare industry

    Directory of Open Access Journals (Sweden)

    Daniel Weinacker

    2013-12-01

    Full Text Available Since the 1970s, the establishment and development of the biotech industry has improved exponentially, allowing the commercial production of biopharmaceutical proteins. Nowadays, new recombinant protein production is considered a multibillion-dollar market, in which about 25% of commercial pharmaceuticals are biopharmaceuticals. But to achieve a competitive production process is not an easy task. Any production process has to be highly productive, efficient and economic. Despite that the perfect host is still not discovered, several research groups have chosen Pichia pastoris as expression system for the production of their protein because of its many features. The attempt of this review is to embrace several research lines that have adopted Pichia pastoris as their expression system to produce a protein on an industrial scale in the health care industry.

  4. How Patent Function Integration with R&D Influence the Value of Patents

    DEFF Research Database (Denmark)

    Beukel, Karin; Valentin, Finn

    Patent strategies are endogenous to firm appropriability. However, to what extent does firm’s R&D teams’ engagement with patent experts influence the value of patents? We estimate the relationship between firm’s R&D use of patent functions on patent value in Biotech firms. Controlling...... for characteristics of scientific team, firm effects, and other patent value indicators, we find that having a firm specific (in-house) internal patent function is a driver of patent value. In addition, we find that the way in which patent functions create patent value differs dependent on whether the firm has...... internal patent function or not. In-house patent functions create value through narrow patents, whereas, firms with no in-house patent function create valuable patents by the use of broader scoped patents. Our results point to a strong effect of firm specific patent functions, but also explain how firms...

  5. Virtual pharmaceutical companies: collaborating flexibly in pharmaceutical development.

    Science.gov (United States)

    Forster, Simon P; Stegmaier, Julia; Spycher, Rene; Seeger, Stefan

    2014-03-01

    Research and development (R&D) collaborations represent one approach chosen by the pharmaceutical industry to tackle current challenges posed by declining internal R&D success rates and fading of the blockbuster model. In recent years, a flexible concept to collaborate in R&D has emerged: virtual pharmaceutical companies (VPCs). These differ from other R&D companies, such as biotech start-ups, collaborating with big pharmaceutical companies, because they solely comprise experienced teams of managers. VPCs have only been described anecdotally in literature. Thus, we present here the characteristics of a VPC and suggest how big pharma can leverage the concept of VPCs by introducing five possible modes of collaboration. We find that one mode, investing, is particularly promising for big pharma.

  6. Structure-Based Virtual Screening of Commercially Available Compound Libraries.

    Science.gov (United States)

    Kireev, Dmitri

    2016-01-01

    Virtual screening (VS) is an efficient hit-finding tool. Its distinctive strength is that it allows one to screen compound libraries that are not available in the lab. Moreover, structure-based (SB) VS also enables an understanding of how the hit compounds bind the protein target, thus laying ground work for the rational hit-to-lead progression. SBVS requires a very limited experimental effort and is particularly well suited for academic labs and small biotech companies that, unlike pharmaceutical companies, do not have physical access to quality small-molecule libraries. Here, we describe SBVS of commercial compound libraries for Mer kinase inhibitors. The screening protocol relies on the docking algorithm Glide complemented by a post-docking filter based on structural protein-ligand interaction fingerprints (SPLIF).

  7. Tissue regeneration the material enablers

    Directory of Open Access Journals (Sweden)

    George Marsh

    2001-05-01

    Full Text Available The potential rewards are well worth the effort. Estimates in the US put the number of patients on transplant waiting lists at over 75,000. Recent figures from the United Network for Organ Sharing indicate that around 5% of these die while waiting for a transplant organ to become available. Interest and investment levels are high—the US National Institute of Standards and Technology's Advanced Technology Program has poured millions of dollars into tissue engineering product development and the National Institute of Health set up a working group last year. Several biotech companies have sprung up to meet demand, such as Organogenesis and Advanced Tissue Sciences (ATS. Gail Naughton, president of ATS, was named the 2000 National Inventor of the Year for her pioneering work in this field.

  8. Gene of LukF-PV-like component of Panton-Valentine leukocidin in Staphylococcus aureus P83 is linked with lukM.

    Science.gov (United States)

    Kaneko, J; Muramoto, K; Kamio, Y

    1997-03-01

    Staphylococcus aureus P83 (ATCC 31890) produces five components, I to V for synergistic toxins, leukocidin and gamma-hemolysin [Sudo et al., Biosci. Biotech. Biochem., 56, 1786-1789 (1995)]. We report here the identification of component II, which is designated LukF-PV(P83) and its gene (lukF-PV(P83)). The lukF-PV(P83) gene was found to be one base downstream of the stop codon of the lukM gene. The deduced amino acid sequence of LukF-PV(P83) showed 78.4% identity with that of LukF-PV. The lukM and lukF-PV(P83) genes were encoded as one operon like that of Panton-Valentine leukocidin.

  9. Perspectives of DNA microarray and next-generation DNA sequencing technologies

    Institute of Scientific and Technical Information of China (English)

    TENG XiaoKun; XIAO HuaSheng

    2009-01-01

    DNA microarray and next-generation DNA sequencing technologies are important tools for high-throughput genome research, in revealing both the structural and functional characteristics of genomes. In the past decade the DNA microarray technologies have been widely applied in the studies of functional genomics, systems biology and pharmacogenomics. The next-generation DNA sequenc-ing method was first introduced by the 454 Company in 2003, immediately followed by the establish-ment of the Solexa and Solid techniques by other biotech companies. Though it has not been long since the first emergence of this technology, with the fast and impressive improvement, the application of this technology has extended to almost all fields of genomics research, as a rival challenging the existing DNA microarray technology. This paper briefly reviews the working principles of these two technologies as well as their application and perspectives in genome research.

  10. FACILITATING RADICAL FRONT-END INNOVATION THROUGH TARGETED HR PRACTICES

    DEFF Research Database (Denmark)

    Aagaard, Annabeth

    2016-01-01

    This study examines how radical front end innovation can be actively facilitated through selected and targeted HR practices and bundles of HR practices. The empirical field is an explorative case study of front end innovation and HR practices in the pharmaceutical industry, with an in-depth case...... study of the Danish pharmaceutical company, H. Lundbeck A/S, and explorative studies of seven European and American pharmaceutical and biotech companies. The study aims to show how companies can apply HR practices in ways that actively supports the development of radical front end innovation. The value...... added and the contribution of this article to the existing FEI and HR literature therefore lies in the exploration and mapping of how radical front end innovation is and can be facilitated through targeted HR practices; and in identifying the unique opportunities and challenges of innovation...

  11. Perspectives of DNA microarray and next-generation DNA sequencing technologies

    Institute of Scientific and Technical Information of China (English)

    2009-01-01

    DNA microarray and next-generation DNA sequencing technologies are important tools for high-throughput genome research,in revealing both the structural and functional characteristics of genomes.In the past decade the DNA microarray technologies have been widely applied in the studies of functional genomics,systems biology and pharmacogenomics.The next-generation DNA sequencing method was first introduced by the 454 Company in 2003,immediately followed by the establishment of the Solexa and Solid techniques by other biotech companies.Though it has not been long since the first emergence of this technology,with the fast and impressive improvement,the application of this technology has extended to almost all fields of genomics research,as a rival challenging the existing DNA microarray technology.This paper briefly reviews the working principles of these two technologies as well as their application and perspectives in genome research.

  12. Diagnostic reliability of somatostatin receptor scintigraphy during continuous treatment with different somatostatin analogs

    International Nuclear Information System (INIS)

    In order to evaluate the diagnostic reliability of somatostatin receptor scintigraphy (SRS) in patients treated with somatostatin analogs, ten patients with metastatic neuroendocrine tumors were investigated before and during continuous treatment. Different somatostatin analogs were used for therapy: five patients received octreotide (Sandostatin, Sandoz, Switzerland) and five were treated with BIM 23014 (Lanreotide, Ipsen Biotech, France) within the scope of a clinical phase II study. The SRS findings were analyzed in terms of biodistribution of the labeled somatostatin analogy and tumor visualization comparing the two studies in each patient. Whereas liver, spleen, and kidney uptake were decreased during octreotide treatment and increased on lanreotide therapy, tumor accumulation was intensified in all but one patient. Our results suggest that the diagnostic value of SRS is not necessarily restricted during treatment with somatostatin analogs. Indeed, tumor visualization may even be enhanced in this therapeutic setting. (orig.)

  13. Exuberant innovation: The Human Genome Project

    CERN Document Server

    Gisler, Monika; Woodard, Ryan

    2010-01-01

    We present a detailed synthesis of the development of the Human Genome Project (HGP) from 1986 to 2003 in order to test the "social bubble" hypothesis that strong social interactions between enthusiastic supporters of the HGP weaved a network of reinforcing feedbacks that led to a widespread endorsement and extraordinary commitment by those involved in the project, beyond what would be rationalized by a standard cost-benefit analysis in the presence of extraordinary uncertainties and risks. The vigorous competition and race between the initially public project and several private initiatives is argued to support the social bubble hypothesis. We also present quantitative analyses of the concomitant financial bubble concentrated on the biotech sector. Confirmation of this hypothesis is offered by the present consensus that it will take decades to exploit the fruits of the HGP, via a slow and arduous process aiming at disentangling the extraordinary complexity of the human complex body. The HGP has ushered other...

  14. Impact of T-shaped skill and top management support on innovation speed; the moderating role of technology uncertainty

    Directory of Open Access Journals (Sweden)

    Shabnam Hamdi

    2016-12-01

    Full Text Available This study examines the moderating role of technology uncertainty on the relationship between team contextual factors of top management support and T-shaped skills with innovation speed. For the purpose of this study, the data were collected from 227 new products from 147 biotechnology firms in Malaysia. The overall results confirmed the moderating effect of technology uncertainty on the relationship between T-shaped skills, as well as top management support with innovation speed. The results further confirmed that under the high technology uncertainty, this effect is higher in comparison to the low and medium uncertainty. This indicates that the effect of top management support and T-shaped skills on innovation speed improves when technology uncertainty increases. On the practical side, the report equips biotech firms with valuable insights to develop effective strategies.

  15. Effects of research tool patents on biotechnology innovation in a developing country: A case study of South Korea

    Directory of Open Access Journals (Sweden)

    Ryu Tae-Kyu

    2009-03-01

    Full Text Available Abstract Background Concerns have recently been raised about the negative effects of patents on innovation. In this study, the effects of patents on innovations in the Korean biotech SMEs (small and medium-sized entrepreneurs were examined using survey data and statistical analysis. Results The survey results of this study provided some evidence that restricted access problems have occurred even though their frequency was not high. Statistical analysis revealed that difficulties in accessing patented research tools were not negatively correlated with the level of innovation performance and attitudes toward the patent system. Conclusion On the basis of the results of this investigation in combination with those of previous studies, we concluded that although restricted access problems have occurred, this has not yet deterred innovation in Korea. However, potential problems do exist, and the effects of restricted access should be constantly scrutinized.

  16. Production and estimation of alkaline protease by immobilized Bacillus licheniformis isolated from poultry farm soil of 24 Parganas and its reusability

    Directory of Open Access Journals (Sweden)

    Shamba Chatterjee

    2015-01-01

    Full Text Available Microbial alkaline protease has become an important industrial and commercial biotech product in the recent years and exerts major applications in food, textile, detergent, and pharmaceutical industries. By immobilization of microbes in different entrapment matrices, the enzyme produced can be more stable, pure, continuous, and can be reused which in turn modulates the enzyme production in an economical manner. There have been reports in support of calcium alginate and corn cab as excellent matrices for immobilization of Bacillus subtilis and Bacillus licheniformis, respectively. This study has been carried out using calcium alginate, κ-carrageenan, agar-agar, polyacrylamide gel, and gelatin which emphasizes not only on enzyme activity of immobilized whole cells by different entrapment matrices but also on their efficiency with respect to their reusability as first attempt. Gelatin was found to be the best matrix among all with highest enzyme activity (517 U/ml at 24 h incubation point and also showed efficiency when reused.

  17. Real intention of the enterprise who looks for such a newcomer; Konna shinjin motomu, kigyo no honne

    Energy Technology Data Exchange (ETDEWEB)

    NONE

    1999-09-01

    The age when the change which to become rapidly global entails is drastic is reached, and that way of having it is renewed, and the Japanese chemical business world is being asked to it. Questionnaire was done to take the reference of the enterprise person of not only the students thinking about employment to the enterprise by making the talented people figure which is necessary in such an age rise from the opinion in the front of the enterprise but also the present post and the persons concerned in education. 1. Asahi Chemical Industry Co., Ltd. 2. Asahi Glass Co., Ltd. 3. Asahi Chiba 4. Ube Industries, Ltd. 5. SDS Biotech6. Kao Corp. 7. Kyowa Hakko Kogyo Co., Ltd. 8. Konica Corp. 9. Sharp and 10. Showa polymer. (NEDO)

  18. Modeling of Filtration Processes—Microfiltration and Depth Filtration for Harvest of a Therapeutic Protein Expressed in Pichia pastoris at Constant Pressure

    Directory of Open Access Journals (Sweden)

    Muthukumar Sampath

    2014-12-01

    Full Text Available Filtration steps are ubiquitous in biotech processes due to the simplicity of operation, ease of scalability and the myriad of operations that they can be used for. Microfiltration, depth filtration, ultrafiltration and diafiltration are some of the most commonly used biotech unit operations. For clean feed streams, when fouling is minimal, scaling of these unit operations is performed linearly based on the filter area per unit volume of feed stream. However, for cases when considerable fouling occurs, such as the case of harvesting a therapeutic product expressed in Pichia pastoris, linear scaling may not be possible and current industrial practices involve use of 20–30% excess filter area over and above the calculated filter area to account for the uncertainty in scaling. In view of the fact that filters used for harvest are likely to have a very limited lifetime, this oversizing of the filters can add considerable cost of goods for the manufacturer. Modeling offers a way out of this conundrum. In this paper, we examine feasibility of using the various proposed models for filtration of a therapeutic product expressed in Pichia pastoris at constant pressure. It is observed that none of the individual models yield a satisfactory fit of the data, thus indicating that more than one fouling mechanism is at work. Filters with smaller pores were found to undergo fouling via complete pore blocking followed by cake filtration. On the other hand, filters with larger pores were found to undergo fouling via intermediate pore blocking followed by cake filtration. The proposed approach can be used for more accurate sizing of microfilters and depth filters.

  19. Comparison of Four Commercial Kits to Detect HSV-2 IgG Antibody

    Institute of Scientific and Technical Information of China (English)

    Song Biao(宋彪); Chen Xiangsheng(陈祥生); Yin Yueping(尹跃平); Yao Xu(姚煦); Li Wengzhong(李文忠)

    2004-01-01

    Objectives: To compare the efficiency of four commercial ELISA kits in detecting type-specific HSV-2 IgG antibodies. Materials and Methods: A total of 125 subjects, including 105 with genital ulcers, and 20 controls without any history of STDs were recruited from the STD clinic for detection of type-specific HSV-2 IgG antibody with different kits. Four kinds of commercially available ELISA kits, including Quida HSV2 IgG ELISA (Aifulang Biochem Co. Ltd., Hangzhou), TORCH-HSV2 IgG (Jingmei Biotech Co. Ltd., Shanghai), CaptiaTM HSV2 IgG (Trinity biotech, USA ) and HerpeSelect TM 2 ELISA IgG (Focus technologies, USA) were used for evaluation. Western Blot assay was performed as a gold standard.Results: Compared to Western Blot results, the sensitivity and specificity of the kits (Quida HSV2, TORCHHSV2, CaptiaTM HSV2 and HerpeSelectTM 2) were 13.1% and 98.4%, 7.5% and 100%, 100% and 11.1%,87.7 % and 96.7 %, respectively. The positive predictive value (PV) and negative PV of the four kits were 88.9%and 54.3%, 100% and 55.5%, 55.6% and 100%, 96.2%and 89.2%, respectively. The areas under the ROC curve of three kits (Quida HSV2, CaptiaTM HSV2 andHerpeSelectTM 2) were 0.885 (0.822~0.948), 0.825 (0.747- 0.902), 0.974 (0.950 - 0.998), respectively Conclusion: The performance of HerpeSelectTM 2 is the best among the four kits. The results also indicate that the commercially available kits for detection of type-specific HSV2 antibody should be re-evaluated in terms of their validity.

  20. Genetically modified foods and social concerns.

    Science.gov (United States)

    Maghari, Behrokh Mohajer; Ardekani, Ali M

    2011-07-01

    Biotechnology is providing us with a wide range of options for how we can use agricultural and commercial forestry lands. The cultivation of genetically modified (GM) crops on millions of hectares of lands and their injection into our food chain is a huge global genetic experiment involving all living beings. Considering the fast pace of new advances in production of genetically modified crops, consumers, farmers and policymakers worldwide are challenged to reach a consensus on a clear vision for the future of world food supply. The current food biotechnology debate illustrates the serious conflict between two groups: 1) Agri-biotech investors and their affiliated scientists who consider agricultural biotechnology as a solution to food shortage, the scarcity of environmental resources and weeds and pests infestations; and 2) independent scientists, environmentalists, farmers and consumers who warn that genetically modified food introduces new risks to food security, the environment and human health such as loss of biodiversity; the emergence of superweeds and superpests; the increase of antibiotic resistance, food allergies and other unintended effects. This article reviews major viewpoints which are currently debated in the food biotechnology sector in the world. It also lays the ground-work for deep debate on benefits and risks of Biotech-crops for human health, ecosystems and biodiversity. In this context, although some regulations exist, there is a need for continuous vigilance for all countries involved in producing genetically engineered food to follow the international scientific bio-safety testing guidelines containing reliable pre-release experiments and post-release track of transgenic plants to protect public health and avoid future environmental harm. PMID:23408723

  1. Monitoring the agricultural landscape for insect resistance

    Science.gov (United States)

    Casas, Joseph; Glaser, J. A.; Copenhaver, Ken

    Farmers in 25 countries on six continents are using plant biotechnology to solve difficult crop production challenges and conserve the environment. In fact, 13.3 million farmers, which include 90 percent of the farming in developing countries, choose to plant biotech crops. Over the past decade, farmers increased area planted in genetically modified (GM) crops by more than 10 percent each year, thus increasing their farm income by more than 44 billion US dollars (1996-2007), and achieved economic, environmental and social benefits in crops such as soybeans, canola, corn and cotton. To date, total acres of biotech crops harvested exceed more than 2 billion with a proven 13-year history of safe use. Over the next decade, expanded adoption combined with current research on 57 crops in 63 countries will broaden the advantages of genetically modified foods for growers, consumers and the environment. Genetically modified (GM) crops with the ability to produce toxins lethal to specific insect pests are covering a larger percentage of the agricultural landscape every year. The United States department of Agriculture (USDA) estimated that 63 percent of corn and 65 percent of cotton contained these specific genetic traits in 2009. The toxins could protect billions of dollars of loss from insect damage for crops valued at greater than 165 billion US dollars in 2008. The stable and efficient production of these crops has taken on even more importance in recent years with their use, not only as a food source, but now also a source of fuel. It is in the best interest of the United States Environmental Protection Agency (USEPA) to ensure the continued efficacy of toxin producing GM crops as their use reduces pesticides harmful to humans and animals. However, population genetics models have indicated the risk of insect pests developing resistance to these toxins if a high percentage of acreage is grown in these crops. The USEPA is developing methods to monitor the agricultural

  2. Comparison of two methods for purification of plantaricin ST31, a bacteriocin produced by Lactobacillus plantarum ST31 Comparação de dois métodos de purificação da plantaricina ST31, a bacteriocina produzida por Lactobacillus plantarum ST31

    Directory of Open Access Journals (Sweden)

    Svetoslav D. Todorov

    2004-06-01

    Full Text Available Two methods of purification of the plantaricin ST31, a bacteriocin produced by Lactobacillus plantarum ST31 are used in this study - the method of ammonium sulfate precipitation, Sep-pack C18 cartridge and reverse-phase HPLC chromatography on C18 Nucleosil column, and the method of direct purification by cation exchange SP Sepharose Fast Flow column Amersham (Pharmacia Biotech. The purity of the products from the two experimental protocols are examined for their molecular weight, aminoacid composition and sequence. Comparison of results show that the plantaricins purified with the two methods are identical. Both methods may be used to purify plantaricin ST31. Comparison of the yield in the purification protocols is 0.8% in the HPLC experimental protocol and 5.9% in the cation-exchange chromatography method.Dois métodos de purificação de plantaricin ST31, uma bacteriocina produzida por Lactobacillus plantarum ST31 foram usados neste estudo - o método de precipitação pelo sulfato de amônia usando cartucho Sep-pack C18 para a filtração e HPLC de fase reversa em coluna de C18 Nucleosil, e o método de purificação direta por troca catiônica SP Sepharose "Fast Flow column Amersham" (Pharmacia Biotech. A pureza dos produtos obtidos pelos dois protocolos foi examinada através da determinação dos pesos moleculares, composição e seqüência dos aminoácidos. A comparação destes resultados revelou que, em termos da pureza dos produtos, não havia diferenças entre os dois métodos de purificação podendo-se, portanto, utilizar qualquer um dos protocolos de purificação testados. No entanto, o rendimento da purificação pelo método da troca catiônica foi de 5.9% enquanto o do método HPLC foi de 0.8%.

  3. Positioning for Success in University-Industry Drug-Discovery Collaborations: Initiatives towards Effective Trans-Constituency Team Science

    Directory of Open Access Journals (Sweden)

    David R Janero

    2015-12-01

    Full Text Available Despite entrenched differences between academia and the industrial sector, business models partnering universities and commercial entities to conduct preclinical drug-discovery team science are increasingly prevalent as attempts to boost and de-risk therapeutics invention. This dichotomy invites consideration of three high-level contextual elements that can help such trans-constituency alliances actualize their potential: an enabling operational profile as strategic roadmap; milestones supporting project progress and inviting improvement; and a critical mass of capable, engaged academic and industrial co-participants working across institutional boundaries and sharing risks and rewards. These elements bring many (intangible and often underappreciated benefits to a research-driven public-private discovery collaboration, e.g., underscoring its translational nature; acknowledging the important roles of vigilant self-evaluation and change; setting trust and quality expectations; establishing lines of communication and accountability; inviting knowledge cross-pollination; and avoiding project compromise by cross- purpose activities and personal/institutional self-interests. Although the inherently unpredictable nature of scientific progress and the heterogeneity of university-industry discovery collaborations preclude a universal success formula, pragmatic enablers discussed can help such alliances between academia and pharma/biotech traverse the rugged terrain at the science-business interface.

  4. Non-invasive biomarkers in pancreatic cancer diagnosis: what we need versus what we have.

    Science.gov (United States)

    Herreros-Villanueva, Marta; Bujanda, Luis

    2016-04-01

    Pancreatic cancer (PC) is probably the most lethal tumor being forecast as the second most fatal cancer by 2020 in developed countries. Only the earliest forms of the disease are a curable disease but it has to be diagnosed before symptoms starts. Detection at curable phase demands screening intervention for early detection and differential diagnosis. Unfortunately, no successful strategy or image technique has been concluded as effective approach and currently non-invasive biomarkers are the hope. Multiple translational research studies have explored minimally or non-invasive biomarkers in biofluids-blood, urine, stool, saliva or pancreatic juice, but diagnostic performance has not been validated yet. Nowadays no biomarker, alone or in combination, has been superior to carbohydrate antigen 19-9 (CA19-9) in sensitivity and specificity. Although the number of novel biomarkers for early diagnosis of PC has been increasing during the last couple of years, no molecular signature is ready to be implemented in clinical routine. Under the uncertain future, miRNAs profiling and methylation status seem to be the most promising biomarkers. However, good results in larger validations are urgently needed before application. Industry efforts through biotech and pharmaceutical companies are urgently required to demonstrate accuracy and validate promising results from basic and translational results. PMID:27162784

  5. Development of agribiotechnology and biosafety regulations used to assess safety of genetically modified crops in Bangladesh.

    Science.gov (United States)

    Nasiruddin, Khondoker M; Nasim, Anwar

    2007-01-01

    Bangladesh is on the verge of adopting genetically modified (GM) crops for commercial cultivation and consumption as feed and food. Most of the laboratories are engaged in tissue culture and molecular characterization on plants, whereas some have started living modified organism research with shortages of trained manpower, infrastructure, and funding. Nutritionally improved Golden Rice, biotech brinjal, and late blight-resistant potato are in contained trials in a greenhouse, and potato ring spot virus-resistant papaya is in the process of approval for a field trial. The government has taken some initiative in support of GM organism research, which include the formation of a Biotechnology Department in all institutes and the formation of the apex body, the National Task Force Committee on Biotechnology of Bangladesh under the chairpersonship of the Prime Minister. Biosafety policy guidelines and related aspects of biotechnology issues have been approved, and the laws are in the process of being promulgated. Being a party to the Cartagena Protocol, proper biosafety measures are regulated by the appropriate authority as stated. Although there are no laws made yet directly for biosafety of GM crops/foods, the relevant laws on agriculture, medicine, food, import, trade, environment, etc. may suffice and explain the situation. PMID:17956000

  6. Development of bioengineering system for stem cell proliferation

    Science.gov (United States)

    Park, H. S.; Shah, R.; Shah, C.

    2016-08-01

    From last decades, intensive research in the field of stem cells proliferation had been promoted due to the unique property of stem cells to self-renew themselves into multiples and has potential to replicate into an organ or tissues and so it's highly demanding though challenging. Bioreactor, a mechanical device, works as a womb for stem cell proliferation by providing nutritious environment for the proper growth of stem cells. Various factors affecting stem cells growth are the bioreactor mechanism, feeding of continuous nutrients, healthy environment, etc., but it always remains a challenge for controlling biological parameters. The present paper unveils the design of mechanical device commonly known as bioreactor in tissues engineering and biotech field, use for proliferation of stem cells and imparts the proper growing condition for stem cells. This high functional bioreactor provides automation mixing of cell culture and stem cells. This design operates in conjunction with mechanism of reciprocating motion. Compare to commercial bioreactors, this proposed design is more convenient, easy to operate and less maintenance is required as bioreactor culture bag is made of polyethylene which is single use purpose. Development of this bioengineering system will be beneficial for better growth and expansion of stem cell

  7. Genetic basis and detection of unintended effects in genetically modified crop plants.

    Science.gov (United States)

    Ladics, Gregory S; Bartholomaeus, Andrew; Bregitzer, Phil; Doerrer, Nancy G; Gray, Alan; Holzhauser, Thomas; Jordan, Mark; Keese, Paul; Kok, Esther; Macdonald, Phil; Parrott, Wayne; Privalle, Laura; Raybould, Alan; Rhee, Seung Yon; Rice, Elena; Romeis, Jörg; Vaughn, Justin; Wal, Jean-Michel; Glenn, Kevin

    2015-08-01

    In January 2014, an international meeting sponsored by the International Life Sciences Institute/Health and Environmental Sciences Institute and the Canadian Food Inspection Agency titled "Genetic Basis of Unintended Effects in Modified Plants" was held in Ottawa, Canada, bringing together over 75 scientists from academia, government, and the agro-biotech industry. The objectives of the meeting were to explore current knowledge and identify areas requiring further study on unintended effects in plants and to discuss how this information can inform and improve genetically modified (GM) crop risk assessments. The meeting featured presentations on the molecular basis of plant genome variability in general, unintended changes at the molecular and phenotypic levels, and the development and use of hypothesis-driven evaluations of unintended effects in assessing conventional and GM crops. The development and role of emerging "omics" technologies in the assessment of unintended effects was also discussed. Several themes recurred in a number of talks; for example, a common observation was that no system for genetic modification, including conventional methods of plant breeding, is without unintended effects. Another common observation was that "unintended" does not necessarily mean "harmful". This paper summarizes key points from the information presented at the meeting to provide readers with current viewpoints on these topics.

  8. Inclusion of Moloney murine leukemia virus elements upstream of the transgene cassette in an E1-deleted adenovirus leads to an unusual genomic integration in epithelial cells

    International Nuclear Information System (INIS)

    Classically, the 5' and 3' long terminal repeats (LTRs) are considered necessary but not sufficient for retroviral integration. Recently, we reported that inclusion of these and additional elements from Moloney murine leukemia virus (MoMLV) facilitated transgene integration, without retroviral integrase, when placed in an adenoviral context (AdLTR-luc vector) (Nat. Biotech. 18 (2000), 176; Biochem. Biophys. Res. Commun. 300 (2003), 115). To help understand this nonhomologous DNA recombination event, we constructed another vector, AdELP-luc, with 2.7 kb of MoMLV elements identically placed into an E1-deleted adenovirus type 5 backbone upstream of a luciferase cDNA reporter gene. Unlike AdLTR-luc, no MoMLV elements were placed downstream of the expression cassette. AdELP-luc readily infected epithelial cells in vitro. Southern hybridizations with DNA from cloned cells showed that disruption of the MoMLV sequences occurred. One cell clone, grown in vitro without any special selection medium for 9 months, exhibited stable vector integration and luciferase activity. Importantly, both Southern hybridization and FISH analyses showed that in addition to the MoMLV elements and expression cassette, substantial adenoviral sequence downstream of the luciferase cDNA was genomically integrated. These results suggest that the 2.7 kb of MoMLV sequence included in AdELP-luc have cis-acting functions and mediates an unusual integration event

  9. Challenges in the clinical development requirements for the marketing authorization of new medicines in southeast Asia.

    Science.gov (United States)

    Kudrin, Alex

    2009-03-01

    A rapid growth of investment into clinical research and new drug development has manifested itself by an exponential increase of new products coming onto the worldwide market. The emerging pharmaceutical and biotech markets in Southeast Asia are believed to be extremely promising from a commercial point of view in the next decade. The unique position of the Asian market and the diversity in clinical research initiatives are linked with diverse regulatory requirements for clinical development and registration of new medicines. Some of these differences have an impact on timelines for marketing authorizations in South Korea, China, Thailand, Japan, Singapore, and other countries. One of the approaches to streamlining regulatory strategy in different countries is the initiation of multicountry international clinical trials trying to address requirements and allowing registration in several regional countries simultaneously. Increasing cooperation between South Asian countries in relation to regulatory requirements and clinical development will facilitate the registration of innovative medicines in this rapidly developing region of the world and enable improved cohesiveness between countries in a drug safety framework. PMID:19168433

  10. Plant Breeding by Using Radiation Mutation

    Energy Technology Data Exchange (ETDEWEB)

    Kang, Si Yong; Kim, Dong Sub; Lee, Geung Joo (and others)

    2007-06-15

    A mutation breeding is to use physical or chemical mutagens to induce mutagenesis, followed by individual selections with favorable traits. The mutation breeding has many advantages over other breeding methods, which include the usefulness for improving one or two inferior characteristics, applications to broad species with different reproductive systems or to diverse plant materials, native or plant introduction with narrow genetic background, time and cost-effectiveness, and valuable mutant resources for genomic researches. Recent applications of the radiation breeding techniques to developments of flowering plants or food crops with improved functional constituents heightened the public's interests in agriculture and in our genetic resources and seed industries. The goals of this project, therefore, include achieving advances in domestic seed industries and agricultural productivities by developing and using new radiation mutants with favored traits, protecting an intellectual property right of domestic seeds or germplasm, and sharing the valuable mutants and mutated gene information for the genomic and biotech researches that eventually leads to economic benefits.

  11. Commercialization of new biotechnology: a systematic review of 16 commercial case studies in a novel manufacturing sector.

    Science.gov (United States)

    Paul, Matthew J; Thangaraj, Harry; Ma, Julian K-C

    2015-10-01

    The 1980s and 1990s saw a major expansion of biotechnology into new areas of science including genomics and recombinant technologies. This was coupled to the widespread emergence of academics into the commercial sector as they were encouraged to spin out companies or commercialize their intellectual property. There were many opportunities to raise investment, and extraordinary success stories were prominent across many areas of technology. The field of plant biotechnology for manufacturing recombinant pharmaceuticals (molecular pharming) emerged and was developed in this period. Like other biotechnologies, this was an exciting new development which offered some very obvious benefits and commercial advantages. In particularly, plant molecular pharming represented a highly novel and potentially disruptive manufacturing technology for recombinant proteins. Twenty-five years on, a series of interviews with senior members of sixteen of the most prominent companies involved in the field provides insight into the original drivers for commercialization, strategic thinking and planning behind key commercial decisions and an insider view into the major reasons for commercial success or failure. These observations and recurring themes identified across a number of commercial ventures remain relevant today, as new biotech companies continue to spin out of the world of academia. PMID:26140440

  12. Detecting authorized and unauthorized genetically modified organisms containing vip3A by real-time PCR and next-generation sequencing.

    Science.gov (United States)

    Liang, Chanjuan; van Dijk, Jeroen P; Scholtens, Ingrid M J; Staats, Martijn; Prins, Theo W; Voorhuijzen, Marleen M; da Silva, Andrea M; Arisi, Ana Carolina Maisonnave; den Dunnen, Johan T; Kok, Esther J

    2014-04-01

    The growing number of biotech crops with novel genetic elements increasingly complicates the detection of genetically modified organisms (GMOs) in food and feed samples using conventional screening methods. Unauthorized GMOs (UGMOs) in food and feed are currently identified through combining GMO element screening with sequencing the DNA flanking these elements. In this study, a specific and sensitive qPCR assay was developed for vip3A element detection based on the vip3Aa20 coding sequences of the recently marketed MIR162 maize and COT102 cotton. Furthermore, SiteFinding-PCR in combination with Sanger, Illumina or Pacific BioSciences (PacBio) sequencing was performed targeting the flanking DNA of the vip3Aa20 element in MIR162. De novo assembly and Basic Local Alignment Search Tool searches were used to mimic UGMO identification. PacBio data resulted in relatively long contigs in the upstream (1,326 nucleotides (nt); 95 % identity) and downstream (1,135 nt; 92 % identity) regions, whereas Illumina data resulted in two smaller contigs of 858 and 1,038 nt with higher sequence identity (>99 % identity). Both approaches outperformed Sanger sequencing, underlining the potential for next-generation sequencing in UGMO identification.

  13. How to deal with the upcoming challenges in GMO detection in food and feed.

    Science.gov (United States)

    Broeders, Sylvia R M; De Keersmaecker, Sigrid C J; Roosens, Nancy H C

    2012-01-01

    Biotech crops are the fastest adopted crop technology in the history of modern agriculture. The commercialisation of GMO is in many countries strictly regulated laying down the need for traceability and labelling. To comply with these legislations, detection methods are needed. To date, GM events have been developed by the introduction of a transgenic insert (i.e., promoter, coding sequence, terminator) into the plant genome and real-time PCR is the detection method of choice. However, new types of genetic elements will be used to construct new GMO and new crops will be transformed. Additionally, the presence of unauthorised GMO in food and feed samples might increase in the near future. To enable enforcement laboratories to continue detecting all GM events and to obtain an idea of the possible presence of unauthorised GMO in a food and feed sample, an intensive screening will become necessary. A pragmatic, cost-effective, and time-saving approach is presented here together with an overview of the evolution of the GMO and the upcoming needs.

  14. How to Deal with the Upcoming Challenges in GMO Detection in Food and Feed

    Directory of Open Access Journals (Sweden)

    Sylvia R. M. Broeders

    2012-01-01

    Full Text Available Biotech crops are the fastest adopted crop technology in the history of modern agriculture. The commercialisation of GMO is in many countries strictly regulated laying down the need for traceability and labelling. To comply with these legislations, detection methods are needed. To date, GM events have been developed by the introduction of a transgenic insert (i.e., promoter, coding sequence, terminator into the plant genome and real-time PCR is the detection method of choice. However, new types of genetic elements will be used to construct new GMO and new crops will be transformed. Additionally, the presence of unauthorised GMO in food and feed samples might increase in the near future. To enable enforcement laboratories to continue detecting all GM events and to obtain an idea of the possible presence of unauthorised GMO in a food and feed sample, an intensive screening will become necessary. A pragmatic, cost-effective, and time-saving approach is presented here together with an overview of the evolution of the GMO and the upcoming needs.

  15. The Sheffield RNAi Screening Facility (SRSF): portfolio growth and technology development.

    Science.gov (United States)

    Brown, Stephen

    2014-05-01

    The Sheffield RNAi Screening Facility (SRSF) (www.rnai.group.shef.ac.uk) was established in 2008 with Wellcome Trust and University of Sheffield funding, with the task to provide the first UK RNAi screening resource for academic groups interested in identifying genes required in a diverse range of biological processes using Drosophila cell culture. The SRSF has carried out a wide range of screens varying in sizes from bespoke small-scale libraries, targeting a few hundred genes, to high-throughput, genome-wide studies. The SRSF has grown and improved with a dedicated partnership of its academic customers based mainly in the UK. We are part of the UK Academics Functional Genomics Network, participating in organizing an annual meeting in London and are part of the University of Sheffield's D3N (www.d3n.org.uk), connecting academics, biotech and pharmaceutical companies with a multidisciplinary network in Drug Discovery and Development. Recently, the SRSF has been funded by the Yorkshire Cancer Research Fund to perform genome-wide RNAi screens using human cells as part of a core facility for regional Yorkshire Universities and screens are now underway. Overall the SRSF has carried out more than 40 screens from Drosophila and human cell culture experiments. PMID:24766065

  16. A Strong Start-up Scene Flourishes in the Life Sciences Capital Basel.

    Science.gov (United States)

    Burckhardt, Peter

    2014-12-01

    Basel is known for its successful global players in Pharma, Agro and Chemicals. The wealth of top-tier companies, universities and academic institutions in such a small region is unparalleled. It creates an optimum climate for world-class research and its translation into successful businesses. This is also reflected in a strong start-up scene. Over the past decades the multinational players have shown that they are able to adapt to the ever-increasing challenges in the market. Basel has seen blue-chip company mergers, accompanied by the transfer of business assets into spin-off companies. This process created a mind-set for change which has positively influenced the local start-up environment. Actelion is one of these former spin-offs that successfully made the transition to become a global player. BioVersys and PIQUR are two of the most promising very early stage Swiss biotech companies. Many other examples can be found in Northwestern Switzerland. The region also offers a solid background of supporting activities. Infrastructure, coaching and all other support are offered and complement national innovation initiatives. PMID:26508602

  17. Nonprofit pharma: solutions to what ails the industry.

    Science.gov (United States)

    Moos, W H; Kodukula, K

    2011-01-01

    Nonprofit organizations (NPOs) play an increasingly important role providing solutions to the significant challenges faced today by both large pharmaceutical and smaller biotechnology companies, not to mention academia. NPOs chartered for the public benefit are common in the USA and in selected other parts of the world. SRI International, originally founded as the Stanford Research Institute in 1946, is one of the largest and most successful independent NPOs. To provide a perspective on NPO business models, a number of SRI case studies spanning a broad range of technical and business initiatives will be summarized, including basic and contract research, discovery and development of new drugs and biologics, pharmaceutical and biotech research and development and contract services, technology pivots, company spin-ins and spin-outs, and the creation of new NPOs. How to bridge the National Institute of Health's "Valley of Death" and how to navigate the Food and Drug Administration's "Critical Path" will be discussed. We conclude with lessons learned about collaborations and routes to commercialization, along with food for thought for bioscience companies and outsourcing participants. Throughout, we attempt to explain why the role of NPOs is important to both the scientific and business communities and to patients and caregivers. PMID:21728955

  18. Yield oil of Jatropha curcas seeds of trees irrigated and fertilized with OMM-Tech; Rendimento de oleo de sementes de pinhao manso submetido a irrigacao e adubacao com OMM-Tech

    Energy Technology Data Exchange (ETDEWEB)

    Evangelista, Adao W.P.; Alves Junior, Jose; Barbosa, Ricardo A.F.; Frazao, Joaquim J.; Araujo, Fausto J.M. [Universidade Federal de Goias (UFG), Goiania, GO (Brazil). Escola de Agronomia e Engenharia de Alimentos. Setor de Engenharia Rural], E-mail: awpego@bol.com.br

    2010-07-01

    The purpose of this study was to evaluate the effects of irrigation and application of Organo-Minerals-Marine + Biotech (OMM-Tech) in yield oil of Jatropha curcas seeds. The experiment was conducted in an experimental area located in Federal University of Lavras, Brazil. A randomized block experimental design with subdivided parcels and three replications was used. The parcels were submitted to different OMM-Tech fertilizer application methods: T1 = control (no OMM-Tech); T2 = soil application (120 kg ha{sup -1} of OMM-Tech in a powder form); T3 = leaf application (OMM-Tech in a liquid form with a 5% concentration); T4 = soil + leaf application (60 kg ha{sup -1} of OMM-Tech in powder form + OMM-Tech in liquid form with a 2.5% concentration). The sub-plots received two different water management treatments: irrigated and no irrigated. A drip irrigation system with drippers spaced by 0.50 m was used. We evaluated yield oil of seeds in first production year. Jatropha trees irrigated showed a higher seeds oil yield than no irrigated trees. However, fertilization with OMM-Tech no influenced seed oil yield. Seeds oil yield of Jatropha trees irrigated was 34%, and no irrigated 27%. (author)

  19. A bright weekend: THE Port develops a better solution for the “Children of the Night”

    CERN Multimedia

    Antonella Del Rosso

    2015-01-01

    THE Port Hackathon took place at CERN and Geneva’s Campus Biotech from 2 to 4 October. Among the various prototypes presented at the final event was a novel solution for the special mask that children suffering from xeroderma pigmentosum have to wear to reduce their risk of getting skin cancer. The whole initiative was triggered by an article published in one of the summer issues of the Bulletin.   Developing and testing the mask prototype at THE Port Hackathon, 2015. (Images: Andrey Loginov, Pierre Freyermuth, Antonio Bellotta/ THE Port)   “The improvements are really substantial and have made the president of the French Children of the Night Association really happy!” says Andy Butterworth from the team that worked on developing a prototype for a new mask during THE Port Hackathon. In his “normal” professional life, Andy is a radio-frequency expert working in the Beams department. During the hackathon, he worked with colleagues from CE...

  20. Statistical experimental design for bioprocess modeling and optimization analysis: repeated-measures method for dynamic biotechnology process.

    Science.gov (United States)

    Lee, Kwang-Min; Gilmore, David F

    2006-11-01

    The statistical design of experiments (DOE) is a collection of predetermined settings of the process variables of interest, which provides an efficient procedure for planning experiments. Experiments on biological processes typically produce long sequences of successive observations on each experimental unit (plant, animal, bioreactor, fermenter, or flask) in response to several treatments (combination of factors). Cell culture and other biotech-related experiments used to be performed by repeated-measures method of experimental design coupled with different levels of several process factors to investigate dynamic biological process. Data collected from this design can be analyzed by several kinds of general linear model (GLM) statistical methods such as multivariate analysis of variance (MANOVA), univariate ANOVA (time split-plot analysis with randomization restriction), and analysis of orthogonal polynomial contrasts of repeated factor (linear coefficient analysis). Last, regression model was introduced to describe responses over time to the different treatments along with model residual analysis. Statistical analysis of biprocess with repeated measurements can help investigate environmental factors and effects affecting physiological and bioprocesses in analyzing and optimizing biotechnology production. PMID:17159235

  1. The year's new drugs & biologics 2014 - Part II: trends & challenges.

    Science.gov (United States)

    Graul, A I; Serebrov, M; Cruces, E; Tracy, M; Dulsat, C

    2015-02-01

    2014 was a year of continued high activity in the pharma and biotech industry, as evidenced in part I of this annual two-part review article published last month in this journal (1). As of December 23, 2014, a total of 55 new chemical and biological entities had reached their first markets worldwide, together with another 29 important new line extensions. Another 19 products were approved for the first time during the year but not yet launched by December 23. Furthermore, during the now-traditional year-end sprint, several regulatory agencies issued last-minute approvals for other compounds that missed the deadline for inclusion in that article, bringing the total of new approvals for the year to a somewhat higher number. In addition to the successful development, registration and launch of new drugs and biologics, there are various other trends and tendencies that serve as indicators of the overall health and status of the industry. These include the pursuit of novel programs designed by regulators to stimulate the development of drugs for diseases that are currently under-treated; the regular and pragmatic culling by companies of their R&D pipelines; and the decision to unify pipelines, portfolios and sales forces through mergers and acquisitions. PMID:25756068

  2. Nonwovens for filtration media%非织造材料过滤介质

    Institute of Scientific and Technical Information of China (English)

    P.Ganesan; T.Karthik; 杜雪子; 李毓陵

    2011-01-01

    目前很多企业将非织造材料用于过滤,其中涉及食品、饮料、生物技术、药物、饮用水、液压用油、燃料、溶剂、酸碱等。不同用途所需去除的杂质也有所不同,非织造材料种类繁多,可满足这些不同应用的需求。非织造材料随着加工原料、加工方法和表面特征的不同而不同。根据成型方法可分成两大类。第一种方法是干法成网工艺,包括梳理、针刺、纺粘和熔喷。第二种方法是湿法成网工艺,一般是在造纸机上完成。两种工艺各具特色,在不同用途上可以发挥各自不同的优势。%There is a wide range of industries that use nonwovens media for filtration applications. They range from food and beverage, biotech, pharmaceutical potable water, hydraulic oils, fuels, solvents, acids and bases. Each application has a different contamin

  3. Walking between academia and industry to find successful solutions to biomedical challenges: an interview with Geoffrey Smith.

    Science.gov (United States)

    Smith, Geoffrey; Cagan, Ross

    2015-10-01

    Geoffrey W. Smith is currently the Managing Director of Mars Ventures. He actually started his studies with a Bachelor of Arts degree and a Doctorate in Law but then, in part by chance and in part by following in his family footsteps, he stepped into the healthcare and biotech field. Since then, he has successfully contributed to the birth of a number of healthcare companies and has also held academic positions at the Icahn School of Medicine at Mount Sinai and at The Rockefeller University in New York, teaching about the interface between science and business. During 2014 he served as Senior Editor on Disease Models & Mechanisms, bringing to the editorial team his valuable experience in drug development and discovery. In this interview, Geoff talks to Ross Cagan, Editor-in-Chief of Disease Models & Mechanisms, about how he developed his incredibly varied career, sharing his views about industry, academia and science publishing, and discussing how academia and industry can fruitfully meet to advance bioscience, train the scientists and stakeholders of the future, and drive the successful discovery of new therapeutics to treat human disease. PMID:26438691

  4. Foundation-industry relationships--a new business model joint-venture philanthropy in therapy development.

    Science.gov (United States)

    Bartek, Ronald J

    2014-01-01

    The business model for medical therapy development has changed drastically. Large companies that once conducted their own Research and Development (R&D) and funded all the preclinical studies, all phases of clinical development and marketing of the products are increasingly turning to others for more and more of the earlier work in hopes of being able to in-license a de-risked program well downstream, take it through the final phases of clinical development and into the marketplace. This new paradigm has required patient-advocacy foundations, especially in the rare-disease space, to become far more effective in building relationships with all the players along the therapy-development pathway -- academic scientists, government agencies, other foundations with overlapping interests, biotechs, small biopharmaceutical entities and even the larger industry companies. From the perspective of the patient-advocacy community, these increasingly essential public-private partnerships have taken on the nature of what could be called joint-venture philanthropy and involve a broad spectrum of collaborations and financial relationships between foundations and industry partners that are not without concerns about potential conflicts of interest. PMID:24283968

  5. Business models and opportunities for cancer vaccine developers.

    Science.gov (United States)

    Kudrin, Alex

    2012-10-01

    Despite of growing oncology pipeline, cancer vaccines contribute only to a minor share of total oncology-attributed revenues. This is mainly because of a limited number of approved products and limited sales from products approved under compassionate or via early access entry in smaller and less developed markets. However revenue contribution from these products is extremely limited and it remains to be established whether developers are breaking even or achieving profitability with existing sales. Cancer vaccine field is well recognized for high development costs and risks, low historical rates of investment return and high probability of failures arising in ventures, partnerships and alliances. The cost of reimbursement for new oncology agents is not universally acceptable to payers limiting the potential for a global expansion, market access and reducing probability of commercial success. In addition, the innovation in cancer immunotherapy is currently focused in small and mid-size biotech companies and academic institutions struggling for investment. Existing R&D innovation models are deemed unsustainable in current "value-for-money" oriented healthcare environment. New business models should be much more open to collaborative, networked and federated styles, which could help to outreach global, markets and increase cost-efficiencies across an entire value chain. Lessons learned from some developing countries and especially from South Korea illustrate that further growth of cancer vaccine industry will depends not only on new business models but also will heavily rely on regional support and initiatives from different bodies, such as governments, payers and regulatory bodies. PMID:22894953

  6. Walking between academia and industry to find successful solutions to biomedical challenges: an interview with Geoffrey Smith

    Directory of Open Access Journals (Sweden)

    2015-10-01

    Full Text Available Geoffrey W. Smith is currently the Managing Director of Mars Ventures. He actually started his studies with a Bachelor of Arts degree and a Doctorate in Law but then, in part by chance and in part by following in his family footsteps, he stepped into the healthcare and biotech field. Since then, he has successfully contributed to the birth of a number of healthcare companies and has also held academic positions at the Icahn School of Medicine at Mount Sinai and at The Rockefeller University in New York, teaching about the interface between science and business. During 2014 he served as Senior Editor on Disease Models & Mechanisms, bringing to the editorial team his valuable experience in drug development and discovery. In this interview, Geoff talks to Ross Cagan, Editor-in-Chief of Disease Models & Mechanisms, about how he developed his incredibly varied career, sharing his views about industry, academia and science publishing, and discussing how academia and industry can fruitfully meet to advance bioscience, train the scientists and stakeholders of the future, and drive the successful discovery of new therapeutics to treat human disease.

  7. A Wide-Field Fluorescence Microscope Extension for Ultrafast Screening of One-Bead One-Compound Libraries Using a Spectral Image Subtraction Approach.

    Science.gov (United States)

    Heusermann, Wolf; Ludin, Beat; Pham, Nhan T; Auer, Manfred; Weidemann, Thomas; Hintersteiner, Martin

    2016-05-01

    The increasing involvement of academic institutions and biotech companies in drug discovery calls for cost-effective methods to identify new bioactive molecules. Affinity-based on-bead screening of combinatorial one-bead one-compound libraries combines a split-mix synthesis design with a simple protein binding assay operating directly at the bead matrix. However, one bottleneck for academic scale on-bead screening is the unavailability of a cheap, automated, and robust screening platform that still provides a quantitative signal related to the amount of target protein binding to individual beads for hit bead ranking. Wide-field fluorescence microscopy has long been considered unsuitable due to significant broad spectrum autofluorescence of the library beads in conjunction with low detection sensitivity. Herein, we demonstrate how such a standard microscope equipped with LED-based excitation and a modern CMOS camera can be successfully used for selecting hit beads. We show that the autofluorescence issue can be overcome by an optical image subtraction approach that yields excellent signal-to-noise ratios for the detection of bead-associated target proteins. A polymer capillary attached to a semiautomated bead-picking device allows the operator to efficiently isolate individual hit beads in less than 20 s. The system can be used for ultrafast screening of >200,000 bead-bound compounds in 1.5 h, thereby making high-throughput screening accessible to a wider group within the scientific community. PMID:27057765

  8. Suppression of cyclooxygenase-2 gene transcription by humulon of beer hop extract studied with reference to glucocorticoid.

    Science.gov (United States)

    Yamamoto, K; Wang, J; Yamamoto, S; Tobe, H

    2000-01-14

    In murine osteoblastic MC3T3-E1 cells which produced prostaglandin E2 as a bone resorption factor, the cyclooxygenase-2 induction by tumor necrosis factor alpha (TNFalpha) was suppressed by dexamethasone with an IC(50) of 1 nM. Humulon isolated from hop extract for beer brewing was reported previously as an inhibitor of bone resorption [Tobe, H. et al. (1997) Biosci. Biotech. Biochem. 61, 158-159]. We showed that the compound suppressed the TNFalpha-dependent cyclooxygenase-2 induction with an IC(50) of as low as about 30 nM as demonstrated experimentally by catalytic activity assay, Northern blot analysis and promoter analysis. Reporter gene experiments suggested that humulon blocked the cyclooxygenase-2 expression mediated by NFkappaB and NF-IL6, but the intracellular glucocorticoid receptor was not involved. The catalytic activity of cyclooxygenase-2 was inhibited by humulon with an IC(50) of as high as 1.6 microM. These results showed that humulon suppressed cyclooxygenase-2 induction at the step of transcription.

  9. Competitive intelligence information management and innovation in small technology-based companies

    Science.gov (United States)

    Tanev, Stoyan

    2007-05-01

    In this article we examine how (i) company type and (ii) the competitive intelligence information used by small technology-based companies affect their innovation performance. The focus is on the specific information types used and not on the information sources. Information topics are classified in four groups - customers (10), company (9), competitor (11) and industry (12). The sample consists of 45 small new technology-based companies, specialized suppliers, and service companies from a variety of sectors - software, photonics, telecommunications, biomedical engineering and biotech, traditional manufacturing etc. The results suggest that the total number of intelligence information topics companies use to make decisions about innovation is not associated with the number of their new products, processes, services and patents. Therefore the companies in our sample do not seem to have the resources, processes or value systems required to use different competitive intelligence information when making decisions on innovation or may rely more on their own internal logic than on external information. Companies are classified using a Pavitt-like taxonomy. Service companies are considered as a separate company type. This allows for explicitly studying both, the innovative role of new services in product driven companies, and the role of new product development in service companies.

  10. From global bioethics to ethical governance of biomedical research collaborations.

    Science.gov (United States)

    Wahlberg, Ayo; Rehmann-Sutter, Christoph; Sleeboom-Faulkner, Margaret; Lu, Guangxiu; Döring, Ole; Cong, Yali; Laska-Formejster, Alicja; He, Jing; Chen, Haidan; Gottweis, Herbert; Rose, Nikolas

    2013-12-01

    One of the features of advanced life sciences research in recent years has been its internationalisation, with countries such as China and South Korea considered 'emerging biotech' locations. As a result, cross-continental collaborations are becoming common generating moves towards ethical and legal standardisation under the rubric of 'global bioethics'. Such a 'global', 'Western' or 'universal' bioethics has in turn been critiqued as an imposition upon resource-poor, non-Western or local medical settings. In this article, we propose that a different tack is necessary if we are to come to grips with the ethical challenges that inter-continental biomedical research collaborations generate. In particular we ask how national systems of ethical governance of life science research might cope with increasingly global research collaborations with a focus on Sino-European collaboration. We propose four 'spheres' - deliberation, regulation, oversight and interaction - as a helpful way to conceptualise national systems of ethical governance. Using a workshop-based mapping methodology (workshops held in Beijing, Shanghai, Changsha, Xian, Shenzen and London) we identified three specific ethical challenges arising from cross-continental research collaborations: (1) ambiguity as to which regulations are applicable; (2) lack of ethical review capacity not only among ethical review board members but also collaborating scientists; (3) already complex, researcher-research subject interaction is further complicated when many nationalities are involved.

  11. OPTIMIZED DESIGN OF BIO-SENSOR USING CONDUCTING POLYMERS AND NANOCOMPOSITES

    Directory of Open Access Journals (Sweden)

    Usha.A,

    2011-04-01

    Full Text Available This Research work is focused on the design, development and technological evolution of emerging fields of Nanotechnology and Conducting Polymer Electronics, Bio-Tech based Embedded Sensors and Smart Systems employing System-0n- Chip (SOC Core, as applied to Health Monitoring of Human and Complex Systems in Engineering and Medicine. With the Invention of Thin-Film Technology, it is now possible to fabricate Novel Conducting-Polymer based sensors and devices with built-in-flexible electronics resulting in high throughput devices and systems that are flexible, lighter, bio-compatible and economical also. The flexible and EmbeddedElectronics is a key enabler for a number of platform methodologies such as Designed Thin-Films, Smart Electronics and Sensor Devices. The integration of the Bio-Sensor with embedded electronics data conditioning and processing SOC and Wireless –Communication System may provide vast opportunities for Biological – Sensor Applications, especially for physiological monitoring of Leukocyte-Counts in blood sample or analyte for Leukemia Patients in the Society.

  12. The challenge of selecting protein kinase assays for lead discovery optimization

    Science.gov (United States)

    Ma, Haiching; Deacon, Sean; Horiuchi, Kurumi

    2009-01-01

    Background Protein kinases represent one of the most promising groups of drug targets owing to their involvement in such pathological conditions as cancer, inflammatory diseases, neural disorders, and metabolism problems. In the last few years, numerous pharmaceutical and biotech companies have established kinase high-throughput screening (HTS) programs, and the reagent and service industries for kinase assay platforms, kits, and profiling services have begun to thrive. Objective The plethora of different assay formats available today poses a great challenge to scientists who want to select a technology that will be cost efficient, convenient to use, and have low false positive and false negative rates. Methods In the current review, we summarize the most commonly used kinase assay methods in the drug discovery process, present the advantages and disadvantages of each of these methods, and discuss the challenges of discovering kinase inhibitors by using these technologies. Conclusions The decision of selecting the assay formats for HTS or service platform for profiling should take into account not only the final goals of the screens but also the limitation of resources. PMID:19662101

  13. Valutazione del nuovo sistema automatizzato Triturus - Grifols nella diagnosi sierologica delle infezioni da complesso ToRCH e da virus di Epstein Barr

    Directory of Open Access Journals (Sweden)

    Monica Sparacino

    2003-03-01

    Full Text Available The laboratory diagnosis of infections belonging to the ToRCH complex is mainly based of the determination of the immune status to each individual microrganism. In this report, the diagnostic performance of a new automated EIA plates processor system (SeraQuest - GRIFOLS, Pisa, Italy has been compared with other automaed methods: Enzygnost (Dade behring, Marburg, Germany, EIA Well (RADIM, Pomezia, Italy,VIDAS (bioMériuex, Marcy l’etoile, France. In addition, the diagnostic performance of SeraQuest has also been evaluated for the detection of specific immune response to Epstein Barr virus, in comparison with a conventional EIA test (Delta, Pomezia, Italy and with an immunoblotting method (Genelabs - AlfaBiotech, Milan, Italy.The overal evaluation of SeraQuest demonstrated that this test has sensitivity and specificity well comaparable with those of the other methods studied and that could be used as an alternative test in the serological diagnosis of ToRCH and EBV infections.

  14. [Development of Human Health Discoveries. 10 years results of Young Innovative Company incubation].

    Science.gov (United States)

    Marsac, Jean

    2014-01-01

    Medicine is evolving every day in its operating procedures and the services offered to patients, emphasizing personalized medicine, safety and medical benefits. The individual patient is more than ever the hub of healthcare organization. Medical innovation is thus a public health priority. However it requires an accurate assessment of medical utility and risk-benefit ratios, and in-depth analysis of economic and organizational impacts. Ten years of experience in the Paris Biotech Santé company incubator has identified key actions for effective support of research projects and the success of innovative companies. Strong expertise is needed to prepare development plans, ensure compliance with regulatory requirements and obtain research funding. During its first decade, this incubator has created 87 innovative companies employing 1500 people, raised more than 90 million euros of funding, and reached a cumulative company value of 1200 million euros. Key factors of success have been identified, but an analysis of the causes of failure shows that operational adjustments are mandatory, particularly a strong commitment from medical experts, in order to promote access to new and useful products for patients while at the same time assessing their social impact.

  15. Commercialization of new biotechnology: a systematic review of 16 commercial case studies in a novel manufacturing sector.

    Science.gov (United States)

    Paul, Matthew J; Thangaraj, Harry; Ma, Julian K-C

    2015-10-01

    The 1980s and 1990s saw a major expansion of biotechnology into new areas of science including genomics and recombinant technologies. This was coupled to the widespread emergence of academics into the commercial sector as they were encouraged to spin out companies or commercialize their intellectual property. There were many opportunities to raise investment, and extraordinary success stories were prominent across many areas of technology. The field of plant biotechnology for manufacturing recombinant pharmaceuticals (molecular pharming) emerged and was developed in this period. Like other biotechnologies, this was an exciting new development which offered some very obvious benefits and commercial advantages. In particularly, plant molecular pharming represented a highly novel and potentially disruptive manufacturing technology for recombinant proteins. Twenty-five years on, a series of interviews with senior members of sixteen of the most prominent companies involved in the field provides insight into the original drivers for commercialization, strategic thinking and planning behind key commercial decisions and an insider view into the major reasons for commercial success or failure. These observations and recurring themes identified across a number of commercial ventures remain relevant today, as new biotech companies continue to spin out of the world of academia.

  16. Entrepreneurism from the ground up: Entrepreneurism, innovation, and responsiveness in a start-up university

    Science.gov (United States)

    Wong, Michael Paul Anthony

    Colleges and universities are under increased pressure from internal and external constituencies for increased innovation and responsiveness. Entrepreneurial private industry models such as start-up businesses, corporate ventures and spin-off organizations have been recognized for their ability to quickly adapt to changing business environments and rapidly innovate to take advantage of new opportunities. This case study investigates these claims with regard to a start-up university founded with the identity of an entrepreneurial, interdisciplinary institution that prepares graduate level students for leadership careers as entrepreneurs in the bio-tech industry. By interviewing twenty-four administrators, faculty, and members of the Board of Trustees, including all but one of the founding full-time faculty, I present an "insider's" depiction of the lived experience of those most closely associated with the founding and subsequent institution building of this unique higher education organization. Initial chapters present a theory of higher education organizations, derived from Birnbaum (1988) and Bolman and Deal (1991), as driven by two primary tasks: resolving identity and establishing power and resources in relation to that identity. I also present Russell and Russell's (1992) theory of "entrepreneurial posture" in relation to a higher education organization. Subsequent chapters analyze the start-up university's environment, strategy, culture, and structure within the framework of the two primary organizational tasks and Russell and Russell's (1992) definition of an entrepreneurial organization.

  17. Adalimumab: a review of the reference product and biosimilars

    Directory of Open Access Journals (Sweden)

    Azevedo VF

    2016-07-01

    Full Text Available Valderílio Feijó Azevedo,1,2 Ludmila Della Coletta Troiano,2 Natalia Bassalobre Galli,1 Alais Kleinfelder,1 Nathan M Catolino,1 Paulo Cesar Urbano Martins2 1Rheumatology Unit, Federal University of Paraná, 2Edumed Health Research and Biotech, Curitiba, Brazil Abstract: Adalimumab was the first fully humanized monoclonal antibody approved by the US Food and Drug Administration (FDA. Launched in 2003, the clinical efficacy and safety of adalimumab were assessed in various trials in rheumatoid arthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, Crohn’s Disease, and ulcerative colitis, among others. At the global level, adalimumab is a major sales success among biologicals. It is still the greatest blockbuster among monoclonal antibodies. The date of its patent expiration paves the road for several potential biosimilars in various markets worldwide. This article discusses the current situation of molecules that are the main candidates to become adalimumab biosimilars. In addition, it also addresses the production processes, clinical studies, and relevant regulatory issues relative to the approval of those molecules, which must meet the challenge of demonstrating similar efficacy and safety to Humira®, but at a lower cost. Keywords: biosimilars, adalimumab, anti-TNF, biosimilarity

  18. Foundation-industry relationships--a new business model joint-venture philanthropy in therapy development.

    Science.gov (United States)

    Bartek, Ronald J

    2014-01-01

    The business model for medical therapy development has changed drastically. Large companies that once conducted their own Research and Development (R&D) and funded all the preclinical studies, all phases of clinical development and marketing of the products are increasingly turning to others for more and more of the earlier work in hopes of being able to in-license a de-risked program well downstream, take it through the final phases of clinical development and into the marketplace. This new paradigm has required patient-advocacy foundations, especially in the rare-disease space, to become far more effective in building relationships with all the players along the therapy-development pathway -- academic scientists, government agencies, other foundations with overlapping interests, biotechs, small biopharmaceutical entities and even the larger industry companies. From the perspective of the patient-advocacy community, these increasingly essential public-private partnerships have taken on the nature of what could be called joint-venture philanthropy and involve a broad spectrum of collaborations and financial relationships between foundations and industry partners that are not without concerns about potential conflicts of interest.

  19. Process development in the QbD paradigm: Role of process integration in process optimization for production of biotherapeutics.

    Science.gov (United States)

    Rathore, Anurag S; Pathak, Mili; Godara, Avinash

    2016-03-01

    Biotherapeutics have become the focus of the pharmaceutical industry due to their proven effectiveness in managing complex diseases. Downstream processes of these molecules consist of several orthogonal, high resolution unit operations designed so as to be able to separate variants having very similar physicochemical properties. Typical process development involves optimization of the individual unit operations based on Quality by Design principles in order to define the design space within which the process can deliver product that meets the predefined specifications. However, limited efforts are dedicated to understanding the interactions between the unit operations. This paper aims to showcase the importance of understanding these interactions and thereby arrive at operating conditions that are optimal for the overall process. It is demonstrated that these are not necessarily same as those obtained from optimization of the individual unit operations. Purification of Granulocyte Colony Stimulating Factor (G-CSF), a biotherapeutic expressed in E. coli., has been used as a case study. It is evident that the suggested approach results in not only higher yield (91.5 vs. 86.4) but also improved product quality (% RP-HPLC purity of 98.3 vs. 97.5) and process robustness. We think that this paper is very relevant to the present times when the biotech industry is in the midst of implementing Quality by Design towards process development. © 2015 American Institute of Chemical Engineers Biotechnol. Prog., 32:355-362, 2016. PMID:26588604

  20. Preeclampsia - will orphan drug status facilitate innovative biological therapies?

    Science.gov (United States)

    Hahn, Sinuhe

    2015-01-01

    It is generally accepted that the development of novel therapies to treat pregnancy-related disorders, such as preeclampsia, is hampered by the paucity of research funding. Hence, it is with great interest to become aware of at least three novel therapeutic approaches for the treatment of this disorder: exploiting either the anticoagulant activity of antithrombin, the free radical scavenging activity of alpha-1-microglobulin, or the regenerative capacity of placenta-derived mesenchymal stem cells. As these projects are being carried out by small biotech enterprises, the question arises of how they are able to fund such undertakings. A novel strategy adopted by two of these companies is that they successfully petitioned US and EU agencies in order that preeclampsia is accepted in the register of rare or orphan diseases. This provides a number of benefits including market exclusivity, assistance with clinical trials, and dedicated funding schemes. Other strategies to supplement meager research funds, especially to test novel approaches, could be crowdfunding, a venture that relies on intimate interaction with advocacy groups. In other words, preeclampsia meets Facebook. Perhaps similar strategies can be adopted to examine novel therapies targeting either the imbalance in pro- or anti-angiogenic growth factors, complement activation, reduced levels of placenta protein 13, or excessive neutrophil activation evident in preeclampsia.

  1. Preeclampsia – will Orphan Drug Status facilitate innovative biological therapies?

    Directory of Open Access Journals (Sweden)

    Sinuhe eHahn

    2015-02-01

    Full Text Available It is generally accepted that development of novel therapies to treat pregnancy-relates disorders, such as preeclampsia, is hampered to the paucity of research funding. Hence, it is with great interest to become aware of at least three novel therapeutic approaches for the treatment of this disorder, exploiting either the anticoagulant activity of antithrombin, the free radical scavenging activity of alpha-1-microglobulin, or the regenerative capacity of placenta-derived mesenchymal stem cells. As these projects are being carried out by small biotech enterprises, the question arises of how they are able to fund such undertakings. A novel strategy adopted by two of these companies is that they successfully petitioned US and EU agencies in order that preeclampsia be accepted in the register of rare or orphan diseases. This provides a number of benefits including market exclusivity, assistance with clinical trials and dedicated funding schemes. Other strategies to supplement meager research funds, especially to test novel approaches, could be crowdfunding, a venture which relies on intimate interaction with advocacy groups. In other words, preeclampsia meets Facebook. Perhaps similar strategies can be adopted to examine novel therapies targeting either the imbalance in angiogenic growth factors, complement activation, reduced levels of placenta protein 13 or excessive neutrophil activation evident in preeclampsia.

  2. The nature of outsourced preclinical research--the example of chemical synthesis.

    Science.gov (United States)

    Festel, Gunter W

    2013-09-01

    The possibility to buy standardized external services or even new and innovative methods within drug discovery has increased dramatically during the last decades. Service providers are able to provide timely and efficient solutions to any given problem within preclinical research. The outsourcing behavior depends on the specific company type. Generally, the outsourcing level of emerging pharmaceutical and biotechnology companies is much higher than established companies due to low or missing internal resources. Whereas the "make-or-buy" decisions of large and fully integrated pharmaceutical companies are mainly competency driven, those of mid-size and small pharmaceutical, as well as biotech companies show a specific combination of cost/capacity and competency. The three different cooperation models "price competition", "project selection," and "strategic partnership" were identified. For all types of companies, the cooperation model of "strategic partnership" offers access to high-level expertise while reducing fixed costs and complexity. This was shown using chemical synthesis as an example but is also true for other areas of preclinical research.

  3. Evolution of the Novalux extended cavity surface-emitting semiconductor laser (NECSEL)

    Science.gov (United States)

    McInerney, John G.

    2016-03-01

    Novalux Inc was an enterprise founded by Aram Mooradian in 1998 to commercialise a novel electrically pumped vertical extended cavity semiconductor laser platform, initially aiming to produce pump lasers for optical fiber telecommunication networks. Following successful major investment in 2000, the company developed a range of single- and multi-mode 980 nm pump lasers emitting from 100-500 mW with excellent beam quality and efficiency. This rapid development required solution of several significant problems in chip and external cavity design, substrate and DBR mirror optimization, thermal engineering and mode selection. Output coupling to single mode fiber was exceptional. Following the collapse of the long haul telecom market in late 2001, a major reorientation of effort was undertaken, initially to develop compact 60-100 mW hybrid monolithically integrated pumplets for metro/local amplified networks, then to frequency-doubled blue light emitters for biotech, reprographics and general scientific applications. During 2001-3 I worked at Novalux on a career break from University College Cork, first as R&D Director managing a small group tasked with producing new capabilities and product options based on the NECSEL platform, including high power, pulsed and frequency doubled versions, then in 2002 as Director of New Product Realization managing the full engineering team, leading the transition to frequency doubled products.

  4. The entrepreneurial state debunking public vs. private sector myths

    CERN Document Server

    Mazzucato, Mariana

    2014-01-01

    This new bestseller from leading economist Mariana Mazzucato – named by the ‘New Republic’ as one of the ‘most important innovation thinkers’ today – is stirring up much-needed debates worldwide about the role of the State in innovation. Debunking the myth of a laggard State at odds with a dynamic private sector, Mazzucato reveals in case study after case study that in fact the opposite situation is true, with the private sector only finding the courage to invest after the entrepreneurial State has made the high-risk investments. Case studies include examples of the State’s role in the ‘green revolution’, in biotech and pharmaceuticals, as well as several detailed examples from Silicon Valley. In an intensely researched chapter, she reveals that every technology that makes the iPhone so ‘smart’ was government funded: the Internet, GPS, its touch-screen display and the voice-activated Siri. Mazzucato also controversially argues that in the history of modern capitalism the State has not on...

  5. Longitudinal Study of Cytokine Expression, Lipid Profile and Neuronal Growth Factors in Human Breast Milk from Term and Preterm Deliveries.

    Science.gov (United States)

    Collado, Maria Carmen; Santaella, Marina; Mira-Pascual, Laia; Martínez-Arias, Elena; Khodayar-Pardo, Parisá; Ros, Gaspar; Martínez-Costa, Cecilia

    2015-10-19

    Breast milk (BM) is considered as a reference for infant nutrition. The role of bioactive components, such as cytokines, hormones, growth factors (GFs) and fatty acids (FAs) is poorly known, but they might be implicated in immune response development. The aim of this study was to identify the lipid profile and the spectrum of cytokines and neuronal GF in BM samples and analyse the influence of gestational age and lactation time on these components. This study used a longitudinal prospective method for the characterization of cytokines, FAs and GFs global profiles in 120 BM samples from 40 healthy mothers (20 preterm and 20 term) collected as colostrum, transitional and mature milk. The cytokines were analysed by protein array (Ray Bio® Human Cytokine Array G6. Ray Biotech, Inc. Norcross, GA, USA) and the FAs were analysed by gas chromatography. The FA profile was similar between the term and the preterm BM samples. Omega-3-α-linoleic and docosahexaenoic acid (DHA) and omega-6-linoleic acid were the most abundant in the term and preterm samples during lactation. Omega-3 ETA and omega-3 EPA we observed exclusively in the preterm samples. The cytokine profile showed a different trend based on gestational age. A significantly higher expression of neurotrophic factors was found in the mature preterm milk samples as compared to the mature term samples. Our study is the first to identify the influence and interactions of perinatal factors on cytokine, GFs and FAs in human milk.

  6. 韩国农业生物技术年报(2011年)%Seung-Ah Chung,Michael G. Francom,Kathryn Ting* Korea Agricultural Biotechnology Annual

    Institute of Scientific and Technical Information of China (English)

    Seung-Ah Chung; Michael G. Francom; Kathryn Ting

    2013-01-01

      韩国正在修改其法律和法规,以体现《卡塔赫纳生物安全议定书》中的最新要求以及其他国际惯例。这些修订将让新转基因成分和转基因产品贸易的审批更加可以预测和透明。消费者对转基因食品的态度开始缓和,但是负面观点仍然存在。发动本地农民支持采用和积极推广这种技术在本地种植的作物中的采用被认为是增强消费者信心的关键。%Korea is in the process of revising its laws and regulations to reflect the current language in the Cartagena Protocol on Biosafety as well as other international practices. These revisions will make the approval of new biotech events and the trade in these products more predictable and transparent. Consumer attitudes toward the use of biotechnology in food are starting to soften, but negative perceptions still persist. Generating local farmers' support to adopt and actively use this technology in locally grown crops is seen as the key to increasing consumer confidence.

  7. Zapatista corn: a case study in biocultural innovation.

    Science.gov (United States)

    Brandt, Marisa

    2014-12-01

    In November 2001, Nature published a letter in which University of California Berkeley's biologists claimed to have found evidence of genetically modified (GM) DNA in regional varieties of maize in Oaxaca, even though the Mexican government had banned transgenic corn agriculture in 1998. While urban protesters marched against the genetic 'contamination' of Mexican corn by US-based agricultural biotech firms, rural indigenous communities needed a framework for understanding concepts such as GM before they could take action. This article analyzes how the indigenous organization, the Zapatistas, mobilized a program to address this novel entity. Their anti-GM project entailed educating local farmers about genetics, importing genetic testing kits, seed-banking landrace corn and sending seeds to 'solidarity growers' around the world. This article explores material-semiotic translations to explain one of the central aspects of this project, the definition and circulation of Zapatista corn--an entity defined not only through cultural geography, but also technological means. Through its circulation, Zapatista corn serves to perform a biocultural engagement with Zapatista's political project of resistance to neoliberalism. While much has been written about both regulatory policy and consumer activism against GM in the Global North, Zapatista corn also provides a case study in indigenous, anti-GM activism founded on biocultural innovation and the creation of alternative networks for circulating corn.

  8. Enhancements Needed in GE Crop and Food Regulation in the U.S.

    Directory of Open Access Journals (Sweden)

    Charles eBenbrook

    2016-03-01

    Full Text Available Genetically engineered (GE crops, multi-ingredient foods derived from one or more GE ingredients, and GE agricultural inputs are regulated in the United States under a Coordinated Framework that was literally cobbled together in the early 1990s. Via this Framework, responsibility is spread across three federal agencies for the assessment and management of potential risks arising from the planting of GE crops, the raising of GE animals, or uses of GE inputs.The Framework was incomplete and conceptually flawed from the beginning. Despite multiple, piecemeal efforts to update aspects of GE risk assessment and regulatory policy, the Coordinated Framework survives to this day largely unchanged. Its shortcomings are recognized in both the scientific and legal communities, but meaningful reforms thus far remain out of reach, blocked by the intense controversy now surrounding all things biotech.Five generic reforms and another five specific initiatives are described to create a more robust, science-driven GE regulatory infrastructure in the U.S.

  9. From Darwinian to technological evolution: forgetting the human lottery.

    Science.gov (United States)

    Tintino, Giorgio

    2014-01-01

    The GRIN technologies (-geno, -robo, -info, -nano) promise to change the inner constitution of human body and its own existence. This transformation involves the structure of our lives and represent a brave new world that we have to explore and to manage. In this sense, the traditional tools of humanism seems very inadequate to think the biotech century and there is a strong demand of a new thought for the evolution and the concrete history of life. The posthuman philosophy tries to take this new path of human existence in all of its novelty since GRIN technologies seem to promise new and unexpected paths of evolution to living beings and, above all, man. For this, the post-human thought, as we see, is a new anthropological overview on the concrete evolution of human being, an overview that involves an epistemological revolution of the categories that humanism uses to conceptualize the journey that divides the Homo sapiens from the man. But, is this right? PMID:25684379

  10. Preeclampsia – Will Orphan Drug Status Facilitate Innovative Biological Therapies?

    Science.gov (United States)

    Hahn, Sinuhe

    2015-01-01

    It is generally accepted that the development of novel therapies to treat pregnancy-related disorders, such as preeclampsia, is hampered by the paucity of research funding. Hence, it is with great interest to become aware of at least three novel therapeutic approaches for the treatment of this disorder: exploiting either the anticoagulant activity of antithrombin, the free radical scavenging activity of alpha-1-microglobulin, or the regenerative capacity of placenta-derived mesenchymal stem cells. As these projects are being carried out by small biotech enterprises, the question arises of how they are able to fund such undertakings. A novel strategy adopted by two of these companies is that they successfully petitioned US and EU agencies in order that preeclampsia is accepted in the register of rare or orphan diseases. This provides a number of benefits including market exclusivity, assistance with clinical trials, and dedicated funding schemes. Other strategies to supplement meager research funds, especially to test novel approaches, could be crowdfunding, a venture that relies on intimate interaction with advocacy groups. In other words, preeclampsia meets Facebook. Perhaps similar strategies can be adopted to examine novel therapies targeting either the imbalance in pro- or anti-angiogenic growth factors, complement activation, reduced levels of placenta protein 13, or excessive neutrophil activation evident in preeclampsia. PMID:25767802

  11. Use of PCR-based assays for the detection of the adventitious agent porcine circovirus type 1 (PCV1) in vaccines, and for confirming the identity of cell substrates and viruses used in vaccine production.

    Science.gov (United States)

    Kumar, Deepak; Beach, Nathan M; Meng, Xiang-Jin; Hegde, Nagendra R

    2012-01-01

    Safety and quality are important issues for vaccines. Whereas reversion to virulence poses a safety risk with live attenuated vaccines, the potential for the presence of adventitious agents is also an issue of vaccine quality. The recent detection or porcine circovirus type 1 (PCV1) in human vaccines has further highlighted the importance of quality control in vaccine production. The purpose of this study was to use a novel conventional PCR to detect PCV1, and subsequently screen materials used in the manufacture of vaccines at Bharat Biotech International Limited, India. The genome or gene fragments of PCV1 were not detected in any of the vaccines and materials tested, including the live attenuated rotavirus vaccine candidate ROTAVAC(®). Further, the identity of the cells and the viruses used as starting materials in the manufacture of these vaccines was confirmed by species-specific PCR or virus-specific RT-PCR, and no cross-contamination was detected in any case. The methods can be applied for regular in-house quality control screening of raw materials and seeds/banks, as well as formulated vaccines.

  12. Advancing Cancer Survivorship in a Country with 1.35 Billion People: The China Lymphoma Project

    Science.gov (United States)

    Coughlin, Steven; Reno, Jamie

    2016-01-01

    Rates of lymphoma are rising rapidly and lymphoma is now the ninth most common cancer among Chinese males. The China Lymphoma Project was founded to increase awareness of lymphoma in China, including the survivability of the disease and the availability of potentially life-saving treatments, and to provide social support for men, women, and children in China who are living with the disease. The project is working with China government officials, several of the top cancer hospitals in China and the U.S., internationally known oncologists and cancer researchers, pharmaceutical and biotech companies in China and the U.S., healthcare and environmental companies, the Confucius Institute at San Diego State University, and the Asian Heritage Society. Advances in e-Health are being utilized to provide patient education and social support. The project will provide free e-books that profile lymphoma survivors (e.g., Kai-Fu Lee, creator of Google China), new videos, websites, pamphlets, blogs, video logs (vlogs), peer-to-peer counseling and support, and information about the latest treatments and oncology clinical trials.

  13. Human Immunodeficiency Virus Seroprevalence among Inmates of the Penitentiary Complex of the Region of Campinas, State of São Paulo, Brazil

    Directory of Open Access Journals (Sweden)

    Neusa Maria Osti

    1999-07-01

    Full Text Available Six hundred and ninety three male inmates from three penitentiaries, two (A and B maximum-security systems and one (C minimum-security facility, located in Campinas, State of São Paulo, Brazil were studied for the presence of human immunodeficiency virus (HIV antibodies, using a cross-sectional design. The search for anti-HIV antibodies in 693 samples of sera collected was carried out by two serological tests: (a the Microparticle enzyme immunoassay-HIV-1 and HIV-2 (MEIA (Abbott Laboratories and (b the Western Blot-HIV-1 (WB (Cambridge Biotech Corporation to confirm positive results with MEIA. Sera reactivity for HIV antibodies was 14.4%. The highest frequency of anti-HIV antibodies was found in the A and B maximum-security prisons: 17% and 21.5%, respectively. In prison C, the frequency of reagents was 10.9%. Seventy three inmates, initially negative in the MEIA test, were checked again five and seven months later. Three of them, all from the maximum-security facilities, became reactive in the MEIA test, with confirmation in the WB, suggesting that serological conversion had occurred after imprisonment.

  14. Awakening interest in the natural sciences - BASF's Kids' Labs.

    Science.gov (United States)

    Lang, Cinthia

    2012-01-01

    At BASF's Ludwigshafen headquarters, kids and young adults in grades 1-13 can learn about chemistry in the Kids' Labs. Different programs exist for different levels of knowledge. In the two 'Hands-on Lab H(2)O & Co.' Kids' Labs, students from grades 1-6 explore the secrets of chemistry. BASF Kids' Labs have now been set up in over 30 countries. In Switzerland alone, almost 2,000 students have taken part in the 'Water Loves Chemistry' Kids' Lab since it was started in 2011. In Alsace, 600 students have participated to date. In the Teens' Lab 'Xplore Middle School', middle school students explore five different programs with the themes 'substance labyrinth', 'nutrition', 'coffee, caffeine & co.', 'cosmetics' and 'energy'. Biotechnological methods are the focus of the Teens' Lab 'Xplore Biotech' for students taking basic and advanced biology courses. In the 'Xplore High School' Teens' Lab, chemistry teachers present their own experimental lab instruction for students in basic and advanced chemistry courses. The Virtual Lab has been expanding the offerings of the BASF Kids' Labs since 2011. The online lab was developed by the company for the International Year Of Chemistry and gives kids and young adults the opportunity to do interactive experiments outside of the lab. PMID:23394237

  15. Progress on the research and development of inactivated EV71 whole-virus vaccines.

    Science.gov (United States)

    Liang, Zheng-Lun; Mao, Qun-Ying; Wang, Yi-Ping; Zhu, Feng-Cai; Li, Jing-Xin; Yao, Xin; Gao, Fan; Wu, Xing; Xu, Miao; Wang, Jun-Zhi

    2013-08-01

    The prevalence of diseases caused by EV71 infection has become a serious public health problem in the Western Pacific region. Due to a lack of effective treatment options, controlling EV71 epidemics has mainly focused on the research and development (R&D) of EV71 vaccines. Thus far, five organizations have completed pre-clinical studies focused on the development of inactivated EV71 whole-virus vaccines, including vaccine strain screening, process optimization, safety and immunogenicity evaluation, and are in different stages of clinical trials. Among these organizations, three companies in Mainland China [Beijing Vigoo Biological Co., Ltd. (Vigoo), Sinovac Biotech Ltd. (Sinovac) and Institute of Medical Biology, Chinese Academy of Medical Science (CAMS)] have recently completed Phase III trials for the vaccines they developed. In addition, the other two vaccines, developed by National Health Research Institutes (NHRI) of Taiwan and Inviragen Pte., Ltd (Inviragen), of Singapore, have also completed Phase I clinical trials. Published clinical trial results indicate that the inactivated EV71 vaccines have good safety and immunogenicity in the target population (infants) and confer a relatively high rate of protection against EV71 infection-related diseases. The results of clinical trials suggest a promising future for the clinical use of EV71 vaccines. Here, we review and highlight the recent progress on the R&D of inactivated EV71 whole-virus vaccines.

  16. [Patentability of DNA sequences: the debate remains open].

    Science.gov (United States)

    Martín Uranga, Amelia

    2013-01-01

    The patentability of human genes was from the beginning of the discussion concerning the Directive on the legal protection of biotechnological inventions, an issue that provoked debates among politicians, scientists, lawyers and civil society itself. Although Directive 98/44 tried to settle the matter by stating that to support the patentability of human genes, it should know what role they fulfill, which protein they encode, all of this as an essential requirement to test its industrial application. However, following the judgment of 13 June 2013 (Supreme Court of the United States of America in the case of Association for Molecular Pathology et al. versus Myriad Genetics Inc.) the debate on this issue has been reopened. There are several issues to be considered, taking into account that the patents on DNA & Gene Sequences have played an important incentive to increase the interest in biotechnology applied to human health. On the other hand, this is a paradigm shift in the R & D of biopharmaceutical companies, and it has moved from an in house research model to a model of open innovation, a model of collaboration between large corporations with biotech SMEs and public and private research centers. This model of innovation, impacts on the issue of the industrial property, and therefore it will be necessary to clearly define what each party brings to the relationship and how they are expected to share the results. But all of this, with the ultimate goal that the patients have access to treatments and medications most innovative, safe and effective.

  17. Scale-up protein separation on stainless steel wide bore toroidal columns in the type-J counter-current chromatography.

    Science.gov (United States)

    Guan, Yue Hugh; Hewitson, Peter; van den Heuvel, Remco N A M; Zhao, Yan; Siebers, Rick P G; Zhuang, Ying-Ping; Sutherland, Ian

    2015-12-11

    Manufacturing high-value added biotech biopharmaceutical products (e.g. therapeutic proteins) requires quick-to-develop, GMP-compliant, easy-to-scale and cost effective preparatory chromatography technologies. In this work, we describe the construction and testing of a set of 5-mm inner diameter stainless steel toroidal columns for use on commercially available preparatory scale synchronous J-type counter-current chromatography (CCC) machinery. We used a 20.2m long column with an aqueous two-phase system containing 14% (w/w) PEG1000 and 14% (w/w) potassium phosphate at pH 7, and tested a sample loading of 5% column volume and a mobile phase flow rate of 20ml/min. We then satisfactorily demonstrated the potential for a weekly protein separation and preparation throughput of ca. 11g based on a normal weekly routine for separating a pair of model proteins by making five stacked injections on a single portion of stationary phase with no stripping. Compared to our previous 1.6mm bore PTFE toroidal column, the present columns enlarged the nominal column processing throughput by nearly 10. For an ideal model protein injection modality, we observed a scaling up factor of at least 21. The 2 scales of protein separation and purification steps were realized on the same commercial CCC device.

  18. ICM: a web server for integrated clustering of multi-dimensional biomedical data.

    Science.gov (United States)

    He, Song; He, Haochen; Xu, Wenjian; Huang, Xin; Jiang, Shuai; Li, Fei; He, Fuchu; Bo, Xiaochen

    2016-07-01

    Large-scale efforts for parallel acquisition of multi-omics profiling continue to generate extensive amounts of multi-dimensional biomedical data. Thus, integrated clustering of multiple types of omics data is essential for developing individual-based treatments and precision medicine. However, while rapid progress has been made, methods for integrated clustering are lacking an intuitive web interface that facilitates the biomedical researchers without sufficient programming skills. Here, we present a web tool, named Integrated Clustering of Multi-dimensional biomedical data (ICM), that provides an interface from which to fuse, cluster and visualize multi-dimensional biomedical data and knowledge. With ICM, users can explore the heterogeneity of a disease or a biological process by identifying subgroups of patients. The results obtained can then be interactively modified by using an intuitive user interface. Researchers can also exchange the results from ICM with collaborators via a web link containing a Project ID number that will directly pull up the analysis results being shared. ICM also support incremental clustering that allows users to add new sample data into the data of a previous study to obtain a clustering result. Currently, the ICM web server is available with no login requirement and at no cost at http://biotech.bmi.ac.cn/icm/.

  19. A perspective on 10-years HTS experience at the Walter and Eliza Hall Institute of Medical Research - eighteen million assays and counting.

    Science.gov (United States)

    Lackovic, Kurt; Lessene, Guillaume; Falk, Hendrik; Leuchowius, Karl-Johan; Baell, Jonathan; Street, Ian

    2014-03-01

    The Walter and Eliza Hall Institute of Medical Research (WEHI) is Australia's longest serving medical research institute. WEHI's High Throughput Screening (HTS) Facility was established in 2003 with $5 million of infrastructure funds invested by WEHI, and the Victorian State Government's Strategic Technology Initiative through Bio21 Australia Ltd. The Facility was Australia's first truly academic HTS facility and was one of only a handful operating in publicly funded institutions worldwide at that time. The objectives were to provide access to enabling HTS technologies, such as assay design, liquid handling automation, compound libraries and expertise to promote translation of basic research in a national setting that has a relatively young biotech sector and does not have a big Pharma research presence. Ten years on and the WEHI HTS Facility has participated in over 92 collaborative projects, generated over 18 million data points, and most importantly, projects that began in the Facility have been commercialized successfully (due to strong ties with Business Development and emphasis on intellectual property management) and now have molecules progressing in clinical trials.

  20. 生物技术专业毕业论文常见问题与改进措施%Common Problems and Improvement Measures for Un- dergraduate Thesis of Biotechnology

    Institute of Scientific and Technical Information of China (English)

    王伟霞; 李福后; 马桂珍; 秦蕾; 孙涛; 谢晓南

    2015-01-01

    毕业论文是本科生实践教学的重要环节,是全面评估学生专业水平的重要指标.为了提高生物技术专业本科生的毕业论文质量,结合多年的教学与管理经验,我们课题组调查分析了毕业论文实践教学中经常存在的问题,同时探讨了这些问题存在的主要原因.结合我校工作实际,提出了毕业论文工作的改进措施.%Thesis is an important content of undergraduate practi-cal teaching, and it is also an important index to evaluate profes-sional level. In order to improve the quality of thesis of biotech-nology undergraduates, the conditions of undergraduate thesis were investigated, and the main reasons of these problems were analyzed in this paper. Combined with practical work, improve-ment measures were proposed for undergraduate thesis.

  1. Hepatitis B virus surface antigen and anti-hepatitis C virus rapid tests underestimate hepatitis prevalence among HIV-infected patients

    DEFF Research Database (Denmark)

    Hønge, Bo Langhoff; Jespersen, S; Medina, C;

    2014-01-01

    OBJECTIVES: In the case of coinfection with HIV and hepatitis B virus (HBV) and/or hepatitis C virus (HCV), hepatic disease progression is often accelerated, with higher rates of liver cirrhosis and liver-related mortality. We aimed to evaluate the performance of the rapid tests used routinely...... to detect HBV surface antigen (HBsAg) and anti-HCV among HIV-infected patients in Guinea-Bissau. METHODS: Blood samples from HIV-infected patients in Guinea-Bissau were stored after testing for HBsAg and anti-HCV with rapid tests. Samples were subsequently re-tested for HBsAg and anti-HCV in Denmark....... RESULTS: Two rapid tests were used in Guinea-Bissau: HBsAg Strip Ref 2034 (VEDA.LAB, Alençon, France; sensitivity 62.3%; specificity 99.2%) and HEPA-SCAN (Bhat Bio-Tech, Bangalore, India; sensitivity 57.1%; specificity 99.7%). In the two tests the ability to obtain the correct outcome depended...

  2. Identification of Resistance to Pythium ultimum in Sunflower Seedlings

    Directory of Open Access Journals (Sweden)

    Mohammad R. Asgharipour

    2012-04-01

    Full Text Available In order to evaluate Pythium-mediated damping-off a laboratory experiment was conducted at Biotech Research Center of the University of Zabol, in 2010. The experimental design was a completely randomized with seven genotypes, together with seven replicates. The seeds were inoculated in oospore suspension of fungi (105 mg/mL for 1 min. After 5 days, seedlings were evaluated with an aim to counting non-germinated seeds, abnormal seedlings and healthy seedlings. Then the healthy seedlings were planted in pots after infecting seedlings through a piece of paper towels contaminated with fungal suspension, and normal seedlings were counted after 12 days. The result showed that there were significant differences among the genotypes for all evaluated traits. The greatest non-germinated seeds were observed in Azargol with 38% and followed by Record and Allstar. Azargol also had the highest abnormal seedlings (86% and the minimum abnormal seedlings were observed in Xaria with 72%. Regarding normal seedlings at pot, Golshid and Hysun- 33 were superior with 60 and 49%, respectively. These findings suggest that all genotypes had a high susceptibility to P. ultimum. Also, results obtained from the paper towel experiment were different to the results of the soil.

  3. Biotechnology and genetic engineering in the new drug development. Part I. DNA technology and recombinant proteins.

    Science.gov (United States)

    Stryjewska, Agnieszka; Kiepura, Katarzyna; Librowski, Tadeusz; Lochyński, Stanisław

    2013-01-01

    Pharmaceutical biotechnology has a long tradition and is rooted in the last century, first exemplified by penicillin and streptomycin as low molecular weight biosynthetic compounds. Today, pharmaceutical biotechnology still has its fundamentals in fermentation and bioprocessing, but the paradigmatic change affected by biotechnology and pharmaceutical sciences has led to an updated definition. The biotechnology revolution redrew the research, development, production and even marketing processes of drugs. Powerful new instruments and biotechnology related scientific disciplines (genomics, proteomics) make it possible to examine and exploit the behavior of proteins and molecules. Recombinant DNA (rDNA) technologies (genetic, protein, and metabolic engineering) allow the production of a wide range of peptides, proteins, and biochemicals from naturally nonproducing cells. This technology, now approximately 25 years old, is becoming one of the most important technologies developed in the 20(th) century. Pharmaceutical products and industrial enzymes were the first biotech products on the world market made by means of rDNA. Despite important advances regarding rDNA applications in mammalian cells, yeasts still represent attractive hosts for the production of heterologous proteins. In this review we describe these processes. PMID:24399704

  4. Science at the supermarket: multiplication, personalization and consumption of science in everyday life.

    Science.gov (United States)

    Tateo, Luca

    2014-06-01

    Which is the kind science's psychological guidance upon everyday life? I will try to discuss some issues about the role that techno-scientific knowledge plays in sense-making and decision making about practical questions of life. This relation of both love and hate, antagonism and connivance is inscribable in a wider debate between a trend of science to intervene in fields that are traditionally prerogative of political, religious or ethical choices, and, on the other side, the position of those who aim at stemming "technocracy" and governing these processes. I argue that multiplication, personalization and consumption are the characteristics of the relationship between science, technology and society in the age of "multiculturalism" and "multi-scientism". This makes more difficult but intriguing the study and understanding of the processes through which scientific knowledge is socialized. Science topics, like biotech, climate change, etc. are today an unavoidable reference frame. It is not possible to not know them and to attach them to the most disparate questions. Like in the case of Moscovici's "Freud for all seasons", the fact itself that the members of a group or a society believe in science as a reference point for others, roots its social representation and the belief that it can solve everyday life problems. PMID:24578069

  5. Nanotechnology Based Treatments for Neurological Disorders from Genetics Perspective

    Directory of Open Access Journals (Sweden)

    Nicholas S. Kurek

    2013-02-01

    Full Text Available Nanotechology involves the application, analysis and manipulation of nanomaterials. These materials have unique and medically useful properties due to their nanoscale parameters. Nanotechnology based treatments and diagnostics might eventually bring great relief to people suffering from neurological disorders including autism spectrum disorders, Alzheimer’s disease and Parkinson’s disorders. A large variety of nonmaterials such as viruses, carbon nanotubes, gold and silica nanoparticles, nanoshells, quantum dots, genetic material and proteins as well as hordes of other forms of nanotechnology have been researched in order to determine their potential in enhancing disease treatments and diagnostics. Nanotechnology has shown countless applications and might eventually be used in every biotech/health industry. Nevertheless, many nanomaterials may pose some safety risks and whether their benefits overweigh the risk is still being debated. Once the proper ethical and safety protocols are established and enough research is completed, nanotechnology is expected to benefit the mankind enormously. In this article, we will discuss and analyze many ways in which, nanotechnology based treatments and diagnostics will be used to help people with neurological disorders through the methods that we currently have at our disposal. [Archives Medical Review Journal 2013; 22(1.000: 12-32

  6. Cooperación y estrategia de apropiación en alta tecnología: el caso de una empresa biofarmacéutica argentina

    Directory of Open Access Journals (Sweden)

    Vladimiro Verre

    2014-10-01

    Full Text Available El artículo presenta el estudio de caso de Delta Biotech S.A., una pyme argentina perteneciente a un sector de alta tecnología como lo es el biofarmacéutico. El análisis apunta a evidenciar cómo la estrategia de apropiación de los resultados de las innovaciones tecnológicas de la firma se basa en la articulación de distintos mecanismos y, al ser la actividad de innovación realizada con el aporte de fuentes externas y públicas de conocimiento, dicha estrategia debe tener en cuenta los riesgos que derivan de este rasgo constitutivo de la innovación. La cooperación público-privada para la innovación genera efectos variados sobre cada uno de los mecanismos de apropiación y, por tanto, las características específicas que asume la misma son relevantes para evaluar cuáles son sus efectos sobre la estrategia de apropiación de la empresa.

  7. Low-cost Negative-pressure Wound Therapy Using Wall Vacuum: A 15 Dollars by Day Alternative

    Science.gov (United States)

    Garrido, Ignacio; Eburdery, Harold; Grolleau, Jean Louis; Chavoin, Jean Pierre

    2015-01-01

    Background: Negative-pressure wound therapy (NPWT) has been marketed for about 20 years and remains popular. The only real obstacle to NPWT is the cost; therefore, we designed an inexpensive NPWT connected to a wall vacuum. Here, we report the feasibility and safety of this product, which we call PROVACUUM (Z-Biotech, Saint-Avertin, France). Methods: As a first step, the constraints imposed on the manufacturer were equipment quality similar to that of commercial NPWT systems, with an average treatment cost of $15/d. Then, we conducted a prospective study of patients with indications for NPWT from September 2013 to January 2015. Data collected included ease of use, quality of materials, and occurrence of complications during treatment. Results: We enrolled 23 patients with a mean age of 50.8 years. The average duration of treatment was 8.5 days (range, 3–21 days). The dressings were changed every 3.3 days (range, 2–4 days). Two hematomas occurred that required surgical revision and the transfusion of 2 units after large debridement of pressure ulcer. No other adverse events or infections occurred. The surgeons found that our device was similar to commercial NPWT devices. Conclusions: We developed an inexpensive NPWT that costs an average of $15/d. Our process is not intended to replace portable or stand-alone devices with batteries, but rather offers a less expensive alternative for hospitalized patients and makes NPWT accessible to the most precarious countries and institutions. PMID:26180719

  8. Regenerative medicine in Europe: global competition and innovation governance.

    Science.gov (United States)

    Hogarth, Stuart; Salter, Brian

    2010-11-01

    Leading European nations with strong biotech sectors, such as the UK and Germany, are investing heavily in regenerative medicine, seeking competitive advantage in this emerging sector. However, in the broader biopharmaceutical sector, the EU is outperformed by the USA on all metrics, reflecting longstanding problems: limited venture capital finance, a fragmented patent system, and relatively weak relations between academia and industry. The current global downturn has exacerbated these difficulties. The crisis comes at a time when the EU is reframing its approach to the governance of innovation and renewing its commitment to the goal of making Europe the leading player in the global knowledge economy. If the EU is to gain a competitive advantage in the regenerative medicine sector then it must coordinate a complex multilevel governance framework that encompasses the EU, member states and regional authorities. This article takes stock of Europe's current competitive position within the global bioeconomy, drawing on a variety of metrics in the three intersecting spheres of innovation governance: science, market and society. These data then provide a platform for reviewing the problems of innovation governance faced by the EU and the strategic choices that have to be confronted in the regenerative medicine sector. PMID:21082895

  9. 卡士奶市场营销策略设计浅析%The Design Analysis of Marketing Strategy about Castel Milk

    Institute of Scientific and Technical Information of China (English)

    汤向东

    2011-01-01

    本文主要研究作为奶业的特殊产品--卡士奶的营销策略如何设计.全文共分成三个部分,第一个部分主要分析卡士奶的产品定位.第二个部分主要分析卡士奶市场现状.第三个部分主要分析绿雪生物公司如何有效地设计卡士奶的营销策略.通过本文的介绍让大家了解卡士奶这种特殊的奶业产品及其有针对性的营销策略.%This paper studies how to design marketing strategy of castel milk-the special dairy products. This paper is divided into three parts. The first part analyzes the product positioning of castel milk. The second part analyzes the marketing situation of castel milk. The third part analyzes how green snow biotech company design marketing strategy about castel milk. Through this introduction, we can know castel milk-the special dairy products and the particular marketing strategy.

  10. Generation and characterization of the first immortalized alpaca cell line suitable for diagnostic and immunization studies.

    Directory of Open Access Journals (Sweden)

    Valentina Franceschi

    Full Text Available Raising of alpacas as exotic livestock for wool and meat production and as companion animals is growing in importance in the United States, Europe and Australia. Furthermore the alpaca, as well as the rest of the camelids, possesses the peculiarity of producing single-chain antibodies from which nanobodies can be generated. Nanobodies, due to their structural simplicity and reduced size, are very versatile in terms of manipulation and bio-therapeutic exploitation. In fact the biotech companies involved in nanobody production and application continue to grow in number and size. Hence, the development of reagents and tools to assist in the further growth of this new scientific and entrepreneurial reality is becoming a necessity. These are needed mainly to address alpaca disease diagnosis and prophylaxis, and to develop alpaca immunization strategies for nanobody generation. For instance an immortalized alpaca cell line would be extremely valuable. In the present work the first stabilized alpaca cell line from alpaca skin stromal cells (ASSCs was generated and characterized. This cell line was shown to be suitable for replication of viruses bovine herpesvirus-1, bovine viral diarrhea virus and caprine herpesvirus-1 and the endocellular parasite Neospora caninum. Moreover ASSCs were easy to transfect and transduce by several methods. These two latter characteristics are extremely useful when recombinant antigens need to be produced in a host homologous system. This work could be considered as a starting point for the expansion of the biotechnologies linked to alpaca farming and industry.

  11. Tecovirimat for smallpox infections.

    Science.gov (United States)

    Bolken, T C; Hruby, D E

    2010-02-01

    SIGA Technologies, Inc. is a small biotech company committed to developing novel products for the prevention and treatment of serious viral diseases, with an emphasis on products to combat outbreaks that could result from bioterrorism. With government support, SIGA has developed the necessary infrastructure to successfully advance new antiviral drugs from the discovery stage through to licensing. Currently, there is a need to develop safe and effective inhibitors for poxvirus-induced diseases such as smallpox caused by variola, which is a potential biological warfare agent. Likewise emerging zoonotic infections due to cowpox virus and monkeypox virus require the development of effective countermeasures. Tecovirimat, also known as ST-246, has shown efficacy in all small animal and nonhuman primate prophylaxis and therapeutic efficacy models of poxvirus-induced disease tested to date. Phase I clinical trials and new drug application-enabling toxicology studies have been completed with tecovirimat. A phase II clinical study is being run and SIGA has initiated commercial scale-up manufacturing and preparation for the pivotal safety and efficacy studies. SIGA is committed to getting approval for tecovirimat and supplying it to the Strategic National Stockpile, the Department of Defense and global health authorities. PMID:20393639

  12. Genetic transformation of major cereal crops.

    Science.gov (United States)

    Ji, Qing; Xu, Xing; Wang, Kan

    2013-01-01

    Of the more than 50,000 edible plant species in the world, at least 10,000 species are cereal grains. Three major cereal crops, rice (Oryza sativa), maize (Zea mays), and wheat (Triticum sp.), provide two-thirds of the world's food energy intake. Although crop yields have improved tremendously thanks to technological advances in the past 50 years, population increases and climate changes continue to threaten the sustainability of current crop productions. Whereas conventional and marker-assisted breeding programs continue to play a major role in crop improvement, genetic engineering has drawn an intense worldwide interest from the scientific community. In the past decade, genetic transformation technologies have revolutionized agricultural practices and millions of hectares of biotech crops have been cultured. Because of its unique ability to insert well-characterized gene sequences into the plant genome, genetic engineering can also provide effective tools to address fundamental biological questions. This technology is expected to continue to be an indispensable approach for both basic and applied research. Here, we overview briefly the development of the genetic transformation in the top seven cereals, namely maize, rice, wheat, barley (Hordeum vulgare), sorghum (Sorghum sp.), oat (Avena sativa), and millets. The advantages and disadvantages of the two major transformation methods, Agrobacterium tumefaciens-mediated and biolistic methods, are also discussed.

  13. Genetic basis and detection of unintended effects in genetically modified crop plants.

    Science.gov (United States)

    Ladics, Gregory S; Bartholomaeus, Andrew; Bregitzer, Phil; Doerrer, Nancy G; Gray, Alan; Holzhauser, Thomas; Jordan, Mark; Keese, Paul; Kok, Esther; Macdonald, Phil; Parrott, Wayne; Privalle, Laura; Raybould, Alan; Rhee, Seung Yon; Rice, Elena; Romeis, Jörg; Vaughn, Justin; Wal, Jean-Michel; Glenn, Kevin

    2015-08-01

    In January 2014, an international meeting sponsored by the International Life Sciences Institute/Health and Environmental Sciences Institute and the Canadian Food Inspection Agency titled "Genetic Basis of Unintended Effects in Modified Plants" was held in Ottawa, Canada, bringing together over 75 scientists from academia, government, and the agro-biotech industry. The objectives of the meeting were to explore current knowledge and identify areas requiring further study on unintended effects in plants and to discuss how this information can inform and improve genetically modified (GM) crop risk assessments. The meeting featured presentations on the molecular basis of plant genome variability in general, unintended changes at the molecular and phenotypic levels, and the development and use of hypothesis-driven evaluations of unintended effects in assessing conventional and GM crops. The development and role of emerging "omics" technologies in the assessment of unintended effects was also discussed. Several themes recurred in a number of talks; for example, a common observation was that no system for genetic modification, including conventional methods of plant breeding, is without unintended effects. Another common observation was that "unintended" does not necessarily mean "harmful". This paper summarizes key points from the information presented at the meeting to provide readers with current viewpoints on these topics. PMID:25716164

  14. Towards personalized agriculture: What chemical genomics can bring to plant biotechnology

    Directory of Open Access Journals (Sweden)

    Michael E Stokes

    2014-07-01

    Full Text Available In contrast to the dominant drug paradigm in which compounds were developed to fit all, new models focused around personalized medicine are appearing where treatments are customized for individual patients. The agricultural biotechnology industry should also think about these new personalized models. For example, most common herbicides are generic in action, which led to the development of genetically modified crops to add specificity. The ease and accessibility of modern genomic analysis should facilitate the discovery of chemicals that are more selective in their utility. Is it possible to develop species-selective herbicides and growth regulators? More generally put, is plant research at a stage where chemicals can be developed that streamline plant development and growth to various environments? We believe the advent of chemical genomics now opens up these and other opportunities to personalize agriculture. Furthermore, chemical genomics does not necessarily require genetically tractable plant models, which in principle should allow quick translation to practical applications. For this to happen, however, will require collaboration between the Ag-biotech industry and academic labs for early-stage research and development.

  15. Global regulatory landscape of biosimilars: emerging and established market perspectives

    Directory of Open Access Journals (Sweden)

    Krishnan A

    2015-02-01

    Full Text Available Anita Krishnan,1 Rustom Mody,1 Hemant Malhotra21Lupin Limited, Biotech Division, Maharashtra, India; 2Division of Medical Oncology, RK Birla Cancer Center, SMS Medical College Hospital, Jaipur, India Abstract: Biological product development for launch in multiple geographies with varied regulatory expectations would require a planned and focused strategy, involving the selection of the appropriate reference product, defining the extent of process and product characterization and design of nonclinical and clinical studies. The development for established markets like the European Union and the United States, which have precedence in regulatory pathways, may face very different challenges compared to emerging markets, many of which are still in the nascent stages of regulatory guidelines. A clear and concise understanding of the regulatory framework of each region and awareness of the limitations of health care policies, with an added knowledge of the local factors that influence the biosimilar market, would be desirable for a good business strategy. Herein it is attempted to outline the stages of regional guideline implementation in the various global locations and compare the variability in regulatory requirement between them. The factors that could potentially impact biosimilars business in these regions are also outlined. Finally, the prevailing competition between manufacturers of innovative and biosimilar drugs, which could influence the availability of lifesaving off-patent drugs for critical diseases and the advent of more effective, alternate, or next-generation molecules, is also briefly described. Keywords: guidelines, India, comparability, EMA, US FDA, WHO

  16. Process development in the QbD paradigm: Role of process integration in process optimization for production of biotherapeutics.

    Science.gov (United States)

    Rathore, Anurag S; Pathak, Mili; Godara, Avinash

    2016-03-01

    Biotherapeutics have become the focus of the pharmaceutical industry due to their proven effectiveness in managing complex diseases. Downstream processes of these molecules consist of several orthogonal, high resolution unit operations designed so as to be able to separate variants having very similar physicochemical properties. Typical process development involves optimization of the individual unit operations based on Quality by Design principles in order to define the design space within which the process can deliver product that meets the predefined specifications. However, limited efforts are dedicated to understanding the interactions between the unit operations. This paper aims to showcase the importance of understanding these interactions and thereby arrive at operating conditions that are optimal for the overall process. It is demonstrated that these are not necessarily same as those obtained from optimization of the individual unit operations. Purification of Granulocyte Colony Stimulating Factor (G-CSF), a biotherapeutic expressed in E. coli., has been used as a case study. It is evident that the suggested approach results in not only higher yield (91.5 vs. 86.4) but also improved product quality (% RP-HPLC purity of 98.3 vs. 97.5) and process robustness. We think that this paper is very relevant to the present times when the biotech industry is in the midst of implementing Quality by Design towards process development. © 2015 American Institute of Chemical Engineers Biotechnol. Prog., 32:355-362, 2016.

  17. Zapatista corn: a case study in biocultural innovation.

    Science.gov (United States)

    Brandt, Marisa

    2014-12-01

    In November 2001, Nature published a letter in which University of California Berkeley's biologists claimed to have found evidence of genetically modified (GM) DNA in regional varieties of maize in Oaxaca, even though the Mexican government had banned transgenic corn agriculture in 1998. While urban protesters marched against the genetic 'contamination' of Mexican corn by US-based agricultural biotech firms, rural indigenous communities needed a framework for understanding concepts such as GM before they could take action. This article analyzes how the indigenous organization, the Zapatistas, mobilized a program to address this novel entity. Their anti-GM project entailed educating local farmers about genetics, importing genetic testing kits, seed-banking landrace corn and sending seeds to 'solidarity growers' around the world. This article explores material-semiotic translations to explain one of the central aspects of this project, the definition and circulation of Zapatista corn--an entity defined not only through cultural geography, but also technological means. Through its circulation, Zapatista corn serves to perform a biocultural engagement with Zapatista's political project of resistance to neoliberalism. While much has been written about both regulatory policy and consumer activism against GM in the Global North, Zapatista corn also provides a case study in indigenous, anti-GM activism founded on biocultural innovation and the creation of alternative networks for circulating corn. PMID:25608442

  18. Hepatitis C Virus infection in apparentenly healthy individuals with family history of diabetes in Vom, Plateau State Nigeria

    Directory of Open Access Journals (Sweden)

    Duru Boniface N

    2009-07-01

    Full Text Available Abstract Hepatitis C virus (HCV infection is an important public health problem worldwide. Its association with, and predisposing nature for diabetes mellitus (DM has been long established. This research was carried out to determine the prevalence of Hepatitis C virus (HCV amongst people with possible genetic predisposition to diabetes mellitus living in and around Vom, Plateau State, Nigeria. 188 subjects were screened after they filled a structured questionnaire to determine some of their demographic data, social habits and possible risk factors. 5 ml of blood was collected from each subject and sera separated out. Biotech's third generation ELISA Kit for HCV antibodies was used for the screening. Liver enzyme analysis was carried out on positive samples to determine their disease status. A prevalence of 14.36% was recorded with the highest seropositive group being those in the age bracket of 18 – 37 years. 13(13.40% of males and 14(15.38% of females were sero-positive. Liver enzyme analysis of sero-positive subjects showed increased levels which may imply early onset of liver damage. These result showed that these individuals could later suffer diabetes which may be triggered by their HCV infection if not treated. This is not over-looking the economic significance of their ill health, assuming they progress to cirrhotic HCV or develop hepatocelluar carcinoma due to HCV chronicity.

  19. Regenerative medicine in Europe: global competition and innovation governance.

    Science.gov (United States)

    Hogarth, Stuart; Salter, Brian

    2010-11-01

    Leading European nations with strong biotech sectors, such as the UK and Germany, are investing heavily in regenerative medicine, seeking competitive advantage in this emerging sector. However, in the broader biopharmaceutical sector, the EU is outperformed by the USA on all metrics, reflecting longstanding problems: limited venture capital finance, a fragmented patent system, and relatively weak relations between academia and industry. The current global downturn has exacerbated these difficulties. The crisis comes at a time when the EU is reframing its approach to the governance of innovation and renewing its commitment to the goal of making Europe the leading player in the global knowledge economy. If the EU is to gain a competitive advantage in the regenerative medicine sector then it must coordinate a complex multilevel governance framework that encompasses the EU, member states and regional authorities. This article takes stock of Europe's current competitive position within the global bioeconomy, drawing on a variety of metrics in the three intersecting spheres of innovation governance: science, market and society. These data then provide a platform for reviewing the problems of innovation governance faced by the EU and the strategic choices that have to be confronted in the regenerative medicine sector.

  20. Preeclampsia - will orphan drug status facilitate innovative biological therapies?

    Science.gov (United States)

    Hahn, Sinuhe

    2015-01-01

    It is generally accepted that the development of novel therapies to treat pregnancy-related disorders, such as preeclampsia, is hampered by the paucity of research funding. Hence, it is with great interest to become aware of at least three novel therapeutic approaches for the treatment of this disorder: exploiting either the anticoagulant activity of antithrombin, the free radical scavenging activity of alpha-1-microglobulin, or the regenerative capacity of placenta-derived mesenchymal stem cells. As these projects are being carried out by small biotech enterprises, the question arises of how they are able to fund such undertakings. A novel strategy adopted by two of these companies is that they successfully petitioned US and EU agencies in order that preeclampsia is accepted in the register of rare or orphan diseases. This provides a number of benefits including market exclusivity, assistance with clinical trials, and dedicated funding schemes. Other strategies to supplement meager research funds, especially to test novel approaches, could be crowdfunding, a venture that relies on intimate interaction with advocacy groups. In other words, preeclampsia meets Facebook. Perhaps similar strategies can be adopted to examine novel therapies targeting either the imbalance in pro- or anti-angiogenic growth factors, complement activation, reduced levels of placenta protein 13, or excessive neutrophil activation evident in preeclampsia. PMID:25767802